NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Primary Outcome Measures,Sponsor,Enrollment,Study Type,Study Design,Start Date
NCT05271539,Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05271539,COMPLETED,Diabetic Macular Edema,DRUG: Lucentis alone group|DRUG: Lucentis dexamethasone group,"Central foveal thickness, Central foveal thickness in microns measured by OCT, 6 months after the first injection|BCVA (Decimal), Best corrected visual acuity measured on Snellen chart in Decimal form, 6 months after the first injection|The number of injections, The total number of injections in each Arm group, over 6 months duration of the study",Cairo University,42,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-07-01
NCT05739539,Assessment of Retinal Vascular Changes With and Without ILM Peeling in Diabetic Vitrectomy Using OCT-A.,https://clinicaltrials.gov/study/NCT05739539,RECRUITING,Diabetic Vitreous Hemorrhage|Tractional Retinal Detachment,DIAGNOSTIC_TEST: optical coherence tomography angiography|DIAGNOSTIC_TEST: spectral domain optical coherence tomography,"Compare the superficial and deep vascular densities using OCT-A with and without ILM peeling in diabetic vitrectomy patients., Compare the superficial and deep vascular densities in percentage compared to normative database using OCT-A (Optovue) with and without ILM peeling in diabetic vitrectomy patients., 18 months|Compare the foveal avascular zone using OCT-A between both groups., Compare the foveal avascular zone measured in micrometer using OCT-A between both groups., 18 months",Kasr El Aini Hospital,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-04-01
NCT05916391,Gene Therapy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05916391,RECRUITING,Diabetic Macular Edema,GENETIC: FT-003,"Safety and tolerability after FT-003 injection, Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0), Whthin 52 weeks after administration",Frontera Therapeutics,18,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-05-19
NCT05704491,AI Screening for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05704491,RECRUITING,Diabetes Mellitus,DIAGNOSTIC_TEST: artificial intelligence (AI) algorithm of the MONA DR model,"PPV, positive predictive value, 12 months|NPV, negative predictive value, 12 months|SEN, sensitivity, 12 months|SPEZ, specificity, 12 months",West German Center of Diabetes and Health,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-30
NCT04547439,"Sleep, Diabetic Retinopathy and Melatonin",https://clinicaltrials.gov/study/NCT04547439,RECRUITING,Diabetes Mellitus|Diabetic Retinopathy,DRUG: Melatonin|OTHER: Placebo,"Sleep pattern, Sleep pattern: Sleep duration and sleep efficiency will be assessed by wrist actigraphy, to be worn by the participants for 14 days, 14 days|Melatonin and Cortisol Rhythm, Melatonin and cortisol pattern (peak times of the levels, dim light melatonin onset) will be assessed from 24 hour blood sampling, 24 hours",University of Illinois at Chicago,36,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-02-03
NCT01232179,Comparison of Two Laser Therapy Methods for PDR,https://clinicaltrials.gov/study/NCT01232179,UNKNOWN,Proiriftrative Diabetic Retinopathy,PROCEDURE: conventional prp|PROCEDURE: targeted prp,"no leakage in widefield fluorescin angiography, 3 months after lasertraphy",Shahid Beheshti University of Medical Sciences,,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: |Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-10
NCT04800679,Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR,https://clinicaltrials.gov/study/NCT04800679,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: receive 4 monthly IVB injections and then rescue IVB|DRUG: PRP group|DRUG: IVB injections and a modified laser,"Extent of neovascular tissues in disc-diameter measured by investigator according to the wide-field FAG, Number of neovascular tissue counted by investigator according to FAG, 12 months",Shahid Beheshti University of Medical Sciences,105,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-01
NCT00999791,Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00999791,UNKNOWN,Diffuse Diabetic Macular Edema,DRUG: Bevacizumab|DRUG: Diclofenac,,Shahid Beheshti University of Medical Sciences,,INTERVENTIONAL,Allocation: |Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT,2009-07
NCT02857491,Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02857491,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: ranibizumab|DRUG: sham|PROCEDURE: pars plana vitrectomy,"perioperative hemorrhage of the surgical eye, 3 month",Sun Yat-sen University,90,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-07
NCT03832179,Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification,https://clinicaltrials.gov/study/NCT03832179,RECRUITING,Diabetic Macular Edema|Cataract,DRUG: Bevacizumab|DRUG: Ranibizumab|DRUG: Aflibercept|DRUG: Ozurdex,"Comparison of central foveal thickness outcomes of anti-vascular endothelial growth factor vs. Ozurdex therapy, Central foveal thickness will be measured in microns by spectral domain optical coherence tomography (Heidelberg) and compared to baseline at post-operative week 1, postoperative month 1, postoperative month 2, and postoperative month 3 for both anti-vascular endothelial growth factor and Ozurdex groups, 3 months after cataract surgery",Bay Area Retina Associates,32,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-11-15
NCT03594591,Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes,https://clinicaltrials.gov/study/NCT03594591,UNKNOWN,Type 2 Diabetes Mellitus|Microangiopathy|Diabetic Retinopathy|Arteriosclerosis|Carotid Atherosclerosis,DRUG: Antidiabetic treatment by usual care,"Changes in retinal microcirculation (perifoveal vessel density), Changes in perifoveal vessel density, OCTA images will be processed to obtain vascular density measurements in this area (mm-1), 0, 1, 3 and 6 months|Changes in arterial wall microcirculation (vasa-vasorum density), Changes vasa-vasorum (VV) density, VV signal as the ratio of the contrast agent signal of the VV and that of the lumen of the artery, 0, 3 and 6 months",Hospital Clinic of Barcelona,20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-02
NCT01909791,Treatment for CI-DME in Eyes With Very Good VA Study,https://clinicaltrials.gov/study/NCT01909791,COMPLETED,Diabetic Macular Edema,PROCEDURE: Prompt Laser|DRUG: Prompt aflibercept|PROCEDURE: Deferred laser|DRUG: Deferred aflibercept,"Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline, Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/12) to 0 letters (Snellen equivalent of 20/800)., 2 years",Jaeb Center for Health Research,702,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-10
NCT03551808,Prophylactic Effect of Ketorolac Tromethamine on the Cystoid Macular Edema After Phacoemulsification in Diabetic Patients,https://clinicaltrials.gov/study/NCT03551808,UNKNOWN,Cystoid Macular Edema After Phacoemulsification,DRUG: using of Ketorolac Tromethamine Eye Drop,"Best Corrected visual acuity, Snellen visual acuity chart, 24 weeks after the surgery",Shahid Beheshti University of Medical Sciences,102,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2017-01-01
NCT02712008,Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02712008,COMPLETED,Diabetic Macular Edema,DRUG: REGN910-3|DRUG: Intravitreal Aflibercept Injection (IAI),"Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12, Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12., Baseline, Week 12|Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36, Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 36., Baseline, Week 36",Regeneron Pharmaceuticals,302,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03-02
NCT03571139,Detecting the Influence of Cataract Surgery on the Development of Diabetic Retinopathy in Patients With Diabetes Mellitus Type 2 With and Without Diabetic Retinopathy Using OCT Angiography,https://clinicaltrials.gov/study/NCT03571139,UNKNOWN,Diabetic Retinopathy,DEVICE: Phacoemulsification,"Detecting changes in the retinal vascular plexuses and choriocapillaris after cataract surgery in type 2 diabetes mellitus patients with and without diabetic retinopathy using OCT angiography., Changes in the retinal vascular plexus, superficial and deep vessel density, foveal avascular zone area, circularity and any developing microaneurysms and areas of retinal ischemia will be measured to see the influence of cataract surgery on diabetic retinopathy., 1 month",Cairo University,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-01
NCT03056079,Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept,https://clinicaltrials.gov/study/NCT03056079,RECRUITING,Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion|Macular Edema,DRUG: Intravitreal aflibercept,"Association between cytokine levels and optimal treatment interval, Optimal interval between injections based on aqueous cytokine levels, 18 months",Unity Health Toronto,168,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-02-28
NCT03112005,Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool,https://clinicaltrials.gov/study/NCT03112005,COMPLETED,Diabetic Retinopathy|Diabetic Eye Problems|Diabetic Macular Edema,PROCEDURE: Color fundus photography|DRUG: Mydriatic Agent,"Number of subject eyes whose EyeArt results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME)., The performance of EyeArt will be evaluated using sensitivity and specificity measures., 1 visit (1 day)|Number of subject eyes whose EyeArt results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME)., The performance of EyeArt will be evaluated using sensitivity and specificity measures., 1 visit (1 day)","Eyenuk, Inc.",942,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-17
NCT05989126,Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS),https://clinicaltrials.gov/study/NCT05989126,NOT_YET_RECRUITING,Diabetic Macular Edema (DME)|Neovascular Age-Related Macular Degeneration (nAMD),DRUG: aflibercept 8 mg PFS,"Number of 8 mg aflibercept injections successfully administered utilizing the PFS, Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS., At Day 1",Regeneron Pharmaceuticals,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-01-09
NCT03246152,Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA,https://clinicaltrials.gov/study/NCT03246152,COMPLETED,Diabetic Macular Edema|Ischemic Maculopathy,DRUG: Bevacizumab,"FAZ Area Change, Effect of repeated intravitreal Anti-VEGF injections on Foveal Avascular Zone (FAZ) area measured using the freehand tool of ImageJ, At baseline and after 3-6 consecutive monthly injections.|Macular Capillary Density Change at Full Retinal Thickness, Effect of repeated intravitreal Anti-VEGF injections on macular capillary density using the change in the skeletonized vascular density and fractal dimension measured by ImageJ, At baseline and after 3-6 consecutive monthly injections.",Cairo University,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-10-23
NCT04468152,Advanced Glycation End Products Are Associated With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04468152,COMPLETED,"Diabetic Macular Edema|Diabetes Mellitus, Type 2",BEHAVIORAL: Dietary habits and intake,"We hypothesize that the AGEs levels of the DME group would found be higher than in the control group., The serum samples collected during the research were delivered to the laboratory while preserving the cold chain. The enzyme-labelled immune ""Enzyme-Linked Immunosorbent Assay (ELISA)"" test was performed with biologists of the company using a Biotek 800TS device. While analyzing the samples, Human CML Elisa Kit 96 tests for serum AGE is used. Carboxymethyl lysine (CML) was considered as the AGE parameter, being the most easily detected and the most abundant type of AGE in humans. The minimum detectable dose of CML in humans is typically less than 15.6 pg/ml., 3 months|We hypothesize that the dietary intake of AGEs wolud be higher in the DME group., The dietary intake of participants was assessed using a validated quantitative food frequency questionnaire (QFFQ). The total food intake was then converted to total nutrient intake based on the food's nutrient profile. Standardized food recipes for Turkey and the Nutrition Information System (BEBIS) program, which is a food composition database for nutrient estimation, were used to determine the average daily energy and nutrient intake for each participant. These values were subsequently compared with the recommended daily allowance values to determine the status of meeting energy and nutrient requirements. After that, the percentages meeting the requirements were calculated. Meanwhile, to assess dietary AGEs from the QFFQ, each food's contribution to dAGEs intake was calculated based on the Advance Glycation End Products in Foods Table published by the Uribarri et al., 1 month|We hypothesize that neck circumference correlated significantly with DME., The neck circumference of the participants will be measured by the researcher Sedat Arslan with a calibrated tape measure on a centimeter scale., 1 month",Hacettepe University,90,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2018-07-07
NCT04795726,"A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)",https://clinicaltrials.gov/study/NCT04795726,COMPLETED,Diabetic Retinopathy,DRUG: Finerenone (BAY94-8862)|DRUG: Placebo,"Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR), Progression of non-proliferative diabetic retinopathy (NPDR) defined by the occurrence of vision-threatening events i.e. proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), anterior segment neovascularization (ASN) until the end of Year 2 after start of treatment, After start of treatment until end of Year 2",Bayer,70,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2021-03-10
NCT03790852,"Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO",https://clinicaltrials.gov/study/NCT03790852,TERMINATED,Wet Age-related Macular Degeneration|Retinal Vein Occlusion|Diabetic Macular Edema,DRUG: KSI-301,"Incidence of ocular (study eye) and systemic adverse events, Week 72",Kodiak Sciences Inc,121,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-12-26
NCT05417152,Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients,https://clinicaltrials.gov/study/NCT05417152,COMPLETED,Diabetic Retinopathy,,"NVHO Total Retinal Fluid (TRF), volume (nl) measured by NOA (automatic OCT analyzer), 5 minutes|NVHO Intra-Retinal Fluid (IRF), volume (nl) measured by NOA (automatic OCT analyzer), 5 minutes|NVHO Sub-Retinal Fluid (SRF), volume (nl) measured by NOA (automatic OCT analyzer), 5 minutes|Zeiss Cirrus OCT Total Retinal Fluid (TRF), volume (nl) measured by a human reader, 10 minutes|Zeiss Cirrus OCT Intra-Retinal Fluid (IRF), volume (nl) measured by a human reader, 10 minutes|Zeiss Cirrus OCT Sub-Retinal Fluid (SRF), volume (nl) measured by a human reader, 10 minutes|Scanning session completion status, complete/incomplete, 5 minutes",Notal Vision Inc.,18,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-29
NCT00123279,Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy,https://clinicaltrials.gov/study/NCT00123279,COMPLETED,Vitreomacular Traction Maculopathy|Eye Diseases,DRUG: Microplasmin,"Grade of Posterior Vitreous Detachment (PVD) preoperatively and release of vitreomacular traction, Baseline, 1,2 and 3hr, 1, 3, 14, 28, 90 and 180 Days",ThromboGenics,60,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2004-12
NCT00647439,Genetics and Markers of Degenerative and Inflammatory Eye Diseases,https://clinicaltrials.gov/study/NCT00647439,COMPLETED,Diabetic Retinopathy|Age-Related Macular Degeneration (AMD)|Uveitis,,,National Eye Institute (NEI),609,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-03-27
NCT05727891,Evaluation of Tonabersat for DME,https://clinicaltrials.gov/study/NCT05727891,RECRUITING,Diabetic Macular Edema,DRUG: Tonabersat|OTHER: Placebo,"Mean change in central subfield thickness, 6 months",Jaeb Center for Health Research,128,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-02
NCT00050479,Laser and Medical Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00050479,COMPLETED,Macular Degeneration,DRUG: Celecoxib (Celebrex),,National Eye Institute (NEI),100,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2002-12
NCT02080091,Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies,https://clinicaltrials.gov/study/NCT02080091,TERMINATED,Diabetic Macular Edema (DME),,"Visual Acuity, Observed and change from baseline visual acuity LogMAR scores will be summarized using descriptive statistics., 24 Months|Number of Patients With Ocular Adverse Events, 24 Months",Alimera Sciences,25,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-12
NCT02359526,A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients,https://clinicaltrials.gov/study/NCT02359526,COMPLETED,Diabetic Macular Edema,DRUG: IlUVIEN,"Changes in best-corrected visual acuity (BCVA) from baseline to Month-12, Baseline to 12 months|Changes in central retinal thickness assessed using spectral domain optical coherence tomography (SD-OCT) from baseline to Month-12, Baseline to 12 months|Occurrence of Adverse events, namely cataract and elevated IOP, 12 months",Association for Innovation and Biomedical Research on Light and Image,12,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-10
NCT03755752,Safety of Trypan Blue on Endothelium of Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT03755752,COMPLETED,Cataract Diabetic,PROCEDURE: Phacoemulsification with and without Trypan Blue capsule staining,"Endothelial cell density, 4 weeks",Assiut University,65,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2018-01-01
NCT00704652,Evaluation of Retinal Changes in Systemic Darbepoetin Alpha Treatment in Patients With Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00704652,TERMINATED,Diabetic Retinopathy,,"Morphologic changes in the retina detected by HD-OCT following darbepoetin alpha therapy compared to control patients, 9 month",Medical University of Vienna,5,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-05
NCT02633852,Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02633852,COMPLETED,Diabetic Macular Edema (DME),DRUG: Aflibercept,"macular thickness changes, Assess macular thickness changes following second line therapy with aflibercept using treat-and-extend algorithm, At week 52",Hadassah Medical Organization,48,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-05-24
NCT03794752,Visual Enhancement Device in Low Vision Patients,https://clinicaltrials.gov/study/NCT03794752,TERMINATED,"Macular Degeneration, Age-Related|Diabetic Retinopathy",DEVICE: Head-Mounted Visual Enhancement Device,"Best Corrected Visual Acuity (BCVA) With the Head-mounted Electronic Visual Enhancement Device, ETDRS chart will be used to assess best corrected visual acuity. The outcome with the participant using head-mounted electronic visual enhancement device.

The single visit, prospective, non-randomized study of low vision individuals diagnosed with Age Related Macular Degeneration or Diabetic macular edema research project is designed to last about 1.5 hours., 5 minutes post intervention|Best Corrected Near Visual Acuity (BCNVA) With the Head-mounted Electronic Visual Enhancement Device, ETDRS chart will be used to assess best corrected visual acuity. The outcome with the participant using head-mounted electronic visual enhancement device.

A single visit, prospective, non-randomized study of low vision individuals diagnosed with Age Related Macular Degeneration or Diabetic macular edema research project is designed to last about 1.5 hours., 10 minutes post intervention|Number of Participants Completing/Not Completing the Reading Assessments With the Head-mounted Electronic Visual Enhancement Device, Reading completion with head-mounted electronic visual enhancement device was measured by reading a standard paragraph from 3-Minute Reading Assessments by Rasinski TV and Padak N, 2005. Scholastic Inc., NY., Day 1 up to 6 minutes post intervention|Number of Participants Able/Unable to Identify Facial Expressions With the Head-mounted Electronic Visual Enhancement Device., Face sheet and video are shown to the subject to identify facial expression and time taken is recorded. Change in response speed to identify facial expressions using the head-mounted electronic visual enhancement device.

A single visit, prospective, non-randomized study of low vision individuals diagnosed with Age Related Macular Degeneration or Diabetic macular edema research project is designed to last about 1.5 hours., Day 1 up to 1 minute post intervention|Response Speed to Visual-motor Skills to Identify Shapes and Objects With the Head-mounted Electronic Visual Enhancement Device, Portable shelf storage is placed at 5-feet distance and time taken to identify shapes and objects is recorded with the head-mounted electronic visual enhancement device.

A single visit, prospective, non-randomized study of low vision individuals diagnosed with Age Related Macular Degeneration or Diabetic macular edema research project is designed to last about 1.5 hours., Initial Baseline and 3 minutes",University of Texas Southwestern Medical Center,8,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2015-02
NCT04240652,"The Diabetic Retinopathy Screening, Prevention and Control Program",https://clinicaltrials.gov/study/NCT04240652,RECRUITING,Diabetic Retinopathy,,"Diabetic retinopathy, diabetic retinopathy, through study completion, up to 20 years|Referable diabetic retinopathy, Referable diabetic retinopathy, through study completion, up to 20 years|Vision threatening diabetic retinopathy, Vision threatening diabetic retinopathy, through study completion, up to 20 years|Diabetic macular edema, Diabetic macular edema, through study completion, up to 20 years",Shanghai Jiao Tong University School of Medicine,500000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-05
NCT04611152,"A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT04611152,TERMINATED,Diabetic Macular Edema,DRUG: KSI-301|DRUG: Aflibercept|OTHER: Sham Procedure,"Changes in BCVA to Assess Non-inferiority of KSI-301 to Aflibercept., Demonstrate that KSI-301 5 mg is non-inferior to aflibercept 2 mg with respect to mean change in best corrected visual acuity (BCVA)., Day 1 to Year 1",Kodiak Sciences Inc,460,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-30
NCT05959304,Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.,https://clinicaltrials.gov/study/NCT05959304,NOT_YET_RECRUITING,Diabetic Macular Edema,OTHER: brolucizumab,"Incidence and characteristics of treatment-emergent adverse events during the 40 weeks of treatment with Brolucizumab., To evaluate ocular \& non-ocular safety of intravitreal brolucizumab in real-world patients with Diabetic Macular Edema (DME)., 40 weeks",Novartis Pharmaceuticals,66,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-12-27
NCT02297204,The Endurance 1 Trial,https://clinicaltrials.gov/study/NCT02297204,COMPLETED,Diabetic Macular Edema,PROCEDURE: Focal Laser Treatment|DRUG: aflibercept 2.0 mg,"Need for ongoing intravitreal aflibercept injections in the management of DME, To assess the need for ongoing intravitreal aflibercept injections for subjects who were enrolled and completed the 3-year VISTA DME (VGFT-OD-1009) trial and to characterize long-term efficacy and safety of aflibercept intravitreal injections in the management of DME by evaluating mean number of injections in 52 weeks and proportion of subjects receiving 0 (zero) injections in 52 weeks., 12 months",Northern California Retina Vitreous Associates,9,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2014-11
NCT05615805,The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections,https://clinicaltrials.gov/study/NCT05615805,COMPLETED,Intravitreal Injection|Ocular Rinse|Age-Related Macular Degeneration|Diabetic Macular Edema|Cystoid Macular Edema,OTHER: OSDI questionnaire|OTHER: SPEEDII questionnaire,"Ocular Surface Disease Index, Patient symptoms questionnaire, range 0-28, higher score is associated with worse outcome., 24-72 hours after injection",University of Oklahoma,142,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE",2021-03-01
NCT05919693,"A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)",https://clinicaltrials.gov/study/NCT05919693,RECRUITING,Neovascular Age-related Macular Degeneration (NVAMD)|Diabetic Macular Edema (DME),DRUG: EYE103,"Adverse Events, Adverse Events, 3 months",EyeBiotech Ltd.,92,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-12
NCT05452993,Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography,https://clinicaltrials.gov/study/NCT05452993,UNKNOWN,Diabetic Retinopathy|Artificial Intelligence|Diabetes Mellitus,DEVICE: Analysed Retinophotography,"diabetic retinopathy screening rate, The screening rate for diabetic retinopathy will be assessed in the 11 participating pharmacies and then compared to literature data (actual diabetic retinopathy screening rate = 64%)

The screening rate will be calculated as follows :

Number of patients screened(Arm 1)/(number of patients screened (Arm 1) + number of patients who refused screening or failed screening (Arm2)).

We hypothesise an improvement of 10 points (≥74%), approximately one year after study start","University Hospital, Caen",330,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-09
NCT04732208,Automated Screening of Diabetic Retinopathy Using a Smartphone-based Camera,https://clinicaltrials.gov/study/NCT04732208,COMPLETED,Diabetic Retinopathy,DIAGNOSTIC_TEST: Colour fundus photography,"Sensitivity and Specificity of the AI in detecting any grade of diabetic retinopathy in those with established diabetes mellitus (DM), 4 months",Tameside General Hospital,410,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-20
NCT00855608,"Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study",https://clinicaltrials.gov/study/NCT00855608,UNKNOWN,Uveitis|Diabetic Retinopathy|Choroidal Neovascularization,DRUG: adalimumab,"The main outcome measure will be visual acuity improvement (3 lines), 6 weeks",Rafic Hariri University Hospital,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-03
NCT03631108,Feasibility Study and Preliminary Application Study on Iris OCTA,https://clinicaltrials.gov/study/NCT03631108,UNKNOWN,"Conjunctivitis|Glaucoma|Myopia|Diabetic Retinopathy|Retinal Detachment|Retinal Neovascularization, Unspecified|Uveitis",DIAGNOSTIC_TEST: OCTA (ZEISS),"Iris Vessel Geometric Characteristics, Iris vascular density and neovascular density, 0:00 8:00 14:00 20:00",Shanghai Eye Disease Prevention and Treatment Center,4000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10
NCT00682539,Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00682539,COMPLETED,Diabetic Macular Edema,DRUG: Bevacizumab (Avastin)|DRUG: Triamcinolone|DRUG: Sham|PROCEDURE: Lucentis,"Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts., Efficacy of the treatment with intravitreal administered injections of anti VEGF (Bevacizumab (Avastin®) or Ranibizumab (Lucentis®) ) compared with triamcinolone (Volon A®) in patients with diabetic macular edema is examined using Visual acuity measurements with ETDRS charts: units: logMAR; scale range: -0.1 to 1.0; higher values are considered worse outcome, 12 month|Efficacy of the Treatment Assessed by Standard Optical Coherence Tomography (OCT), Efficacy of the treatment with intravitreal administered injections of anti VEGF (Bevacizumab (Avastin®) or Ranibizumab (Lucentis®) ) compared with triamcinolone (Volon A®) in patients with diabetic macular edema is measured with standard Optical Coherence Tomography - (OCT): units: µm; scale range: 200-800; higher values are considered worse outcome, 12 months",Medical University of Vienna,71,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2007-10
NCT00997191,Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA),https://clinicaltrials.gov/study/NCT00997191,COMPLETED,Diabetic Macular Edema,PROCEDURE: Laser photocoagulation|DRUG: Intravitreal triamcinolone|DRUG: Intravitreal bevacizumab,"Best Corrected Visual acuity, One Year",University of Sao Paulo,12,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-10
NCT00406991,Retinal Blood Flow and Microthrombi in Type 1 Diabetes,https://clinicaltrials.gov/study/NCT00406991,COMPLETED,Diabetes|Diabetic Retinopathy,DRUG: aspirin|DRUG: clopidogrel,Retinal blood flow,Schepens Eye Research Institute,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: DIAGNOSTIC,2003-06
NCT04690608,Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema and CRVO,https://clinicaltrials.gov/study/NCT04690608,NOT_YET_RECRUITING,Retinal Edema,"DRUG: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1","Improvement of central macular thickness, Reduction of the central macular thickness below 300 um, 1 month",Tanta University,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-01
NCT03238963,"A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.",https://clinicaltrials.gov/study/NCT03238963,COMPLETED,Diabetic Retinopathy,DRUG: BI 1467335|DRUG: Placebo,"Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period, Percentage of participants with any ocular adverse events over the on-treatment period was reported., On-treatment period: from first dose of study drug until end of follow-up period, up to 24 weeks.",Boehringer Ingelheim,79,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-09-19
NCT01476449,Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema,https://clinicaltrials.gov/study/NCT01476449,COMPLETED,Diabetic Retinopathy|Macular Edema,DRUG: Ranibizumab|DRUG: Ranibizumab,"Mean Change in Early Treatment for Diabetic Retinopathy Study (ETDRS) Eye Chart Vision., The ETDRS eye chart was used to assess vision at each visit, with the change through month 24 reported., Baseline through 24 months",Retina Vitreous Associates of Florida,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-11
NCT01746563,Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01746563,COMPLETED,Diabetic Retinopathy|Retinal Diseases|Eye Diseases|Diabetic Angiopathies|Vascular Diseases|Cardiovascular Diseases,DRUG: Ranibizumab|PROCEDURE: Laser therapy,"Macular Evaluation, Changes between visual acuity from baseline to month 6., 6 Months",University of Sao Paulo,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2011-05
NCT00496405,Unilateral Bevacizumab for Bilateral Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00496405,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy,DRUG: bevacizumab,"Retinal thickness, Interventional",Asociación para Evitar la Ceguera en México,13,INTERVENTIONAL,"Allocation: |Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: ",2007-04
NCT04089605,Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04089605,COMPLETED,Diabetic Macular Edema,DRUG: dexamethasone implant|DRUG: Ranibizumab,"BCVA at Month 6, best-corrected visual acuity (BCVA) at the end of intervention, Month 6|CFT at Month 6, central foveal thickness (CFT) at the end of intervention, Month 6",Far Eastern Memorial Hospital,48,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-06-01
NCT04387604,Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04387604,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS],"assess the number of IV injections needed to control DME between groups, DME control is defined as 1) BCVA of 85 letters and OCT CFT ""normal"" (CFT≤300 μm and non-existent intra- or sub-retinal fluid); or 2) OCT CFT ""normal"" (CFT≤300 μm) and stable BCVA (defined as \<5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CFT ""normal"" and stable BCVA)., 18 months",Centro Hospitalar do Porto,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-01
NCT02718326,Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR),https://clinicaltrials.gov/study/NCT02718326,COMPLETED,Nonproliferative Diabetic Retinopathy,DRUG: Intravitreal aflibercept injection [IAI]|DRUG: Sham,"Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups, The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24 from baseline., At Week 24|Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline, The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Severity range from level 10 (DR absent) to level 85 (advanced proliferative DR: posterior fundus obscured, or center of macula detached). Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 52 from baseline., At Week 52",Regeneron Pharmaceuticals,402,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03-29
NCT05695417,"Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT05695417,ACTIVE_NOT_RECRUITING,Non-proliferative Diabetic Retinopathy,DRUG: OTX-TKI|DRUG: Sham,"Safety and Tolerability, Frequency of treatment emergent adverse events, Baseline up to Week 52","Ocular Therapeutix, Inc.",21,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-01-15
NCT02871817,A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools,https://clinicaltrials.gov/study/NCT02871817,UNKNOWN,Age - Related Macular Degeneration|Diabetic Retinopathy|Metamorphopsia,OTHER: Paxos Checkup Study Mobile Medical Application,"Near Corrected Visual Acuity, Corrected Near Visual Acuity (CNVA) assessed with the Checkup System will be compared to the reference method CNVA (Lebensohn Near Card) in replicated measurements at each of two in-office visits., Eight weeks|Amsler Grid, The Amsler Grid assessment with the Checkup will be compared to the reference method Amsler Grid in replicated measurements at each of two in-office visits, Eight weeks","Digisight Technologies, Inc.",143,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-07
NCT01220804,Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT01220804,COMPLETED,Diabetic Retinopathy,,"Optical reflectivity as measured by optical coherence tomography, To analyse OCT reflectivity distribution between areas with and without fluorescein leakage in type 2 diabetic eyes. In previous studies our group found differences, when comparing the histograms of the optical reflectivity distribution, suggesting that the optical reflectivity, as measured by OCT, may change under BRB alterations, 14 months",Association for Innovation and Biomedical Research on Light and Image,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-11
NCT00105404,Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation,https://clinicaltrials.gov/study/NCT00105404,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema|DME,DRUG: Triamcinolone Acetonide,,National Eye Institute (NEI),5,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2005-03-09
NCT04278417,Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04278417,ACTIVE_NOT_RECRUITING,Proliferative Diabetic Retinopathy,BIOLOGICAL: Brolucizumab 6 mg|PROCEDURE: Panretinal photocoagulation laser,"Change from Baseline in BCVA, To demonstrate that brolucizumab is non-inferior to PRP with respect to the change from Baseline in visual acuity at Week 54, At Week 54",Novartis Pharmaceuticals,694,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-11-19
NCT04637217,Retinal Neurodegenerative and Vascular Changes in Diabetic Patients,https://clinicaltrials.gov/study/NCT04637217,COMPLETED,Diabetic Retinopathy|Neurodegeneration,DIAGNOSTIC_TEST: Optical Coherence Tomography,"Correlation between choroid and outer retina using SD-OCT- based binarization technique, starting from EDI-OCT scans the investigators will analyze choroidal parameters such as Luminal area, Stromal area, Total choroidal area, Chorodial vascularity index and correlate them with retinal pigment epithelium (RPE),outer nuclear layer(ONL) and photoreceptors' thickness (PR), 2018-2019|Correlation between neurodegeneration and retinal vessels characteristics, using full width at half maximum method, the investigators will measure peripapillary arteries and veins' diameters, their wall thickness and correlate them with RNFL and ganglion cell layer(GCL) thickness, 2018-2019",Iuliu Hatieganu University of Medicine and Pharmacy,97,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-01
NCT05642793,Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients,https://clinicaltrials.gov/study/NCT05642793,RECRUITING,Proliferative Diabetic Retinopathy,DRUG: proactive Anti-VEGF (conbercept) use|DRUG: passive Anti-VEGF (conbercept) use,"rate of postvitrectomy complication, postvitrectomy DME, VH (recurrent or nonabsorbent), NVG, 6 months",Peking University Third Hospital,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-04-01
NCT01892163,Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone,https://clinicaltrials.gov/study/NCT01892163,COMPLETED,Diabetic Macular Edema,DEVICE: Ozurdex,"The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months, Baseline and 12 months",Moorfields Eye Hospital NHS Foundation Trust,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-03
NCT02834663,Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02834663,COMPLETED,Nonproliferative Diabetic Retinopathy,DRUG: Lucentis,"The Best Corrected Visual Acuity (BCVA), BCVA was performed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline and 6 months. The BCVA compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline), 6 months|Central Macular Thickness(CMT), CRT was performed using OCT at each visit. The OCT measured at each visit was analyzed statistically. the CMT compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline), 6 months",Wonkwang University Hospital,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2016-08
NCT02625649,Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients,https://clinicaltrials.gov/study/NCT02625649,COMPLETED,Type 2 Diabetes Mellitus|Obesity|Diabetic Retinopathy|Diabetic Nephropathy,,"Number of patients with HbA1c<48 mmol/mol., Maximum follow-up is 121 months (january 2006-february 2016)",University of Aarhus,148,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01
NCT01950663,RETeval Study for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01950663,COMPLETED,Diabetic Retinopathy,DEVICE: RETeval,"Per Patient Referral Accuracy, Accuracy will be reported as count of participants with referral status correctly identified, sensitivity, and specificity, with ETDRS photography and reading as the gold standard., During a single visit, implicit time, measured by the RETeval device, and ETDRS photography, will be performed to support the analysis of the accuracy of the RETeval device.",Inoveon Corporation,468,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-09
NCT01478763,Vitrous Analysis in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01478763,COMPLETED,Proliferative Diabetic Retinopathy,,,Anders Kvanta,200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01
NCT01627249,"Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT01627249,COMPLETED,Diabetic Macular Edema,DRUG: 2.0 mg intravitreal aflibercept|DRUG: 1.25 mg intravitreal bevacizumab|DRUG: 0.3 mg intravitreal ranibizumab,"Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year, Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best., Baseline to 1-year|Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score <69, Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best., Baseline to 1-year|Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score 78-69, Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best., Baseline to 1-year",Jaeb Center for Health Research,660,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2012-08
NCT01698749,"Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT01698749,COMPLETED,"Diabetic Macular Edema|Macular Edema, Cystoid|Vision Disorders|Clinically Significant Macular Edema",DRUG: long acting intravitreal dexamethasone implant,"change in central macular thickness, The primary outcome is the change in the central macular thickness, either an increase or decrease, as measured by optical coherence tomography as compared to baseline central macular thickness, Baseline and 6 months",Postgraduate Institute of Medical Education and Research,61,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-12
NCT00720317,Diabetic Retinopathy and Sickle Trait,https://clinicaltrials.gov/study/NCT00720317,COMPLETED,Diabetic Retinopathy|Sickle Cell Trait,,"We aim to screen African-American diabetic patients with retinopathy to ascertain whether sickle trait is present, and if so whether there is increased severity of diabetic retinopathy in the group with sickle trait., One Year",Medical University of South Carolina,48,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-05
NCT00403026,Intravitreal Bevacizumab for Retinal Disorders,https://clinicaltrials.gov/study/NCT00403026,UNKNOWN,Wet AMD|Macular Oedema|Proliferative Diabetic Retinopathy,DRUG: Bevacizumab ( Avastin),"Vision change|Anatomical changes (Regression of NVE, CNVM, reduction in macular thickness)|Electrophysiological changes (ERG, VEP)",Narayana Nethralaya,150,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-08
NCT00782717,A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT00782717,COMPLETED,Macular Edema,"DRUG: Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|OTHER: Nepafenac ophthalmic suspension vehicle|DRUG: Prednisolone acetate ophthalmic suspension (OMNIPRED)","Percent of Patients Who Developed Macular Edema (ME) Within 90 Days Following Cataract Surgery, Macular edema (thickening of the center of the back of the eye) was defined as 30% or greater increase from pre-operative baseline measurement in central subfield macular thickness as measured using Optical Coherence Tomography(OCT)., 3 Months",Alcon Research,263,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2008-11
NCT04101604,Biomarkers of Common Eye Diseases,https://clinicaltrials.gov/study/NCT04101604,UNKNOWN,Uveitis|Diabetic Retinopathy|Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy|VKH Syndrome|Behçet Disease,OTHER: Collection of blood samples,"Peripheral blood mononuclear cell (PBMC) signatures, PBMC signatures, derived from single cell sequencing and mass spectrometry, will be compared for the same patient before and after treatment, among patients of different symptoms and severity measures, and also between patients and healthy subjects. Upon these comparisons, biomarkers will be established for the patient population., 1 year",Sun Yat-sen University,220,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-26
NCT05566717,An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity,https://clinicaltrials.gov/study/NCT05566717,RECRUITING,Diabetic Retinopathy|Neurotrophic Keratitis,,"Primary Endpoint, • To associate the Diabetic Retinopathy Severity Scale level 3 or higher (as confirmed by masked reading center) with the level of decreased corneal sensitivity in patients with Type 1 and Type 2 diabetes, 3months",Medical Center Ophthalmology Associates,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-07-01
NCT02875704,"Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT02875704,TERMINATED,Stargardt Disease|Diabetic Retinopathy|Macular Degeneration (Age Related),OTHER: Anterior Chamber (AC) Tap,"Aqueous levels of oxidized adducts on protein (i.e. oxidative biomarker) in patients with stargardt disease, AMD, DR and controls, Baseline = Day of clinic visit for stargardt disease, AMD, DR patients and day of surgery for patients undergoing cataract surgery. No follow up is required., Baseline",Johns Hopkins University,77,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-03
NCT03571217,Shanghai Beixinjing Diabetic Eyes Study,https://clinicaltrials.gov/study/NCT03571217,RECRUITING,Diabetic Retinopathy|Visual Impairment|Diabetic Maculopathy,,"Diabetic retinopathy, The DR grades are according to the well-accepted ''International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scale'', December 31，2024|mild visual impairment, Mild visual impairment was present if BCVA was \< 20/25 but ≥ 20/63., December 31，2024|macular choriocapillaris vessel density(MCVD), macular choriocapillaris vessel density, December 31，2024|glycosylated hemoglobin, This test measures the average blood sugar control for the previous three months or so., December 31，2024|retinal thickness (RT), Retinal thickness was defined as the distance from the internal limiting membrane to the interface of the photoreceptor outer segments and retinal pigment epithelium., December 31，2024|choroidal thickness (CT), Choroidal thickness was measured from the outer border of the RPE to the inner border of the choroidoscleral interface., December 31，2024",Shanghai Eye Disease Prevention and Treatment Center,2500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-10-01
NCT00665106,"Safety and Tolerability of NOVA63035 ""Corticosteroid"" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT00665106,COMPLETED,Diabetic Macular Edema,"DRUG: NOVA63035 ""Corticosteroid""","Ocular safety, Over one year",Santen SAS,20,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2008-04
NCT04505306,Short-pulse Subthreshold vs Infrared Micropulse for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04505306,COMPLETED,Diabetic Macular Edema,PROCEDURE: Macular Laser,"Central foveal thickness, All patients had central retinal thickness measurement using spectral-domain optical coherence tomography (SD-OCT)(Spectralis, Heidelberg Engineering, Heidelberg, Germany). The SD-OCT B-scan was based on the Spectralis macular raster consisting of 19 horizontals 6 millimeter line scans and a real-time eye tracking system., 6 months|Best corrected visual acuity, ETDRS visual acuity charts, 6 months",Moorfields Eye Hospital Centre Abu Dhabi,113,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2015-01-01
NCT02077127,Monocyte Chemoattractant Protein-1 2518A/G Polymorphism,https://clinicaltrials.gov/study/NCT02077127,COMPLETED,Diabetic Retinopathy,,"Genetic association, age at diagnosis of diabetes ≥30 years and a known duration of diabetes of ≥5 years., 1 year",Harbin Medical University,1043,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-09
NCT04418427,ADVM-022 Intravitreal Gene Therapy for DME,https://clinicaltrials.gov/study/NCT04418427,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy,BIOLOGICAL: 6E11 vg/eye of ADVM-022|BIOLOGICAL: 2E11 vg/eye of ADVM-022|BIOLOGICAL: Aflibercept,"Time to worsening of DME disease activity in the study eye., Time to worsening of DME disease activity in the study eye., 96 weeks","Adverum Biotechnologies, Inc.",36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05-28
NCT03135327,Clinical Applications of Advanced Ophthalmic Imaging,https://clinicaltrials.gov/study/NCT03135327,RECRUITING,Multiple Sclerosis|Dry Eye Syndromes|Diabetic Retinopathy|Presbyopia|Myopia|Dementia,DIETARY_SUPPLEMENT: Ocufolin,"Retinal microstructure using OCT., Optical coherence tomography is used to measure the thickness of intraretinal layers. The measurement is in micrometer., up to 2 years|Retinal vasculature by optical coherence tomography angiography (OCTA), Retinal vascular network density in percentage., up to 2 years|Conjunctival vasculature by functional slit-lamp (FSLB), Conjunctival vascular network density in percentage., up to 2 years|Corneal epithelial thickness, Measured in micrometers using ultra high resolution OCT, up to 2 years|Tear film thickness, Measured in micrometers using ultra high resolution OCT, up to 2 years",University of Miami,5000,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2007-01-01
NCT03478306,Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm,https://clinicaltrials.gov/study/NCT03478306,COMPLETED,"Diabetic Retinopathy|Melatonin|Circadian Dysrhythmia|Circadian Rhythm Sleep Disorder, Unspecified Type",DRUG: Melatonin 4 mg Tablet,"Progression of diabetic retinopathy, oscillary potential, Progression of diabetic retinopati measured with electroretinography, 3 weeks","Glostrup University Hospital, Copenhagen",31,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-03-27
NCT05140304,Analysis of FAZ in Diabetic Retinopathy Using OCT Angiography,https://clinicaltrials.gov/study/NCT05140304,UNKNOWN,Diabetic Retinopathy,DEVICE: OCT angiography,"Mean area of FAZ in various stages of diabetic retinopathy and difference between these groups in superficial and deep capillary plexuses, analysis of foveal avascular zone in different stages of diabetic retinopathy using OCT angiography, baseline",Kareem Mohammad Ali,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-11-30
NCT03113006,The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study (TREAT),https://clinicaltrials.gov/study/NCT03113006,COMPLETED,Proliferative Diabetic Retinopathy|PDR|Diabetes,PROCEDURE: Panretinal Photocoagulation,"Need for retreatment between the groups, Change in the progression of PDR, hence the difference in the need for retreatment between the standard laser treatment group vs. the individualized laser treatment group., At month 3 and 6|Loss of visual fields between the groups, Loss of visual field between the standard laser treatment group vs. the individualized laser treatment group., From baseline to month 6|Change in dark adaptation between the groups, Change in dark adaptation between the standard laser treatment group vs. the individualized laser treatment group., From baseline to month 6|Sensitivity and specificity of OCT angiography as an expression of disease activity in PDR, The specificity and sensitivity of OCT-A in detecting progression in PDR, At month 6",Odense University Hospital,53,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-05-01
NCT00687804,A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study,https://clinicaltrials.gov/study/NCT00687804,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|PROCEDURE: Laser|PROCEDURE: Sham laser|DRUG: Sham to ranibizumab,"Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12, Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters., Baseline through the end of study (Month 12)|Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study, Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.

Additional information about adverse events can be found in the Adverse Event section., Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]|Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study, Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant.

Additional information about adverse events can be found in the Adverse Event section., Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]",Novartis,345,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-05
NCT02302079,A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02302079,COMPLETED,Diabetes Mellitus|Diabetic Macular Edema,DRUG: ASP8232|DRUG: ranibizumab|DRUG: Placebo|OTHER: Sham intravitreal (IVT) injection,"Percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT) at Month 3, Baseline and Month 3",Astellas Pharma Europe B.V.,96,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-01-12
NCT05600179,OCTA in Epivascular Glia After Dex Implant,https://clinicaltrials.gov/study/NCT05600179,COMPLETED,Diabetic Retinopathy,DRUG: Dexamethasone intravitreal implant,"Changes in epivascular glia after Dexamethasone implant in patients with diabetic retinopathy and inflammatory macular edema, up to 6 months",Federico II University,38,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-01
NCT00668239,Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser,https://clinicaltrials.gov/study/NCT00668239,COMPLETED,Macular Edema,DRUG: intravitreous triamcinolone|PROCEDURE: laser therapy,"diffuse macular oedema, 1, 3 and 6 months",Hospital de Clinicas de Porto Alegre,14,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-09
NCT06205979,Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents,https://clinicaltrials.gov/study/NCT06205979,RECRUITING,Diabetic Macular Edema,DRUG: Ranibizumab Injection [Lucentis]|DRUG: Aflibercept Injection [Eylea],"change in the best corrected visual acuity in meters, measure of the ability of the eye to distinguish shapes and the details of objects at a given distance with the help of corrective lenses, 2 months|change in the retina and macula measurements by Optical coherence tomography (OCT), assess the state of the retina and macula by measuring :

* Average Thickness in (μm), 2 months|change in the retina and macula measurements by Optical coherence tomography (OCT), assess the state of the retina and macula by measuring :

* Center thickness in (μm), 2 months|change in the retina and macula measurements by Optical coherence tomography (OCT), assess the state of the retina and macula by measuring :

* Total volume in (mm3), 2 months",Sohag University,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-12-12
NCT00035906,Research Study in Patients With Persistent Macular Edema,https://clinicaltrials.gov/study/NCT00035906,COMPLETED,"Diabetes|Macular Edema|Diabetic Retinopathy|Retinal Disease|Uveitis, Posterior",DRUG: DEX PS DDS®,,Allergan,315,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT,2001-10
NCT06181227,A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT06181227,RECRUITING,Diabetic Macular Edema|Diabetic Retinopathy,DRUG: AVD-104,"Safety of AVD-104, Number of participants with any evidence of adverse or serious adverse events as assessed by ocular examination, 3 months","Aviceda Therapeutics, Inc.",30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11-30
NCT00071227,Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders,https://clinicaltrials.gov/study/NCT00071227,COMPLETED,Macular Degeneration|Retinal Vein Occlusion,DRUG: Triamcinolone Acetonide (TAC-PF),,National Eye Institute (NEI),16,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2003-10-15
NCT00211406,Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg),https://clinicaltrials.gov/study/NCT00211406,TERMINATED,Diabetic Retinopathy,DRUG: Anecortave Acetate Sterile Suspension (15 mg),,"Manhattan Eye, Ear & Throat Hospital",,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,
NCT01614327,Computer-based Screening for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01614327,COMPLETED,Diabetic Retinopathy,,"Sensitivity and specificity of retinal screening for risk stratification of DR using digital fundus photographs with and without the assistance of the RiskAnalyzer., Using the gold standard, the sensitivity and specificity are calculated as:

Sens=TP/(TP+FN) Spec=TN/(TN+FP) Where TP is the number of true positives (DR subjects correctly classified), FN is the number of false negatives (DR subjects incorrectly classified as normal), TN is the number of true negatives (Normal subjects correctly classified), and FP is the number of false positives (Normal subjects incorrectly classified as abnormals)., 24 months",VisionQuest Biomedical LLC,19199,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-08
NCT04660006,Diabetic Retinopathy and OCT-A Changes Post-cataract Surgery,https://clinicaltrials.gov/study/NCT04660006,UNKNOWN,Cataract|Diabetic Retinopathy|Macular Edema Due to Diabetes Mellitus,PROCEDURE: Cataract surgery,"Change from baseline of retinal vessel density up to 3 months post-cataract surgery., Optical coherence tomography angiography (OCT-A) scans will be taken at baseline and postoperative week one, month one, and month three. This imaging modality provides measurements for retinal vessel density to be compared between groups and time., Preoperative (Baseline); Postoperative (1 Week, 1 Month, 3 Months)|Change from baseline of retinal perfusion density up to 3 months post-cataract surgery., Optical coherence tomography angiography (OCT-A) scans will be taken at baseline and postoperative week one, month one, and month three. This imaging modality provides measurements for retinal perfusion density to be compared between groups and time., Preoperative (Baseline); Postoperative (1 Week, 1 Month, 3 Months)|Change from baseline of foveal avascular zone up to 3 months post-cataract surgery., Optical coherence tomography angiography (OCT-A) scans will be taken at baseline and postoperative week one, month one, and month three. This imaging modality provides measurements for foveal avascular zone (FAZ), particularly FAZ area, perimeter, and circularity index, to be compared between groups and time., Preoperative (Baseline); Postoperative (1 Week, 1 Month, 3 Months)|Change from baseline of retinal thickness up to 3 months post-cataract surgery., Optical coherence tomography (OCT) scans will be taken at baseline and postoperative week one, month one, and month three. This imaging modality provides measurements of retinal thickness, particularly, central subfield and average macular cube thickness, to be compared between groups and time., Preoperative (Baseline); Postoperative (1 Week, 1 Month, 3 Months)",Uptown Eye Specialists,170,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-05-27
NCT01304706,Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study,https://clinicaltrials.gov/study/NCT01304706,COMPLETED,Diabetic Macular Edema,DRUG: Fluocinolone Acetonide,"Number of Participants With Adverse Events, This is a measurement of the number of subjects who experienced an adverse event and/or a serious adverse event during the trial., 12 months",Alimera Sciences,120,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-04
NCT00306904,Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00306904,COMPLETED,Diabetic Macular Edema,DRUG: bevasiranib,Change from baseline at the 12-week evaluation in macular edema as measured by optical coherence tomography.,"OPKO Health, Inc.",48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-01
NCT00799227,Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00799227,COMPLETED,Diabetic Macular Edema|Vitrectomy,DRUG: Dexamethasone,"Change From Baseline in Central Retinal Thickness in the Study Eye, Central retinal thickness is assessed in the study eye by Optical Coherence Tomography (OCT). OCT is a laser-based, noninvasive, diagnostic system that provides high-resolution, three-dimensional images of the retina from which retinal thickness can be measured. A negative change from baseline in retinal thickness indicates an improvement and a positive change from baseline indicates a worsening., Baseline, Week 26",Allergan,56,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-01-01
NCT04808804,Retinal Neurodegeneration In Type 2 Diabetes Mellitus Detected by Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT04808804,UNKNOWN,Retinal Neuropathy|Neurodegeneration,DIAGNOSTIC_TEST: Optical Coherence Tomography (OCT),"RNFL thickness, retinal nerve fiber layer (RNFL) will be evaluated, Baseline",Assiut University,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06
NCT02462304,To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02462304,UNKNOWN,Diabetic Macula Edema,PROCEDURE: End-Point-Management grid laser|DRUG: ranibizumab|DRUG: Bevacizumab,"Difference in number of anti-VEGF required, The number of injections of anti-VEGF required at the end of the 6 months period., 6 months",The University of Hong Kong,60,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-06
NCT02311504,Eye Screening in German Secondary Diabetes Care Centers,https://clinicaltrials.gov/study/NCT02311504,COMPLETED,Diabetic Retinopathy,DEVICE: OCT examination,"presence of diabetic retinopathy, day",University Hospital Tuebingen,831,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT04271709,Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT),https://clinicaltrials.gov/study/NCT04271709,ACTIVE_NOT_RECRUITING,Glaucoma|Vision Impairment and Blindness|Cataract|Diabetic Retinopathy|Eye Diseases,BEHAVIORAL: Enhanced Intervention Using Patient Navigators|OTHER: Usual Care,"Proportion of Subjects with Visual Acuity Worse than 20/40, Visual acuity (VA) is a measure of the spatial resolution of the visual processing system. Visual acuity will be measured in each eye and measured as ≤20/40 or \>20/40. Since there are two best corrected distance visual acuity measurements per person (right eye and left eye), the visual acuity in the worse eye will be used in the analysis and reported at the patient level, rather than the eye level. Visual acuity analysis will be handled as a dichotomous variable and the proportion of subjects with visual acuity 20/40 or worse will be considered abnormal., 2 years",Columbia University,749,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2019-09-30
NCT01552408,Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE),https://clinicaltrials.gov/study/NCT01552408,COMPLETED,Diabetic Macular Edema,DRUG: 0.3 mg ranibizumab|PROCEDURE: Targeted Pan Retinal Photocoagulation,"Total Number of Ranibizumab Injections in Each of the Two Cohorts in a 36 Month Period, Assess the number of ranibizumab injections in the ranibizumab and targeted panretinal photocoagulation (PRP) with ranibizumab cohorts through Month 36., 36 Months|Mean Change Over Time in Early Treatment Diabetic Retinopathy Study Best Corrected Visual Acuity (ETDRS BCVA) Through Month 36, Evaluate the mean change over time in ETDRS BCVA in the ranibizumab and targeted PRP with ranibizumab cohorts through Month 36., 36 Months|Incidence and Severity of Ocular and Non-ocular Adverse Events (AE's) Through Month 36., Incidence and severity of ocular and non-ocular adverse events (AE's) in the monotherapy and combination cohorts through Month 36., 36 Months","David M. Brown, M.D.",29,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-03
NCT00404209,Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment,https://clinicaltrials.gov/study/NCT00404209,UNKNOWN,Retinal Detachment,PROCEDURE: Vitrectomy,"Perfluorocarbon liquids consumption, two months",Asociación para Evitar la Ceguera en México,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03
NCT02339909,Incentives in Diabetic Eye Assessment by Screening,https://clinicaltrials.gov/study/NCT02339909,COMPLETED,Diabetes|Diabetic Retinopathy,BEHAVIORAL: Fixed financial incentive|BEHAVIORAL: Probabilistic financial incentive|BEHAVIORAL: Control,"Number of Patients Attending Screening Appointment, The participants will be invited to a specific appointment between three months and one year from their previous missed appointment. The primary outcome refers to the number of participants who did attend their appointment., At designated appointment date (between three months and one year from previous missed appointment)",Imperial College London,1051,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2015-03
NCT03157206,Diabetic Retinopathy Assessed by Ultra-wide,https://clinicaltrials.gov/study/NCT03157206,UNKNOWN,Diabetic Macular Edema,,"AntiVEGF effects on best visual acuity, Retinian peripheral ischemia decrease, 12 months",Association Pour La Recherche En Vision Du Service D'Ophtalmologie De L'Hôpital,49,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-19
NCT00440609,Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00440609,COMPLETED,Clinically Significant Diabetic Macular Edema,DRUG: ranibizumab,"To evaluate safety and tolerability of ranibizumab in patients with clinically significant diabetic macular edema, month 12|To compare the treatment of clinically significant diabetic macular edema with 0.5 mg of ranibizumab to 1.0 mg ranibizumab, month 12","Philip J. ferrone, M.D.",50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-03
NCT00211471,Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).,https://clinicaltrials.gov/study/NCT00211471,TERMINATED,Severe Diabetic Retinopathy|Central Retinal Vein Occlusion|Chronic Inflammation|Infectious Diseases,DRUG: anecortave acetate,"tyo investigate the use of anecortave acetate in rubeosis iridis, 24 months","Manhattan Eye, Ear & Throat Hospital",0,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2002-03
NCT00880139,Study Investigating the Levels and Effects of Low-grade Inflammation in Diabetic Retinopathy of Type 1 Diabetes,https://clinicaltrials.gov/study/NCT00880139,TERMINATED,Diabetic Retinopathy|Inflammation,"PROCEDURE: Blood sampling|PROCEDURE: Noninvasive measurement of systemic hemodynamics|PROCEDURE: Visual acuity assessment|DEVICE: Blue field entoptic technique (Blue field stimulator, BFS-2050)|PROCEDURE: Ophthalmic examination and fundus photography|DEVICE: Retinal Vessel Analyzer (DVA)|DEVICE: High resolution optical coherence tomography (OCT)","Plasma biomarkers for inflammation (CRP, TNF-α, IL-6, vWF, e-Selektin), 1 day|Perifoveal white cell blood flow (Blue field entoptic technique), 1 day|Retinal vessel reactivity to flicker stimulation (Retinal Vessel Analyzer), 1 day|Arteriolar to venous ratio, 1 day",Medical University of Vienna,33,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-06
NCT01482871,Safety Study of ALG- 1001 to Treat Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01482871,WITHDRAWN,Diabetic Macular Edema,DRUG: ALG-1001|DRUG: ALG-1001|DRUG: ALG-1001|DRUG: ALG-1001,"Observation of dose limiting toxicity, The primary endpoint of this study is observation of dose limiting toxicity and the maximum tolerated dose. This determination will be made by the following criteria : Ocular Adverse Events by standard Clinical Ophthalmic examination Visual acuity changes from BCVA (ETDRS equivalent) at baseline by Slit Lamp Bio-microscopy, Tonometry, Indirect Ophthalmoscopy/ Fundus Photography, Fluorescein Angiography, OCT Central Macular Thickness, and ERG Examination, 6 months","Allegro Ophthalmics, LLC",0,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-01
NCT02325271,Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers,https://clinicaltrials.gov/study/NCT02325271,COMPLETED,Diabetic Macular Edema,OTHER: Frequent blood and urine sampling and blood pressure measurement,"VEGF-A, Plasma levels determined in the morning under fasted conditions, Baseline, month 1, 2, 3, 4, 5 and 6|VEGF-B, Plasma levels determined in the morning under fasted conditions, Baseline, month 1, 2, 3, 4, 5 and 6|VEGF-C, Plasma levels determined in the morning under fasted conditions, Baseline, month 1, 2, 3, 4, 5 and 6|Placental growth factor, Plasma levels determined in the morning under fasted conditions, Baseline, month 1, 2, 3, 4, 5 and 6|VEGF-A, Plasma levels determined over the day, Hourly over 12 hours|VEGF-B, Plasma levels determined over the day, Hourly over 12 hours|VEGF-C, Plasma levels determined over the day, Hourly over 12 hours|Placental growth factor, Plasma levels determined over the day, Hourly over 12 hours",GWT-TUD GmbH,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02
NCT00198471,Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment,https://clinicaltrials.gov/study/NCT00198471,COMPLETED,Vitreous Detachment|Diabetic Retinopathy,DRUG: Vitrase,"Vitreous detachment, The proportion of subjects achieving a complete posterior vitreous detachment by Study Day 28, Day 28",Bausch & Lomb Incorporated,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-07
NCT00737971,Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00737971,COMPLETED,Diabetic Macular Edema,DRUG: Bevacizumab intravitreal|DRUG: Triamcinolone|DRUG: Triamcinolone + Bevacizumab,"Measurement of visual acuity (E Snellen), monthly",Rubens Belfort Jr.,142,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-08
NCT05209971,Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients,https://clinicaltrials.gov/study/NCT05209971,UNKNOWN,Macular Edema,,"macular thickness in diabetic hypertensive patients, measurement of central macular thickness by optical coherence tomography, June 2022",Sohag University,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01
NCT04359771,Transfoveal Micropulse Laser for Center Involving Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04359771,COMPLETED,Diabetic Retinopathy|Macula Edema,DEVICE: Yellow micro-pulse laser|DEVICE: Diode micro-pulse laser,"Change in Central Retinal Thickness (CRT), detecting changes in the thickness of the center of the macula, baseline, at 1 month and 3 months after the intervention|Change in the Best Corrected Visual Acuity (BCVA), detecting changes in the the best corrected visual acuity in logMAR. A LogMAR chart comprises rows of letters and is used by ophthalmologists, optometrists and vision scientists to estimate visual acuity. This chart was developed at the National Vision Research Institute of Australia in 1976, and is designed to enable a more accurate estimate of acuity than do other charts (e.g., the Snellen chart). For this reason, the LogMAR chart is recommended, particularly in a research setting. A Snellen score of 6/6 (20/20), indicating that an observer can resolve details as small as 1 minute of visual angle, corresponds to a LogMAR of 0 (since the base-10 logarithm of 1 is 0); a Snellen score of 6/12 (20/40), indicating an observer can resolve details as small as 2 minutes of visual angle, corresponds to a LogMAR of 0.3 (since the base-10 logarithm of 2 is near-approximately 0.3), and so on.Therefore, a higher logMAR scores mean a worse outcome., baseline, at 1 month and 3 months after the intervention",Cairo University,15,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-01-22
NCT02258009,Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02258009,WITHDRAWN,Visual Impairment Due to Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Aflibercept,"Systemic VEGF-A protein levels, Systemic VEGF-A protein levels following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept (Area under the curve), From baseline to study week 12",Novartis Pharmaceuticals,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2015-10
NCT05383209,Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR),https://clinicaltrials.gov/study/NCT05383209,RECRUITING,Nonproliferative Diabetic Retinopathy,DRUG: EYP-1901|OTHER: Sham IVT,"Percentage of subjects improving ≥2 steps in the Diabetic Retinopathy Severity Scale (DRSS) score each EYP-1901 dose level versus the sham IVT injection group., Baseline, Week 24","EyePoint Pharmaceuticals, Inc.",105,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-08-31
NCT02475109,Study of Topical Ocular PAN-90806 in PDR,https://clinicaltrials.gov/study/NCT02475109,COMPLETED,Diabetic Retinopathy,DRUG: PAN-90806 Ophthalmic Solution,"Number of Patients with Adverse Events, Safety will be assessed based upon the incidence of all adverse events, ocular and systemic, 2 months","PanOptica, Inc.",10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08
NCT02681809,A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR,https://clinicaltrials.gov/study/NCT02681809,TERMINATED,Diabetic Retinopathy|Posterior Vitreous Detachment|Disease Progression,DRUG: ocriplasmin 0.0625mg|DRUG: ocriplasmin 0.125mg|DRUG: Sham injection,"Number of Subjects With Total PVD by the Month 3 Visit, Total PVD should be confirmed on both B-scan ultrasound and spectral domain optical coherence tomography (SD-OCT), as assessed by the masked central reading centres, Month 3",ThromboGenics,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-12
NCT00407108,Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00407108,UNKNOWN,Diabetic Retinopathy,PROCEDURE: Vitrectomy,Surgical time|Facility of surgical maneuvers,Asociación para Evitar la Ceguera en México,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-03
NCT00814008,The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp,https://clinicaltrials.gov/study/NCT00814008,COMPLETED,"Diabetes Mellitus, Type 1|Insulin|Retina|Regional Blood Flow",DRUG: Insulin|DRUG: Glucose,"retinal blood flow after 1 hour of insulin clamp, 2 x 2 minutes",Medical University of Vienna,64,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,1999-03
NCT01259609,Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy,https://clinicaltrials.gov/study/NCT01259609,COMPLETED,Diabetic Macular Edema,PROCEDURE: Pars Plana Vitrectomy,"ciliary body thickness, ciliary body thickness was determined using ultrasound biomicroscopy, up to four months after surgery",Seoul National University Hospital,82,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2008-09
NCT05697809,Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05697809,RECRUITING,Diabetic Macular Edema,DRUG: OXU-001|DEVICE: Semi-automated suprachoroidal illuminated microcatheter|DRUG: Ozurdex® Ophthalmic Intravitreal Implant,"Frequency and severity of ocular and systemic treatment emergent adverse events, serious adverse events, and adverse events of special interest, Treatment-emergent adverse events are defined as events emerging following administration of study treatment at Visit 2 (Baseline, Day 0), Week 24|Frequency and severity of treatment-emergent device adverse effects, Treatment-emergent device adverse effects are defined as effecs emerging following administration of study treatment at Visit 2 (Baseline, Day 0), Week 24",Oxular Limited,128,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-08-07
NCT05773209,Choroidal and Retinal Changes After RLRL Therapy in Diabetes and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05773209,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2|Diabetic Retinopathy",DEVICE: RLRL device,"Changes in subfoveal choroidal thickness, Changes in subfoveal choroidal thickness after 1-month RLRL treatment, which is measured by optical coherence tomography., 1 month",The Second People's Hospital of Foshan,58,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-04-30
NCT06112691,ARTIFICIAL INTELLIGENCE FOR MASS SCREENING OF THE DIABETIC RETINOPATHY IN THE CHERNIVTSI REGION (Pilot Study),https://clinicaltrials.gov/study/NCT06112691,RECRUITING,Diabetic Retinopathy,DEVICE: taking fundus photos using non-mydriatic fundus camera - FundusScope Rodenstock,"The accuracy, The accuracy of detecting of DR, Baseline-Month 12",The Filatov Institute of Eye Diseases and Tissue Therapy,660,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-01
NCT04722991,Non-proliferative Diabetic Retinopathy Treated With Runcaciguat,https://clinicaltrials.gov/study/NCT04722991,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,DRUG: Runcaciguat (BAY1101042)|OTHER: Placebo,"DRSS improvement ≥2 steps at 48 weeks of treatment in the study eye, DRSS (Diabetic Retinopathy Severity Scale) will be graded centrally., At 48 weeks of treatment",Bayer,104,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-03-17
NCT05716308,The Effect Evaluation of Continuous Nursing Intervention in Patients With Type 2 Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05716308,COMPLETED,Type 2 Diabetic Retinopathy,BEHAVIORAL: A continuous nursing intervention group was established.,"DR patient care satisfaction questionnaire during follow-up, Each item was scored according to three levels of 10 points, 6 points and 2 points, with a total score of 20-100 points. The higher the score, the higher the nursing satisfaction, 2 years|The Summary of Diabetes Self-Care Activities (SDSCA), The translated Chinese version of the SDSCA scale consists of 11 items, reflecting five parts of self-management : diet, exercise, blood glucose monitoring, foot care, and drugs. Each item is scored by 8 levels of 0-7 points, of which 1 item is a reverse question. The purpose of this scale is to measure the self-management behavior of patients within 7 days. The total score is 0\~77 points. The higher the score, the better the self-management ability. Above 56 points is good for self-management ability, 42\~56 points is medium, and below 42 points is poor., 2 years|Criteria for visual acuity changes, 1. Significant improvement: visual acuity improvement≥4 lines.
2. improvement: vision improvement≥2 lines.
3. unchanged: visual acuity increased by 1 line or decreased by 1 line.
4. decline: visual decline≥2 lines., 2 years",Beijing Tongren Hospital,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2019-06-01
NCT05938491,OCT and OCT-A Afer Diabetic Vitrectomy in PDR,https://clinicaltrials.gov/study/NCT05938491,NOT_YET_RECRUITING,Proliferative Diabetic Retinopathy,DIAGNOSTIC_TEST: OCT and OCT-A,"OCT and OCT angiography to assess the macular thickness , outline and vascularity, Detection of any structural or vascular changes at the macula after Pars Plana Vitrectomy ( PPV ) in cases with complicated proliferative diabetic retinopathy ( PDR ) ., 3 months after surgery",Assiut University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-08-01
NCT04955171,BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04955171,UNKNOWN,Macular Edema,DRUG: BEOVU intravitreal injection,"Best corrected visual acuity (BCVA), Change in BCVA in LOG MARS(logarithm minimum angle of resolution, 12 months",Benha University,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2021-01-12
NCT01045239,Micropulse 577 nm Laser Photocoagulation Versus Conventional 532 nm Laser Photocoagulation for Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT01045239,UNKNOWN,Diabetic Macular Edema,DEVICE: Micropulse 577 nm yellow diode laser|DEVICE: 532 nm green diode laser,"Best corrected visual acuity by logarithm of the minimum angle of resolution (LogMAR), 1 year",University of Malaya,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-10
NCT03660371,ILM Peeling in PDR Patients Undergoing PPV for VH,https://clinicaltrials.gov/study/NCT03660371,COMPLETED,Diabetic Retinopathy|Macular Edema,PROCEDURE: PPV/MP|PROCEDURE: PPV without MP,"BCVA, best-corrected visual acuity, 6 months",Rush Eye Associates,258,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-09-04
NCT01640171,Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival,https://clinicaltrials.gov/study/NCT01640171,COMPLETED,Age-related Macular Degeneration|Central Retinal Vein Occlusion|Diabetic Macular Edema,PROCEDURE: Xylocaine 2% Injectable Anesthetic|DRUG: Proparacaine Hydrochloride 0.5% Drop|DRUG: Tetravisc 0.5% Gel|DRUG: Acuvail|DRUG: Intra-vitreal Anti-VEGF Drug,"Number of Participants Who Preferred Subconjunctival Anesthetic at the Third Follow-up Visit, Participants received anesthetic over several treatment visits. They were allowed to change there preference at each visit. The final outcome was the preference indicated at the third follow-up visit., up to 6 months",Retina Vitreous Associates of Florida,57,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2012-07
NCT04103671,Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR,https://clinicaltrials.gov/study/NCT04103671,RECRUITING,Non Proliferative Diabetic Retinopathy,PROCEDURE: Prompt panretinal photocoagulation|PROCEDURE: 25G Pars-plana vitrectomy,"progression rate of severe non proliferative diabetic retinopathy, the number of patients with severe non proliferative diabetic retinopathy progressed to proliferative diabetic retinopathy in each group from the baseline to 12 months, 12 months","Zhongshan Ophthalmic Center, Sun Yat-sen University",272,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-12-04
NCT03635671,Diabetic Retinopathy and Subclinical Signs of Disease Transition,https://clinicaltrials.gov/study/NCT03635671,TERMINATED,Diabetic Retinopathy,DIAGNOSTIC_TEST: Optical Coherence Tomography Angiography,"Perfusion density, Mean change of perfusion density of the macula evaluated within the 9 ETDRS subfields for the superior and inferior vascular plexus separately., 6 months",University of British Columbia,5,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-01
NCT03608839,"Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial",https://clinicaltrials.gov/study/NCT03608839,COMPLETED,Diabetic Macular Edema,"DRUG: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|DRUG: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|DRUG: Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml","Macular Thickness at 3 Days After Intravitreous Dexamethasone, Measure macular thickness at 3 days after intravitreous dexamethasone with OCT - unit µm, Three days after intravitreous dexamethasone",Universidade Federal de Pernambuco,27,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-05-01
NCT01486771,Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED),https://clinicaltrials.gov/study/NCT01486771,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Macugen ® (pegaptanib sodium),"Establish efficacy of intravitreal pegaptanib sodium injections in causing regression of high risk proliferative diabetic retinopathy as compared to panretinal photocoagulation, To assess the efficacy of intravitreal pegaptanib sodium injections in inducing regression of high risk PDR (as determined by percentage of eyes without treatment failure) using standard panretinal photocoagulation (PRP) as the control arm. Treatment failure is defined as:

* Development of increased NVD and/or NVE
* NVD and/or NVE that is not regressed at least 50% compared to the baseline amount within 3 weeks
* Development of significant vitreous hemorrhage that is sufficient in quantity to obscure visualization of the entire macula, optic disc, and the major temporal arcade vessels, 54 weeks",Valley Retina Institute,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2007-11
NCT01918371,A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01918371,COMPLETED,Retinal Vein Occlusion|Macular Edema,DRUG: Anti-VEGF,"Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 2, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 2 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 3, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 3 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 4, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 4 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 5, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 5 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 6, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 6 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 7, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 7 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 8, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 8 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 9, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 9 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 10, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 10 (Up to 4 Years)|Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT Up to Injection 11, BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation., Up to Time of Injection 11 (Up to 4 Years)",Allergan,323,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-08-02
NCT04708145,Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial,https://clinicaltrials.gov/study/NCT04708145,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,DRUG: Aflibercept Injection,"DRSS Level Achievement in the VOYAGE study, Proportion of subjects achieving a DRSS level of 43 or less in the VOYAGE study., 112 weeks",Greater Houston Retina Research,150,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-06-01
NCT00130845,Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00130845,COMPLETED,Diabetic Retinopathy,DRUG: Octreotide Acetate in Microspheres|DRUG: Placebo,time to progression of diabetic retinopathy,Novartis,312,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2000-02
NCT02390245,Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study,https://clinicaltrials.gov/study/NCT02390245,COMPLETED,Glaucoma|Glaucoma Suspect|Diabetic Retinopathy|Ocular Hypertension|Cataract|Branch Retinal Vein Occlusion|Branch Retinal Arterial Occlusion|Central Retinal Vein Occlusion|Central Retinal Artery Occlusion|Epi-retinal Membrane|Macular Degeneration|Drusen|Loss of Vision,OTHER: Free Eye Screenings|OTHER: Enhanced Intervention|OTHER: Usual Care,"Fundus Camera Images Via Telemedicine, Phase I. Detection of glaucoma and other eye diseases using non contact, autofocus, hand-held fundus camera (Volk Optical, Mentor, Ohio, USA) with images of optic nerve and macula and confirmed at follow-up full dilated eye examination by ophthalmologists., 1 hour eye exam|Intraocular Pressure, Phase I. Intraocular pressure (IOP) as measured in millimeters of mercury (mm Hg) with non contact rebound tonometer TA01I (ICare, Helsinki, Finland). Single IOP taken for each eye. If IOP \> 22 mm Hg, a second IOP was taken of that eye. If difference between 2 measurements \< 2 mm Hg, average was recorded. If difference between 2 measurements \> 2 mm Hg, a third measurement was obtained, and median was recorded. If final IOP \> 30 mm Hg, participant was Fast Tracked to Visit 2., 1 hour eye exam|Diagnostic Image Confirmation by Ophthalmologist, Phase I. Confirmation of telemedicine screen Visit 1 findings with a diagnosis following complete dilated eye examination and visual field by study team and Ophthalmologist at Visit 2., 1 hour eye examination",Wills Eye,906,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2014-09
NCT05752045,OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases,https://clinicaltrials.gov/study/NCT05752045,RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema|Age-Related Macular Degeneration|Age-related Maculopathy|Glaucoma,DEVICE: Eye Fundus Double Capture for Eye Diseases Screening with OphtAI Medical Device,"Referable Diabetic Retinopathy screening sensitivity/specificity, Referable Diabetic Retinopathy screening sensitivity/specificity evaluation (OphtAI software vs Expert reader) for RDR-EOphtha and RDR-OphDiaT_full algorithms, 1 year",Evolucare Technologies,1389,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2023-06-28
NCT01878045,Mechanisms of Diabetic Kidney Disease in American Indians,https://clinicaltrials.gov/study/NCT01878045,SUSPENDED,"Nervous System|Diabetic Kidney Disease|Diabetes Mellitus, Type 2",,"End-Stage Renal Disease, Need for chronic renal replacement therapy or death attributed to kidney failure., Continuous surveillance performed independent of the research examinations",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),141,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11-07
NCT00690768,Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA),https://clinicaltrials.gov/study/NCT00690768,COMPLETED,Diabetic Retinopathy|Retinal Detachment,DRUG: Bevacizumab|PROCEDURE: pars plana vitrectomy,"amount of intraoperative intra-ocular bleeding, three weeks",University of Sao Paulo,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03
NCT03713268,Intraoperative OCT Guidance of Intraocular Surgery II,https://clinicaltrials.gov/study/NCT03713268,RECRUITING,Macular Holes|Epiretinal Membrane|Diabetic Retinopathy|Retinal Detachment|Retinal Disease|Preretinal Fibrosis|Cataract|Ocular Tumor|Strabismus|Healthy,DEVICE: Microscope integrated optical coherence tomography,"Retinal and/or corneal microscope integrated optical coherence tomography image capture, Ability to capture images, Year 1|Quality of retinal and/or corneal microscope integrated optical coherence tomography image capture, Quality of MIOCT images scored based on standard microanatomy and ability to detect presence or absence of ocular pathologies based on review by a masked grader., Year 1|Retinal vascular flow on optical coherence tomography angiography (OCTA) versus fluorescein angiography, Cross correlation of ability to capture vessels and vessel pathology between OCTA and fluorescein angiographic images., Year 1|Assessment of change in pattern of ocular vascular flow before and after standard clinical surgical steps., Presence or absence of change in ocular morphology in pattern of vascular flow compared to prior to surgical steps, Year 1|Assessment of change in ocular morphology before and after standard surgical steps, Presence or absence of change in ocular morphology before and after standard surgical steps, Year 1|Estimate of subretinal fluid volume before and after surgery for retinal detachment based on surgical view versus based on OCT output, Volume estimates from surgeons analyzed relative to the postoperative calculated volume from the intraoperative MIOCT, Year 1",Duke University,262,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-30
NCT02651168,Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study,https://clinicaltrials.gov/study/NCT02651168,UNKNOWN,Diabetic Macular Edema,BIOLOGICAL: aflibercept,"Change in cytokine levels (picograms per mL) in patients with DME who were previously non-responders to ranibizumab (non-responders) between baseline aflibercept injection., 1month, 2 months, 3 months",Unity Health Toronto,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-03
NCT05112445,"Retinal Ischemia Characterization in Diabetes - ""RICHARD""",https://clinicaltrials.gov/study/NCT05112445,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,,"OCTA metrics and predict progression to PDR and/ or CI- DME, Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function., Change from baseline to Month 12|OCTA metrics and predict progression to PDR and/ or CI- DME, Identify which baseline OCTA metrics and predict progression to PDR and/ or CI- DME best correlate with visual function., Change from baseline to Month 24",Association for Innovation and Biomedical Research on Light and Image,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-03
NCT03821168,The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03821168,UNKNOWN,Refractory Diabetic Macular Edema,DRUG: injection of bevacizumab and erythropoietin|DRUG: injection of bevacizumab,"best corrected visual acuity, Snellen chart, 1 month",Shahid Beheshti University of Medical Sciences,58,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-03-01
NCT01934920,Identifying Patients With Unrecognized Treatable Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01934920,UNKNOWN,Diabetic Macular Edema,,"Assess the incidence of new and/or undiagnosed diabetic macular edema., This trial will assess the incidence of new and/or undiagnosed diabetic macular edema (DME) in diabetic patients that undergo a DME screening exam. The screening exam will consist of medical history, Electronic ETDRS visual acuity assessment, SD-OCT and color fundus photography, 1 day (Patients are only seen once for assessments)",Elman Retina Group,500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-08
NCT05105620,Deep Learning for Fluorescein Angiography and Optical Coherence Tomography Macular Thickness Map Image Translation,https://clinicaltrials.gov/study/NCT05105620,COMPLETED,Eye Diseases|Diabetic Retinopathy,DIAGNOSTIC_TEST: Fluorescein Angiography|DIAGNOSTIC_TEST: Optical coherence tomography,"Fréchet inception distance (FID) score., 1 day",Assiut University,708,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-08-01
NCT03528720,Evaluation System and Clinical Application for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03528720,COMPLETED,Diabetic Retinopathy,,"The earliest and most frequently occurring fundus quadrant of diabetic retinopathy in fundus fluorescein angiography., The study is to find the earliest and most frequently occurring fundus quadrant of diabetic retinopathy.Based on the the retrospective analysis results, a prospective comparative study will be conducted to build up a evaluation system and clinical application for diabetic retinopathy.We divided the FFA images into nine quadrants: posterior pole, superior, superior nasal, nasal, inferior nasal, inferior, inferior temporal, temporal, and superior temporal. The qualitative analysis of diabetic retinopathy in each quadrant was performed. The earliest and most common fundus quadrant of diabetic retinopathy was then assessed using a rank sum test, t-test, and analysis of variance., 2 years",Guangdong Provincial People's Hospital,225,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-13
NCT00252720,DIabetic Retinopathy Candesartan Trials.,https://clinicaltrials.gov/study/NCT00252720,COMPLETED,Type 1 Diabetes,DRUG: candesartan,"Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale, Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments., From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.",AstraZeneca,1850,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-08
NCT01255293,Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments,https://clinicaltrials.gov/study/NCT01255293,COMPLETED,Retinal Detachment|Vitrectomy|Proliferative Vitreoretinopathy|Diabetic Retinopathy,PROCEDURE: 1000 centistoke silicone oil|PROCEDURE: 5000 centistoke silicone oil,"Retinal redetachment rate, Six months",Mid Atlantic Retina,15,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-11
NCT04499820,Effect of OMEGA3 Supplementation in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04499820,RECRUITING,Diabetic Retinopathy,DIETARY_SUPPLEMENT: Nutrof|DIETARY_SUPPLEMENT: Meralut,"density of the deep capillary plexus in optical coherence tomography angiography (OCTA), Macular vascularization consists of three interconnected capillary plexuses: the superficial capillary plexus (SCp) located at the level of the optic fibres and the intermediate (ICP) and deep (DCP) capillary plexuses located respectively at the level of the inner and outer part of the inner nuclear layer.16 OCTA is a non-invasive imaging method of retinal vasculature that allows a qualitative but mainly quantitative analysis of the capillary plexuses. A last parameter that could not be evaluated precisely with the old fluorescein and OCT angiography techniques. OCTA is performed without injection of intravenous contrast agent and has no side effects. Several studies have shown that PCP is the plexus most affected by non-perfusion areas in diabetic retinopathy., six months",Centre Hospitalier Intercommunal Creteil,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-06-26
NCT04141891,Advancing Understanding of Transportation Options,https://clinicaltrials.gov/study/NCT04141891,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy|Macular Degeneration|Glaucoma|Retinitis Pigmentosa|Vision Disorders|Acute Coronary Syndrome|Implantable Defibrillator User|Congestive Heart Failure|Hypertrophic Obstructive Cardiomyopathy|Orthostatic Hypotension|Syncope|Presyncope|Narcolepsy|Dementia|Multiple Sclerosis|Parkinson Disease|Brain Injuries|Spinal Cord Injuries|Stroke|Vertigo|Dizziness|Seizures|Substance Use|Insulin Dependent Diabetes Mellitus|Arthritis|Foot--Abnormalities|Chronic Obstructive Pulmonary Disease|Obstructive Sleep Apnea|End Stage Renal Disease|Sleep Apnea|Insomnia|Restless Legs Syndrome,BEHAVIORAL: Driving Decision Aid|BEHAVIORAL: Older Drivers Website,"Decisional Conflict Scale (DCS) Scores at Day 0 (Post-intervention), The DCS is a 16-item scale (with Likert scale response options) that has high reliability and test-retest correlation (Cronbach's alpha coefficients \> 0.78). In prior work, the DCS has been shown to discriminate between known groups who make or delay decisions (effect size 0.4-0.8),53 with lower scores indicating low decision conflict (and greater likelihood of implementing a decision). Scores \<25 (out of 100 total) are associated with implementing decisions; scores \<25 represent positive outcomes. The measure will be assessed immediately following administration of control condition or intervention, Day 0 (Post-intervention)","University of Colorado, Denver",530,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-12-12
NCT00333671,Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema),https://clinicaltrials.gov/study/NCT00333671,COMPLETED,Diabetic Macular Oedema,DRUG: Glycerol,"Retinal thickness by fast retinal thickness mapping by optical coherence tomography at times 0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 minutes after the last swallow of glycerol.","Glostrup University Hospital, Copenhagen",15,INTERVENTIONAL,Allocation: |Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2004-12
NCT01510691,Vitrectomy Retinal Oxygenation,https://clinicaltrials.gov/study/NCT01510691,WITHDRAWN,Diabetic Macular Edema,,"Clinical Data, Visus, OCT, 6 months|Blood Flow Data, Oxygenation of retinal blood vessles and retinal blood flow, 6 months",Stefan Sacu,0,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-10
NCT05038020,A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI),https://clinicaltrials.gov/study/NCT05038020,TERMINATED,Diabetic Retinopathy,DRUG: AKST4290|DRUG: Placebo,"To Investigate the Efficacy of AKST4290 Assessed by the Improvement in the DRSS Score From Baseline., The Diabetic Retinopathy Severity Scale (DRSS) divides DR into 13 levels ranging from the absence of retinopathy to severe retinopathy and is used to describe overall DR severity as well as the change in severity over time. Higher scores indicate more severe DR.

To be eligible for the study, participants needed to have moderately severe non-proliferative DR (NPDR) (DRSS Level 47) to severe NPDR (DRSS Level 53) in one eye, and at least mild NPDR (DRSS Level 35) to mild proliferative DR (PDR) (DRSS Level 61) in the other eye at baseline.

The DRSS score is derived from fundus photography (FP) and fluorescein angiography (FA) findings.

The primary efficacy endpoint is the proportion of participants with a ≥ 3-step improvement from baseline on the DRSS score as compared with Week 24., Baseline to Week 24","Alkahest, Inc.",3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-17
NCT06076720,Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision,https://clinicaltrials.gov/study/NCT06076720,NOT_YET_RECRUITING,Glaucoma|Age-related Macular Degeneration|Retinitis Pigmentosa|Diabetic Retinopathy,DEVICE: New head-mounted visual aids,"Comparison of changes in the Glaucoma Visual Functioning Questionnaire-40 (GVFQ-40) scores at different time points, The GVFQ-40 consists of 40 items and measures the difficulty of daily activities of glaucoma patients in five domains of functioning (mobility, visual tracking, reading, identification and night vision ). Each item has six answer options, that is, no difficulty (score = 1), mild difficulty (score = 2), moderate difficulty (score = 3), extremely difficult (score = 4), completely unable to complete (score = 5), and do not perform for nonvisual reasons (no score). The GVFQ-40 was administered at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention., 8 weeks after intervention|Comparison of changes in the National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25) scores at different time points, The National Eye Institute-Visual Function Questionnaire-25 (NEI VFQ-25) is a valid and reliable vision-related quality of life (QOL) questionnaire designed for persons who have chronic eye diseases or low vision. It includes 25 items that comprise 11 subscales on different aspects of vision-related functioning and QOL and 1 item on general health. NEI VFQ-25 scores range from 0 to 100, with a higher score representing better functioning. The NEI VFQ-25 was administered at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention., 8 weeks after intervention|Comparison of changes in the Low Vision Quality-of-Life Questionnaire (LVQOL) scores at different time points, The Low Vision Quality-of-Life Questionnaire (LVQOL) specifically examines the QOL of patients with visual disability. The LVQOL is of the latter type, with the 25 items producing a summed score between 0 and 125 (the higher the score, the higher the quality of life). The 25 items are grouped into 4 subscales: distance vision, mobility and lighting; adjustment; reading and fine work; and daily life activities. As a convenient tool, LVQOL is widely used in clinical settings to evaluate effects of clinical treatment and corresponding strategies of low-vision rehabilitation. The LVQOL was tested at baseline and 1 day, 1 week, 4 weeks, and 8 weeks after intervention., 8 weeks after intervention","Zhongshan Ophthalmic Center, Sun Yat-sen University",50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-10-10
NCT00936520,SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy,https://clinicaltrials.gov/study/NCT00936520,TERMINATED,Diabetic Macular Edema (DME)|Pars Plana Vitrectomy,DRUG: SAR 1118 0.1%|DRUG: SAR 1118 1.0%|DRUG: SAR 1118 5.0%,"Primary outcome variable: frequency of ocular and non-ocular adverse events judged related to administration of SAR 1118 Ophthalmic Solution, or of inability to tolerate the medication., 35 days",Johns Hopkins University,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2009-08
NCT05712720,Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT05712720,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Experimental: Group 1|DRUG: Experimental: Group 2|DRUG: Experimental: Group 3|OTHER: Placebo: Group 4,"Safety Events, Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs), 16 weeks|Change in Central Subfield Thickness, Change from baseline in Central Subfield Thickness (CST), as measured by Spectral Domain Ocular Coherence Tomography (SD-OCT), compared to placebo., 12 weeks",Rezolute,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-02-06
NCT04137120,Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice,https://clinicaltrials.gov/study/NCT04137120,COMPLETED,Retinal Disease,"DRUG: Aflibercept (BAY86-5321, Eylea)","Number of ocular adverse events, Up to 12 months|Number of serious ocular adverse events, Up to 12 months|Seriousness reason for ocular adverse events, Seriousness reasons may be death, life-threatening character of event, hospitalization or prolongation of hospitalization, congenital anomaly/ birth defect, persistent or significant impairment, or medical relevance of adverse event., Up to 12 months|Severity of ocular adverse events, The severity of adverse events is classified as mild, moderate or severe by treating physician., Up to 12 months|Number of treatment-related ocular adverse events, Up to 12 months|Number of injection-related ocular adverse events, Up to 12 months|Action taken with drug after ocular adverse event, Options: Withdrawn, Interrupted, Injection schedule changed, Injection schedule not changed, Up to 12 months|Clinical outcome of ocular adverse event, Options: Resolved, Resolving, Resolved with sequelae, Not resolved, Fatal, Unknown, Up to 12 months|Duration of ocular adverse events, Up to 12 months|Duration of patient follow-up after ocular adverse event (in months), Up to 12 months|Number of non-ocular adverse events, Up to 12 months|Number of serious non-ocular adverse events, Up to 12 months|Seriousness reason for non-ocular adverse events, Seriousness reasons may be death, life-threatening character of event, hospitalization or prolongation of hospitalization, congenital anomaly/ birth defect, persistent or significant impairment, or medical relevance of adverse event., Up to 12 months|Severity of non-ocular adverse events, The severity of adverse events is classified as mild, moderate or severe by treating physician., Up to 12 months|Number of treatment-related non-ocular adverse events, Up to 12 months|Number of injection-related non-ocular adverse events, Up to 12 months|Action taken with drug after non-ocular adverse event, Options: Withdrawn, Interrupted, Injection schedule changed, Injection schedule not changed, Up to 12 months|Clinical outcome of non-ocular adverse event, Options: Resolved, Resolving, Resolved with sequelae, Not resolved, Fatal, Unknown, Up to 12 months|Duration of non-ocular adverse events, Up to 12 months|Duration of patient follow-up after non-ocular adverse event (in months), Up to 12 months",Bayer,73,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-19
NCT03439345,Lowering Events in Non-proliferative Retinopathy in Scotland,https://clinicaltrials.gov/study/NCT03439345,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,DRUG: Fenofibrate 145 mg|DRUG: Placebo Oral Tablet,"Progression to referable diabetic retinopathy/maculopathy, The composite of progression to referable diabetic retinopathy/maculopathy or any of retinal laser therapy, vitrectomy or intra-vitreal injection of medication for the treatment of diabetic retinopathy/maculopathy

Referable diabetic retinopathy is defined according to NHS Scotland's grading criteria., Approximately 4 years",University of Oxford,1151,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-07-23
NCT05310916,Effect of SGLT2i on Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients,https://clinicaltrials.gov/study/NCT05310916,RECRUITING,Diabetic Retinopathy,DRUG: Dapagliflozin 10mg Tab plus another oral hypoglycemic agent|DRUG: Two oral hypoglycemic agents other than dapagliflozin,"Severity of retinopathy, evaluate the change of stage of disease according to diabetic retinopathy severity scale,, Which is the International Clinical Disease Severity Scale (ICDSS) for DR. This scale classified the severity of disease into five stages ( No apparent retinopathy, Mild Non proliferative Diabetic retinopathy (NPDR) ,Mod NPDR, Severe NPDR ,Proliferative Diabetic Retinopathy) depend on eye examination. higher scores mean worse outcome., 12 weeks|Evaluation of the study biomarkers, IL-6, and VEGF, Interleukin-6 (IL-6)//inflammatory biomarker Vascular endothelial growth factor (VEGF)//angiogenic biomarker, 12 weeks",Nidae Alaa,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2022-06-06
NCT06173245,Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06173245,COMPLETED,Subfoveal Choroidal Thickness|Intravitreal|Ranibizumab|Visual Acuity|Diabetic Retinopathy,PROCEDURE: Intravitreal injection of ranibizumab,"Change of subfoveal choroidal thickness (SFCT), All patients will be scheduled for subfoveal choroidal thickness (SFCT) evaluation on the first month, two month and three months by Optical coherence tomography (OCT)., 3 months",Egyptian Biomedical Research Network,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01
NCT02366468,Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema,https://clinicaltrials.gov/study/NCT02366468,COMPLETED,Diabetic Retinopathy,DRUG: ranibizumab 0.5 mg,"Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12), BCVA was assessed as letters read using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. The mean average change from baseline was defined as the difference between the average level of BCVA (ETDRS letters) over all post-baseline assessments from Month 1 to Month 12. A positive change represents an improvement in visual acuity, Baseline, Month 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12",Novartis Pharmaceuticals,135,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-02-23
NCT05414149,Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05414149,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: preoperative intravitreal injections of ranibizumab or conbercept,"BCVA, best-corrected visual acuity, from preoperation to 3 months follow-up|CRT, central retinal thickness, from preoperation to 3 months follow-up",Peking University People's Hospital,80,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-09-01
NCT01389505,Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01389505,UNKNOWN,Proliferative Diabetic Retinopathy,PROCEDURE: Panretinal photocoagulation|PROCEDURE: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab,"Functional Macular Evaluation, During this 24 weeks of follow-up the Visual acuity (ETDRS), Contrast vision will be measured at baseline, 4, 12 and finally at 24 week, 24 weeks",Instituto do Coracao,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2011-02
NCT03622593,A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03622593,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept|DRUG: Faricimab|PROCEDURE: Sham Procedure,"Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations, Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI., From Baseline through Week 56",Hoffmann-La Roche,951,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-10-09
NCT04499768,A Longitudinal Study of Choroidal Changes After Cataract Surgery in Eyes With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04499768,UNKNOWN,Optical Coherence Tomography|Diabetic Retinopathy|Choroid,,"CVI at baseline, choroidal vascularity index(CVI) was defined as the proportion of vascular area to total circumscribed area., CVI was assessed at baseline(within 1 week before surgery)|CVI at 1 week postoperatively, choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area., CVI was assessed 1 week after surgery.|CVI at 1 month postoperatively, choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area., CVI was assessed 1 month after surgery.|CVI at 3 months postoperatively, choroidal vascularity index (CVI)was defined as the proportion of vascular area to total circumscribed area., CVI was assessed 3 months after surgery.|CT at baseline, Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device., CT was assessed at baseline and 1 week, 1 month, 3 month after surgery.|CT at 1 week postoperatively, Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device., CT was assessed at 1 week after surgery.|CT at 1 month postoperatively, Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device., CT was assessed at 1 month after surgery.|CT at 3 months postoperatively, Choroid thickness (CT) was the thickness of the choroidal layer, CT values were obtained with the built-in software of the SS-OCT device., CT was assessed at 3 months after surgery.|VD at baseline, VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid., VD of the choriocapillaris was assessed at baseline.|VD at 1 week postoperatively, VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid., VD of the choriocapillaris was assessed 1 week after surgery.|VD at 1 month postoperatively, VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid., VD of the choriocapillaris was assessed 1 month after surgery.|VD at 3 months postoperatively, VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid, VD of the choriocapillaris was assessed 3 months after surgery.",Ruijin Hospital,46,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-01
NCT00873106,Retinal Thickness and Volume Estimates Given by Time Domain and Spectral Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT00873106,COMPLETED,Healthy|Diabetic Maculopathy,DEVICE: Optical coherence tomography,"Retinal thickness and retinal volume from each OCT scan, within 24 hours","Glostrup University Hospital, Copenhagen",20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-02
NCT00886808,Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00886808,COMPLETED,Diffuse Diabetic Macular Edema,DRUG: iCo-007 Intravitreal Injection,"Safety and tolerability of 4 dose levels of intravitreal administration of iCo-007., At multiple points after injection up to and including 6 months",iCo Therapeutics Inc.,15,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-02
NCT01994291,"A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT01994291,TERMINATED,"Macular Edema, Diabetic",DRUG: Ranibizumab|DRUG: Placebo|DRUG: PF-04634817|DRUG: Masked Sham Therapy,"Mean Letter Change From Baseline at Week 12 in Best Corrected Visual Acuity (BCVA), Refraction and visual acuity were assessed through the BCVA obtained using the retro illuminated early treatment diabetic retinopathy study (ETDRS) charts. Distance visual acuity was expressed as an ETDRS score (number of letters correctly read)., Baseline (Day 0) and Week 12",Pfizer,199,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-11
NCT04739306,Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04739306,COMPLETED,Diabetic Macular Edema (DME),BIOLOGICAL: CT-P42|BIOLOGICAL: Eylea,"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8, Mean change from baseline in BCVA as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 8.

Subjects with a BCVA ETDRS letter score of 73 to 34 (= Acuity of 20/40 to 20/200) in the study eye at Screening and Day 1 were included. Visual acuity of the study eye was assessed using the ETDRS charts; a higher score represents better functioning., Baseline and Week 8",Celltrion,348,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-22
NCT02217306,Contrast Sensitivity and Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02217306,COMPLETED,DIABETES MELLITUS|DIABETIC RETINOPATHY|MACULAR EDEMA,,"Contrast Sensitivity, Diabetic patients who are attended at Ophthalmology service in a general hospital undergo to contrast sensitivity test evaluating all frequency by software with 5 spacial frequency (1.5, 3, 6, 12 and 18 cycle grade, Stereoptical Co 1996) in the Visual Basic program., up to 8 months",Hospital Juarez de Mexico,132,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT03762226,Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study,https://clinicaltrials.gov/study/NCT03762226,UNKNOWN,Diabetic Macular Edema|Macular Edema|Retinal Vein Occlusion,DRUG: Anti-VEGF,"Correlation of systemic factors on functional and anatomical outcome at month 6., Correlation between blood pressure and serological Parameters at baseline and visual acuity/central subfield thickness at month 6., 6 months",University of Leipzig,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-09-01
NCT00594152,Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT),https://clinicaltrials.gov/study/NCT00594152,COMPLETED,Diabetic Nephropathy|Diabetic Retinopathy,DRUG: CIIIT,"Rate of loss of creatinine clearance, 18 months",Joslin Diabetes Center,71,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,1993-01
NCT05476926,A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products,https://clinicaltrials.gov/study/NCT05476926,RECRUITING,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,DRUG: Faricimab|COMBINATION_PRODUCT: Port Delivery System with Ranibizumab,"Change in Visual Acuity per Eye from Baseline at 1 Year, per Approved Retinal Indication and Product, Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score., Baseline and 1 year",Hoffmann-La Roche,5000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-21
NCT01412905,Telemedicine Retinal Screening Utilizing a Mobile Medical Unit,https://clinicaltrials.gov/study/NCT01412905,COMPLETED,Diabetes|Retinopathy,,,Scripps Whittier Diabetes Institute,1229,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-02
NCT03598205,Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03598205,COMPLETED,Diabetic Macular Edema,COMBINATION_PRODUCT: DIABEC plus intravitreal dexamethazone,"Mean difference in CRT from baseline to 6 months, To explore the effect of curcumin formulation in addition to intravitreal dexamethasone therapy on OCT central retinal thickness after 6 months of therapy, 6 months","Fondazione G.B. Bietti, IRCCS",72,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-02-05
NCT05415826,Ozurdex in Reducing PVR After Vitreotomy in PDR,https://clinicaltrials.gov/study/NCT05415826,NOT_YET_RECRUITING,Diabetic Retinopathy,PROCEDURE: slow-release dexamethasone implant,"PVR, proliferative vitreoretinopathy after sugery, during 3 months after surgery|CRT, central retina thickness, from preoperation to 3 months follow-up",Peking University People's Hospital,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-06-15
NCT04018326,Loss to Follow-up in PDR Patients,https://clinicaltrials.gov/study/NCT04018326,COMPLETED,Diabetic Retinopathy,,"Final BCVA, logMAR BCVA at final follow up (Snellen equivalent), ""through study completion, an average of 1 year"",|Final UCVA, Final logMAR UCVA (Snellen equivalent), ""through study completion, an average of 1 year"",",Assiut University,467,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-05-01
NCT03161652,Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03161652,RECRUITING,Diabetic Macular Edema|Diabetic Retinopathy,DRUG: DME lactose pill|DRUG: DME levosulpiride|DRUG: DR lactose pill|DRUG: DR levosulpiride|DRUG: DR vitrectomy lactose pill|DRUG: DR vitrectomy levosulpiride|DRUG: DME plus ranibizumab lactose pill|DRUG: DME plus ranibizumab levosulpiride,"Visual acuity, Number of letters recognized in the Early Treatment Diabetic Retinopathy Study (ETDRS) chart test after correcting for any refractive error (myopia, hyperopia, or astigmatism), 5 minutes|Retinal thickness, Retinal thickness is evaluated by non-invasive optical coherence tomography (OCT) imaging via qualitative and quantitative analyses. For qualitative analyses, OCT images approaching the histological level of retinal morphology are interpreted based on normal and diseased features (hyper-reflective or hypo-reflective lesions, shadowing, and anatomical changes). Quantitative analysis evaluates retinal reflective signals and their correlation with retinal morphology by computer image-processing algorithms (retinal thickness map, volume, area, 1, 3, and 6 mm ETDRS circle diameters)., Pupils are dilated (eye drops) for 10 to 15 minutes and optical coherence tomography (OCT) images recorded during 5 minutes.|Retinal hard exudates and hemorrhages, Number, size, and location of retinal hard exudates and hemorrhages evaluated by indirect ophthalmoscopy, Pupils are dilated (eye drops) for 10 to 15 minutes and fundus images recorded during 5 minutes|Retinal microaneurisms, leakage area, cotton-wool spots, venous beading, microvascular and vascular abnormalities, Location, intensity, and source of above alterations evaluated by fundus fluorescein angiography imaging qualitative and quantitative analysis of hyper-fluorescent or hypo-fluorescent regions., Pupils are dilated (eye drops) for 10 to 15 minutes and fundus images recorded before and at different times (0.5 to 5 minutes) after fluorescein injection.|Prolactin serum levels, ng/ml levels of prolactin quantified in serum samples using the IMMULITE 2000 XPi immunoassay system, 1-2 minutes (duration of blood withdrawal)|Prolactin vitreous levels, ng/ml levels of prolactin quantified in vitreous samples using the IMMULITE 2000 XPi immunoassay system, 2 minutes (duration of vitreous withdrawal during medically prescribed vitrectomy)|Vasoinhibin vitreous levels, Optical density values of vasoinhibins obtained by the immunoprecipitation-Western blot analysis of vitreous samples, 2 minutes (duration of vitreous withdrawal during medically prescribed vitrectomy)",Carmen Clapp,120,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-05-24
NCT00133952,Effect of Ruboxistaurin on Clinically Significant Macular Edema,https://clinicaltrials.gov/study/NCT00133952,COMPLETED,Diabetic Macular Edema,DRUG: Ruboxistaurin|DRUG: Placebo,"Percentage of Participants With Sustained Moderate Visual Loss (SMVL) Any Time Baseline Through Month 48, SMVL is defined as a 15 letter or more decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity that is sustained for the participant's last 6 months of study participation. ETDRS visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly)., Baseline through 48 months","Chromaderm, Inc.",309,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-08
NCT04772105,Clinical Study of the Safety and Efficacy of BAT5906 Injection,https://clinicaltrials.gov/study/NCT04772105,UNKNOWN,Diabetic Macular Edema,DRUG: 2.5mg of BAT5906|DRUG: 4.0mg of BAT5906,"Vital signs（ body temperature）, the patient's body temperature (axillary temperature) Any clinically significant abnormality should be reported as an adverse event and recorded in the original, After patient resting for more than 3 minutes|Vital signs（heart rate/pulse）, heart rate/pulse Any clinically significant abnormality should be reported as an adverse event and recorded in the original, After patient resting for more than 3 minutes|Vital signs（respiratory rate）, respiratory rate Any clinically significant abnormality should be reported as an adverse event and recorded in the original, After patient resting for more than 3 minutes|Vital signs（blood pressure）, blood pressure Any clinically significant abnormality should be reported as an adverse event and recorded in the original, After patient resting for more than 3 minutes|physical examination, Physical examination should include at least general conditions, head and face, skin, lymph nodes, ears, nose, throat, respiratory system, cardiovascular system, abdomen (including liver and spleen), genitourinary system, musculoskeletal system, nervous system, and mental condition, The investigator or other authorized and qualified investigator shall perform the prescribed physical examination according to the evaluation schedule. During the visit, the investigator performed a physical examination as indicated by symptoms|laboratory examination（blood routine）, In the test process will be carried out in accordance with the testing program flow chart of blood routine, the laboratory testing results of the subjects to evaluate the change of relative to the baseline, the each evaluate clinical significance of abnormal experimental value, the researchers don't think with basic diseases related to abnormal subjects as AE record, Screening period，Week 12, Week 24, Week 48 of the last visit|laboratory examination（outine urine）, In the test process will be carried out in accordance with the testing program flow chart of routine urine , the laboratory testing results of the subjects to evaluate the change of relative to the baseline, the each evaluate clinical significance of abnormal experimental value, the researchers don't think with basic diseases related to abnormal subjects as AE record, Screening period，Week 12, Week 24, Week 48 of the last visit|laboratory examination（blood biochemical examination）, In the test process will be carried out in accordance with the testing program flow chart of blood biochemical examination, the laboratory testing results of the subjects to evaluate the change of relative to the baseline, the each evaluate clinical significance of abnormal experimental value, the researchers don't think with basic diseases related to abnormal subjects as AE record, Screening period，Week 12, Week 24, Week 48 of the last visit|laboratory examination（blood coagulation function）, In the test process will be carried out in accordance with the testing program flow chart of blood coagulation function, the laboratory testing results of the subjects to evaluate the change of relative to the baseline, the each evaluate clinical significance of abnormal experimental value, the researchers don't think with basic diseases related to abnormal subjects as AE record, Screening period，Week 12, Week 24, Week 48 of the last visit|electrocardiogram（12- Lead ECG）, During the trial, the examination of the electrocardiogram (ecg) method must be consistent, and to evaluate the clinical significance of the results, will any researchers to make judgment for clinical significance of abnormal as adverse events were reported, and recorded in the original records and case report form, the subjects in the process of the entire study if there is clinical indications by researchers to determine whether the need for ecg examination., Screening period of the first visit: Week 12 of the fifth visit, Week 24 of the eighth visit, and Week 48 of the last visit|anti-drug antibody (ADA), Plasma samples for anti-drug antibody (ADA) detection were collected to detect the positive incidence of ADA associated with plasma levels of BAT5906, 24 hours before 1, 2, 3, 4 dosing, 5 dosing to last visit, each dosing before and 24 hours before the last visit as needed|ocular and non-ocular adverse events (AE) and serious adverse events (SAE), Any adverse medical event that occurs after a subject participates in a clinical trial and receives the investigational drug, but is not necessarily cause-and-effect with the treatment.

An adverse event can be any adverse or unexpected sign (including abnormal laboratory tests), symptom, or disease, whether or not it is drug related., Adverse events were collected from the time the patient signed the informed consent to the time 28 days after the last dication",Bio-Thera Solutions,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-14
NCT02734407,Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02734407,COMPLETED,Clinically Significant Diabetic Macular Edema,PROCEDURE: Assigned Intervention|DRUG: aflibercept 2.0 mg,"Mean number of intravitreal aflibercept injections in 52 weeks, 12 months|Proportion of subjects receiving 0 aflibercept injections in 52 weeks, 12 months|Longer-term efficacy of aflibercept intravitreal injections as assessed by the mean number of injections in 52 weeks, 12 months|Safety of ongoing aflibercept intravitreal injections as assessed by the incidence and severity of ocular and systemic adverse events, 12 months",Retina-Vitreous Associates Medical Group,9,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01
NCT02441907,Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02441907,COMPLETED,Diabetic Macular Edema,DRUG: aflibercept,"Change in cytokine levels (picograms per mL) between baseline aflibercept injection and at 1, 2, and 3 months, 3 months",Unity Health Toronto,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08
NCT05857943,Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Funduscopic Images,https://clinicaltrials.gov/study/NCT05857943,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy,DEVICE: AEYE-DS Software,"Sensitivity and Specificity, 1 year",AEYE Health Inc,363,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-03-29
NCT00656643,Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00656643,COMPLETED,Diabetic Macular Edema,DRUG: Sirolimus|DRUG: Placebo|DRUG: Sirolimus|DRUG: Sirolimus,"Best-corrected visual acuity by ETDRS, 180 days",Santen Inc.,131,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-06
NCT02026843,Analysis of Angiogenic Factor Levels in Eyes With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02026843,UNKNOWN,Diabetic Retinopathy,,"Aqueous secretory angiogenic and anti-angiogenic protein concentration, To establish if certain type of diabetic retinopathy and nondiabetic retinal disease group are associated to different concentrations of angiogenic or anti-angiogenic protein concentration., one month",Kyungpook National University Hospital,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04
NCT01785667,Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark,https://clinicaltrials.gov/study/NCT01785667,COMPLETED,Type 1 Diabetes|Diabetic Retinopathy,,"Incidence of diabetic retinopathy and proliferative diabetic retinopathy, Using the ETDRS grading protocol the degree of retinopathy in 2011 will be assessed by grading 7-field fundus photographs taken at follow-up examination. This will be related to the degree of retinopathy found in the patients in 1995, where the last study of the cohort took place., 16 years",Odense University Hospital,132,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01
NCT05961007,Evaluation of IBI302 Injection in nAMD or DME,https://clinicaltrials.gov/study/NCT05961007,SUSPENDED,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,BIOLOGICAL: Intravitreal injection of IBI302(dose 1)|BIOLOGICAL: Intravitreal injection of IBI302(dose 2)|BIOLOGICAL: Intravitreal injection of IBI302(dose 3)|DRUG: Intravitreal injection of Aflibercept,"Incidence and severity of ocular and non-ocular adverse events., To evaluate the number of subjects with ocular and non-ocular adverse events, treatment emergent adverse event, adverse event of special interest, serious adverse events; number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations., Up to week 20|DLT in each group, 7 days",Innovent Biologics (Suzhou) Co. Ltd.,234,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-11-18
NCT04187443,MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema,https://clinicaltrials.gov/study/NCT04187443,RECRUITING,Diabetic Macular Edema|Macular Edema|Type 2 Diabetes With Diabetic Macular Edema|Type 1 Diabetes With Diabetic Macular Edema|Diabetic Retinopathy,DRUG: MS-553,"Treatment-emergent adverse events, Baseline to Day 56","Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.",45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-02
NCT03071068,A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME),https://clinicaltrials.gov/study/NCT03071068,COMPLETED,Diabetic Retinopathy|Macular Edema,"DRUG: Anti-PlGF recombinant monoclonal antibody, 4mg dose|DRUG: Anti-PlGF recombinant monoclonal antibody, 8mg dose","Incidence of acute (up to the 7-day follow-up visit) ocular (serious) adverse events ([S]AEs) in the study eye, after each injection and across injections per subject, up to the 7-day follow-up visit after each injection",ThromboGenics,49,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-12-22
NCT03476967,Effect of Laser Treatment for Diabetic Retinopathy on the Optic Disc Topography,https://clinicaltrials.gov/study/NCT03476967,COMPLETED,Diabetic Retinopathy,PROCEDURE: Panretinal photocoagulation,"Cup area, Change in cup area (mm2) measured by Heidelberg retinal tomograph (HRT) before and one year after PRP, 12 months",University of Sao Paulo General Hospital,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT04151407,The Study of Drug 601 in Patients With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT04151407,UNKNOWN,Diabetic Macular Edema,DRUG: Drug 601,"DLT, Incidence of dose-limiting toxicities up to the Day 28, From Day 0 up to Day 28|MTD, Maximum tolerated dose, From Day 0 up to Day 56/112.","Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",50,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-03-08
NCT03475407,The Effects of Intravitreal Ozurdex Implant in DME,https://clinicaltrials.gov/study/NCT03475407,UNKNOWN,Diabetic Macular Edema,DRUG: Ozurdex intravitreal injection,"Changes of Central foveal thickness(CFT, height in micrometers), Baseline, 1 week, 6 weeks, 12 weeks, 18 weeks, 24 weeks","Nune Eye Hospital, Seoul, Korea",20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-03
NCT01824043,Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage,https://clinicaltrials.gov/study/NCT01824043,UNKNOWN,Diabetic Retinopathy|Vitreous Hemorrhage,DRUG: intravitreal ranibizumab injections,"Gain in visual acuity and transparence of vitreous in treated eyes., 90 days",Hospital Regional de São José - Dr. Homero de Miranda Gomes,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-03
NCT03314467,Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.,https://clinicaltrials.gov/study/NCT03314467,COMPLETED,Diabetes Mellitus|Obstructive Sleep Apnea,DIAGNOSTIC_TEST: polysomnography,"Presence of obstructive sleep apnea in diabetic patients is a predictive factor for diabetic retinopathy occurence, obstructive sleep apnea is defined as apnea-hypopnea index \> 15 on polysomnography, 1 month",Centre Hospitalier Universitaire Saint Pierre,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-06
NCT04794907,Retinal Care Data Repository,https://clinicaltrials.gov/study/NCT04794907,NOT_YET_RECRUITING,Diabetic Retinopathy|Age Related Macular Degeneration,OTHER: Observation,"Risk Stratification, Predict the participant's risk of developing specific severity levels of DR and AMD, Decade",Retinal Care Inc.,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-31
NCT00596297,Preoperative Bevacizumab for Vitreous Hemorrhage,https://clinicaltrials.gov/study/NCT00596297,COMPLETED,Diabetic Retinopathy|Vitreous Hemorrhage,DRUG: bevacizumab|PROCEDURE: pars plana vitrectomy,"Intra- and postoperative intra-ocular bleeding, 12 weeks",University of Sao Paulo,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-11
NCT01607190,Biomarkers of Diabetic Retinopathy Progression,https://clinicaltrials.gov/study/NCT01607190,COMPLETED,Type 2 Diabetes Mellitus|Mild Nonproliferative Diabetic Retinopathy,,"CSME needing treatment either photocoagulation or ITV., Months 0, 6, 12 and 24.",Association for Innovation and Biomedical Research on Light and Image,200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-11
NCT04067856,Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery,https://clinicaltrials.gov/study/NCT04067856,WITHDRAWN,Diabetic Macular Edema|Cataract,DRUG: Bevacizumab Injection,"Final visual acuity, 6 month",Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-01-01
NCT04424290,HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia,https://clinicaltrials.gov/study/NCT04424290,COMPLETED,Diabetic Retinopathy,DRUG: BI 764524|DRUG: Sham control of BI 764524,"Single rising dose (SRD) part: Number of participants with dose limiting events, Number of patients with dose limiting events (DLEs) from drug administration till day 8 (7 days after treatment)., 14 weeks|Multiple dosing (MD) part: Number of patients with drug related adverse events (AEs) from drug administration till end of study (EOS), 22 weeks",Boehringer Ingelheim,45,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-12
NCT05066997,Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05066997,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Active treatment arm: OCS-01 (dexamethasone)|DRUG: Vehicle,"Mean change in BCVA (Best Corrected Visual Acuity) ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the EDTRS chart representing better visual acuity, Stage 1:

Mean change in BCVA ETDRS letters score at Visit 5 (Week 6) compared with baseline.

Stage 2:

Mean change in BCVA ETDRS letters score at Visit 9 (Week 52) compared with baseline., Week 52",Oculis,497,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-10-19
NCT03828890,Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic,https://clinicaltrials.gov/study/NCT03828890,COMPLETED,Diabetes Mellitus,OTHER: Screening eye exam using Optos technology,"Family Physicians Screening for Diabetic Retinopathy - Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist, Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist. These photographs are obtained using retinal imaging and after the initial read by the family physicians trained to interpret the images, the images will be reviewed by the retinal specialist to determine if the interpreted results are accurate., 6 months.",Mayo Clinic,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2019-06-12
NCT01517490,Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes,https://clinicaltrials.gov/study/NCT01517490,UNKNOWN,Diabetes Mellitus|Diabetic Retinopathy,OTHER: Insulin pump|OTHER: Multiple daily insulin injections|PROCEDURE: Bariatric surgery|OTHER: Medical therapy for type 2 diabetes,"Changes in dark adaptation kinetics and threshold values, amplitudes/implicit times, retinal vessel diameters, perfusion velocity and oximetry., Baseline, 1 week, 1 month, 4 months, 7 months, 12 months, 18 months, 24 months, 42 months|Changes in visual acuity, diabetic retinopathy grading and OCT, Baseline, 1 week, 1 month, 4 months, 7 months, 12 months, 18 months, 24 months, 42 months","Glostrup University Hospital, Copenhagen",100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-08
NCT03010397,Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes,https://clinicaltrials.gov/study/NCT03010397,COMPLETED,Diabetic Retinopathy,,"Phenotypic classification of DR in a 5-year period, Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy), 5 years",Association for Innovation and Biomedical Research on Light and Image,212,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12
NCT00500097,Diabetic Retinopathy and Diabetic Macular Edema Screening by Non-Physicians With Limited Training,https://clinicaltrials.gov/study/NCT00500097,COMPLETED,Diabetic Retinopathy,DEVICE: Digital retina image|DEVICE: direct ophthalmoscopy|PROCEDURE: comprehensive eye exam,"Sensitivity, specificity, kappa coefficient, cross-sectional","Ministry of Health, Thailand",840,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SCREENING,2005-05
NCT03672656,Pattern Laser Versus Conventional Laser in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03672656,COMPLETED,Diabetic Retinopathy,DEVICE: lasercoagulation by Pascal system|DEVICE: conventional laser,"Clinical efficiency - progression of diabetic retinopathy, scored by calculating of microaneurisms and intraretinal hemorrhages, progression of diabetic retinopathy after pattern PASCAL laser versus conventional laser. Each item is scored by calculating of microaneurisms and intraretinal hemorrhages, 1 year|Pain assessed by NRS, painfulness of pattern PASCAL laser versus conventional laser Each item is scored 0-10 (0 - no pain, 10 - pain as bad as can be), 1 day",University Hospital Ostrava,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-01-01
NCT01041690,Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT01041690,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Bevacizumab,"Intra- and post-operative bleedings were recorded., 3 months",Cairo University,19,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-06
NCT03665090,Shanghai Cohort Study of Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT03665090,UNKNOWN,Diabetic Macular Edema of Both Eyes (Diagnosis)|Diabetic Retinopathy Visually Threatening,BEHAVIORAL: Diabetic eye disease screening,"Prevalence and incidence rate of diabetic eye disease, SCODE was performed to evaluate the prevalence and rate of new cases of diabetic eye disease, especially DR, in a three-year community-based cohort study for the people with diabetes, and to identify the associated factors related with diabetic eye disease., December 31, 2018",Shanghai Eye Disease Prevention and Treatment Center,8000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01-01
NCT00711490,Sirolimus to Treat Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00711490,COMPLETED,Diabetic Retinopathy,DRUG: Sirolimus,"Change in Visual Acuity From Baseline to 6 Months, Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. This acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters the Snellen measurement is 20/20., 6 months",National Eye Institute (NEI),5,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-07
NCT00442156,The Course of Response to Focal Photocoagulation for DME,https://clinicaltrials.gov/study/NCT00442156,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema,PROCEDURE: Laser photocoagulation,"OCT-measured retinal thickness and visual acuity, 16 weeks",Jaeb Center for Health Research,122,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01
NCT03956797,Long Term Safety of Cooling Anesthesia for Intravitreal Injection,https://clinicaltrials.gov/study/NCT03956797,COMPLETED,"Anesthesia, Local|Intravitreal Injection|Macular Edema|Macular Degeneration|Diabetic Retinopathy|Diabetic Macular Edema",DEVICE: Recens Cooling Anesthesia Device,"Pain of Intravitreal Injection: VAS, Pain of intravitreal injection as measured by 10-point visual analog scale (VAS) (0 meaning no pain, 10 meaning the most severe pain)., Immediately after injection|Incidence of Anesthesia-Related Adverse Events, % of patients that experience cooling anesthesia device-related adverse events, as assessed by anterior segment and posterior segment examination., 30 minutes after injection","Recens Medical, Inc.",80,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-04-15
NCT01934556,A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01934556,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab 0.3 mg intravitreal injection|DEVICE: Guided Laser Photocoagulation,"Mean Change in Vision at 24 Months, Mean change in ETDRS (Early Treatment in Diabetic Retinopathy Study) visual acuity at 24 months (week 92-week 107) from Day 0. Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard. A higher letter score represents better functioning"", 2 Years","Palmetto Retina Center, LLC",150,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2013-11
NCT03927690,Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03927690,COMPLETED,Diabetic Macular Edema,DRUG: LKA651|DRUG: Lucentis,"Number of Participants With Adverse Events, An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient.

The severity of the AEs (mild, moderate, severe) was based on the Common Terminology Criteria for Adverse Events (CTCAE).

Number of participants in each category is reported in the table. A participant who falls multiple times in one category is counted only once., Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).|Number of Participants With Ocular Adverse Events by Preferred Term in Study Eye, An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient., Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).|Number of Participants With Non-ocular Adverse Events (>=2%), An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation patient., Adverse events are reported from first dose of study treatment until end of study treatment plus 12 weeks post treatment, up to a maximum timeframe of approximately 24 weeks (approximately 168 days).|Intraocular Pressure (IOP) in Study Eye, Intraocular pressure was measured per the study site's regular practice., Screening, and Day 85|Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Charts in Study Eye, BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.

Visual function of the study eye was assessed using the ETDRS protocol.

BCVA in study eye was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Baseline BCVA value and treatment naïve and treatment experienced variable were used as covariates.

Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning., Days 2, 8, 15, 29, 43, 57, and 85|Inner Macular Thickness (Inferior), Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT)., Week 12 (Day 85)|Inner Macular Thickness (Temporal), Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT)., Week 12 (Day 85)|Outer Macular Thickness (Inferior), Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT)., Week 12 (Day 85)|Outer Macular Thickness (Temporal), Macular thickness was measured by spectral domain optical coherence tomography (SD-OCT)., Week 12 (Day 85)|Number of Participants Without Changes in Foveal Avascular Zone as Measured by Fluorescein Angiography (FA) in Study Eye, Foveal avascular zone was assessed by fluorescein angiography (FA)., Days 29, 57, 85, End of Study (Up to Day 140)|Mixed Model Repeated Measures Analysis of Ratio to Baseline in Central Subfield Retinal Thickness (CSFT) in the Study Eye, Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT). Central subfield retinal thickness was analyzed with a mixed model for repeated measures. The model included treatment, visit, and the treatment by visit interaction as independent variables. An unstructured residual covariance structure was used. Log-transformed baseline central subfield retinal thickness and treatment naïve and treatment experienced variable were used as covariates. Results were back-transformed to show results as a ratio to baseline., Days 8, 15, 29, 43, 57, 85",Novartis Pharmaceuticals,91,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-05-24
NCT05344690,SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05344690,RECRUITING,Diabetic Retinopathy,GENETIC: SLMAP and EPO genetic polymorphism,"Association of SLMAP gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis, the odds ratio of being diagnosed with diabetic retinopathy in those with SLMAP rs17058639 single nucleotide polymorphism compared to wild type, At baseline (upon confirmed diagnosis of diabetic retinopathy)|Association of EPO gene polymorphism and the risk of confirmed diabetic retinopathy diagnosis, The odds ratio of being diagnosed with diabetic retinopathy in those with EPO rs551238 single nucleotide polymorphism compared to wild type, At baseline (upon confirmed diagnosis of diabetic retinopathy)",Ain Shams University,180,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-20
NCT01689090,Diameter Changes of Retinal Vessels During Hypoxia,https://clinicaltrials.gov/study/NCT01689090,COMPLETED,Diabetes Mellitus Type 1|Diabetic Maculopathy,OTHER: COX inhibitor|OTHER: L-NG-monomethyl arginine citrate|OTHER: COX inhibitor + L-NG-monomethyl arginine citrate,"Diameter changes of retinal vessels, Comparing the differences of diameter changes occuring during each of the interventions., Examination day 1 and 2",University of Aarhus,58,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2012-11
NCT01635790,Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME),https://clinicaltrials.gov/study/NCT01635790,UNKNOWN,Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Bevacizumab,"Best Corrected Visual Acuity, Primary outcome measure will be the change in best-corrected visual acuity (BCVA) in the study eye from baseline to month 6., 6 months",Prof. dr. R.O. Schlingemann,246,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-06
NCT04856397,Ozurdex in Suboptimal Diabetic Macular Edema Patients,https://clinicaltrials.gov/study/NCT04856397,UNKNOWN,Diabetic Macular Edema,DRUG: Intravitreal Implant in Applicator|DRUG: Eylea,"Visual acuity, best corrected visual acuity (BCVA), 1 year",Uptown Eye Specialists,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-25
NCT04058067,To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04058067,COMPLETED,Diabetic Macular Edema,DRUG: Brolucizumab|DRUG: Aflibercept,"Change in best-corrected visual acuity (BCVA), To demonstrate that brolucizumab is non-inferior to aflibercept with respect to the visual outcome, Baseline to Week 52",Novartis Pharmaceuticals,263,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-08-23
NCT02555956,Grid Laser for Diffuse Diabetic Maculopathy,https://clinicaltrials.gov/study/NCT02555956,COMPLETED,Diabetic Macular Edema,,"Improvement of visual acuity after grid laser, Visual acuity will be mesured pre laser and 06 weeks post laser, 6 week",Dow University of Health Sciences,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04
NCT03784443,Combined Ranibizumab and Iluvien for Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT03784443,WITHDRAWN,Diabetic Macular Edema|Diabetes,DRUG: Iluvien 0.19 MG Drug Implant|DRUG: Ranibizumab Injection [Lucentis]|PROCEDURE: Sham Intravitreal Injection,"Number of Lucentis Injections received in the study eye, The total number of Lucentis injections needed over 24 months following the intravitreal injection PRN protocol, 24 months",Imperial College London,0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-09-01
NCT02511067,Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study,https://clinicaltrials.gov/study/NCT02511067,WITHDRAWN,Diabetic Macular Edema,DRUG: Tocilizumab|DRUG: Ranibizumab,"Adverse Events, To evaluate the safety of IV infusions of tocilizumab in treatment of subjects with diabetic macular edema (DME) as monotherapy and in combination with Ranibizumab, 6 months|Anatomic Retinal Changes, To evaluate the percentage change in central retinal thickness (CRT) from Baseline to Month 6 in the study eye as assessed by spectral domain-optical coherence tomography (SD-OCT)., Month 6",University of Nebraska,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2016-10-01
NCT01946997,Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT01946997,COMPLETED,Diabetic Retinopathy,OTHER: OCT Imaging both Normal and diabetic groups,"Normative retinal thickness data for comparison, Normative retinal thickness data for comparison, one year",Johns Hopkins University,200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-07
NCT02121197,Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.,https://clinicaltrials.gov/study/NCT02121197,COMPLETED,Diabetic Macular Edema,DRUG: Ozurdex,"Percentage of patients with Best Corrected Visual Acuity (BCVA) from baseline to 4 - 6 months after last injection, with comparison between early (<9 month duration of DME) vs late (≥9 month duration of DME), and naïve vs previously treated patients., Percentage of patients with Best Corrected Visual Acuity (BCVA) from baseline to 4 - 6 months after last injection, with comparison between early (\<9 month duration of DME) vs late (≥9 month duration of DME), and naïve vs previously treated patients., 6 month",Association for Innovation and Biomedical Research on Light and Image,321,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-08
NCT03345667,Assessment of Color Vision in Diabetic Patients,https://clinicaltrials.gov/study/NCT03345667,COMPLETED,"Retinopathy, Diabetic",DRUG: lucentis,"Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema, Using the Ishihara's test to analise the possible loss of vision, 3 months",Instituto de Olhos de Goiania,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-01
NCT05746975,Diabetic Retinopathy Classification: ETDRS 7-fields vs Widefield Imaging (ClarusDR),https://clinicaltrials.gov/study/NCT05746975,RECRUITING,"Retinopathy, Diabetic",,"ETDRS severity level according to the Early Treatment Diabetic Retinopathy Study - Diabetic Retinopathy Severity Scale (ETDRS-DRSS)., Compare DR severity level between the ETDRS 7-fields imaging and the wide-field imaging techniques: Clarus 500TM and OptosTM. The ETDRS - DRSS goes from level 10 - no presence of DR to level 75 - Severe proliferative DR, 12 months|One or more than 2-steps change on ETDRS - DRSS severity level, Compare ETDRS -DRSS between the two imaging techniques and evaluate the presence of 1 step or more than 2 steps difference between ETDRS 7-fields imaging and the wide-field imaging techniques: Clarus 500TM and OptosTM, 12 months|Peripheral DR lesions characterization, Investigate the peripheral area and analyze the presence, distribution, and severity of peripheral DR lesions, in wide-field images: Clarus 500TM and OptosTM.

Presence and distribution of lesions in the periphery will be evaluated as 1) Not observed; 2) predominantly observed outside ETDRS fields; 3) Uniformly distributed within and outside ETDRS fields. 4) Ungradable.

Severity of the peripheral lesions will be evaluated using the same ETDRS-DRSS scale described above and will vary between level 35 and level 65.

Also, it will then be compared with the ETDRS 7-field area and graded as less, equivalent or greater than the observed inside ETDRS 7-fields area., 12 months",Association for Innovation and Biomedical Research on Light and Image,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-03
NCT04601675,Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.,https://clinicaltrials.gov/study/NCT04601675,UNKNOWN,Macular Edema,DRUG: Ranibizumab Ophthalmic and Intravitreal Dexamethasone|DRUG: Ranibizumab Ophthalmic only,"Mean change in monocular BCVA in the treatment eye, Monocular BCVA in the treatment eye is assessed by using ETDRS visual acuity charts at 4 meters at baseline (pre-treatment) and 1 week, 1month, 2 months, 3 months, and 6 months after treatment., Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.|Mean change in binocular BCVA, Binocular BCVA is assessed by using ETDRS visual acuity charts at 4 meters at baseline (pre-treatment) and 1 week, 1month, 2 months, 3 months, and 6 months after treatment., Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.",He Eye Hospital,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10-31
NCT00000154,Diabetic Retinopathy Vitrectomy Study (DRVS),https://clinicaltrials.gov/study/NCT00000154,COMPLETED,Diabetic Retinopathy|Retinal Detachment|Vitreous Hemorrhage,PROCEDURE: Vitrectomy,,National Eye Institute (NEI),,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,1976-10
NCT00417833,Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment,https://clinicaltrials.gov/study/NCT00417833,COMPLETED,Diabetic Proliferative Retinopathy|Vascular Vein Oclussion|Choroidal Neovascularization,DRUG: Intravitreal Bevacizumab,,Asociación para Evitar la Ceguera en México,,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: ",2005-12
NCT01728883,Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study,https://clinicaltrials.gov/study/NCT01728883,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema,DEVICE: Home vision monitoring using myVisionTrack®,"Test efficacy of the test algorithm improvements, To test the efficacy of test algorithm improvements and usability enhancements on the overall rate of patient compliance and on test-retest variability., Twelve months",Vital Art and Science Incorporated,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-04
NCT02634333,Anti-VEGF Treatment for Prevention of PDR/DME,https://clinicaltrials.gov/study/NCT02634333,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema,PROCEDURE: Prompt Sham|DRUG: Prompt aflibercept|PROCEDURE: Deferred laser|DRUG: Deferred aflibercept,"Development of PDR and/or DME (Whichever Came First), CI-DME = center-involved diabetic macular edema, PDR = proliferative diabetic macular edema. First development of criteria meeting end point. Eyes that met any criteria are then censored from contributing to the next criteria. Eyes that did not meet the outcome were censored at the time of the last completed visit. Each outcome appears only once under ""First PDR and/or DME criteria met."" Outcomes appear under ""Development of PDR"" if PDR developed at any time in the study (regardless of if or when DME developed) and outcomes appear under ""Development of DME"" if DME developed at any time in the study (regardless of if or when PDR developed), 2 years|Change in Visual Acuity From Baseline, Visual acuity is measured as a continuous integer letter score from 0 to 100, with higher numbers indicating better visual acuity. A letter score of 85 is approximately 20/20 and a letter score of 70 is approximately 20/40, the legal unrestricted driving limit in most states. A 5-letter change for an individual is approximately equal to a 1-line change on a vision chart., 2 years",Jaeb Center for Health Research,399,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2016-01
NCT00385333,Metabolic Mapping to Measure Retinal Metabolism,https://clinicaltrials.gov/study/NCT00385333,COMPLETED,Macular Degeneration|Diabetic Retinopathy|Hippel-Landau Disease|Mitochondria,PROCEDURE: Feasibility Study - Imaging System,Fluorescence anisotropy,National Eye Institute (NEI),28,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2006-09-29
NCT03635814,The Study to YD312 Tablet in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03635814,UNKNOWN,Diabetic Macular Edema(DME),DRUG: YD312 50mg|DRUG: YD312 150mg|DRUG: YD312 350mg|DRUG: Placebo,"Change in ETDRS BCVA latter score from baseline at Week 12 ( ETDRS chart reading at least 3 letters), BCVA ERDRS measure at V1(screening), V2(baseline,week0), V3(week4), V4(week8), V5(week12)","YD Global Life Science Co., Ltd.",100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-10-19
NCT01876914,Pilot Study of OCT Versus Fluorescein Angiography in DME,https://clinicaltrials.gov/study/NCT01876914,COMPLETED,Diabetic Macular Edema,,"Total retinal blood flow & visual acuity, Total retinal blood flow, as measured by Doppler OCT, is correlated with visual acuity and the area of macular ischemia as evaluated by FA. This will be performed by the following analysis:

1. Pearson's correlation test of total retinal blood flow with logMAR visual acuity;
2. Pearson's correlation test of total retinal blood flow with the area of macular ischemia on FA., 1 year",Oregon Health and Science University,20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-06
NCT05387837,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT05387837,RECRUITING,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,DRUG: D-4517.2,"Number of participants with Treatment-Emergent Adverse Events [Safety], Safety of single dose of D-4517.2 as measured by treatment-related adverse events as assessed by CTCAE v5.0, Safety and tolerability of a single SC dose of D-4517.2 at 26 weeks","Ashvattha Therapeutics, Inc.",30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-31
NCT00718614,Choroidal Blood Flow Changes During Dark/Light Transitions in Patients With Insulin-dependent Diabetes Mellitus (IDDM),https://clinicaltrials.gov/study/NCT00718614,TERMINATED,"Diabetes Mellitus, Type 1|Diabetic Retinopathy",PROCEDURE: Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.,"fundus pulsation amplitude, 3 hours|choroidal blood flow, 3 hours",Medical University of Vienna,80,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2007-06
NCT01769183,Squalamine for the Treatment in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01769183,COMPLETED,Retinal Neovascularization,DRUG: Squalamine Lactate ophthalmic solution 0.2%,"Proportion with complete regression of neovascularization on fundus photography at one month, 1 Month",Elman Retina Group,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-02
NCT00411333,Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00411333,COMPLETED,Diabetic Retinopathy,DRUG: triamcinolone acetonide (Kenalog),Change in retinal vascular density from baseline on fluorescein angiography,National Eye Institute (NEI),100,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2006-07
NCT04603937,"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT04603937,TERMINATED,Diabetic Macular Edema,DRUG: KSI-301|DRUG: Aflibercept|OTHER: Sham Procedure,"Non-inferiority of KSI-301 to Aflibercept measured by changes in BCVA., Demonstrate that KSI-301 5 mg is non-inferior to aflibercept 2 mg with respect to mean change in best corrected visual acuity (BCVA)., Day 1 to Year 1",Kodiak Sciences Inc,459,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-30
NCT03403283,Dyslipidemia and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03403283,RECRUITING,Diabetic Retinopathy|Dyslipidemia,"OTHER: 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|OTHER: Healthy Controls 15 age matched control subjects","Increase in acid sphingomyelinase (ASM) expression and activity in bone marrow-derived endothelial progenitor cells (EPCs), Peripheral blood of 150 cc, about 8-10 tablespoons will be collected from vein in the arm of both diabetic and control subjects, 3 years",University of Alabama at Birmingham,45,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT00001733,Screening for Studies on Retinovascular Diseases,https://clinicaltrials.gov/study/NCT00001733,COMPLETED,Diabetic Retinopathy|Macular Degeneration|Pathologic Neovascularization|Retinal Disease,,,National Eye Institute (NEI),2000,OBSERVATIONAL,Observational Model: |Time Perspective: p,1998-03-06
NCT04018833,Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04018833,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy,DRUG: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|DRUG: Aflibercept 40 MG/ML Intraocular Solution [EYLEA],"Anatomical change, The central foveal thickness (CFT), measured by Optical Coherence Tomography, was automatically measured by the software in the central 1 mm. A CFT \<250 µm or \>300 µm is considered pathological. A CFT between 200 and 300 µm is considered physiological. CFT has no defined minimum or maximum values.

Since patients with diabetic macular edema usually have CFT \>300 µm the goal of treatment is to lower the CFT to values between 200 and 300 µm. A clinical significant anatomical improvement was considered for a change in CFT≥10%., Immediately before switch (one month after last bevacizumab intravitreal injection); 4 months after switch. Minimum of three intravitreal injections before and after switch.|Functional change, Functional change was measure by the Early Treatment Diabetic Retinopathy Scale (ETDRS) which measures the best-corrected visual acuity with an ETDRS-like chart at 4 meters in number letters or at 1 meter when patients are unable to read any letters on the ETDRS chart at 4 meters. The ETDRS scale varies from 1 to 85 letters (85 letters correspond to a 20/20 in the Snellen scale).

The higher the value the better the outcome. A clinical significant functional improvement was considered for a gain of ≥5 EDTRS letters., Immediately before switch (one month after last bevacizumab intravitreal injection); 4 months after switch. Minimum of three intravitreal injections before and after switch.",Bernardete Pessoa MD,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01-01
NCT04624737,Intelligent Evaluation of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04624737,RECRUITING,Diabetic Retinopathy,,"Progression to severe retinopathy, Progression towards severe diabetic retinopathy form., month 12",Assistance Publique - Hôpitaux de Paris,5000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-12-21
NCT02579837,CLEAR SIGHT: A Trial of Non-Mydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT02579837,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy,DEVICE: Optos 200Tx|DEVICE: Zeiss Cirrus,"Proportion of participants with Actionable Eye Disease (AED), Usual Screening Group: AED will be based upon DR grading and the disposition recommendation as that information is provided on the exam report from the participant's usual eye care professional. Any one of the following will be considered indicative of AED if noted on the report: a) moderate or severe non-proliferative DR; b) any proliferative DR; c) clinically significant macular edema (CSME); d) referral to an ophthalmologist; e) recommendation for re-examination in \<12 months.

On-Site Screening Group: AED will be based on interpretation of non-mydriatic UWF images by a retinal specialist where AED will require at least 1 finding of: DR (intra-retinal microvascular abnormalities or venous beading \>/= 2 quadrants, neovascularization elsewhere, neovascularization of the disc, vitreous hemorrhage) or diabetic maculopathy (microaneurysms, retinal hemorrhages or exudates within 1 disc diameter of the fovea), within 12 months of randomization","Western University, Canada",742,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2016-03
NCT01478737,Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01478737,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Intravitreal dexamethasone implant|PROCEDURE: Vitrectomy,"Reoperation, The proportion of patients that, due to re-bleeding within 12 months, have a second PPV, 12 months",Anders Kvanta,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2011-11
NCT02464800,Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02464800,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Vitrectomy for proliferative diabetic retinopathy,"Visual acuity, 6 months",Kyorin University,326,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-04
NCT00900887,Topic Antiinflammatory Therapy Added to Selective Photocoagulation in Macular Edema,https://clinicaltrials.gov/study/NCT00900887,COMPLETED,Diabetic Retinopathy|Macular Edema,"DRUG: Ketorolac|DRUG: Nepafenac|DRUG: Polietilenglicol 400, propilenglicol","ocular topic antiinflammatory therapy (ketorolac, nepafenac or placebo) applied 3 times a day in the treated eye for a week after selective photocoagulation, one week after treatment",Hospital Juarez de Mexico,84,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2008-04
NCT03571100,Comfort and Antimicrobial Efficacy of Chlorhexidine vs Betadine for Intravitreal Injections,https://clinicaltrials.gov/study/NCT03571100,UNKNOWN,Age-related Macular Degeneration|Diabetic Vascular Diseases|Proliferative Retinopathy|Retina Vein Occlusion,DRUG: Chlorhexidine|DRUG: Povidine-Iodine,"Patient Comfort, Patient Comfort using the Wong Baker FACES Pain Scale \[Scale: 0(No pain) - 10 (Worst Pain)\], One day following injection",MidAtlantic Retina,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2018-05-07
NCT04436900,Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04436900,COMPLETED,"Diabetes Mellitus, Type 2",PROCEDURE: Panretinal Photocoagulation (PRP),"Life Quality, A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease Which is measured by a quality of life questionnaire, up to 3 months|RNFL, retinal nerve fiber layer which measured by PP-OCT (optical coherence tomography), up to 30 days|BCVA, best corrected visual acuity which measured by SD-OCT, up to 3 months|Retinal thickness in the central part of Fovea, Measured by SD-OCT, up to 30 days|Choroid thickness in the central part of Fovea, Measured by EDI-OCT, up to 30 days|Physical examination of PDR, An eye exam performed by an ophthalmologist will determine if there is retinopathy, up to 3 months|Contrast sensitivity, Contrast sensitivity which measured by Melbourne edge test, up to 3 months|Angiography with fluorescein, By injecting fluorescein into the vein and then taking an X-ray to diagnose PDR, up to 3 months",Baqiyatallah Medical Sciences University,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-04-10
NCT01075347,Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries,https://clinicaltrials.gov/study/NCT01075347,COMPLETED,Corneal Epithelial Defect|Diabetic Retinopathy|Penetrating Keratoplasty,OTHER: autologous serum|OTHER: Non-autologous serum,"Patients With Corneal Epithelial Healing Time Within 14 Days, Patients were hospitalized and examined daily for graft re-epithelialization, which was the main outcome measure.Corneal epithelial healing(the process which the new corneal epithelial cells regenerated to cover the bare cornea lost of its epithelium, the cornea's outer layer) was recorded daily by slit-lamp examination with fluorescein staining.Patients with post-operative chronic persistent epithelial defects for \>14 days after the operation were treated with therapeutic contact lens (TCL) application and followed up as outpatients., every day till total re-epithelization up to 14 days",National Taiwan University Hospital,165,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-03
NCT04552600,Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.,https://clinicaltrials.gov/study/NCT04552600,UNKNOWN,Diabetic Retinopathy,DRUG: Nuvastatic|OTHER: Placebo,"To evaluate efficacy of Nuvastatic - Retinal Thickness, Central Subfield Retinal Thickness, 12 months|To evaluate efficacy of Nuvastatic - protein biomarkers, protein biomarkers, 12 months|To evaluate safety of Nuvastatic - Letter Score, Visual Acuity Letter Score, 12 months",Natureceuticals Sdn Bhd,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2019-09-01
NCT00370422,Bevacizumab Versus Combined Bevacizumab and Triamcinolone for Refractory Diabetic Macular Edema; a Randomized Clinical Trial,https://clinicaltrials.gov/study/NCT00370422,UNKNOWN,Diabetic Macular Edema,"DRUG: Triamcinolone, Bevacizumab",Visual acuity|Central macular thickness,Shahid Beheshti University of Medical Sciences,,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2005-11
NCT02432547,Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO),https://clinicaltrials.gov/study/NCT02432547,COMPLETED,Diabetic Retinopathy,DRUG: Aflibercept|PROCEDURE: Targeted laser therapy,"Number of intravitreal aflibercept injections over 24 months, Number of intravitreal aflibercept injections in each of the 2 groups required over 24 months, 24 months",University of Sydney,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-15
NCT05978622,Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant,https://clinicaltrials.gov/study/NCT05978622,RECRUITING,Diabetic Macular Edema,,"Number of Additional Anti-VEGF Injections after Baseline and before DEX-I Initiation, Number of Additional Anti-VEGF Injections after Baseline and before DEX-I Initiation, Baseline to 18 Months",AbbVie,327,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-10-30
NCT02334137,A Pilot Project to Assess the Impact of Diabetes Education During Ophthalmology Visits,https://clinicaltrials.gov/study/NCT02334137,COMPLETED,Diabetes Complications|Diabetic Retinopathy,BEHAVIORAL: iPad app|BEHAVIORAL: Educator sessions|BEHAVIORAL: Retinal photos,"Change from Baseline in Patient Knowledge about Diabetes at 3 months (via multiple-choice surveys), Objective assessment of patient knowledge about diabetes using 13 multiple-choice questions, Participants will be re-surveyed at their next follow-up eye appointment, an expected average of 3 months post-intervention",California Pacific Medical Center Research Institute,36,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11
NCT00168337,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00168337,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone|OTHER: Sham,"Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye, BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening., Baseline, Month 39/Final Visit",Allergan,554,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-05
NCT00692614,A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001),https://clinicaltrials.gov/study/NCT00692614,TERMINATED,Macular Edema,DRUG: triamcinolone acetonide,"Change from baseline in OCT retinal thickness; evaluate the safety and tolerability of doses., After 12 months of therapy.",Merck Sharp & Dohme LLC,2,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2008-06
NCT01717937,Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging,https://clinicaltrials.gov/study/NCT01717937,TERMINATED,Age-related Macular Degeneration|Diabetic Retinopathy|Hypertensive Retinopathy|Retinal Vein Occlusion|Retinal Artery Occlusion,PROCEDURE: Phase variance optical coherence tomography (PV-OCT),"Measurement of to be determined physical characteristics of retinovascular structures seen on phase variance optical coherence tomography (PV-OCT) and fluorescein angiography(FA)., Masked examiners (retina specialists) will evaluate and grade coded PV-OCT and FA images for the presence and features of various retinovascular abnormalities (e.g., choroidal neovascular membranes, microaneurysms, venous dilation, etc.). Metrics to determined and may include: size, depth, area, volume, and relative position. Each subject's graded PV-OCT images will be compared to their graded FA images., On the day in which a patient receives PV-OCT and FA imaging, estimated to take 2 hours.","University of California, San Francisco",10,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-02
NCT01840683,HELP Therapy for Dry AMD,https://clinicaltrials.gov/study/NCT01840683,COMPLETED,Non-exudative (Dry) Age-related Macular Degeneration (AMD),DEVICE: H.E.L.P. therapy (H.E.L.P. Plasmat Futura System),"To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD., Change from Baseline in the best corrected visual acuity (BCVA) at Week 24 after completion of H.E.L.P. therapy",B.Braun Avitum AG,22,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-05
NCT02796183,The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02796183,COMPLETED,Diabetic Macular Edema,DRUG: Subconjunctival bevacizumab (Altuzan),"Central Macular Thickness, one year (between May 2015 and May 2016)",Neon Hospital,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01
NCT04332133,Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04332133,COMPLETED,Diabetic Macular Edema,"PROCEDURE: laser interference,INTRAVITREAL INJECTION","central subfield thickness in micrometer, OCT for the macular area with measuring CST in micron, 6 months|p1 amplitude of mfERG, p1 amplitude of multifocal ERG measured in nv/deg2, 6mnths|BCVA, BCVA is measured in decimal of Snellen visual acuity, 6 months",Minia University,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-12
NCT00996437,Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N),https://clinicaltrials.gov/study/NCT00996437,COMPLETED,Vitreous Hemorrhage|Proliferative Diabetic Retinopathy,DRUG: Ranibizumab|DRUG: Saline,"Treatment or ""Failure"" Defined as Vitrectomy, The cumulative probabilities of vitrectomy by 16 weks (112 days) in each group were computed using the life-table method. The treatment group comparison was made using the log-rank test. Data were censored at the time point of the participant's last completed visit., within 112 days of randomization|Safety (Injected-related, Ocular Drug-related and Systemic Drug-related), Baseline to 16 weeks",Jaeb Center for Health Research,261,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-06
NCT00907114,Topic Ketorolac Added to Panphotocoagulation in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00907114,COMPLETED,Proliferative Diabetic Retinopathy|Macular Edema,DRUG: Ketorolac tromethamine|DRUG: Polivynilic alcohol,"center subfield mean thickness using Stratus OCT measured in microns, baseline, 24, 48 and 168 hours after treatment",Hospital Juarez de Mexico,44,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2009-06
NCT02181400,Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT02181400,COMPLETED,Diabetic Macular Oedema,DEVICE: Ellex Integre NIR laser,"Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month, Change in measurement( in microns) in central macular thickness as measured by Spectral Domain Optical Coherence Tomography( OCT), Change from baseline in central macular thickness at one month|Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography (OCT) at Two Months, Change in measurement (in microns) in central macular thickness as measured by Spectral Domain Optical Coherence Tomography (OCT), Change from baseline central macular thickness at two months|Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at One Month., The change in total macular volume was taken as the difference between the total macular volume as measured by Spectral Domain Optical Coherence Tomography at 1 month and the total macular volume at baseline, Change from baseline total macular volume at one month|Change in Total Macular Volume as Measured by Spectral Domain Optical Coherence Tomography at Two Months., The change in total macular volume was taken as the difference between the total macular volume as measured by Spectral Domain Optical Coherence Tomography at 2 month and the total macular volume at baseline, Change from baseline total macular volume as measured by OCT at two months",University of Sydney,21,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-04-19
NCT05166122,Implementation of an Integrated System of Artificial Intelligence and Referral Tracking for Real-time Diabetic Retinopathy Screening,https://clinicaltrials.gov/study/NCT05166122,RECRUITING,Diabetic Retinopathy|Artificial Intelligence|Screening,DIAGNOSTIC_TEST: Artificial Intelligence,"Referral adherence, Total number of patients who completed referral visit in each arm (ie, presented to tertiary eye care center), 6 months",Rajavithi Hospital,1600,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2022-01-01
NCT00320814,Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00320814,COMPLETED,Diabetic Macular Edema,DRUG: VEGF Trap-Eye,"To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME), Assessments for safety and tolerablity are performed at each visit (Visit 1 - Visit 10)",Regeneron Pharmaceuticals,5,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-04
NCT02177747,Smartphone-based Ophthalmoscopy,https://clinicaltrials.gov/study/NCT02177747,COMPLETED,Diabetic Retinopathy Grading,OTHER: Ophthalmoscopy conducted using a smartphone equipped with a compact addon|DEVICE: Smartphone,"Diabetic retinopathy grading, The grading was performed according to the Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy classification.

Grade 0: no diabetic retinopathy Grade 1: mild non-proliferative diabetic retinopathy Grade 2: average non-proliferative diabetic retinopathy Grade 3: severe non-proliferative diabetic retinopathy Grade 4: proliferative diabetic retinopathy, The same day as dilated ophthalmic examination",Università degli Studi di Brescia,120,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: |Primary Purpose: ",2013-11
NCT05296447,Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05296447,ENROLLING_BY_INVITATION,"Diabetic Retinopathy, DR",OTHER: No Intervention,"To evaluate the long-term safety of RGX-314, Incidence of overall and ocular adverse events, serious adverse events, and all adverse events of special interest, 5 years inclusive of the parent study",AbbVie,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-04
NCT00498147,Determining Rates of Cardiovascular Complications Among Patients of a Managed Diabetes Care Program,https://clinicaltrials.gov/study/NCT00498147,UNKNOWN,Disease Management|Diabetes Complications|Diabetic Vascular Complications|Diabetic Neuropathy|Diabetic Nephropathy|Diabetic Retinopathy,OTHER: ADEC Program,"Rates of cardiovascular events and other complications of diabetes compared to provincial and national rates, 1 year",Group Health Centre,1213,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-07
NCT04774822,"Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device",https://clinicaltrials.gov/study/NCT04774822,COMPLETED,Diabetic Retinopathy|Diabetic Eye Problems|Diabetic Macular Edema,PROCEDURE: Color Fundus Photography|DRUG: Mydriatics Agent|PROCEDURE: Optical Coherence Tomography (OCT),"To determine the sensitivity and specificity of RETINA-AI Galaxy to detect more than mild diabetic retinopathy in the primary care setting, To determine the sensitivity and specificity of RETINA-AI Galaxy for detecting more than mild diabetic retinopathy (mtmDR) defined as moderate non-proliferative diabetic retinopathy, severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, or clinically significant diabetic macula edema., 1 visit (1 day)|To determine the sensitivity and specificity of RETINA-AI Galaxy to detect vision-threatening diabetic retinopathy in the primary care setting, To determine the sensitivity and specificity of RETINA-AI Galaxy for detecting vision threatening diabetic retinopathy (vtDR) defined as severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, or clinically significant diabetic macula edema., 1 visit (1 day)","RETINA-AI Health, Inc.",397,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-03-25
NCT02879422,Genetic Markers and Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02879422,COMPLETED,Proliferative Diabetic Retinopathy,GENETIC: genetic analysis,"Proliferative retinopathy diabetic, diabetic retinopathy with a preretinal and / or prepapillary neovascularization diagnosed using ultra-wide-field imaging, Day 0",CHU de Reims,302,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2013-10-16
NCT04117022,Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG,https://clinicaltrials.gov/study/NCT04117022,UNKNOWN,Diabetes|Diabetic Retinopathy,DIETARY_SUPPLEMENT: DVS supplementation,"Chromatic ERG (ChERG) Outcome Measurements: B wave and PhNR latency (milliseconds) Full field ERG outcome measurements and Chromatic ERG Outcome Measurements, The Chromatic Electroretinogram (chERG) and the full field ERG will be recorded using a commercially available system Diopsys® NOVA (Diopsys, Inc. Pine Brook, New Jersey). The Red-Blue stimulus will be presented using a mini-Ganzfeld handheld device. The entire process consists of two tests per eye, with twenty-five seconds allocated for each test; thus, the total duration of the test is one hundred seconds. The chERG will be consecutively recorded from both eyes by means of proprietary adhesive skin electrodes on the lower eyelid and forehead., Change from Baseline to 6 months|Full-field flicker ERG (ffERG) Measurements: magnitude (microvolts) and the phase (milliseconds) and the area ratio for magnitude and the area ratio for Phase, The Flicker ERG will be recorded using a commercially available system, Diopsys® NOVA (Diopsys, Inc., Pine brook, NJ), version 2.19.19778.7332). The Flicker ERG will be consecutively recorded from both eyes by means of adhesive skin electrodes on the lower eyelid and skin. The stimulus will consist of white flashes flickering at 32 Hz over a white background as well as a sequence of 6 steps of increasing luminance., Change from Baseline to 6 months","ZeaVision, LLC",45,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2019-09-01
NCT05573100,The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT05573100,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: CU06-1004,"The change of central subfield thickness (CST), Change in CST in the study eye assessed by SD-OCT at Week 12 compared to baseline, Baseline and 12 weeks|To determine the optimal doses, The 1:1:1 randomization is fitting for the study objective to determine the optimal doses for a phase 2b study., 12 weeks","Curacle Co., Ltd.",60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-12-21
NCT05677685,VISUPRIME® Eye Drops,https://clinicaltrials.gov/study/NCT05677685,NOT_YET_RECRUITING,"Macular Degeneration, Age Related|Myopic Choroidal Neovascularisation|Proliferative Diabetic Retinopathy|Diabetic Macular Edema|Macular Edema of Right Retina (Diagnosis)",DEVICE: VISUPRIME|DEVICE: Placebo,"CFU (Colony Forming Units), Primary endpoint is to evaluate the change in bacterial loads in terms of CFU/ sample in the two groups at V0 compared to V1., three days",VISUfarma SpA,76,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2023-01-30
NCT01783886,Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement,https://clinicaltrials.gov/study/NCT01783886,COMPLETED,Macular Edema,"BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|BIOLOGICAL: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF), Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard for macular laser photocoagulation treatment. A higher score represents better functioning. LOCF censored measurements after additional treatment., Baseline up to week 52",Bayer,381,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02
NCT01175486,Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy,https://clinicaltrials.gov/study/NCT01175486,UNKNOWN,Diabetes,DRUG: Actos (Pioglitazone)|DRUG: Acarbose,"Diabetic retinopathy, The macular thickness changes, 6 months|Diabetic nephropathy, The changes in the level of urinary albumin-to-creatinine ratio, 6 months","Taipei Veterans General Hospital, Taiwan",200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-07
NCT05715385,Comparison of Treatments in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05715385,COMPLETED,Diabetic Macular Edema,PROCEDURE: laser photocoagulation|DRUG: eye drop bromfenac 0.09%|DRUG: Placebo,"Change in visual acuity in laser photocoagulation group, Best corrected visual acuity will be measured by logMAR scale, Baseline and 6 weeks|Change in visual acuity in bromfenac group, Best corrected visual acuity will be measured by logMAR scale, Baseline and 6 weeks|Change in visual acuity in observation group, Best corrected visual acuity will be measured by logMAR scale, Baseline and 6 weeks",Babasaheb Ambedkar Memorial Hospital,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2014-11
NCT00668785,Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II),https://clinicaltrials.gov/study/NCT00668785,TERMINATED,Proliferative Diabetic Retinopathy|Macular Edema,DRUG: ranibizumab,"Mean Change From Pre-PRP Best Corrected Visual Acuity (BCVA) at 3 Months as Expressed as an Early Treatment Diabetic Retinopathy Study (ETDRS) Score (Number of Letters Correctly Read.), No outcome measures were obtained for this study. Study was terminated by Investigator/Sponsor due to low enrollment. The data was not formally analyzed but reviewed only on a case study basis., March 2010","Jumper, J. Michael, M.D.",6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-03
NCT01724385,Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01724385,COMPLETED,Vitreous Hemorrhage|Proliferative Diabetic Retinopathy,DRUG: intravitreal injection of bevacizumab,"The percentage of eyes that vitreous hemorrhage has been completely resolved, The patients with PDR and prior complete laser treatment who presented with new dense VH. All eyes were treated with intravitreal bevacizumab injection. Complete ophthalmic examination and/or ocular ultrasonography were performed at baseline and 1, 6, 12 weeks and 6, 9, 12 months after first injection., 12 months",Khon Kaen University,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-08
NCT05130385,High Resolution Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT05130385,RECRUITING,Retinal Disease|Retinal Detachment|Retinal Vein Occlusion|Retinal Dystrophy|Retinal Artery Occlusion|Retinal Edema|Retinal Neovascularization|Uveitis|Diabetic Retinopathy|Diabetic Macular Edema|Macular Edema|Macular Degeneration|Macular Disease|Glaucoma|Optic Nerve Diseases|Hypertensive Retinopathy,DEVICE: High-resolution optical coherence tomography (High-Res-OCT)|DEVICE: Standard spectral domain OCT (SD-OCT),"Evaluation of the sensitivity and specificity of High-Res-OCT for retinal fluid, The primary objective of this observational study is to evaluate the sensitivity and specificity to diagnose retinal morphological abnormalities with High-Resolution OCT compared to conventional imaging method (SD-OCT). The main parameter that will be assessed is the presence/absence of retinal fluid. The incidence (binary) of retinal fluid will be assessed in High-Resolution OCT and compared to conventional imaging method, such as standard-OCT (SD-OCT), 2 years","Insel Gruppe AG, University Hospital Bern",550,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-11-30
NCT02447185,25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial,https://clinicaltrials.gov/study/NCT02447185,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Ranibizumab|DRUG: Triamcinolone Acetonide,"intraoperative bleeding, during operation of 25-G Vitrectomy",JUNYAN ZHANG,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2015-06
NCT03485586,Comparison of the Visual Quality of Traditional Ultrasound Biometrics and Lenstar on the Cataract After Pars Plana Vitrectomy,https://clinicaltrials.gov/study/NCT03485586,UNKNOWN,Diabetic Retinopathy Patients After Vitrectomy,DEVICE: Traditional ultrasound biometrics|DEVICE: Lenstar,"the visual quality of the eye after surgery, the visual quality of the eye after surgery through optical path difference scan（OPD Scan）, one month|the visual quality of the eye after surgery, the visual quality of the eye after surgery through optical path difference scan（OPD Scan）, three month",Bojie Hu,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-04-03
NCT01131585,Safety and Efficacy of Ranibizumab in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01131585,TERMINATED,Visual Impairment Due to Diabetic Macular Edema,PROCEDURE: Active laser photocoagulation|DRUG: Sham injections|DRUG: Ranibizumab 0.5 mg,"Change in Best-Corrected Visual Acuity (BCVA) From Baseline to Month 12, Mean change in Best-Corrected Visual Acuity (BCVA) letters at 12 months compared to baseline was measured using Visual acuity (VA). VA accounts for the number of letters a participant can see using Early Treatment Diabetic Retinopathy Study (EDTRS)-like visual acuity testing charts, from a sitting position at a testing distance of 4 meters. BCVA means that the participant's refraction is already taken into account when VA is determined. A higher BCVA number at 12 months in reference to baseline indicates improved BCVA., 12 months",Novartis Pharmaceuticals,128,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-06
NCT03126786,Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03126786,COMPLETED,Diabetic Macular Edema,DRUG: IVT aflibercept|DRUG: Sham SC|DRUG: SC CLS-TA,"Mean Change From Baseline in Best Corrected Visual Acuity Letter Score, Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement., Baseline, 6 months","Clearside Biomedical, Inc.",71,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-07-11
NCT05610319,"Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial",https://clinicaltrials.gov/study/NCT05610319,RECRUITING,Diabetic Macular Edema,DRUG: Faricimab,"Change in Best Corrected Visual Acuity, Change in best corrected visual acuity (3.9 letter non-inferiority margin), Baseline to Week 100",McMaster University,446,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2023-05-01
NCT00090519,Reduction in the Occurrence of Center-Involved Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00090519,COMPLETED,Diabetic Retinopathy,DRUG: ruboxistaurin|DRUG: placebo,"Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME), Duration of center of macula involvement when primary study outcome (DME involvement in center of macula determined by central grading of stereoscopic fundus photographs) was identified at a visit, participant was considered to have had definite center involvement for a specified length of time between the adjacent visits. Total duration of center involvement was calculated. Mean duration was total duration of center involvement divided by total number of participants. Participant durations were summarized, total number of months of center involvement in both treatment groups were displayed., 6 Months through 36 Months|Occurrence of Sustained Moderate Visual Loss (SMVL) in a Diabetic Retinopathy (DR) Study Eye, The occurrence of SMVL was defined as ≥15 letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) in any DR study eye relative to baseline that is sustained for the last 6 months of participation. ETDRS VA: participant starts at the top of the chart containing 5 letters per row and reads down the chart until reaching a row where a minimum of 3 letters on a line cannot be read. Participant is scored by how many letters could be correctly identified. A higher number of letters correctly identified represents better visual acuity., Baseline, 36 Months","Chromaderm, Inc.",731,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2004-02
NCT04488887,OCTA Metrics Repeatability and Reproducibility in Different Disorders,https://clinicaltrials.gov/study/NCT04488887,UNKNOWN,Diabetic Retinopathy|Myopia|Choroidal Neovascularization|Healthy,DIAGNOSTIC_TEST: Optical coherence tomography angiography,"The intraclass correlation coefficient (ICC), ICC is the correlation between two variables measured at the same time point, with values ranging from 0 to 1 (\<0.40, poor; 0.40-0.59, fair; 0.60-0.74, good; 0.75-1.00, excellent)., 5 months|coefficient of variation (CV), The CV (%) will be calculated as 100 × standard deviation/overall mean, and a value \<10% represents good repeatability of the measurement., 5 months",Tanta University,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-01
NCT02510885,SD-OCT Angiography,https://clinicaltrials.gov/study/NCT02510885,TERMINATED,Neovascular Age-related Macular Degeneration|Age-related Macular Degeneration|Diabetic Retinopathy|Retinal Vein Occlusion|Diabetic Macular Edema,DEVICE: AngioVue SD-OCT,"Number of Participants With Image Quality Sensitive Enough to Identify Specific New Vessel Morphology, Day 0",Duke University,39,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2015-07
NCT00464685,Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00464685,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone|DRUG: Sham injection|PROCEDURE: Laser Photocoagulation,"Percentage of Patients With at Least 10 Letters of Improvement in Best Corrected Visual Acuity (BCVA) From Baseline in the Study Eye, BCVA is measured in the study eye using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening., Baseline, Month 12",Allergan,253,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-05-01
NCT06124586,Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS),https://clinicaltrials.gov/study/NCT06124586,NOT_YET_RECRUITING,Diabetic Foot|Diabetes Mellitus|Peripheral Arterial Disease|Diabetic Neuropathies|Diabetic Retinopathy|Anemia|Ulcer Foot|Ulcer Ischemic|Diabetic Polyneuropathy,PROCEDURE: percutaneous transluminal angioplasty,"effect of an immediate (within first 48h) PTA intervention on microbiome composition, assessed by whole-genome sequencing techniques) in diabetic foot ulcera compared to an elective (Standard of Care group) PTA intervention., Baseline to one year follow up","Heinrich-Heine University, Duesseldorf",200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-10
NCT03732287,Cooling Anesthesia for Intravitreal Injection,https://clinicaltrials.gov/study/NCT03732287,COMPLETED,"Anesthesia, Local|Intravitreal Injection|Macular Degeneration|Diabetic Macular Edema",DEVICE: Cooling Anesthesia,"Subjective Pain, Pain as measured by the visual analogue scale (VAS). This was used in the previously presented SOLAR study (Clinical trials.gov, NCT01926977). Total range is 0-10, with 0 being no pain, and 10 being unbearable pain., 24-48 hours after injection|Number of patients with treatment adverse events as measured by slit lamp examination, Full slit lamp examination of anterior and posterior segment after intravitreal injection, 30 minutes after injection","Recens Medical, Inc.",40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-11-30
NCT00369486,A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00369486,COMPLETED,Diabetic Macular Edema,PROCEDURE: Focal laser photocoagulation|DRUG: 40mg triamcinolone|DRUG: 20mg triamcinolone|DRUG: 40mg triamcinolone + laser|DRUG: 20mg triamcinolone + laser,"Change in Central Subfield Thickening From Baseline Through 34 Weeks, Change in Central Subfield Thickening from Baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. Negative changes represent a decrease in retinal thickening., 4, 8, 17, 34 weeks|Change in Visual Acuity Letter Score From Baseline Through 34 Weeks, Change in visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the electronic Early Treatment for Diabetic Retinopathy Study(E-ETDRS) technique. Letter score best value = 97 and worst value = 0; an increase in a letter score by 10 is considered clinically significant. Negative changes represent a worsening in visual acuity., 4, 8, 17, and 34 weeks|Mean Visual Acuity Letter Score at Each Follow-up Visit, Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) mean visual acuity letter score: best value = 97; letter score worst value = 0, 4, 8, 17, and 34 weeks",Jaeb Center for Health Research,113,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2004-12
NCT00604383,Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study,https://clinicaltrials.gov/study/NCT00604383,COMPLETED,Diabetic Retinopathy,DRUG: ruboxistaurin|DRUG: placebo,"Percentage of Participants Who Had Sustained Moderate Visual Loss (SMVL) as Defined as a Visual Acuity Loss of ≥15 Letters Measured Twice During a 6-month Period, SMVL is defined as a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that the participant sustained during the last 6 months of study participation (Months 30-36). Participants who discontinued the study early may have had SMVL if there was a 6-month period of ≥15 letters lost in VA ending with the last visit at which VA was assessed. ETDRS visual acuity uses an eye chart with 5 letters per line. The scores range from 0 (no letters read correctly) to 100 (all letters read correctly). Percentage of participants = (number of participants who had SMVL) / (number of participants who were randomized) \* 100., Baseline through 36 months","Chromaderm, Inc.",685,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2001-03
NCT00915837,Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00915837,COMPLETED,Diabetic Macular Edema,DRUG: triamcinolone acetonide|DRUG: triamcinolone acetonide,"Best Corrected Visual Acuity, every 3 months for 36 months","SurModics, Inc.",31,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-06
NCT01415037,Annular Array Ultrasound in Ophthalmology,https://clinicaltrials.gov/study/NCT01415037,COMPLETED,Posterior Vitreous Detachment|Diabetic Retinopathy,PROCEDURE: annular array ultrasound exam,"Change in detection of posterior vitreous detachment: 20MHz annular array versus 10MHz single element, The investigators will examine eyes with both conventional 10MHz ultrasound and a 20MHz annular array with synthetic focusing. The investigators will evaluate and compare images acquired with both techniques and determine their relative efficacy in visualizing the presence or absence of posterior vitreous detachment., Subjects will be examined with both the 20MHz annular array and 10MHz single element ultrasound during the same exam, approximately 30 minutes in duration.",Columbia University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-10
NCT02645383,PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System,https://clinicaltrials.gov/study/NCT02645383,COMPLETED,Diabetic Retinopathy,DEVICE: PASCAL laser|DEVICE: Conventional laser,"Verbal Score for pain, Verbal Score for pain was measured as units on the scale 10 minutes after the completion the laser procedure., 3 months|Visual analog score for pain, Visual Analog Score for pain was measured as units on the scale 10 minutes after the completion the laser procedure., 3 months",Kocatepe University,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2014-05
NCT00849537,The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00849537,UNKNOWN,Diabetic Retinopathy,DRUG: Triamcinolone,"Macula diameter, 6th week, 3, 6 months",Shahid Beheshti University of Medical Sciences,,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2008-04
NCT03606733,Suprachoroidal Injection of Triamcinolone Acetonide Using Custom Made Needle to Treat Retinal Disorders,https://clinicaltrials.gov/study/NCT03606733,UNKNOWN,"Diabetic Macular Edema, Cystoid Macular Edema, Chorodial Neovascularzation, Posterior Uveitis",PROCEDURE: Custom suorachoroidal needle,"Proportion of patients achieved visual acuity improvement, To measure best corrected visual acuity using using Snellen chart or equivalent, 12 weeks",Marashi Eye Clinic,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-07-01
NCT05222633,Anti-VEGF in Real-world,https://clinicaltrials.gov/study/NCT05222633,RECRUITING,Neovascular Age-related Macular Edema|Diabetic Macular Edema|Choroidal Neovascular Membrane|Non-proliferative Diabetic Retinopathy|Retinal Vein Occlusion|Proliferative Diabetic Retinopathy,DRUG: Ranibizumab|DRUG: Aflibercept|DRUG: Conbercept,"Visual acuity, LogMAR visual acuity, 1 year|Central subfield thickness, he central subfield is defined as the circular area 1 mm in diameter centered around the center point of the fovea, 1 year",Wenbin Wei,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-01
NCT01869933,Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X,https://clinicaltrials.gov/study/NCT01869933,COMPLETED,Proliferative Diabetic Retinopathy (PDR),DRUG: OC-10X,"Ocular Safety and Tolerability, Ocular safety and tolerability will be assessed by subject query, biomicroscopy of anterior segment, ophthalmoscopy, measuring intraocular pressure (IOP) and checking visual acuity by modified Early Treatment Diabetic Retinopathy Study (ETDRS)., 17 Days","OcuCure Therapeutics, Inc.",10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-04
NCT00252733,Diabetic Retinopathy Candesartan Trials,https://clinicaltrials.gov/study/NCT00252733,COMPLETED,Type 1 Diabetes,DRUG: candesartan cilexetil,"Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale., Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments., From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.",AstraZeneca,5238,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-06
NCT02772497,3 Month Outcome of Ziv-aflibercept for DME,https://clinicaltrials.gov/study/NCT02772497,COMPLETED,Diabetic Macular Edema,DRUG: Ziv aflibercept,"Proportion of visual acuity improvement using Snellen chart or equivalent, 3 months",Marashi Eye Clinic,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-01
NCT03579797,Shanghai Diabetic Eye Study in Diabetics,https://clinicaltrials.gov/study/NCT03579797,UNKNOWN,Diabetic Eye Diseases|Diabetic Retinopathy,"BEHAVIORAL: Screening, referral, follow-up and health management","Diabetic retinopathy, Prevalence of DR and diabetic macular edema. The DR grades are according to the well-accepted""International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scale""., December 31, 2018|Diabetic eye diseases, Prevalence of eye diseases due to diabetes., December 31, 2018|Visual impairment, Visual impairment was present if best corrected visual acuity \<20/25, December 31, 2018|Glycosylated hemoglobin, This test measure the average blood sugar control for the previous three months or so., December 31, 2018|Diabetics adherence to Diabetic Eye Diseases Study, Predicting adherence in the research were obtained by Questionnaire for the study participants., December 31, 2018|Diabetics satisfaction for the SDES, Diabetics satisfaction for the screening study，the community health service centers (CHSC)，and the designated medical institutions were obtained by Questionnaire for the study participants., December 31, 2018|Referral compliance, Referral compliance of diabetics were obtained by Questionnaire and Shanghai eye health information service system for the study participants., December 31, 2018|Human resources and ophthalmic equipment resources, Compared to human resources and ophthalmic equipment resources in the community health service centers (CHSC)，and the designated medical institutions before and after the SDES by Questionnaire., December 31, 2018|Eye health management, All the study participants will be recommended appropriate eye health management., December 31, 2018",Shanghai Eye Disease Prevention and Treatment Center,200000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-01-01
NCT04776343,"Study Comparing Two Populations of Patients Treated With Anti VEGF for Diabetic Macular Edema, One Being Followed at the Hospital and the Other One Being Followed at Home Using a Software Allowing Self-assessment of Visual Acuity",https://clinicaltrials.gov/study/NCT04776343,NOT_YET_RECRUITING,Diabetic Macular Edema,OTHER: telemedecine follow-up,"Rate of patients with VA evolution in the two groups, rate in percentage, 36 months","Hospital St. Joseph, Marseille, France",88,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-04
NCT00069056,Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00069056,COMPLETED,Diabetic Retinopathy,PROCEDURE: Laser Treatment,,National Eye Institute (NEI),4,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2003-09-10
NCT03076697,Smartphone Screening for Eye Diseases,https://clinicaltrials.gov/study/NCT03076697,ENROLLING_BY_INVITATION,Diabetes Mellitus|Glaucoma|Age Related Macular Degeneration|ROP|Diabetic Retinopathy|Retinal Disease,DIAGNOSTIC_TEST: Fundus photography,"Disease diagnosis based on photography, Ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination for agreement between the graders for the diagnosis of eye disease along with the sensitivity and specificity., The outcome measure will be assessed and data will be presented through study completion, an average of 1 month.",University of Michigan,550,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-04-16
NCT00548197,Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment,https://clinicaltrials.gov/study/NCT00548197,COMPLETED,Intravitreal Bevacizumab Injection|Pars Plana Vitrectomy|Tractional Retinal Detachment|Diabetic Retinopathy,DRUG: Bevacizumab,"Best Corrected Visual Acuity, Post operative best corrected visual acuity ( best distance vision with eyeglasses or contact lenses), last follow up, an average of 7 months post-operation",Iran University of Medical Sciences,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2007-02
NCT05478967,The Effect of IVA for Preventing Postvitrectomy Hemorrhage in PDR,https://clinicaltrials.gov/study/NCT05478967,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: IVA injection before vitrectomy,"Incidence of VH, Postoperative VH was defined as a new episode of VH of grade 1 or above occurring later than 3 days after primary surgery and was evaluated according to the Diabetic Retinopathy Vitrectomy Study grading system., one month after vitrectomy",Peking University People's Hospital,154,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2019-08-08
NCT00563043,Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment,https://clinicaltrials.gov/study/NCT00563043,UNKNOWN,Non Proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy,PROCEDURE: PASCAL laser treatment,"Changes in a wave amplitude, 12 weeks|changes in b wave amplitude, 12 weeks|changes in ERG implicit time, 12 weeks",Asociación para Evitar la Ceguera en México,8,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-10
NCT06198543,Study on Exosome Changes in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06198543,NOT_YET_RECRUITING,Diabetic Retinopathy,,"differential proteins of exosomes, Exosomes from plasma, atrial fluid and vitreous fluid were isolated and extracted, and proteomic analysis of proteins in exosomes was performed to analyse the number of differentially expressed protein species in the test and control groups, and bioinformatics analysis of up-regulated or down-regulated expressed proteins was performed., January 2024 - January 2025","Xuanwu Hospital, Beijing",60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-01
NCT00198497,Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage,https://clinicaltrials.gov/study/NCT00198497,COMPLETED,Vitreous Hemorrhage|Diabetic Retinopathy,DRUG: Placebo|DRUG: Vitrase|DRUG: Vitrase,"Vitreous hemorrhage resolution, laser treatment of underlying cause of vitreous hemorrhage, or other surgical treatment, or documented evidence of macula \& at least 180 degrees of vitreous base, that vitreous hemorrhage cause is resolved, 3 months",Bausch & Lomb Incorporated,510,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",1999-06
NCT01112085,MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2),https://clinicaltrials.gov/study/NCT01112085,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab 0.05mg|DRUG: Ranibizumab 0.5mg,"Best corrected visual acuity, Improvement in vision of best corrected visual acuity of 15 or more letters, or a final vision of 20/25 (50 letters) or better if best corrected visual acuity (BCVA) was 20/40 (40 letters), 12 months",Especialistas en Retina Medica y Quirurgica Grupo de Investigacion,72,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-04
NCT00427986,Clinical Study of the Effect of Intravenous Galactose on Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT00427986,TERMINATED,Diabetic Macular Oedema,"DRUG: Galactose, intravenous","Retinal thickness estimated by the fast protocol of the StratusOCT (0, 2, 4, 8, 10, 15, 20, 30, 60, 90, 120 and 180 min)., three hours","Glostrup University Hospital, Copenhagen",1,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT,2007-01
NCT03403686,Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR),https://clinicaltrials.gov/study/NCT03403686,RECRUITING,Diabetic Retinopathy,BIOLOGICAL: blood draw,"Assessing CD34+ cells function, We are isolating CD34+ cells from peripheral blood and then examining the cell membrane characteristics of CD34+ cells and their in vitro function., from blood draw to 48 hours",University of Alabama at Birmingham,104,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-11
NCT02823600,Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers,https://clinicaltrials.gov/study/NCT02823600,COMPLETED,"Kidney Failure, Chronic|Eye Diseases|Diabetic Retinopathy",DEVICE: RetinaVue 100 camera,"Usability of the RetinaVue Hand-Held 100 Camera, Usability of RetinaVue camera assessed by determining the number and percentage of inadequate images and the number and percentage of adequate images., baseline visit","University of North Carolina, Chapel Hill",68,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2016-07
NCT00444600,Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00444600,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Triamcinolone Acetonide + laser|DRUG: Ranibizumab + laser|DRUG: Sham injection + laser|DRUG: Ranibizumab + deferred laser,"Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity, Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., from baseline to 1 Year|Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year, Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method., from baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline, from baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema, from baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score, Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., from baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness, Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., from baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity, Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., from baseline to 1 Year|Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator, Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., from baseline to 1 Year",Jaeb Center for Health Research,691,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-03
NCT04635800,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients",https://clinicaltrials.gov/study/NCT04635800,COMPLETED,Macular Edema|Diabetic Macular Edema|Neovascular Age-related Macular Degeneration|Retinal Vein Occlusion,DRUG: MHU650,"Number of participants with ocular and nonocular adverse events, An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study., Day 1 to Day 60|Change from baseline in Best Correct Visual Acuity (BCVA ) by dose level and timepoint - Study Eye, Best Correct Visual Acuity was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts., Day 1 to Day 60|Change from baseline in Central subfield thickness (CSFT) (µm) in the study eye by dose level and timepoint, Central subfield thickness was measured by spectral domain optical coherence tomography (SD-OCT)., Day 1 to Day 60|Change from baseline in Intraocular pressure (IOP) (mmHg) in the study eye by dose level and timepoint, Intraocular pressure was measured per the sites' local standard operating procedures, via tonometry., Day 1 to Day 60",Novartis Pharmaceuticals,21,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-10
NCT00737022,Macular Appearance After Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT00737022,COMPLETED,Proliferative Diabetic Retinopathy|Vitrectomy,,"Macular appearance, Six months",National Taiwan University Hospital,108,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-05
NCT04674800,Extension Study of MYL-1701P-3001 for Safety and Efficacy,https://clinicaltrials.gov/study/NCT04674800,COMPLETED,Diabetic Macular Edema,"BIOLOGICAL: MYL-1701P, a proposed biosimilar to Eylea","Incidence of Treatment emergent adverse events (TEAEs)., Number of participants with TEAEs, Week 20",Mylan Pharmaceuticals Inc,52,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-23
NCT04984200,Assessment of EyeArt Performance With Retinal Cameras,https://clinicaltrials.gov/study/NCT04984200,COMPLETED,Diabetic Retinopathy,PROCEDURE: Retinal imaging|DRUG: Mydriatic Agent,"Overall agreement between the results from multiple EyeArt operations, Overall agreement is defined as the fraction of cases where the multiple EyeArt operation results agree with each other., 1 visit (1 day)","Eyenuk, Inc.",246,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-13
NCT05333055,Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05333055,NOT_YET_RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema|Other Retinal Disorders,,"Aqueous Humor Levels of VEGF-A, Baseline|Aqueous Humor Levels of Plasma Kallikrein, Total Kallikrein (KLKB1), Active Kallikrein (pKal), Factor Xlla, Baseline|Aqueous Humor Levels of Angiopoietin-2, Baseline",Greater Houston Retina Research,150,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-11
NCT04992325,AS-OCT Study in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04992325,COMPLETED,Diabetes Mellitus,DIAGNOSTIC_TEST: Anterior segment-optical coherence tomography,"The measurements of corneal features in patients with type 2 diabetes mellitus, using anterior segment-optical coherence tomography, The parameters analyzed by anterior segment-optical coherence tomography angiography were: total corneal, epithelial and stromal thicknesses, twelve months",Federico II University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-01
NCT00309192,Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00309192,COMPLETED,Diabetes Mellitus|Macular Edema,DRUG: Triamcinolone Acetonide|PROCEDURE: Grid laser|PROCEDURE: Sham Injection,"Visual acuity stabilization or improvement 6 months after treatment., 6 months|Macular edema reduction or stabilization 6 months after treatment., 6 months",Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA,292,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-04
NCT04038125,Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME,https://clinicaltrials.gov/study/NCT04038125,UNKNOWN,Diabetic Macular Edema|Diabetic Retinopathy|Retinal Ischemia,DRUG: Ozurdex Drug Implant Product,"Evaluate re perfusion following Ozurdex use., Determined by OCT-A, 6 Months","Retina Macula Specialists of Miami, LLC",20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-08-22
NCT05514925,Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT05514925,RECRUITING,Proliferative Diabetic Retinopathy|Vitreous Hemorrhage|Tractional Retinal Detachment,DRUG: Bevacizumab Injection [Avastin]|PROCEDURE: Peripheral Retinal Cryoapplication,"Total surgical time, Duration of vitrectomy from the placement of the trocars until their removal, at the end of the vitrectomy|Intraoperative bleeding, occurrence of intravitreal bleeding during vitrectomy, at the end of the vitrectomy",Khairallah Moncef,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-11-21
NCT03399825,Optical Coherence Tomography Angiography (OCT-A) in Children (≥ 6 <14 Years of Age),https://clinicaltrials.gov/study/NCT03399825,WITHDRAWN,Retinopathy of Prematurity|Diabetic Retinopathy,DEVICE: OCT-A,"Evaluation of the sensitivity and specificity of OCTA, The primary objective of this observational study is to evaluate the sensitivity and specificity to diagnose vascular abnormalities with OCTA compared to conventional imaging methods. The main parameter that will be assessed is area of nonperfusion of the retina. The incidence (binary) of nonperfusion areas will be assessed in OCTA and compared to conventional imaging methods such as fluorescein angiography., 2 years","Insel Gruppe AG, University Hospital Bern",0,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01
NCT01304225,Panretinal Photocoagulation for Diabetic Retinopathy With PASCAL Laser,https://clinicaltrials.gov/study/NCT01304225,UNKNOWN,Diabetic Retinopathy,PROCEDURE: Panretinal photocoagulation|PROCEDURE: Panretinal photocoagulation|PROCEDURE: Panretinal photocoagulation,"Incidence of severe visual loss after 1 year, Severe visual loss is defined as visual acuity worse or equal to 5/200 in two consecutive visits (DRS/ETDRS primary outcome), 1 year",Federal University of São Paulo,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-09
NCT01196325,Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01196325,UNKNOWN,Diabetic Macular Edema,,"Quantitative inner retinal blood flow, Inner retinal blood flow will be measured using Canon Laser Blood Flowmeter, Baseline, 3, 7, 30 days and 3 months",University of Toronto,64,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-07
NCT04853355,Non-Responsive Diabetic Macular Edema and Spironolactone,https://clinicaltrials.gov/study/NCT04853355,WITHDRAWN,Diabetic Maculopathy,DRUG: Spironolactone 50 mg,"Proportion of eyes with complete reabsorption of intraretinal fluid, 1 year|Macular Edema - Central Subgroup Thickening, 1 year|Macular Edema - Volume, Macular volume, 1 year|Vision, best corrected, logMAR units, 1 year",Wake Forest University Health Sciences,0,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-07
NCT02614625,Spectral-domain Optical Coherence Tomography of the Eye,https://clinicaltrials.gov/study/NCT02614625,UNKNOWN,Cornea|Retina|Refractive Surgery|Macular Edema|Diabetes|Diabetic Macular Edema,,"Sensitivity as the proportion of anatomical structures that are detectable with the two instruments, Anatomical structures include e.g. sublayers of the cornea, sublayers of the retina, retinal vessels etc., 6 months",Augenabteilung Allgemeines Krankenhaus Linz,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-12
NCT01309451,Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01309451,COMPLETED,Diabetic Macular Edema,DRUG: Bevacizumab|DRUG: dexamethasone intravitreal implant,"Change in Best Corrected Visual Acuity (BCVA) Measured Using Early Treatment of Diabetic Retinopathy Study (ETDRS) Methodology at Month 12 Compared to Baseline, Visual Acuity was measured with the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity test. Unit of measure is based on the ETDRS letter score scale, 0-97, where 0 = worst and 97 = best., baseline to 12 month|OCT CST, change in optical coherence tomography central subfield thickness, change in OCT CST from baseline to twelve months","Maturi, Raj K., M.D., P.C.",40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2011-03
NCT01998412,Iluvien Registry Safety Study,https://clinicaltrials.gov/study/NCT01998412,UNKNOWN,Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies,,"Number of participants with adverse events., 5 years",Alimera Sciences,559,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-12
NCT05131451,ACCESS: AI for pediatriC diabetiC Eye examS Study,https://clinicaltrials.gov/study/NCT05131451,COMPLETED,Type 1 Diabetes|Type 2 Diabetes,DIAGNOSTIC_TEST: Point of Care Autonomous AI diabetic retinopathy exam,"Number of Participants Who Get Screened With a Diabetic Eye Exam, The number of participants who get screened with a diabetic eye exam will be assessed for the AI group and the standard of care group referral to an eye care provider (ECP)., 6 months",Johns Hopkins University,164,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-11-24
NCT01951066,Diabetic Macular Edema Treated With Ozurdex (DMEO),https://clinicaltrials.gov/study/NCT01951066,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone Implant|DRUG: Anti-VEGF injection,"Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent, Changes in propermeability factor levels were correlated with changes in edema using the person correlation coefficient (this was calculated using data from all time points)., 1, 2, 3, and 4 months after injection of a dexamethasone implant or anti-VEGF agent",Johns Hopkins University,20,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2013-10
NCT02645266,Mean Visual Acuity Changes Following Five Injections of Aflibercept,https://clinicaltrials.gov/study/NCT02645266,RECRUITING,Diabetic Macular Edema,DRUG: Aflibercept Injection [Eylea],"To determine change in BCVA from baseline to month 5 of aflibercept treatment, To determine mean visual acuity letters gain following 4 injections Aflibercept compared to baseline., 5 months",McMaster University,48,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-05-01
NCT04588948,A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04588948,WITHDRAWN,Diabetic Macular Edema,DRUG: Intravitreal Aflibercept,"Intravitreal Aflibercept Pharmacokinetics, Intraocular aflibercept levels (free and bound) after intravitreal aflibercept injection.The primary objective is to investigate and characterize the intraocular pharmacokinetics (free and bound) following intravitreal aflibercept injection (IAI) in vitrectomized and non-vitrectomized eyes with diabetic macular edema, 12 months",Stanford University,0,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-12
NCT00468351,Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study),https://clinicaltrials.gov/study/NCT00468351,UNKNOWN,Diabetic Macular Edema,"PROCEDURE: Intravitreal Injection of 1,5 mg of bevacizumab|PROCEDURE: Intravitreal injection of 4 mg of Triamcinolone acetonide","Central Macular Thickness, Best Corrected Visual Acuity, six months",University of Sao Paulo,,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2006-04
NCT01375166,Coupling of Neural Activity and Retinal Blood Flow in Diabetes,https://clinicaltrials.gov/study/NCT01375166,TERMINATED,Diabetic Retinopathy,,"Retinal vessel diameters, 18 months|Retinal blood flow velocities, 18 months",Medical University of Vienna,1,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-03-06
NCT01473251,Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration,https://clinicaltrials.gov/study/NCT01473251,COMPLETED,Exudative Macular Degeneration|Diabetic Macular Edema,DRUG: Avastin|DRUG: Avastin|DRUG: Lucentis,"Analysis of collected vitreous samples to identify biomarkers., Analysis of collected vitreous samples in regards to identification of biomarkers that are prognostic for response to anti-angiogenic treatment of retinopathy, and the exploration of a more effective dosing regiment for intravitreal injections of Lucentis/Avastin for exudative macular degeneration and Avastin for diabetic macular edema., End of study","Vitreo-Retinal Associates, Michigan",16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2011-11
NCT04505566,INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study,https://clinicaltrials.gov/study/NCT04505566,RECRUITING,Diabetic Retinopathy,DRUG: Ketorolac 0.45% ophthalmic solution|DRUG: Placebo - Preservative-free artificial tears|OTHER: Aqueous PGE2 and inflammatory cytokines measurements,"PGE2 level during Diabetic Retinopathy progression, Aqueous samples will be analyzed using liquid chromatography electrospray ionization tandem mass spectrometry to measure all PGE2 levels. PGE2 will be measured every 4 months during 1 year of study to determine whether their mean mediator levels associate with DR severity stage using a linear mixed effects model. The DR severity stage will be included as a continuous or categorical variable, and potential confounding factors as well as baseline measurements for each inflammatory mediator, will be adjusted in the analysis., 1 year|Vascular Endothelial Growth Factor (VEGF) level during Diabetic Retinopathy progression, Aqueous samples will be analyzed using a microparticle bead-based multiplex assay will be used to measure VEGF levels. VEGF will be measured every 4 months during 1 year of study to determine whether their mean mediator levels associate with DR severity stage using a linear mixed effects model. The DR severity stage will be included as a continuous or categorical variable, and potential confounding factors as well as baseline measurements for each inflammatory mediator, will be adjusted in the analysis., 1 year|Interleukin 6 (IL-6) level during Diabetic Retinopathy progression, Aqueous samples will be analyzed using a microparticle bead-based multiplex assay will be used to measure IL-6 levels. VEGF will be measured every 4 months during 1 year of study to determine whether their mean mediator levels associate with DR severity stage using a linear mixed effects model. The DR severity stage will be included as a continuous or categorical variable, and potential confounding factors as well as baseline measurements for each inflammatory mediator, will be adjusted in the analysis., 1 year|Interleukin 8 (IL-8) level during Diabetic Retinopathy progression, Aqueous samples will be analyzed using a microparticle bead-based multiplex assay will be used to measure IL-8 levels. VEGF will be measured every 4 months during 1 year of study to determine whether their mean mediator levels associate with DR severity stage using a linear mixed effects model. The DR severity stage will be included as a continuous or categorical variable, and potential confounding factors as well as baseline measurements for each inflammatory mediator, will be adjusted in the analysis., 1 year|Progression of Diabetic Retinopathy (DR), To determine progression of DR, we will analyze data from the 118 diabetic patients randomized to either Ketorolac or placebo. Diabetic retinopathy progresses in discrete steps defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale (15-step scale: minimum value of 10 and maximum value of 65, with higher scores meaning a worse outcome). With each advancing level, the risk of developing DME and/or PDR increases. A 2-stage or more worsening on the ETDRS severity scale is associated with an increased risk of vision loss., 3 years|Severity of Diabetic Retinopathy (DR), A blinded sub-investigator will grade DR by utilizing the 15-step severity scale established by the ETDRS. A 2-step or more increase or decrease in severity scale, observed on 2 consecutive follow-up appointments, will define a change in DR (progression or improvement)., 3 years","Stephen J. Kim, MD",264,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2020-11-09
NCT03038048,30g vs 33g Needle for Intravitreal Injections,https://clinicaltrials.gov/study/NCT03038048,COMPLETED,Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,PROCEDURE: Varying needle size with intravitreal ranibizumab or aflibercept,"Difference in discomfort between 30g and 33g needle, Intravitreal injection study pain questionnaire to evaluate discomfort associated with intravitreal injections, Day 1",Wills Eye,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-01-27
NCT01097551,Endothelial Dysfunction and Diabetes,https://clinicaltrials.gov/study/NCT01097551,COMPLETED,Type 1 Diabetes Mellitus,DRUG: Trinitrin|DRUG: Neosynephrine 10% collyrium|DRUG: Iontophoresis with acetylcholine delivery|DEVICE: Dynamic Vessel Analyzer,"Evaluation of the presence of a retinal endothelial dysfunction in patients with type 1 diabetes mellitus with Dynamic vessel analyser(assessment study visit), up to 4 months",Assistance Publique - Hôpitaux de Paris,38,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01
NCT03226951,SDM Laser for Non Central Diabetic CSME,https://clinicaltrials.gov/study/NCT03226951,COMPLETED,Non Central Diabetic Macular Edema,DEVICE: Subthreshold 532nm laser,"Number of eyes with reduced macular thickness, Measurements of retinal thickness in the area of edema, 24 weeks",Marashi Eye Clinic,8,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-07-01
NCT05861466,Comparative Study Between IVI of Ranibizumab With and Without Prior ACP in Patients With DME Using OCT-A,https://clinicaltrials.gov/study/NCT05861466,RECRUITING,Diabetic Macular Edema,DRUG: intra-vitreal injection of Ranibizumab|PROCEDURE: anterior chamber paracentesis,"the acute change in angiographic parameters, OCTA of macula and peripapillary region with documentation of vessel density, 1 day",Ain Shams University,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: SUPPORTIVE_CARE",2023-01-01
NCT01512966,Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema),https://clinicaltrials.gov/study/NCT01512966,COMPLETED,Macular Edema,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321),"Adverse Event collection, Week 52",Bayer,73,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-01
NCT05569148,A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe,https://clinicaltrials.gov/study/NCT05569148,COMPLETED,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,COMBINATION_PRODUCT: Faricimab PFS Configuration,"Percentage of Injection Procedures With Successful Completions on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe Configuration, Thirteen healthcare providers (HCP; seven retina specialists and six assistants) across three sites participated in the study, and they worked mostly in pairs to administer a single intravitreal (IVT) injection of 6-mg faricimab to each of the 35 patients using the prefilled syringe (PFS). For each IVT injection, two Human Factors (HF) observers were positioned such that they could clearly observe the entire preparation and administration process. Each HCP team (i.e., retina specialist alone or retina specialist with assistant, as per local procedure) were asked to perform all preparation and administration steps in view of the HF observers. Critical tasks were observed by the HF observers who documented HCP performance using an assessment checklist. A successful task completion for each critical task was defined as normal use without use error, and the percentages of successful completions are calculated out of the total 35 PFS IVT injections administered., Day 1|Percentage of Injection Procedures With Use Errors on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe Configuration, Thirteen healthcare providers (HCP) across 3 sites participated in the study, and they worked mostly in pairs to administer a single intravitreal (IVT) injection of 6-mg faricimab to each of the 35 patients using the prefilled syringe (PFS). For each IVT injection, two Human Factors (HF) observers were positioned such that they could clearly observe the entire preparation and administration process. Each HCP team (i.e., retina specialist alone or retina specialist with assistant, as per local procedure) were asked to perform all preparation and administration steps in view of the HF observers. Critical tasks were observed by the HF observers who documented HCP performance using an assessment checklist. A use error was defined as user action or lack of user action while using the medical device that leads to a different result than that intended by the manufacturer or expected by the user. The percentages of use errors are calculated out of the total 35 PFS IVT injections administered., Day 1",Hoffmann-La Roche,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-10-17
NCT00649766,Tailored Messages to Increase Eye Examination Behavior,https://clinicaltrials.gov/study/NCT00649766,UNKNOWN,Eye Disease|Eye Care,BEHAVIORAL: tailored newsletter|BEHAVIORAL: targeted newsletter,"doctor-confirmed dilated eye examination, 3 and 6 months",National Eye Institute (NEI),330,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2006-06
NCT03161912,"A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease",https://clinicaltrials.gov/study/NCT03161912,COMPLETED,Macular Edema,"DRUG: Aflibercept (Eylea, BAY86-5321)","Mean change of visual acuity (VA) from baseline to 12 months as evaluated in routine clinical practice per cohort and per country., Analysis will be done per cohort and country., Baseline and at 12 months",Bayer,2481,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-24
NCT04285151,Nd:YAG Laser Hyaloidotomy for Premacular Hemorrhage in Diabetic Eyes,https://clinicaltrials.gov/study/NCT04285151,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Nd:YAG laser Hyaloidotomy,"Visual acuity improvement, Testing VA after YAG laser, 1 week",Tanta University,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01
NCT00412451,A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT00412451,COMPLETED,Diabetic Macular Edema,DRUG: ocriplasmin|OTHER: Sham injection,"PVD Induction, The primary efficacy variable was the proportion of patients with total posterior vitreous detachment (PVD) on Day 14 as determined by a masked central reading center (CRC) using 4-quadrant B-scan and optical coherence tomography (OCT), Day 14 post-injection",ThromboGenics,51,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-12
NCT00287651,Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00287651,TERMINATED,"Diabetes Mellitus, With Complications",PROCEDURE: Pulsatile IV Insulin|PROCEDURE: Effects of Pulsatile IV Insulin on Diabetic Retinopathy|PROCEDURE: Effects of Pulsatile IV Insulin on Diabetic Retinopathy,"Serial fundus photography, Stabilization of retinal blood vessel degeneration",Florida Atlantic University,150,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2005-11
NCT00000151,Early Treatment Diabetic Retinopathy Study (ETDRS),https://clinicaltrials.gov/study/NCT00000151,COMPLETED,Blindness|Diabetic Retinopathy,DRUG: Aspirin|PROCEDURE: Argon Laser Photocoagulation,,National Eye Institute (NEI),,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,1979-12
NCT01208948,Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01208948,COMPLETED,Diabetes Mellitus|Macular Edema,"DRUG: 1,2 dithiolane 3 valeric acid","occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years, two years",Ludwig-Maximilians - University of Munich,520,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2000-07
NCT04503551,"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm",https://clinicaltrials.gov/study/NCT04503551,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,DRUG: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|DRUG: Intravitreal Ranibizumab 0.5 mg Injection,"Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52, ETDRS = Early Treatment Diabetic Retinopathy Study

DRSS = Diabetic Retinopathy Severity Scale

The ETDRS-DRSS includes 13 score levels, ranging from the absence of retinopathy to PDR, including neovascularization and/or vitreous/preretinal hemorrhage., Week 52",Hoffmann-La Roche,174,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-08-10
NCT03437551,Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy,https://clinicaltrials.gov/study/NCT03437551,COMPLETED,Insulin-Dependent Diabetes Mellitus 1,OTHER: cross-sectional observation,"prevalence (percentages) of the stages of diabetic retinopathy (DR), the outcome is evaluated for different patient groups relating to the duration of diabetic retinopathy disease (5-10 years, 11-15 years, more than 15 years), 2 hours (one cross-sectional examination only)",Vista Klinik,150,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09
NCT02691312,Pediatric Type 1 Diabetes and Retinopathy,https://clinicaltrials.gov/study/NCT02691312,COMPLETED,Diabetic Retinopathy,DEVICE: Digital Retinography System,"Number of participants diagnosed with retinopathy, Using a CenterVue Digital Retinography System (DRS) the participants with a positive or inconclusive screen will be called with the results and recommended to undergo a dilated eye examination by a skilled ophthalmologist. The results from the ophthalmologist will be compared to the DRS results., Baseline",University of Florida,500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-07
NCT04302012,Assessment of EyeArt Performance With Retinal Imaging Devices,https://clinicaltrials.gov/study/NCT04302012,COMPLETED,Diabetic Retinopathy,PROCEDURE: Color fundus photography|DRUG: Mydriatic Agent,"Agreement between multiple EyeArt operations, 1 visit (1 day)","Eyenuk, Inc.",62,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-18
NCT01823965,Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment,https://clinicaltrials.gov/study/NCT01823965,COMPLETED,Diabetic Macular Edema,DRUG: ranibizumab,"Number of intravitreal injections of ranibizumab, 1 years",Poitiers University Hospital,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-10
NCT01270542,Avastin for PDR (Proliferative Diabetic Retinopathy),https://clinicaltrials.gov/study/NCT01270542,COMPLETED,Retinal Detachment|Diabetic Retinopathy,DRUG: Avastin (bevacizumab)|OTHER: Sham injection,"The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction Retinal Detachment Due to PDR, Comparison of vitreous VEGF levels (pg/mL) and aqueous VEGF (pg/mL) levels in bevacizumab and control groups., 3 months after last surgery",University of Southern California,20,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-06
NCT06074731,Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT06074731,RECRUITING,Retinal Disease|Diabetic Retinopathy|Macular Degeneration,DIAGNOSTIC_TEST: SS-OCT system Plex Elite 9000,"Morphological changes using Swept Source Optical Coherence Tomography, Morphological changes in retinal diseases provided by Swept Source Optical, through study completion, an average of 1 year",Johannes Kepler University of Linz,500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-06-01
NCT00170742,Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.,https://clinicaltrials.gov/study/NCT00170742,TERMINATED,Proliferative Diabetic Retinopathy,"DRUG: Octreotide, 30 mg i.m. LAR formulation",regression of neovascularization.,Novartis,17,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2003-12
NCT03242031,Medico-economic Comparison Between Treatment With Panretinal Photocoagulation by Laser in 1 Session Versus 4 Sessions in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03242031,UNKNOWN,Diabetic Retinopathy,PROCEDURE: monospot panretinal photocoagulation|PROCEDURE: multispot panretinal photocoagulation,"cost of treatment, 9 months after the start of treatment",Centre Hospitalier Universitaire Dijon,96,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-06-21
NCT01568242,Changes in Vitreous Temperature During Phacoemulsification,https://clinicaltrials.gov/study/NCT01568242,UNKNOWN,Proliferative Diabetic Retinopathy,DEVICE: Phacoemlsification,"Vitreous temperature, Temperature of the vitreous is taken every five minutes from the start of a phacoemulsification. Also Temperature is take after every step of the surgery (capsulorhexis, hydrodissection, phacoemulsification, irrigation/aspiration, IOL implantation)., Every five minutes during a phacoemulsification procedure, and at every step of the surgery",Asociación para Evitar la Ceguera en México,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2012-02
NCT00229931,Triamcinolone vs. Laser for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00229931,COMPLETED,DIABETIC MACULAR EDEMA,DRUG: Triamcinolone acetonide|PROCEDURE: laser,"Main Outcome Measures Will be Quantitative Changes in OCT Central Thickness, Visual Acuity, and Number of Snellen Acuity Lines Gained/Lost., 3 years",University of Oklahoma,11,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-11
NCT02107131,Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab,https://clinicaltrials.gov/study/NCT02107131,COMPLETED,Diabetic Macular Edema,DRUG: Intravitreal ranibizumab 0.3mg,"A Change Between Two Time Points is Reported for Maximum Reading Speed, A change between two time points (Baseline and 12 months) is reported for Maximum Reading Speed., Month 12",California Retina Consultants,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-03-13
NCT02985242,Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02985242,TERMINATED,"Diabetes Mellitus, Type II",DRUG: Empagliflozin|DRUG: Glimepiride|DRUG: Empagliflozin placebo|DRUG: Glimepiride placebo,"Microaneurysm formation rate over 12 months, i.e. number of newly developed microaneurysms within 12 months, Weeks 27 and 52",Hannover Medical School,6,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-06-12
NCT00308542,A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00308542,COMPLETED,Diabetic Macular Edema,DRUG: dexamethasone,,"Sanwa Kagaku Kenkyusho Co., Ltd.",,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,
NCT00148265,A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT00148265,COMPLETED,Diabetic Macular Oedema,DRUG: Triamcinolone acetate,"The proportion of eyes showing an improvement of visual acuity by 10 letters on a LogMAR chart compared with the pre-injection level 24 months after treatment, At 24 months, improvement of ≥10 LogMAR letters was seen in 15/42 (36%) eyes treated with IVTA plus laser compared with 7/42 (17%) eyes treated with laser only (p=0.047, odds ratio 2.79, 95% CI, 1.01, 7.67)., 24 month",University of Sydney,54,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-04
NCT05151731,A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05151731,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Vamikibart|DRUG: Ranibizumab|OTHER: Sham Procedure,"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants, Baseline, Week 44 and Week 48",Hoffmann-La Roche,394,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-31
NCT05074342,Project Open - Use of Administrative Health Data to Increase Diabetic Retinopathy Screening,https://clinicaltrials.gov/study/NCT05074342,ENROLLING_BY_INVITATION,Diabetes|Diabetic Retinopathy,,"The provision of a DRS status list to primary health care settings will increase the rate of annual DR screening in patients with type 1 or type 2 diabetes who have attended the centres., To increase the screening rate of individuals who are at risk for DR within the primary care settings, and to refer to treatment those at risk of vision loss., 425 days","University Health Network, Toronto",2000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-01
NCT00248131,Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00248131,TERMINATED,Diabetic Retinopathy,DRUG: Octreotide acetate in microspheres,long-term safety and tolerability,Novartis Pharmaceuticals,260,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-11
NCT00779142,Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies,https://clinicaltrials.gov/study/NCT00779142,TERMINATED,Diabetic Macular Edema,DRUG: Methotrexate intravenous 25mg/ml,"30% Decrease in One Subfield Thickness on Optical Coherence Tomography (OCT) 4 Weeks After the Last Intraocular Injection, 4 weeks",Wake Forest University,2,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-09
NCT00712842,Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy,https://clinicaltrials.gov/study/NCT00712842,COMPLETED,Diabetic Retinopathy,OTHER: Ocular blood flow measurements,"Intraocular pressure, 90 minutes|Retinal arterial and venous diameter, 90 minutes|Retinal blood velocity, 90 minutes|Pattern ERG, measured once on the study day",Gerhard Garhofer,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01
NCT03583242,Multimodal Image Study of Retinal Inflammation Markers After Corticoid and Antiangiogenic Treatment in Pacients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03583242,UNKNOWN,Diabetic Macular Edema,DRUG: Antiangiogenic Agents|DRUG: Corticosteroid,"Macular thickness, Measured by OCT in micrometer, At first visit and 4 months after the first intravitreal injection|Coroidal thickness, Measured by OCT (EDI mode) in micrometer, At first visit and 4 months after the first intravitreal injection|Numbers of hyperreflective intraretinal spots, Measured by OCT scans, At first visit and 4 months after the first intravitreal injection|Increased macular autofluorescence, Autofluorescence of the fundus, At first visit and 4 months after the first intravitreal injection",Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-05-23
NCT03903042,Comparison of Aurora Fundus Camera With Traditional Camera in Diabetic Retinopathy With Visual Artificial Intelligence,https://clinicaltrials.gov/study/NCT03903042,UNKNOWN,Diabetic Retinopathy,,"Image Quality of Aurora camera, Score of Image Quality, within 3 months","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",300,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-11-01
NCT00055042,Laser and Antioxidant Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00055042,COMPLETED,Macular Edema|Diabetes Mellitus,DRUG: Vitamin E,,National Eye Institute (NEI),40,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2003-02
NCT02471651,Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02471651,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone intravitreal implant (0.7 mg)|DRUG: Intravitreal anti-VEGF injection,"Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months, Mean change in central 1 mm sub-field thickness between baseline and 9 months as measured by Spectral Domain Optical Coherence Tomography (SDOCT)., baseline and 9 months",California Retina Consultants,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-06
NCT01946451,Gene Expression in Patients With Epiretinal Membranes,https://clinicaltrials.gov/study/NCT01946451,UNKNOWN,Proliferative Diabetic Retinopathy,,"Gene expression in patients with idiopathic and secondary epiretinal membranes in proliferative diabetic retinopathy., The period between the diagnosis of the ERMs and the actual surgery for the condition was between 2 and 43 months.",Medical University of Silesia,,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-06
NCT04834648,Improve Timely Referral Flow and Compliance of Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT04834648,COMPLETED,Diabetes|Diabetic Retinopathy,BEHAVIORAL: Structured Counseling,"Primary Outcome, Percentage of referral compliance before and after intervention, 8 months",Seva Foundation,150,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-03-15
NCT02732951,Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02732951,COMPLETED,Macular Edema,DRUG: BI 1026706|DRUG: Placebo,"Change From Baseline in Central Subfield Foveal Thickness (CSFT) at Week 12, The change from baseline in CSFT at Week 12 and the BI 1026706 effect was compared between the BI 1026706 treatment group and the placebo group as measured by Spectral-domain Optical Coherence Tomography (SD-OCT). Baseline was defined as the CSFT value measured at the visit when patients were randomised. Mean presented here is an adjusted mean., Baseline and Week 12",Boehringer Ingelheim,105,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-04-14
NCT02951351,Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections,https://clinicaltrials.gov/study/NCT02951351,COMPLETED,"Age-related Macular Degeneration|Diabetic Macular Edema|Injection Site|Injection Site Infection|Pain, Postoperative",DRUG: Proparacaine|PROCEDURE: Conjunctival culture,"Number of Study Participants With Positive Conjunctival Culture, Conjunctival samples were collected after participants received either an additional drop of proparacaine or povidone iodine. Bacterial cultures were performed from conjunctival samples by the Mayo Clinic Microbiology laboratory. Bacterial species identification was performed on any and all bacteria that grew., pre-injection|Pain at the Time of Injection, Subjects were asked to complete a survey about their experience with intravitreal injections after the procedure was completed. The survey was scored on a 0 to 10 numeric rating scale (NRS) where 0 was a positive response and 10 was a negative response. The lower the score, the lesser the perceived pain, the higher the score, the higher the perceived pain., post-injection",Mayo Clinic,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2016-10-12
NCT01546766,"Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)",https://clinicaltrials.gov/study/NCT01546766,COMPLETED,Diabetes|Retinal Disorders,DEVICE: Pupillometry testing.,"Pupillary response, We will analyze the following three components of the pupillary response: latency, constriction velocity and amplitude. The measurements will be taken after initiation of the light stimulus.

These functions will be determined for each eye of each subject using both the central and annular stimuli. Each set of experimental conditions will yield a unique relative luminance ratio that can be used to compare the relative functional integrity of the peripheral retina with respect to the central macula., 3 months","University of California, Los Angeles",315,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-02
NCT03633266,Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03633266,UNKNOWN,Anti-VEGF|Proliferative Diabetic Retinopathy|PRP|Vitrectomy,PROCEDURE: anti-VEGF|PROCEDURE: PRP,"Mean change from baseline in best-corrected visual acuity (BCVA), Assessed using the ETDRS protocol, 3 years",Wenzhou Medical University,220,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-01
NCT01323348,Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control,https://clinicaltrials.gov/study/NCT01323348,COMPLETED,Diabetes|Diabetic Retinopathy,BEHAVIORAL: Diabetes Education,"Change in HbA1c, Mean change in HbA1c from baseline to 12 months in intervention versus control for study participants being seen for standard care more frequently than every 12 months, 12 Months",Jaeb Center for Health Research,1875,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2011-10
NCT04702048,Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye,https://clinicaltrials.gov/study/NCT04702048,WITHDRAWN,"Retinopathy, Diabetic",DRUG: Aflibercept Injection|DRUG: Sham injection,"Mean change in photoreceptor mosaic, Adaptive optics imaging will be used to visualize the photoreceptor cells in the eye and the number of photoreceptor cells will be quantified at baseline and 52 weeks., baseline to 52 weeks|Mean change in photoreceptor cell density, Adaptive optics imaging will be used to visualize the photoreceptor cells in the eye and the number of photoreceptor cells per square micron of image will be quantified at baseline and 52 weeks., baseline to 52 weeks|Mean change in photoreceptor cell spacing, Adaptive optics imaging will be used to visualize the photoreceptor cells in the eye and a measurement of the space between photoreceptor cells will be calculated at baseline and 52 weeks., baseline to 52 weeks",University of Rochester,0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-01
NCT01565148,"A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)",https://clinicaltrials.gov/study/NCT01565148,TERMINATED,Diabetic Macular Edema,DRUG: iCo-007 350 mcg|DRUG: iCo-007 700 mcg|DRUG: iCo-007 350 mcg and Laser|DRUG: Ranibizumab and iCo-007 350 mcg,"Change in VA From Baseline to Month 8, The primary efficacy variable is the change in visual acuity (mean change in number of letters) from baseline to month 8, Baseline to month 8",Johns Hopkins University,185,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2012-02
NCT06003751,A Study of PER-001 in Participants With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06003751,RECRUITING,Diabetic Retinopathy,DRUG: PER-001 Intravitreal Implant - Low Dose|DRUG: PER-001 Intravitreal Implant - High Dose|DRUG: PER-001 Intravitreal Implant - Sham,"Best-corrected Visual Acuity (BCVA), Change in BCVA from Baseline at Week 24 using BETDRS or modified ETDRS chart (Charts 1, 2, and R as applicable) with standardized distance and lighting ill be used to calculate the LogMAR score, End of Study(Week 24)|Intraocular Pressure (IOP), IOP change from Baseline at Week 24 as measured by a calibrated Goldmann applanation tonometry., End of Study(Week 24)|Ocular Adverse events, Frequency, severity and timing of ocular adverse events reported during the study will have verbatim terms mapped to corresponding thesaurus terms from the Medical Dictionary for Regulatory Activities coding dictionary and reported in a table summary for each active and sham participants, End of Study(Week 24)|Systemic Adverse events, Frequency, severity and timing of systemic adverse events reported during the study will have verbatim terms mapped to corresponding thesaurus terms from the Medical Dictionary for Regulatory Activities coding dictionary and reported in a table summary for each active and sham participants, End of Study(Week 24)","Perfuse Therapeutics, Inc.",24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2023-08-05
NCT01759121,Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR,https://clinicaltrials.gov/study/NCT01759121,UNKNOWN,Severe Non-proliferative Diabetic Retinopathy,RADIATION: T-PRP|RADIATION: S-PRP,"change of best corrected visual acuity, best corrected visual acuity, 1 year|the probability of vitreous haemorrhage, 1 year",Sun Yat-sen University,84,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-03
NCT00370721,Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR),https://clinicaltrials.gov/study/NCT00370721,UNKNOWN,Diabetic Retinopathy,DRUG: bevacizumab,Regression of diabetic retinopathy|visual acuity,Shahid Beheshti University of Medical Sciences,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-03
NCT03078231,Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool,https://clinicaltrials.gov/study/NCT03078231,COMPLETED,Diabetic Retinopathy,PROCEDURE: Color fundus photography|DRUG: Mydriatic Agent,"Number of subjects whose EyeArt results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME)., The performance of EyeArt will be evaluated using overall accuracy, sensitivity, and specificity measures., 1 visit","Eyenuk, Inc.",52,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-02-17
NCT04432831,A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04432831,COMPLETED,Diabetic Macular Edema,DRUG: Faricimab|OTHER: Sham Procedure,"Incidence and Severity of Ocular Adverse Events, Up to 2 years|Incidence and Severity of Systemic (Non-Ocular) Adverse Events, Up to 2 years|Number of Participants with Presence of Anti-Drug Antibodies (ADAs) at Baseline and Incidence of ADAs During the Study, From Baseline up to 2 years",Hoffmann-La Roche,1479,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-08-05
NCT04096131,Influence of Cataract Surgery on Early DME The DICAT-II Study,https://clinicaltrials.gov/study/NCT04096131,COMPLETED,Diabetic Macular Edema|Cataract Senile|Surgery--Complications,PROCEDURE: cataract surgery,"Influence of cataract surgery on E-DME, Changes in central subfield thickness (CST) and/or macular volume (MV) measured by SD-OCT in eyes with E-DME during the first 4 months after cataract surgery (Group 1) compared to eyes with the same condition but without any surgical intervention (Group 2).

Eyes in both groups developing a ""significant worsening"" of E-DME, defined as an increase of at least 50 microns in central subfield thickness (CST) or 0.5 mm3 in macular volume (MV) measured by SD-OCT will be withdrawn from the study to receive adequate therapeutic intervention., 4 months",European School of Advanced Studies in Ophthalmology,143,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-01-28
NCT02063321,Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic,https://clinicaltrials.gov/study/NCT02063321,UNKNOWN,Diabetic Macular Edema|Diabetic Retinopathy,,"Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema, Image of fundus taken in NIED securely sent via internet and electronic Clinical Report Form (eCRF) to ophthalmology reading center to assess stage and severity of potential retina damage, feedback to NIED within the stay of screened individual essential for further disease management, Patients screened during hospitalization in National Institute of Endocrinology and Diabetology (NIED), usually in 10 days",Emil Martinka,762,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-12
NCT05156021,A Study on the Treatment Strategy of NVG Secondary to PDR,https://clinicaltrials.gov/study/NCT05156021,COMPLETED,Neovascular Glaucoma|Proliferative Diabetic Retinopathy,DRUG: anti-VEGF,"Changes in Best Corrected Visual Acuity from baseline to 12 months after surgery, Follow-up on the first day, first week, 1, 3, 6, 9 and 12 months after surgery|Changes in Intraocular Pressure from baseline to 12 months after surgery, Follow-up on the first day, first week, 1, 3, 6, 9 and 12 months after surgery",Ruijin Hospital,39,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-12-12
NCT03258242,A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03258242,UNKNOWN,Moderately Severe to Severe NPDR,DRUG: Keluo Xin capsule|DRUG: Placebo oral capsule,"Mean change from DR severity as measured by the early treatment diabetic retinopathy score chart at 24 weeks, Based on the classification criteria of Early Treatment of Diabetic Retinopathy Study to grade DR severity., Baseline and 24 weeks|Mean change from DR severity as measured by the early treatment diabetic retinopathy score chart at 48 weeks, Based on the classification criteria of Early Treatment of Diabetic Retinopathy Study to grade DR severity., Baseline and 48 weeks|Pathological changes from baseline at 24 weeks as measured by optical coherence tomography (OCT) ., Baseline and 24 weeks|Pathological changes from baseline at 48 weeks as measured by optical coherence tomography (OCT) ., Baseline and 48 weeks|Pathological changes from baseline at 24 weeks as measured by fluorescence angiography (FFA)., Baseline and 24 weeks|Pathological changes from baseline at 48 weeks as measured by fluorescence angiography (FFA)., Baseline and 48 weeks|Mean change from baseline in Chinese medicine syndrome score chart at 24 weeks, The score chart is based on the typical symptoms and signs both in the eye and whole body on patients with DR and is used to assess DR severity., Baseline and 24 weeks|Mean change from baseline in Chinese medicine syndrome score chart at 48 weeks, The score chart is based on the typical symptoms and signs both in the eye and whole body on patients with DR and is used to assess DR severity., Baseline and 48 weeks","Chengdu Kanghong Pharmaceutical Co., Ltd.",198,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-08-31
NCT04079231,Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04079231,WITHDRAWN,Diabetic Macula Edema,DRUG: Brolucizumab|DRUG: Aflibercept,"Proportion of patients with a gain in Best Corrected Visual Acurity (BCVA) of ≥15 ETDRS letters at week 48, BCVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts, Week 48|Mean change in BCVA from baseline to Week 48, BCVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts, Baseline, Week 48",Novartis Pharmaceuticals,0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-02-01
NCT04428242,Study Evaluating Retinal Health Monitoring System Thickness Module,https://clinicaltrials.gov/study/NCT04428242,WITHDRAWN,Macular Edema|Macular Degeneration,DEVICE: RHMS-RTM|DIAGNOSTIC_TEST: SD-OCT,"Evaluation of the RHMS-RTM retinal thickness measurements, To evaluate the ability of the RHMS-RTM device to measure retinal thickness, 1 day|RHMS-RTM repeatability, To assess repeatability of the RHMS-RTM device, 1 day|Comparison of retinal thickness measurements between the RHMS-RTM and the SD-OCT, To evaluate the agreement of measurements by the RHMS-RTM and SD-OCT, 1 month",Kubota Vision Inc.,0,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-04
NCT01837121,a Trial of Using SMS Reminder Among Diabetic Retinopathy Patients in Rural China,https://clinicaltrials.gov/study/NCT01837121,COMPLETED,Compliance|Diabetic Retinopathy|SMS,OTHER: the SMS reminder message,"Not-attended rate, Compare the SMS patient not-attended rate with the control group to show the impact of SMS reminder on the compliance with scheduled follow-up visit, up to 1.5 years",Sun Yat-sen University,237,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2015-01
NCT02118831,Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF,https://clinicaltrials.gov/study/NCT02118831,COMPLETED,Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,BIOLOGICAL: Blood Sample Collection|DRUG: Aflibercept|DRUG: Bevacizumab|DRUG: Ranibizumab,"Serum Pharmacokinetics Following Treatment From 1st and 3rd Doses, Maximum serum levels of ranibizumab, bevacizumab or aflibercept will be measured after the first and third injections, up to 28 days following each treatment., Up to 4 months",California Retina Consultants,56,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2012-03
NCT02363621,Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME,https://clinicaltrials.gov/study/NCT02363621,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab 0.3 mg|DRUG: Aflibercept 2.0 mg,"Number of Participants With Intraocular Inflammation, Number of participants with intraocular inflammation as seen on slide lamp and dilated fundus exam., 24 to 48 hours (visit #1)|Number of Participants With Intraocular Inflammation, Number of Participants With Intraocular Inflammation as seen on slit lamp and dilated fundus exam, 5 to 7 days (visit #2)",Arshad Khanani,101,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2015-01
NCT02330042,OCT Biomarkers for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02330042,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,,"Number of participants with decreased total retinal blood flow by OCT angiography, Total retinal blood flow will be measured in uL/min., 1 year|Number of participants with capillary dropout and/or new abnormal retinal blood vessel growth by OCT angiography, Neovascular membrane area will be measured in mm2., 1 year|Number of participants with measureable macular edema by OCT imaging, Retinal thickening area will be measured in mm2., 1 year",Oregon Health and Science University,165,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09
NCT02979665,Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02979665,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab Ophthalmic,"Effects of anti-VEGF drugs on intraocular pressure (mmHg), 2 year",Lawson Health Research Institute,51,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09
NCT03270865,Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging,https://clinicaltrials.gov/study/NCT03270865,COMPLETED,AMD Population - Intermediate or Advanced AMD|DR Population- With or Without Diabetic Macular Edema,DEVICE: PAF (Positioning And Fixation device),"spatial location of the pupil, during an eye examination, documentation of pupil location by a camera, 1 year",Notal Vision Ltd.,16,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2017-09-30
NCT05190965,Optical Coherence Tomography Angiography and in Fluorescein Angiography in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05190965,NOT_YET_RECRUITING,OctA .FFA Findings in DR,DEVICE: OCTAngiography .FFangiography,"Compare findings in OCTA.Ffa in DR, Number of microaneurysm.degree of ischemia.size of FAZ, Baseline",Assiut University,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-01
NCT04292912,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT04292912,COMPLETED,Macular Edema,DRUG: GSK2798745,"Number of participants with abnormal ophthalmic examination findings, Up to Day 28|Number of participants with abnormal refraction and visual acuity, Up to Day 28|Number of participants with abnormal physical examination findings, Up to Day 28|Number of participants with clinically significant changes in laboratory parameters, vital signs, and 12-lead electrocardiogram (ECG) findings, Up to Day 28|Number of participants with adverse events (AE) and serious adverse events (SAE), Up to Day 28|Mean change from Baseline in center subfield retinal thickness as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT), Baseline and at Day 28",GlaxoSmithKline,17,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-09-07
NCT01223612,Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation,https://clinicaltrials.gov/study/NCT01223612,COMPLETED,Diabetic Retinopathy,DRUG: Ranibizumab|PROCEDURE: Modified ETDRS laser,"Functional and anatomical change in the retina, This is an exploratory study. The primary outcome measure is the change in retinal function and anatomy at 48 weeks compared to baseline, as assessed by fluorescein angiography, microperimetry and electrophysiological testing., 48 weeks",Moorfields Eye Hospital NHS Foundation Trust,37,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-10
NCT02207712,Noctura400 Treatment for Diabetic Retinopathy (CANDLE),https://clinicaltrials.gov/study/NCT02207712,TERMINATED,Diabetic Macular Oedema,DEVICE: Noctura 400 Eye Mask|DRUG: Ranibizumab,"The number of intravitreal injections of ranibizumab required by each study eye at 48 weeks, 48 Weeks",PolyPhotonix Medical,252,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-11
NCT00804921,"Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab",https://clinicaltrials.gov/study/NCT00804921,COMPLETED,Macular Edema|Diabetic Retinopathy|Macular Degeneration,DRUG: bevacizumab|PROCEDURE: anterior chamber paracentesis|DRUG: acetazolamide|DRUG: brimonidine,Intra-ocular pressure variation after intra-vitreous injection of bevacizumab,University of Sao Paulo,,INTERVENTIONAL,"Allocation: |Intervention Model: |Masking: |Primary Purpose: ",
NCT01009021,Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01009021,COMPLETED,Pain,DRUG: potassium diclofenac,"Pain recorded using a Visual Analog Scale, 15 minutes after the procedure",University of Sao Paulo,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2008-03
NCT04511715,Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04511715,UNKNOWN,Non-proliferative Diabetic Retinopathy,DRUG: Intravitreal Bevacizumab IVB|OTHER: Follow-up with regular examination for determination of DR progression,"Percentage of patients with equal or more than 2 stages of progression in diabetic retinopathy staging, Multiple fundus photographs interpreted by a single vitreoretinal surgeon who is blind to the study groups, 12 months",Shahid Beheshti University of Medical Sciences,100,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-09-01
NCT03597815,Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study,https://clinicaltrials.gov/study/NCT03597815,UNKNOWN,Diabetic Macular Edema|Sleep Apnea|Non Proliferative Diabetic Retinopathy,DRUG: Aflibercept 40 MG/ML [Eylea]|DIAGNOSTIC_TEST: OSA diagnostic test - overnight sleep study|DEVICE: CPAP therapy for OSA positive patients,"Presence of DME, First visit, 0 months|Presence of OSA, First visit, 0 months|Snellen visual acuity, 12 months|Apnea-Hypopnea Index, 12 months",Uptown Eye Specialists,150,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-01
NCT04991350,Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04991350,TERMINATED,Diabetic Macular Edema|Macular Ischemia|Diabetic Retinopathy|Vascular Endothelial Growth Factor Overexpression,DRUG: Intravitreal ranibizumab|DRUG: Intravitreal bevacizumab,"Change in foveal avascular zone area, The change in the foveal avascular zone area will be compared between the two treatment arms as a measure of macular perfusion change., 0 and 3 months.|Change in vascular density of the superficial retinal capillary plexus, The change in the superficial retinal capillary plexus vascular density will be compared between the two treatment arms as a measure of macular perfusion change., 0 and 3 months.|Change in vascular density of the deep retinal capillary plexus, The change in the deep retinal capillary plexus vascular density will be compared between the two treatment arms as a measure of macular perfusion change., 0 and 3 months.",Cairo University,5,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-26
NCT02650050,Micropulsed Laser in Association With Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).,https://clinicaltrials.gov/study/NCT02650050,TERMINATED,Macular Edema|Mellitus Diabetes,RADIATION: Micropulsed laser photocoagulation,"Number of intra-vitreal anti-VEGF injections, One year",Fondation Ophtalmologique Adolphe de Rothschild,5,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-01-19
NCT01131650,Prevalence of Diabetic Retinopathy in São José do Rio Preto-SP-Brazil,https://clinicaltrials.gov/study/NCT01131650,COMPLETED,Diabetic Retinopathy,,Prevalence of diabetic retinopathy,Hospital do Olho Rio Preto,710,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-03
NCT05992415,New York City Eye Study (NYCES),https://clinicaltrials.gov/study/NCT05992415,NOT_YET_RECRUITING,Glaucoma|Vision Impairment and Blindness|Cataract|Diabetic Retinopathy,OTHER: Intervention Using Patient Navigators|OTHER: Usual Care Without Patient Navigators,"Adherence to Follow-up Eye Care, The Outcome Measure is ADHERENCE TO FOLLOW-UP EYE EXAM APPOINTMENT, and will be measured by appointment attendance at the initial eye exam appointment. The unit of measure is the eye exam appointment, which will be scheduled within 6-months of the referral at either Harkness Eye Institute or Harlem Hospital. The measure will assess the rate of adherence at the initial appointment. Comparison will be made between the 9 developments randomized to the Intervention Arm compared to 5 developments randomized to the Usual Care Arm., 1-year",Columbia University,10000,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2024-07-01
NCT04612868,Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images,https://clinicaltrials.gov/study/NCT04612868,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy,DEVICE: AEYE Software Device,"Sensitivity and Specificity, Based on Two Macula-centered Images (One Image From Each Eye of the Patient), Sensitivity and specificity of the AEYE-DS device to detect mtmDR on digital funduscopic images, acquired by the Topcon NW400 fundoscopy device, based on two macula-centered images (one image from each eye of the patient). Sensitivity and specificity were calculated by comparing the output results of the AEYE-DS device to the ground truth (diagnostic determination by an independent, blinded panel of expert ophthalmologists at a reading center). The worst of two eyes was compared with the AEYE-DS output at the participant level., 1 day",AEYE Health Inc,531,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-10-16
NCT01572350,"Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT01572350,COMPLETED,Diabetic Macular Edema,OTHER: Grid laser|DRUG: Triamcinolone Acetonide|DRUG: Bevacizumab,"Best-Corrected Visual Acuity (BCVA), To evaluate the effect on best-corrected visual acuity (BCVA) of intravitreal triamcinolone (Triesence ®) or bevacizumab (Avastin ®) in combination with grid laser therapy compared to grid laser therapy alone after 12 months of treatment, in diabetic patients with not tractional diffuse macular edema (NTDDEM), 12 months",Hospital Universitario de Canarias,105,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-10
NCT04128150,High Resolution Retina Imaging,https://clinicaltrials.gov/study/NCT04128150,RECRUITING,"Retinitis Pigmentosa|Maculopathy, Age Related|Macular Dystrophy|Macular Edema|Retinal Degeneration|Diabetic Retinopathy|Occlusion Retinal Vein|Hypertension",,"Evolution of retina diseases, Increase the clinical experience of using the rtx1 camera in various conditions with retinal impact, From date of inclusion until the date of last documented progression , assessed up to 5 years",Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-17
NCT03690050,A Comparison of Standard Laser With Micropulse Laser for the Treatment of Diabetic Macular Oedema.,https://clinicaltrials.gov/study/NCT03690050,COMPLETED,Diabetic Macular Edema,PROCEDURE: Diode 577 nm subthreshold micropulse laser|PROCEDURE: Standard threshold laser (532 nm laser),"Mean change in BCdVA in the study eye at 24 months, BCdVA in the study eye is assessed by a BCdVA test (using ETDRS visual acuity charts at 4 meters) at baseline and months 4,8,12,16,20 and 24., 4, 8, 12, 16, 20 and 24 months",Belfast Health and Social Care Trust,266,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-11-01
NCT01613716,Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study),https://clinicaltrials.gov/study/NCT01613716,COMPLETED,Diabetic Macular Edema|Epiretinal Membrane,DRUG: Ozurdex,"Central Retinal Thickness, At 3 months, central retinal thickness as measured by optical coherence tomography will be measured, 3 months|Visual Acuity, ETDRS visual acuity will be measured at 3 months. Visual function of the study eye was assessed using the ETDRS protocol, which is a widely accepted international standard. A higher letter score represents better functioning., 3 months",The Cleveland Clinic,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-07
NCT02227745,Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema,https://clinicaltrials.gov/study/NCT02227745,UNKNOWN,Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Dorzolamide hydrochloride (2%)|DRUG: Placebo Sodium hyaluronate 4mg,"efficiency in visual function with dorzolamide after photocoagulation, Effectiveness of dorzolamide (2%) in visual function (visual acuity, contrast sensitivity, retinal sensitivity) after 2 months of photocoagulation (treatment for focal Clinically Significant Macular Edema), two months",Hospital Juarez de Mexico,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT01790945,Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography,https://clinicaltrials.gov/study/NCT01790945,UNKNOWN,Mild Nonproliferative Diabetic Retinopathy|Moderate Nonproliferative Diabetic Retinopathy|Severe Nonproliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy|Diabetic Macular Edema,,"% change in Diabetic Retinopahy/Diabetic Macular Edema diagnosis with pre-screening system compared to post-screening system, 6 months",Retina Institute of Hawaii,500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-02
NCT04018482,Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study),https://clinicaltrials.gov/study/NCT04018482,COMPLETED,Age-related Macular Degeneration|Diabetic Retinopathy|Diabetic Macular Edema,OTHER: Povidone Iodine|OTHER: Hypochlorous Acid,"Comfort of Povidone Iodine vs Avenova immediately post-treatment based on an 11-point numerical scale (0-10, with 0 being no pain, and 10 being extreme pain), Reported comfort levels will be collected immediately after the injection procedure. Average reported comfort levels in the Povidone Iodine group will be compared with average reported comfort levels from the Avenova group at each time point using a paired Student's T-test., Immediately following the subject's injection.|Comfort of Povidone Iodine vs Avenova 1-2 hours post treatment based on an 11-point numerical scale (0-10, with 0 being no pain, and 10 being extreme pain), Reported comfort levels will be collected 1-2 hours post-injection. Average reported comfort levels in the Povidone Iodine group will be compared with average reported comfort levels from the Avenova group at each time point using a paired Student's T-test., 1-2 hours post-injection.",California Retina Consultants,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-07-16
NCT01622816,Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart,https://clinicaltrials.gov/study/NCT01622816,COMPLETED,Diabetic Retinopathy,,"ETDRS Letter Score, To determine the visual acuity measurement using this handheld internally illuminated ETDRS chart, and a standard back illuminated EDTRS chart. This will be done during the visual acuity test., 1 Day",Julia Haller,70,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-03
NCT01320345,The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.,https://clinicaltrials.gov/study/NCT01320345,RECRUITING,Type 1 Diabetes Mellitus|Diabetic Retinopathy|Diabetic Nephropathies,DRUG: Fenofibrate|DRUG: Inert lactose placebo,"Occurrence of clinical significant retinopathy progression., Comprising 2-step progression of ETDRS score (to at least moderately severe grade), clinically significant macular oedema, need for laser surgery, need for intraocular anti-VEGF or corticosteroid therapy or vitrectomy, adjudicated to be for diabetic retinopathy (DR), As reported throughout the study and/or annual eye assessment post-randomisation",University of Sydney,450,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-11-03
NCT00839150,Retinal Function in Diabetic Patients Without Retinopathy,https://clinicaltrials.gov/study/NCT00839150,COMPLETED,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2",,,Assistance Publique - Hôpitaux de Paris,56,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-05
NCT03097068,Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis,https://clinicaltrials.gov/study/NCT03097068,COMPLETED,Diabetic Macular Edema,DRUG: Lucentis,"Vascular Endothelial Growth Factor Levels, An aqueous humor specimen was obtained at baseline and at 12 weeks to determine if the levels of VEGF had decreased with treatment., 12 weeks","Vitreo-Retinal Associates, Michigan",10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2017-04-19
NCT04567550,RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME),https://clinicaltrials.gov/study/NCT04567550,RECRUITING,Diabetic Retinopathy (DR),GENETIC: RGX-314 Dose 1|GENETIC: RGX-314 Dose 2|GENETIC: RGX-314 Dose 3|DRUG: Topical Steroid,"To evaluate the effect of RGX-314 on DR by the Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at week 48, Proportion of participants achieving a 2-step or greater improvement in DR by Early Treatment Diabetic Retinopathy Study (ETDRS)-Diabetic Retinopathy Severity Scale (-DRSS) at Week 48 scored from Levels 10-85 with higher levels indicating greater DR severity., 48 weeks",AbbVie,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-11-20
NCT00490815,Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00490815,COMPLETED,Diabetic Macular Edema,DRUG: Fluocinolone Acetonide|DRUG: Fluocinolone Acetonide,"Levels of Fluocinolone Acetonide in Plasma and Aqueous Humor, This was a combined assessment of the levels of fluocinolone acetonide in the plasma and aqueous humor. The average values of the data collected is entered in Outcome Data., over 36 months",Alimera Sciences,37,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2007-08
NCT02637245,Imaging Parameters and DME Treatment Response,https://clinicaltrials.gov/study/NCT02637245,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy,OTHER: No intervention,"Changes in disease state characteristics in response to therapy, Generated software will be used to analyze FA and OCT images at the start, duration and end of the study. We have developed automated segmentation software for both optical coherence tomography (OCT) and fluorescein angiography (FA). This software will be used to quantify specific imaging parameters including leakage area, diffuse leakage, focal leakage from FA and cyst volume, cyst location, inner retinal volume and outer retinal volume from OCT., Six months post treatment",Duke University,32,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-05
NCT02647515,Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma,https://clinicaltrials.gov/study/NCT02647515,COMPLETED,"Diabetic Retinopathy|Glaucoma, Neovascular",DRUG: ranibizumab,"vitreous hemorrhage, 12 months|intraocular pressure, 12 months",Ruijin Hospital,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-01
NCT01928550,Diabetes PRP and OCT,https://clinicaltrials.gov/study/NCT01928550,COMPLETED,Proliferative Diabetic Retinopathy,,"Total retinal blood flow & visual acuity, 1) Total retinal blood flow, as measured by Doppler OCT, will be correlated with visual acuity and the severity of PDR. This will be performed by the following analysis:

1. Pearson's correlation test of total retinal blood flow with logMAR (Logarithm of the Minimal Angle of Resolution) visual acuity before and after PRP;
2. Pearson's correlation test of total retinal blood flow with area of capillary drop-out on FA before and after PRP;
3. Pearson's correlation test of total retinal blood flow with areas of leakage on FA before and after PRP;
4. Pearson's correlation test of total retinal blood flow with areas of thickening on OCT before and after PRP.
5. Paired t test of total retinal blood flow on OCT before and after PRP., 1 year",Oregon Health and Science University,8,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-08
NCT02157350,The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT,https://clinicaltrials.gov/study/NCT02157350,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Panretinal laser photocoagulation,"Proliferative diabetic retinopathy progression/regression., Progression/regression of proliferative diabetic retinopathy will be evaluated by measuring the amount of fluorescein leakage by wide-field fluorescein angiography at 1, 5 and 10 minutes. These measurements will be performed at baseline, and during followup after panretinal photocoagulation (3 months and 6 months)., Change from baseline in proliferative diabetic retinopathy at 6 months",Odense University Hospital,65,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-08
NCT01257815,Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment,https://clinicaltrials.gov/study/NCT01257815,COMPLETED,Diabetic Retinopathy|Macular Oedema,DRUG: Ranibizumab,"The change in mean Best Corrected Visual Acuity (BCVA), Baseline to 12 months",Novartis Pharmaceuticals,111,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01
NCT00284050,Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement,https://clinicaltrials.gov/study/NCT00284050,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab 0.3 mg|DRUG: Ranibizumab 0.5 mg|DRUG: Sham injection,"Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12, Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual., Baseline through the end of study (Month 12)|Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye at Month 12, Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters as described in the Study Operations Manual., Baseline through the end of study (Month 12)",Novartis,151,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-10
NCT01218750,Triple Therapy for Diffuse Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01218750,UNKNOWN,Diffuse Diabetic Macular Edema,PROCEDURE: Triple therapy for diffuse diabetic macular edema,"Best-corrected visual acuity (BCVA) and central macular thickness (CMT), The best corrected visual acuity (BCVA) for ETDRS chart and central macular thickness (CMT) are assessed preoperatively and during the follow-up period. OCT is performed 1 mm and 6 mm diameter topography centered at the patient fixation point. We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter., up to 1 week before surgery|Best-corrected visual acuity (BCVA) and central macular thickness (CMT), The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis. The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO. We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter., 16 up to 17 weeks after surgery|Best-corrected visual acuity (BCVA) and central macular thickness (CMT), A follow-up examination include: The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis. The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO. We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter., 32 up to 33 weeks after surgery|Best-corrected visual acuity (BCVA) and central macular thickness (CMT), A follow-up examination include: The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis. The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO. We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter., 48 up to 49 weeks after surgery|Best-corrected visual acuity (BCVA) and central macular thickness (CMT), A follow-up examination include: The best corrected visual acuity (BCVA) for ETDRS chart, results are converted to log MAR for statistical analysis. The central macular thickness (CMT) are assessed 1 mm diameter topography centered at the patient fixation point for OCT-SLO. We evaluate mean central retinal thickness and central retinal volume 1 mm and 6 mm in diameter., 64 up to 65 weeks after surgery",Military Institute od Medicine National Research Institute,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-12
NCT00407849,Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00407849,UNKNOWN,Diabetic Retinopathy,DRUG: triamcinolone acetonide,"Best corrected visual acuity after 12 months of single intravitreal injection of triamcinolone acetonide., 12 months|Macular thickness measured by optical coherence tomography (OCT) after 12 months of treatment., 12 months|Safety of intravitreal triamcinolone acetonide after 12 months of treatment., 12 months",Federal University of São Paulo,50,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-10
NCT04935749,Epidemiologic Assessment of Diabetic Retinopathy in Egypt Using Ultrawide Field Fundus Photographs,https://clinicaltrials.gov/study/NCT04935749,RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema|Retinal Disease,DEVICE: Ultra wide-field retinal imaging,"Epidemiology, Describing the distribution of different DR severity levels using UWF imaging, 1 year|DR Progression, Assessing the number of patients with at least 4 years of follow up who have a 2 step or more DR progression, 4 years|Progression to PDR, Assessing the number of patients with at least 4 years of follow up who progress to PDR, 4 years|Epidemiology, Prevalence of predominantly peripheral lesions (PPL) in eyes with DR using UWF imaging, 1 year",Alexandria University,10000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-07-01
NCT00776763,Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab,https://clinicaltrials.gov/study/NCT00776763,COMPLETED,Proliferative Diabetic Retinopathy|Age Related Macular Degeneration,DRUG: Avastin intravitreal injection,"Growth Factors and Other Cytokines Measurements, 1 month interval",Ophthalmological Association Edelweiss,150,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2008-10
NCT01854593,Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01854593,COMPLETED,Proliferative Diabetic Retinopathy|Diabetic Traction Retinal Detachment|Vitreous Hemorrhage,DRUG: Bevacizumab|PROCEDURE: Vitrectomy|DEVICE: Sham injection,"Reoperation, Vitreoretinal reoperation due to recurrent vitreous hemorrhage., 1 month",Nihon University,69,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2012-05
NCT03750149,Reading Analysis in Ophthalmologic Patients,https://clinicaltrials.gov/study/NCT03750149,UNKNOWN,Diabetic Maculopathy|Age Related Macular Degeneration|Glaucoma|Epiretinal Membrane,DEVICE: EyeTracker,"Reading speed, Reading speed (words per minute) will be analysed using the EyeTracker device. The patient has to read 4 texts with different contrast levels. The faster the patient can read a text, the better the results., 12 months","Prim. Prof. Dr. Oliver Findl, MBA",100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-01-01
NCT04610749,Diabetic Retinopathy as a Marker of Cognitive Dysfunction and Depression,https://clinicaltrials.gov/study/NCT04610749,COMPLETED,Diabetic Retinopathy|Depression|Cognitive Impairment|Cognitive Dysfunction,,"Retinal metabolism, Measured by retinal oximetry, 1 day",Region of Southern Denmark,148,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-25
NCT02850263,A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT02850263,COMPLETED,Macular Edema,"DRUG: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|DRUG: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|DRUG: Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)","Change in Best Corrected Visual Acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with DMO treated with intravitreal aflibercept, BCVA (Best Corrected Visual Acuity): process to measure with the help of a retinoscope, auto-refractor or phoropter how much power is needed to bring the eye to normal, perfectly focused vision) when performed in addition to that at baseline and 12 months. ETDRS Chart: charts imprinted with lines of letters decreasing in size from largest on top to smallest on the bottom to determine visual acuity., Baseline and 12 months|Change in central subfield thickness (CST) as determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in patients with DMO treated with intravitreal aflibercept, Baseline and 12 months",Bayer,750,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-07-05
NCT01899963,Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study,https://clinicaltrials.gov/study/NCT01899963,COMPLETED,Wet Age Related Macular Degeneration|Diabetic Macular Edema,,"Time to Treatment, Defined as defined as the time between when the retina specialist reviews the information collected by either system to when the patient receives treatment by the specialist in the clinic., Average 5-6 Weeks.",McMaster University,83,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-11
NCT04411693,Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04411693,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Dexamethasone implant|DRUG: Aflibercept,"The mean change in central subfield thickness, 6 months",The Cleveland Clinic,23,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-04-10
NCT02876393,A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT02876393,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,,"Presence of DMO evaluated from the optical coherence tomography (OCT) images, The outcome measures will be assessed at the end of 3 months","Queen's University, Belfast",172,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-11
NCT00369863,"A Randomized, Placebo-Controlled Clinical Trial of Intravitreal Triamcinolone for Refractory Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT00369863,COMPLETED,Diabetic Macular Edema,DRUG: Triamcinolone acetonide,Central macular thickness,Shahid Beheshti University of Medical Sciences,76,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2002-06
NCT00524875,Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients,https://clinicaltrials.gov/study/NCT00524875,UNKNOWN,Diabetic Retinopathy,DRUG: Bevacizumab,early post-vitrectomy vitreous hemorrhage,Shahid Beheshti University of Medical Sciences,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: PREVENTION,2007-01
NCT01044875,Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01044875,UNKNOWN,Proliferative Diabetic Retinopathy,PROCEDURE: Pan retinal photocoagulation laser treatment,"Visual acuity measurement by logarithm of the minimum angle of resolution (logMAR), 2 years",University of Malaya,120,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-09
NCT05699759,Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05699759,RECRUITING,Diabetic Macular Edema,DRUG: K8,"Mean change in central subfield thickness, Central subfield thickness (CST) measured on spectral domain-optical coherence tomography (SD-OCT), At week 4 (change as measured from baseline)|Mean change in best-corrected visual acuity (BCVA), best-corrected visual acuity as defined by the number of letters read on the scale set by the ETDRS (Early Treatment of Diabetic Retinopathy Study). (More letters read equates to better visual acuity), At week 4 (change as measured from baseline)|Adverse Events, Frequency of participants experiencing ocular or systemic adverse events., Within the study period (of 24 weeks)",Michelle Abou-Jaoude,5,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-02-28
NCT05631054,Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients,https://clinicaltrials.gov/study/NCT05631054,RECRUITING,Proliferative Diabetic Retinopathy|Pars Plana Vitrectomy|Risk Prediction Model,,"Best corrected visual acuity at the last follow-up, Standard logarithmic visual acuity scale, 1 year",Tianjin Medical University Eye Hospital,250,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-10
NCT03150654,The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes,https://clinicaltrials.gov/study/NCT03150654,COMPLETED,Diabetic Retinopathy|Retinal Degeneration|Macula Abnormality|Laser Burn of Retina,DEVICE: Laser pan-retinal photocoagulation,"Change macular pigment optical density from baseline at 6 months, Macular pigment optical density measures were repeated and recorded at 1st, 2nd, 3rd month before laser treatments and 6th month, 1 month and 3 months",Afyon Kocatepe University Hospital,36,INTERVENTIONAL,Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2015-10-01
NCT00423059,Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00423059,COMPLETED,Diabetic Retinopathy,DRUG: bevacizumab,expression level of VEFG|PEDG|Factor VIII,Yonsei University,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-12
NCT01788475,Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery,https://clinicaltrials.gov/study/NCT01788475,TERMINATED,Diabetic Macular Edema,DRUG: Dexamethasone,"Visual Acuity Gain, Measured visual acuity gain in number of letters improved as a result of treatment, 13 months",Lahey Clinic,3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-02-22
NCT00906659,"Visual Function, Center Point Thickness and Macular Volume After Photocoagulation",https://clinicaltrials.gov/study/NCT00906659,COMPLETED,Diabetic Retinopathy|Macular Edema,,"visual capacity (under subjective refractive correction was measured in decimal equivalent), before the treatment and 3 weeks after photocoagulation|center point thickness (measured in µm), before the treatment and 3 weeks after photocoagulation|macular volume (measured in mm3), before the treatment and 3 weeks after photocoagulation",Hospital Juarez de Mexico,89,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-01
NCT01342159,Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01342159,COMPLETED,Diabetic Macular Edema,PROCEDURE: Intravitreal injection,"Visual acuity, baseline, 1 month, 3 months, 6month, 9 month, 12 month",Hallym University Medical Center,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-03
NCT01928654,Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01928654,UNKNOWN,Diabetic Macular Edema,DEVICE: Micropulse laser treatment|DEVICE: Laser modified ETDRS,"Mean change in visual acuity (ETDRS letters), 12 months",Luigi Sacco University Hospital,32,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-07
NCT02457975,Photobiomodulation for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02457975,COMPLETED,Diabetic Retinopathy,DEVICE: 670nm PBM|DRUG: intravitreous VEGF-inhibitors,"Visual Acuity as assessed by the Early Treatment of Diabetic Retinopathy Study (EDTRS) Classification, Change from baseline at 8 weeks; Change from baseline at 24 weeks",Medical College of Wisconsin,16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-06
NCT01295775,Diabetic Retinopathy Sulodexide Study,https://clinicaltrials.gov/study/NCT01295775,COMPLETED,Diabetic Retinopathy,DRUG: sulodexide,"Hard exudates, The lesion will be evaluated by fundus photography and fluorescein angiography, graded according to Modefied Airlie House Classification and ETDRS., T12: 360 +/- 7 days from T0",Ajou University School of Medicine,127,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2009-02
NCT03571659,Comparison of Different Fluence Settings for Yellow Subthreshold Laser Treatment in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03571659,COMPLETED,Diabetic Retinopathy,PROCEDURE: Laser,"1. Decrease in number of leaking Mas on FFA 2. Decrease in diffuse leakage on FFA, Comparing the number of leaking microaneuyrms baseline to 6 weeks with 3 types of lasers (two subthreshold parameters (5% and 15% duty cycle (DC)) compared to standard ETDRS continuous wave (CW) laser., 3 months",L.V. Prasad Eye Institute,32,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-12-22
NCT02874859,Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02874859,COMPLETED,Diabetic Macular Edema,,"Estimation of visual acuity Early Treatment Diabetic Retinopathy Study (ETDRS), Estimation of visual acuity after 96 weeks of treatment with Aflibercept, 96 weeks",Lille Catholic University,49,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-11-09
NCT01736059,Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy,https://clinicaltrials.gov/study/NCT01736059,ACTIVE_NOT_RECRUITING,Non-exudative Age-related Macular Degeneration|Diabetic Retinopathy|Retina Vein Occlusion|Retinitis Pigmentosa|Hereditary Macular Degeneration,DRUG: CD34+ bone marrow stem cells intravitreal,"Incidence and severity of ocular adverse events, As evident on eye examination by severe decrease in vision and/or adverse effect requiring major treatment intervention directly attributable to study treatment., 1 day to 6 months","University of California, Davis",15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-07
NCT00000159,Sorbinil Retinopathy Trial (SRT),https://clinicaltrials.gov/study/NCT00000159,COMPLETED,Diabetic Retinopathy|Diabetes Mellitus,DRUG: Sorbinil,,National Eye Institute (NEI),,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: DOUBLE|Primary Purpose: TREATMENT,1983-08
NCT00155454,Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT00155454,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Vitreous Hemorrhage,PROCEDURE: Intravitreal long acting gas (10% C3F8),"Recurrent vitreous hemorrhage rate, Initial time to vitreous clearing , percentage of prolonged vitreous clearing, and early versus late manifest postoperative recurrent vitreous hemorrhage in groups 1 and 2 were compared to determine the effects of long acting gas on prevention of early recurrent vitreous hemorrhage., Within 6 months after vitrectomy",National Taiwan University Hospital,61,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2004-09
NCT04674254,Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04674254,COMPLETED,Proliferative Diabetic Retinopathy|Vascular Endothelial Growth Factor Overexpression|Diabetic Retinopathy,DRUG: Bevacizumab Injection|PROCEDURE: Targeted retinal photocoagulation|PROCEDURE: Standard pan-retinal photocoagulation,"Change in foveal avascular zone area, The change in the foveal avascular zone area will be compared between the different treatment arms as a measure of macular perfusion change., 0, 3, 6, 9, and 12 months|Change in vascular density of the retinal capillary plexuses, The change in retinal capillary vascular densities at different capillary layers will be compared between the different treatment arms as a measure of macular perfusion change., 0, 3, 6, 9, and 12 months",Cairo University,43,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-30
NCT05745116,"Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT",https://clinicaltrials.gov/study/NCT05745116,RECRUITING,Diabetic Macular Edema,DEVICE: Notal Vision Home OCT,"Evaluate subjects' ability to perform multiple OCT self-scanning following a self-tutorial on the Notal Vision Home OCT (NVHO), % of completion a self-imaging session, within 2 hours of an office visit|Evaluate the repeatability of the Notal OCT Analyzer (NOA) automatic fluid volume quantification in volume scan from self-scanning with the NVHO in the central 10 degrees of the macula of Diabetic Retinopathy (DR) patients, NVHO volume scan Total Retinal Fluid (TRF) amount measured by NOA, NVHO volume scan Intra-Retinal Fluid (IRF) amount measured by NOA, NVHO volume scan Sub-Retinal Fluid (SRF) amount measured by NOA, within 2 hours of an office visit|Compare fluid quantification in images from NVHO and a commercial OCT, Compare fluid quantification in images captured by the NVHO, as calculated by the Notal OCT Analyzer (NOA) algorithm and the fluid quantification in images captured by a commercial OCT, as marked by a human reader - in the central 10 degrees of the macula of DR patients Zeiss Cirrus or Spectralis OCT volume scan Total Retinal Fluid (TRF), Intra-Retinal Fluid (IRF), Sub-Retinal Fluid (SRF) amount measured by a human reader, within 2 hours of an office visit|Scanning session completion status - complete/incomplete, within 2 hours of an office visit",Notal Vision Inc.,150,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-07
NCT03385382,Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03385382,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone intravitreal implant 0.7 mg|DRUG: Ranibizumab Injection,"Central macular thickness, Decrease of macular thickness, 6 months",G. d'Annunzio University,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-12-06
NCT01478516,Autologous Plasmin and Fibrinolytic System in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01478516,UNKNOWN,Macular Edema,PROCEDURE: Intravitreal injection,"Central macular thickness after intravitreal autologous plasmin injection, Central macular thickness measured by optocal coherence tompgraphy, 1 month after intervention|Visual acuity after intravitreal autologous plasmin, logMAR visual acuity, 1 Month after intervention",Hallym University Medical Center,40,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-11
NCT01298245,Genetic Association of Diabetic Retinopathy-1,https://clinicaltrials.gov/study/NCT01298245,UNKNOWN,Diabetes|Diabetic Retinopathy,,"The differences in the distribution of candidate genotypes and alleles between the study groups, Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study. The eligible participants will be grouped by the results of prior fundus examination: those with known history of diabetic retinopathy; those without known history of diabetic retinopathy., 12 months","Taipei Veterans General Hospital, Taiwan",200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-02
NCT02245516,Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02245516,COMPLETED,Retinal Vein Occlusion|Diabetic Macular Edema,DRUG: KPI-121 0.25% Ophthalmic Suspension|DRUG: KPI-121 1.0% Ophthalmic Suspension,"Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS), Best Corrected Visual Acuity (BCVA) was measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. More letters read correctly results in a higher letter score, which represents better visual acuity., Day 1 to Day 57|Macular Volume by SD-OCT, Change in measurement (in microns) in macular volume as measured by Spectral Domain Optical Coherence Tomography (OCT), Day 1 to Day 57|Center Subfield Retinal Thickness by SD-OCT, Change in measurement (in microns) in the central subfield retinal thickness as measured by Spectral Domain Optical Coherence Tomography (OCT), Day 1 to Day 57|Investigator's Assessment of Leakage on the Fluorescein Angiogram, Change in leakage by investigator's assessment of the fluorescein angiogram, Day 1 to Day 57","Kala Pharmaceuticals, Inc.",16,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2014-07
NCT00695682,Intravitreal Infliximab for Diabetic Macular Edema (DME) and Choroidal Neovascularization (CNV),https://clinicaltrials.gov/study/NCT00695682,UNKNOWN,Diabetic Retinopathy|Macular Degeneration,DRUG: intravitreal injection of infliximab,"This is a pilot study to study the safety and tolerability of intravitreal Infliximab in patients with refractory diabetic macular edema and choroidal neovascularization (CNV), 3 m",Retina Research Foundation,4,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-06
NCT02521116,Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap,https://clinicaltrials.gov/study/NCT02521116,COMPLETED,Healthy Subjects|Diabetic Retinopathy|Retinal Vein Occlusion,OTHER: Dynamic Vessel Analyzer|OTHER: Oxymap T1,"Difference of oxygen saturation of retinal vessels between DVA and Oxymap T1, participants will be followed for the duration of outpatient clinic visit, an expected average of 1 days",Medical University of Vienna,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2016-02
NCT02699450,A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02699450,COMPLETED,Diabetic Macular Edema,DRUG: Faricimab|DRUG: Ranibizumab,"Mean Change From Baseline in BCVA Letter Score at Week 24, in Treatment-Naive Participants, Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Linear Mixed Effects Model for Repeated Measurements. Missing values were not imputed; it was assumed that the data were missing at random., Baseline, Week 24",Hoffmann-La Roche,229,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-04-27
NCT05902650,Correlation of Biochemical Indexes and Retinal Hemodynamic in Patients With Different Degrees of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05902650,RECRUITING,Diabetic Retinopathy,DIAGNOSTIC_TEST: imaging,"fasting blood glucose (FBG), biochemical indexes, the time of the patient's first 1 day visit|glycosylated hemoglobin (HbAlc), biochemical indexes, the time of the patient's first 1 day visit|OCTA data, An image of the 3mm×3mm and 6 mm×6 mm macular areas detected by OCTA were captured. Quantitative analysis of vascular density and perfusion density of superficial capillary plexus in the macular area were automatically calculated using built-in software on the device., the time of the patient's first 1 day visit",Mingzhe Cao,200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-01-01
NCT04782115,Evaluation of RC28-E Injection in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04782115,COMPLETED,Diabetic Macular Edema,BIOLOGICAL: intravitreal injection of RC28-E|BIOLOGICAL: Conbercept,"Mean change from baseline in BCVA at 24 week;, BCVA=Best-corrected visual acuity;Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts., Baseline,week 24|Mean change from baseline in BCVA at 52 week;, Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts., Baseline, Week 52","RemeGen Co., Ltd.",156,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-03-17
NCT03506750,Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT),https://clinicaltrials.gov/study/NCT03506750,UNKNOWN,Proliferative Diabetic Retinopathy|VEGF Overexpression,"DRUG: IVC|PROCEDURE: Blood and aqueous humor at the time of IVC|PROCEDURE: Collect blood, aqueous humor, and initial vitreous at the time of surgery.|PROCEDURE: IVC-sham","Changes of intraocular VEGF and PLGF of patients with proliferative diabetic retinopathy post-IVC (intravitreous injection of Conbercept)., 1-7 days",The First Affiliated Hospital with Nanjing Medical University,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2017-06-03
NCT00801450,Intravitreal Injection Versus Sub-Tenon's Infusion of Triamcinolone Acetonide for Refractory Diabetic Macular Edema During Cataract Surgery,https://clinicaltrials.gov/study/NCT00801450,UNKNOWN,Diabetic Macular Edema,DRUG: Triamcinolone acetonide|DRUG: Triamcinolone acetonide,"central subfield macular thickness, baseline and at 2, 4, 8±1 ,12±2 and 24±2 weeks postoperatively",University of Sao Paulo,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-09
NCT03328715,iOCT for Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03328715,RECRUITING,Diabetic Macular Edema,DEVICE: intraoperative OCT|DEVICE: stand-alone OCT,"macular thickness, macular thickness is measured with the central subfield thickness function, 2 hours",Vienna Institute for Research in Ocular Surgery,48,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2016-12-01
NCT01927315,Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes,https://clinicaltrials.gov/study/NCT01927315,COMPLETED,Diabetes|Diabetic Retinopathy,DRUG: Fenofibrate 145 mg|DRUG: Placebo,"Endothelial progenitor cells, Change in endothelial progenitor cell (EPC) levels in fenofibrate-treated vs placebo-treated patients over 12 weeks., 12 weeks|Circulating progenitor cells, Change in circulating progenitor cell (CPC) levels in fenofibrate-treated vs placebo-treated patients over 12 weeks., 12 weeks",University of Padova,41,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE,2013-08
NCT05022615,Comparing 3 Imaging Systems,https://clinicaltrials.gov/study/NCT05022615,COMPLETED,Diabetic Retinopathy,DIAGNOSTIC_TEST: Topcon Camera|DIAGNOSTIC_TEST: Optos Camera|DIAGNOSTIC_TEST: Clarus Camera,"Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Level within the 7 standard fields of Clarus, Optos, and Standard 7 Field imaging and statistical comparison, The images captured within the 7 standard fields on each camera will be graded using the ETDRS severity scale. The total range of possible scores for severity level is from 10 (no DR) to 80 (PDR with vitreous hemorrhage); higher scores indicate increasing severity.

Details of ETDRS severity scale: 10-No DR, 15-Probable DR, no MAs, 20-MAs only, 35-Mild NPDR, 43,47-Moderate NPDR, 53-Severe NPDR, 60-PDR status post scatter photocoagulation, 61,65,71-PDR, 80-PDR with vitreous hemorrhage, 90,95-Ungradable.

ETDRS level agreement will be cross-tabulated and κ statistics calculated and assessed: \<0.20, poor; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; and 0.81-1.00, almost perfect strength of agreement. Unweighted κ will be used to avoid potential bias by weighting. Agreement will also be tested for each severity level and k statistics analyzed., 1 day|Number of Ungradable ETDRS Images within the 7 standard fields of Clarus, Optos, and Standard 7 Field imaging, The images captured within the 7 standard fields on each camera will be graded using the ETDRS severity scale. The proportion of ungradable images will be documented. On all tests, P \< 0.05 will be considered significant, and nonparametric testing will be applied where appropriate., 1 day","University of Wisconsin, Madison",51,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-29
NCT00401115,Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00401115,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy,DRUG: MS-R001 (rapamycin)|DRUG: MS-R001 (rapamycin),"Safety and tolerability as assessed by visual acuity, intraocular pressure, slit lamp and indirect ophthalmoscope, 12 months",Santen Inc.,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-09
NCT02326259,Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia,https://clinicaltrials.gov/study/NCT02326259,COMPLETED,Diabetic Retinopathy,OTHER: Initiation of treatment of diabetes,"Progression of diabetic retinopathy, 90 days",Temple University,20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-03
NCT04905459,ARDA Software for the Detection of mtmDR,https://clinicaltrials.gov/study/NCT04905459,COMPLETED,Diabetic Retinopathy,DIAGNOSTIC_TEST: ARDA software application,"Sensitivity of ARDA mtmDR for detection of mtmDR in 45 degree images, 1 day|Specificity of ARDA mtmDR for detection of mtmDR in 45 degree images, 1 day|Sensitivity of ARDA mtmDR for detection of mtmDR in UWF images, 1 day|Specificity of ARDA mtmDR for detection of mtmDR in UWF images, 1 day",Verily Life Sciences LLC,1012,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-30
NCT00687154,Observational Study of DME Following Scatter Laser Photocoagulation,https://clinicaltrials.gov/study/NCT00687154,COMPLETED,Diabetic Macular Edema,PROCEDURE: Scatter Laser Photocoagulation in 1 Sitting|PROCEDURE: Scatter Laser Photocoagulation in 4 Sittings,"Retinal thickening (measured with OCT), 34 weeks",Jaeb Center for Health Research,155,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2005-09
NCT02790775,Pain and Visual Outcome in Intravitreal Bevacizumab Injection,https://clinicaltrials.gov/study/NCT02790775,COMPLETED,Diabetic Macular Edema,DRUG: Anti-VEGF in quadrant 1|DRUG: Anti-VEGF in quadrant 2|DRUG: Anti-VEGF in quadrant 3|DRUG: Anti-VEGF in quadrant 4,"Pain, Visual Analog Scale (VAS), immediately after Intravitreal Bevacizumab Injection",Shahid Beheshti University of Medical Sciences,1004,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: PREVENTION",2015-12
NCT04682054,Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics,https://clinicaltrials.gov/study/NCT04682054,UNKNOWN,Diabetic Retinopathy|Proliferative Vitreoretinopathy|Pterygium|Glaucoma,PROCEDURE: ocular surgery,"counts of each cell type, single-cell sequencing identify what cells and the counts within the eye tissue, 1 month",The First Affiliated Hospital with Nanjing Medical University,80,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2021-01-15
NCT01411254,Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA),https://clinicaltrials.gov/study/NCT01411254,COMPLETED,Diabetic Macular Edema,DRUG: Betamethasone Microsphere (DE-102） Low Dose|DRUG: Betamethasone Microsphere (DE-102） High Dose|DRUG: Sham,"Best Corrected Visual Acuity(BCVA), Change from baseline of Best Corrected Visual Acuity(BCVA) in ETDRS letter score","Santen Pharmaceutical Co., Ltd.",,INTERVENTIONAL,"Allocation: |Intervention Model: |Masking: |Primary Purpose: ",
NCT02863354,Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02863354,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Aflibercept,"Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0, • Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 and week 100., 52 and 100 weeks","Charles C Wykoff, PhD, MD",43,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-08
NCT04429503,Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT04429503,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,DRUG: aflibercept|DRUG: High-dose aflibercept,"Change From Baseline in Best Corrected Visual Acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] Letter Score) in the Study Eye at Week 48, Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. BCVA scale range is 0 (worst) to 100 (best)., Baseline, Week 48",Regeneron Pharmaceuticals,660,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-06-29
NCT01975103,Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases,https://clinicaltrials.gov/study/NCT01975103,UNKNOWN,Diabetic Macular Edema|Branch Retinal Vein Occlusion|Chronic Central Serous Retinopathy|Macular Telangiectasia,PROCEDURE: Topcon Endpoint Management,"Best corrected visual acuity, 6 months",Federal University of Rio Grande do Sul,20,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-03
NCT04499703,Evaluation of the Retinal Health Monitoring System Thickness Module,https://clinicaltrials.gov/study/NCT04499703,COMPLETED,Macular Edema|Macular Degeneration,DEVICE: RHMS-RTM|DIAGNOSTIC_TEST: SD-OCT,"Evaluation of the RHMS-RTM retinal thickness measurements, To evaluate the ability of the RHMS-RTM device to measure retinal thickness, 1 day",Kubota Vision Inc.,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-11
NCT02870803,OCT-angiography in Diabetic Patients,https://clinicaltrials.gov/study/NCT02870803,UNKNOWN,Diabetic Macular Edema,,"OCT-angiography qualitative changes, Assess the OCT-angiography qualitative changes observed in intermediate and deep capillary networks in diabetic patients after the resolution of macular edema with intravitreal drug treatment, 12 months","Retina Clinic, Sao Paulo, Brazil",20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-07
NCT00846716,"Shiga Progression of Diabetes, Nephropathy and Retinopathy",https://clinicaltrials.gov/study/NCT00846716,UNKNOWN,Type 2 Diabetes Mellitus,DRUG: Pioglitazone add on to SU or biguanide|DRUG: SU or Biguanide,"Onset and progression of diabetic nephropathy, 2 years",Shiga University,400,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-03
NCT00387582,Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00387582,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Ranibizumab (Lucentis)|PROCEDURE: Argon Laser,"Prevention of vision loss at one year as evidenced by ETDRS visual acuity., 6 and 12 months",Rocky Mountain Retina Consultants,49,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-07
NCT02349516,Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02349516,WITHDRAWN,Diabetic Retinopathy,DRUG: Squalamine Lactate Ophthalmic Solution 0.2%,"To explore the effect of Squalamine Lactate eye drops on Best Corrected Visual Acuity in subjects with diabetic macular edema, Proportion of patients gaining at least 3,4 and 5 lines in best corrected visual acuity from baseline to week 24, Mean change from baseline to Week 24",Starr Muscle,0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-02
NCT05408416,Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR,https://clinicaltrials.gov/study/NCT05408416,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: preoperative group and intraoperative group,"best-corrected visual acuity (BCVA), every visit time, from preoperation to 3 months follow-up|central retinal thickness, every visit time, from preoperation to 3 months follow-up",Peking University People's Hospital,102,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2021-09-01
NCT00417716,Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00417716,UNKNOWN,Diabetes Mellitus Type 2|Diabetic Macular Edema,DRUG: Intravitreal Bevacizumab,BCVA|Fluorescein Angiography|Optical Coherence Tomography,Asociación para Evitar la Ceguera en México,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-09
NCT04120077,Combined Effects of Diabetes Self-Management Education and Nutritional Supplementation on Visual Function and Retinopathy,https://clinicaltrials.gov/study/NCT04120077,UNKNOWN,Diabetes Mellitus|Diabetic Retinopathy,"DIETARY_SUPPLEMENT: EyePromise DVS, EyePromise DVS plus EyePromise EZTears","full-field flicker electroretinogram (ffERG) implicit time (milliseconds), The Flicker ERG will be recorded using a commercially available system, (RetEval, Konan Medical, Irvine, CA). The test will be performed in an illuminated room, free of visual and audible distractions. Subjects will be instructed to fixate on a target using the fellow eye (eye not been tested) and results will be consecutively recorded from both eyes by means of skin electrodes, Change from baseline to 12 months|full-field flicker electroretinogram (ffERG) amplitude (microvolts), The Flicker ERG will be recorded using a commercially available system, (RetEval, Konan Medical, Irvine, CA). The test will be performed in an illuminated room, free of visual and audible distractions. Subjects will be instructed to fixate on a target using the fellow eye (eye not been tested) and results will be consecutively recorded from both eyes by means of skin electrodes, Change from baseline to 12 months|glycosylated hemoglobin (HbA1c) percentage, HbA1c is a measure of mean blood glucose over a 8-12 week duration and requires a simple fingerstick blood draw., Change from baseline to 12 months","ZeaVision, LLC",150,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-01-01
NCT02706977,The Effect of Dopamine on Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02706977,COMPLETED,Diabetes,DRUG: Low Dose Sinemet CR|DRUG: High Dose Sinemet CR|DEVICE: RETeval Electroretinogram (ERG) Testing|OTHER: Contrast Sensitivity Testing|OTHER: Visual Acuity Testing,"Change in Retinal Function assessed by Electroretinogram (ERG) Device, The RETeval device consists of a hand-held wand with a pupil tracker. A skin electrode placed below the eye or DTL fiber records the response to flash stimuli. The pupil tracker provides feedback to the system so that the flash stimuli can compensate for the pupil size and produce the proper illumination to the retina. RETeval is intended to generate photopic signals and measure and display the electrical response signals generated by the retina and the visual nervous system using flash stimuli., Baseline, Week 4|Change in Contrast Sensitivity assessed by the Contrast Sensitivity Function v1.0 (CSF v1.0) Tablet Application, Participants will view the screen monocularly while wearing their normal correction. A drifting grating will be presented at 60 cm for 3, 6, 12 and 18 c/d. Following photopic testing (100 lux), the participant will be dark-adapted and a neutral density filter will be applied to the tablet screen to produce luminance of \~1 lux., Baseline, Week 4|Change in Contrast Sensitivity assessed by the Sine Wave Grafting Test (CSV-1000E), The CSV-1000E is self-illuminated (85 cd/m2). A drifting grating will be presented at 60 cm for 3, 6, 12 and 18 c/d. The participant will view the chart from 2.5m. The intensity of the CSV-1000 will be reduced to 1 lux with neutral density filters for scotopic testing., Baseline, Week 4|Change in Visual Acuity assessed by the Standard Snellen Static Chart, The common Snellen chart is printed with eleven lines of block letters. The first line consists of one very large letter, which may be one of several letters, for example E, H, or N. Subsequent rows have increasing numbers of letters that decrease in size. Participants will cover one eye from 6 metres or 20 feet away, and read aloud the letters of each row, beginning at the top. The smallest row that can be read accurately indicates the visual acuity in that specific eye. The test will be repeated covering the opposite eye., Baseline, Week 4",Emory University,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2016-01
NCT05223569,Home Monitoring of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05223569,RECRUITING,Macular Edema Due to Diabetes Mellitus,DEVICE: Home OCT monitoring model|DEVICE: Hospital-based monitoring with a staff-administrated OCT,"Changes in visual acuity, Changes in visual acuity from baseline to 12 weeks adjusted for baseline visual acuity, 12 weeks","Zhongshan Ophthalmic Center, Sun Yat-sen University",120,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2022-03-03
NCT05135195,A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training,https://clinicaltrials.gov/study/NCT05135195,COMPLETED,Visual Impairment|Age-Related Macular Degeneration|Diabetic Retinopathy|Glaucoma,"OTHER: In-House Developed VR Platform - AMD, DR, Glaucoma|OTHER: In-House Developed VR Platform - Glaucoma","Average time to complete the trial, 1 Day of Intervention|Average number of obstacle collisions during the trial, 1 Day of Intervention|Average travel time, 1 Day of Intervention|Average distance traveled by the participant, 1 Day of Intervention|Preferred walking speed, 1 Day of Intervention|Orientation, Orientation is measured through the time average of a polarization index, measured as the cosin of the angle between the direction of the instantaneous velocity vector and the straight line linking the instantaneous position of the participant and the following waypoint., 1 Day of Intervention|Number of instances in which the participant stop for more than 2 seconds, 1 Day of Intervention|Total time spent during stops of more than 2 seconds, 1 Day of Intervention|Average time it takes to understand how to interact with the system and run the simulation of the bus ride, 1 Day of Intervention",NYU Langone Health,98,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2021-10-24
NCT04469595,A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT04469595,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Iluvien 0.19 MG Drug Implant|DRUG: Aflibercept,"The mean total number of supplemental aflibercept injections needed during the study, The mean total number of supplemental aflibercept injections needed during, Baseline to 18 months",Alimera Sciences,300,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-08-31
NCT02151695,Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.,https://clinicaltrials.gov/study/NCT02151695,COMPLETED,Naive Patients With Uncomplicated Proliferative Diabetic Retinopathy,PROCEDURE: panretinal photocoagulation|DRUG: Aflibercept intravitreal injections,"Percentage of patients with regression of retinal neovascularization between baseline and 12th month., 12 months",Poitiers University Hospital,41,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT,2015-05
NCT02310295,"Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT02310295,COMPLETED,Diabetic Macular Edema,DEVICE: Laser|DRUG: Bevacizumab|DRUG: Triamcinolone Acetonide,"Central subfield macular thickness, retinal thickness measured with optical coherence tomography, 12 months|Visual acuity, Best corrected visual acuity, 12 months",University of Sao Paulo,45,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-01
NCT00001310,Tissue Studies of Human Eye Diseases,https://clinicaltrials.gov/study/NCT00001310,TERMINATED,Retinal Disease|Corneal Disease|Diabetic Retinopathy|Uveitis|Age-Related Macular Degeneration,,,National Eye Institute (NEI),3833,OBSERVATIONAL,Observational Model: |Time Perspective: p,1992-03-05
NCT03696810,Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2,https://clinicaltrials.gov/study/NCT03696810,COMPLETED,NPDR - Non Proliferative Diabetic Retinopathy,DIAGNOSTIC_TEST: Laboratory tests,"Development of CIME or PDR, Characterization of retinal microvascular changes occurring in eyes with mild to moderate NPDR, 24 months|Capillary closure in the superficial and deep retinal vascular layers, Capillary closure in the superficial and deep retinal vascular layers by vessel density calculation, quantified by OCTA software (Angioplex, Zeiss);, 24 months|LOR ratios, LOR ratios obtained with OCT-L analysis in the full retina and layer by layer., 24 months",Association for Innovation and Biomedical Research on Light and Image,141,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-10-30
NCT02307110,Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy,https://clinicaltrials.gov/study/NCT02307110,COMPLETED,Insulin-Dependent Diabetes Mellitus 1,OTHER: cross-sectional observation,"prevalence (percentages) of the stages of diabetic retinopathy (DR), one cross-sectional examination only",Vista Klinik,150,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2010-08
NCT02059772,Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02059772,UNKNOWN,Diabetic Macular Edema,DRUG: ranibizumab|PROCEDURE: micropulse diode laser,"change in best corrected visual acuity (BCVA), baseline, 12 month",GWT-TUD GmbH,25,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-04-30
NCT03629210,Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03629210,WITHDRAWN,Diabetic Macular Edema,DRUG: OZURDEX|BIOLOGICAL: Eylea,"Central Subfield Thickness, Foveal central subfield (FCS) thickness is defined as the average thickness in the central 1mm diameter circle of the ETDRS grid., At 24 Weeks",Pradeepa Yoganathan,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-09
NCT04283162,Using Calcium Dobesilate to Treat Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04283162,UNKNOWN,Diabetic Retinopathy,DRUG: Calcium Dobesilate|OTHER: conventional treatment,"The rate of the progression of diabetic retinopathy, Diabetic retinopathy progression is defined as an increase of 2 or more steps on the Early Treatment Diabetic Retinopathy Study scale during follow-up., from baseline to the end of treatment (12 months later)",Zhongda Hospital,1200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-03-01
NCT01760746,Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis,https://clinicaltrials.gov/study/NCT01760746,COMPLETED,Proliferative Diabetic Retinopathy (PDR),"OTHER: Injection of Avastin / Lucentis, sampling aqueous humour","The primary outcome will be the change in global levels of intraocular inflammatory cytokines in the aqueous humour of patients with Proliferative Diabetic Retinopathy., No single inflammatory cytokine or any summary measure of the cytokines has been shown to characterize the effect of anti-VEGF (Vascular Endothelial Growth Factor)treatment; therefore, we will employ a global test to compare the difference of all inflammatory cytokines between the two treatment groups. For each cytokine the endpoint will be defined as percentage change from baseline. We will employ O'Brien's rank-sum global test to simultaneously evaluate all the inflammatory cytokine endpoints. O'Brien's test is a nonparametric test procedure for testing whether multiple outcomes in one treatment group have consistently larger values than outcomes in the other treatment group., Baseline and two weeks",University of British Columbia,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-07
NCT05463289,ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2,https://clinicaltrials.gov/study/NCT05463289,RECRUITING,Type 1 Diabetes|Type 2 Diabetes|Cystic Fibrosis-related Diabetes,DIAGNOSTIC_TEST: Point of Care Autonomous AI diabetic retinopathy exam,"Proportion screened for diabetic retinopathy, Equivalence in proportion screened for diabetic retinopathy of white and non-white youth with autonomous AI, 2 years",Johns Hopkins University,500,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2022-07-11
NCT05847088,Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:,https://clinicaltrials.gov/study/NCT05847088,COMPLETED,Diabetic Macular Edema,DRUG: Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:,"Change in Central macular thickness (in microns) (CMT change ), Change in Central macular thickness (in microns) (CMT change ), between baseline and 6 months|Change in Best corrected visual acuity (BCVA change) ), lines of Change in Best corrected visual acuity (BCVA change) ), between baseline and 6 months",Dar El Oyoun Hospital,58,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-02-15
NCT03495765,To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus,https://clinicaltrials.gov/study/NCT03495765,COMPLETED,Diabetic Macular Oedema,DRUG: Ranibizumab,"The primary endpoint for the study will be the mean change in best-corrected visual acuity (BCVA) from baseline to the mean level at Month 12., 12 months",Marsden Eye Specialists,160,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03
NCT00168389,A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00168389,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone|OTHER: Sham,"Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye, BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates improvement and a decrease in the number of letters read correctly indicates a worsening., Baseline, Month 39/Final Visit",Allergan,494,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-02
NCT04576689,"Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy",https://clinicaltrials.gov/study/NCT04576689,ACTIVE_NOT_RECRUITING,Diabetic Macular Oedema|Retinal Vein Occlusion With Macular Oedema,DRUG: IBE-814 70ug|DRUG: IBE-814 140ug,"Best Corrected Visual Acuity, Mean change in LogMAR best corrected visual acuity in the study eye, Measurements from baseline to 6 months (24 weeks)|Central Subfield Thickness, Mean change in central subfield thickness on optical coherence tomography, Measurements from baseline to 6 months (24 weeks)|Ocular and Non-Ocular Treatment Emergent Adverse Events, Number of ocular and non-ocular treatment emergent adverse events, summarized at the patient level by system organ class and preferred term, Baseline through 18 months|Study Drug-Related Ocular Adverse Events, The number of study drug-related ocular adverse events, summarized separately for study and fellow eyes, by system organ class and preferred term, Baseline through 18 months|Drug-Related Adverse Events, Drug-related adverse events including: a) any new rise in intraocular pressure \>27 mmHg in the study eye, at any visit; b) requirement for additional neuroprotective or IOP-lowering therapy, at any visit; c) requirement for surgery to reduce IOP, at any visit; d) any new diagnosis of cataract or significant lens opacification at any visit, significant worsening of cataract in the study eye during the study., Baseline through 18 months|Post-Injection Complications, Post-injection complications including worsening visual acuity, change in vision, worsening macular oedema, vitreous hemorrhage, retinal tear or detachments, inflammation, IOP alterations, Baseline through 18 months|Adverse Events, Frequency and severity of adverse events throughout the primary outcome assessment period, Baseline through 18 months",Ripple Therapeutics Pty Ltd,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-10-30
NCT04692688,Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04692688,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema|NPDR - Non Proliferative Diabetic Retinopathy|PDR - Proliferative Diabetic Retinopathy,DRUG: APX3330|DRUG: Placebo,"Percent of Subjects with an improvement in Diabetic Retinopathy Severity Score (DRSS), Percent of subjects with a ≥ 2-step improvement in DRSS in the study eye, 24 Weeks","Ocuphire Pharma, Inc.",103,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-04-08
NCT02259088,"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients",https://clinicaltrials.gov/study/NCT02259088,COMPLETED,Diabetic Macular Edema|Visual Impairment,DRUG: Ranibizumab (RFB002)|PROCEDURE: Laser|DRUG: Sham injection|PROCEDURE: Sham laser,"Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12, Visual acuity with eyeglasses was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like charts at an initial testing distance of 4 meters. A letter score was calculated based on the number of letters correctly identified at the specified distance. Twelve monthly BCVA values were averaged \[(Month1+Month2+...+Month12)/12\], and the baseline BCVA value was subtracted from the average. A positive change value indicates an improvement in visual acuity, while a negative change value indicates a worsening. One eye (study eye) contributed to the analysis., Baseline, Monthly from Month 1 through Month 12",Novartis Pharmaceuticals,384,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-11-05
NCT04378972,"Anti-inflammatory Effect of Curcumin, Homotaurine, Vitamin D3 on Human Vitreous in Patients With Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT04378972,COMPLETED,Diabetic Retinopathy,"OTHER: curcumin, homotaurine, vitamin D3|OTHER: control","pro-inflammatory cytokines analysis, Evaluation of the anti-inflammatory effect of curcumin, homotaurine and vitamin D3 on the expression of inflammatory cytokines in human vitreous samples of patients suffering from diabetic retinopathy., 7 days",University of Molise,25,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-16
NCT01766362,Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.,https://clinicaltrials.gov/study/NCT01766362,COMPLETED,Diabetes Type 1 or 2 With Diabetic Retinopathy,PROCEDURE: PRPC using Pascal laser,"Macular thickness, Central macular thickness at 9 months after the start of PRPC using Pascal laser., 9 months after the start of traitement",Centre Hospitalier Universitaire Dijon,83,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-10
NCT03984110,"The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial (COED Trial)",https://clinicaltrials.gov/study/NCT03984110,UNKNOWN,Diabetic Macular Edema,DRUG: Ozurdex|DRUG: Eylea,"Central Subfield Thickness, Change in Central Subfield Thickness on OCT, 48 weeks",Texas Retina Associates,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-06-11
NCT03973762,"A Blinded, Self-control Trial to Evaluate an Artificial Intelligence Based CAD System for Diabetic Retinography",https://clinicaltrials.gov/study/NCT03973762,COMPLETED,Diabetic Retinopathy,DEVICE: DR Grading with CAD|OTHER: DR Grading by expert panel,"Se and Sp under investigation target 3, 1.investigation target 3: Negative: DR grading of 0 or 1; Positive: DR grading of 2 or higher; After completion of DR grading by expert panel and CAD system, results of the CAD system were compared to the results of human grading, which is considered the gold standard, using measures as sensitivity(Se) and specificity(Sp)., through study completion，an average of four months",Peking Union Medical College Hospital,1081,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: DIAGNOSTIC,2019-05-31
NCT01661946,Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye,https://clinicaltrials.gov/study/NCT01661946,COMPLETED,Diabetic Macular Edema,DRUG: Bevacizumab|DRUG: Ranibizumab,"Maximum Concentration (Cmax) of Anti-VEGF Antibody, The serum concentrations of anti-VEGF antibody (bevacizumab or ranibizumab) will be measured pre-injection as well as at various time points after injection (1 day, 1 week, 2 weeks, 1 month). These time points are selected based on previously completed animal studies. The Cmax will be compared between bevacizumab and ranibizumab., 1 month",Queen's University,10,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2012-08
NCT00198510,Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage,https://clinicaltrials.gov/study/NCT00198510,COMPLETED,Vitreous Hemorrhage|Diabetic Retinopathy,DRUG: Vitrase|DRUG: Vitrase|DRUG: Vitrase,"Resolution of Vitreous Hemorrhage, Laser treatment of underlying cause of vitreous hemorrhage, or other surgical treatment, or documented evidence of macula \& at least 180 degrees of vitreous base, that vitreous hemorrhage cause is resolved, 3 months",Bausch & Lomb Incorporated,750,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",1998-11
NCT01348672,"Prospective Study Phase: Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye",https://clinicaltrials.gov/study/NCT01348672,UNKNOWN,Age Related Macular Degeneration|Glaucoma|Diabetic Retinopathy.,,"Cross-sectional relationship between retinal / ON oxygen saturation, vascular dysregulation and retinal morphometry, To investigate the cross-sectional relationship between retinal / ON oxygen saturation, vascular dysregulation and retinal morphometry in groups of patients at risk of progres, 5 years|Prospective relationship between retinal/ON oxygen saturation disturbances, vascular dysregulation, retinal morphometry and clinical outcomes, To establish the prospective relationship between retinal/ON oxygen saturation disturbances, vascular dysregulation, retinal morphometry and clinical outcomes in patients at risk of progression of ARMD, POAG and DR and age-matched healthy controls, 5 years|Topographic distribution of retinal / ON oxygen saturation disturbance, vascular dysfunction and change in morphometric parameters, To investigate the topographic distribution of retinal / ON oxygen saturation disturbance, vascular dysfunction and change in morphometric parameters in groups of patients at risk of progression of ARMD, POAG and DR, 5 years",University of Toronto,381,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-03
NCT00371410,"Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT00371410,COMPLETED,Diabetic Macular Edema,PROCEDURE: vitrectomy|DRUG: intravitreal triamcinolone acetonide|PROCEDURE: macular focal laser photocoagulation,Best-corrected visual acuity|Central macular thickness,Samsung Medical Center,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-04
NCT03602989,A Multi-center Study on the Artificial Intelligence Enabled Diabetic Retinopathy Screening Based on Fundus Images,https://clinicaltrials.gov/study/NCT03602989,UNKNOWN,Diabetic Retinopathy,DEVICE: AI-enabled Diabetic Retinopathy Screening Software,"Sensitivity and specificity, To evaluate the sensitivity and specificity of the device in detecting referable DR (more than mild NPDR), No more than 1 day for each subject","Shenzhen SiBright Co., Ltd.",1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-05
NCT05083689,Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05083689,UNKNOWN,Diabetic Macular Edema,DRUG: Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide|DRUG: Injections of 1.25 mg of intravitreal bevacizumab with artificial tears,"Central macular thickness, Measured by EDI-OCT, 1 month",Shahid Beheshti University of Medical Sciences,62,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-10-06
NCT05324189,Automated AI-based System for Early Diagnosis of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05324189,NOT_YET_RECRUITING,Diabetic Retinopathy,DIAGNOSTIC_TEST: Referable versus Non Referable Diabetic Retinopathy diagnostic test,"Sensitivity of identification of referable and non-referable Diabetic Retinopathy (DR) for early diagnosis of DR, iPredict DR can detect non-referable DR (normal retina or mild DR) and referable DR (moderate or severe DR including non-proliferative, proliferative DR and diabetic macular edema) at a similar level of expert ophthalmologists. The output of AI model and ophthalmologists' grading will be compared for image level and subject level accuracy measurement.

Using the gold standard (i.e., the ophthalmologist's grading following ETDRS protocol), the sensitivity, specificity, precision, recall, accuracy, F-measure, positive predictive value and negative predictive value are calculated as: Sens=TP/(TP+FN) Spec=TN/(TN+FP) where TP is the number of true positives (referable DR subjects correctly classified), FN is the number of false negatives (referable DR subjects incorrectly classified as non-referable), TN is the number of true negatives (non-referable subjects correctly classified), and FP is the number of false positives (non-referable DR subjects incorrectly classified as referable DR)., 2 years|Specificity of identification of referable and non-referable Diabetic, iPredict DR can detect non-referable DR (normal retina or mild DR) and referable DR (moderate or severe DR including non-proliferative, proliferative DR and diabetic macular edema) at a similar level of expert ophthalmologists. The output of AI model and ophthalmologists' grading will be compared for image level and subject level accuracy measurement., 2 years",The New York Eye & Ear Infirmary,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-18
NCT05610488,Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept,https://clinicaltrials.gov/study/NCT05610488,NOT_YET_RECRUITING,Diabetic Macular Edema,"DRUG: FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO]","maximum treatment interval with intravitreal faricimab at month 12., maximum treatment interval with intravitreal faricimab at month 12., 12 months",Vista Klinik,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-11
NCT02119689,Vascular Reparative Mechanism in Diabetes,https://clinicaltrials.gov/study/NCT02119689,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,OTHER: Diabetic Patients|OTHER: Healthy Controls,"The ACE/ACE2 ratio within EPC's, Peripheral blood of 150cc, approximately 8-10 tablespoons will be collected from a vein in the arm of both diabetic and healthy control patients., up to 216 weeks",University of Alabama at Birmingham,78,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-10-30
NCT05731089,IVI Aflibercept Before and After Phaco in DME.,https://clinicaltrials.gov/study/NCT05731089,COMPLETED,Diabetic Macular Edema,PROCEDURE: Phacoemulsification with IVI of aflibercept,"resolving of macular edema, change in central macular thickness, Sixth month",Al Hadi Hospital,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-09-01
NCT01031888,Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries,https://clinicaltrials.gov/study/NCT01031888,COMPLETED,Corneal Epithelial Defects After Ocular Surgeries,DRUG: Topical insulin eye drops|DRUG: Conventional postoperative eye drops,"Duration for the corneal surface to completely re-epithelize, 1week, 2 weeks, 1 month, 2 month, 3 month, 6 month",National Taiwan University Hospital,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2008-03
NCT05608265,Real-time Eye Tracking and Imaging of the Eye in Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT05608265,COMPLETED,Diabetic Retinopathy|Retinal Imaging,DEVICE: OSNAT 800 IO,"Successful performance of the real-time eye tracking function by post-image processing, Successful acquisition of retinal images, Through study completion, an average of 6 months",PulseMedica,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2022-08-31
NCT04000789,"The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)",https://clinicaltrials.gov/study/NCT04000789,UNKNOWN,Non-Proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy New Vessels on Disc|Dry Eye Syndromes,"DRUG: Sodium Hyaluronate, Vitamin A, Vitamin E","Ocular Surface Disease Index (OSDI) questionnaire, A questionnaire to measure subjective symptoms of dry eyes. Possible score of 0 (no dry eye) to 100 (severe dry eye). Measured at baseline, day 14 and day 28., 4 weeks|Tear Film Breakup Time, Measurement in seconds of tear film stability. The shorter the fluorescein tear break up time, the lower the tear film stability. Measured at baseline and day 28., 4 weeks|Schirmer I Test, Measurement of tear production. The amount of tears are measured in total millimeters after 5 minutes has elapsed. Measured at baseline and day 28., 4 weeks|Conjunctival Goblet Cell Density, Measurement of conjunctival goblet cell count per mm2. Measured at baseline and day 28., 4 weeks",Dr Cipto Mangunkusumo General Hospital,96,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2019-07
NCT05547789,Assessment Of Diabetic Maculopathy Changes After Phacoemulsification by Using Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT05547789,NOT_YET_RECRUITING,Maculopathy,DRUG: non steroidal anti inflammatory drugs,"Macular changes in diabetic patients after phacoemulsification, Invgatorsiest aimed to examine the macular changes with OCT after uncomplicated phacoemulsification surgery in diabetic patients with non proliferative diabetic retinopathy (NPDR) at the time of surgery and the effect of perioperative and postoperative topical NSAIDS on macular changes ., baseline",Assiut University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03
NCT05529589,Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane,https://clinicaltrials.gov/study/NCT05529589,RECRUITING,Macular Edema Due to Diabetes Mellitus|Vitreous Hemorrhage,,"Thickness change of retinal macular area, measurement of thickness of retinal macular area with macular optical coherence tomography after operation (0 day, 1 week, 1 months, 3 months, 6 months, 12 months), 12 months|Change of visual acuity, measurement of distance visual acuity with subjective refraction after operation (0 day, 1 week, 1 month, 3 months, 6 months, 12 months), 12 months","Second Affiliated Hospital, School of Medicine, Zhejiang University",120,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-02-10
NCT01213888,Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01213888,TERMINATED,Diabetic Retinopathy,DRUG: Trientine Hydrochloride|DRUG: Oral placebo capsules,"To evaluate the effect of a copper chelator in suppressing post-PRP macular edema in eyes with retinal neovascularization., The treatment effect will be measured by assessing changes in photoreceptor function (via visual acuity and contrast sensitivity) as well as retinal inflammation and thickening (via Fluorescein Angiography and Ocular Coherence Tomography).",University of British Columbia,3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: ",2010-11
NCT00864838,"Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab",https://clinicaltrials.gov/study/NCT00864838,COMPLETED,Age Related Macular Degeneration|Diabetic Retinopathy,DRUG: Acetazolamide|DRUG: Brimonidine tartarate|PROCEDURE: Anterior chamber paracentesis,"Intraocular pressure (mmHg), 1 hour and, 3 minutes before IVI. 3,10,20, 30 minutes after IVI",University of Sao Paulo,56,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-06
NCT00989989,Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00989989,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|PROCEDURE: Laser photocoagulation|DRUG: Sham ranibizumab|PROCEDURE: Sham laser photocoagulation,"Average Change From Baseline of Best-Corrected Visual Acuity (BCVA) Over 12 Months (From Month 1 to Month 12 Compared to Baseline), Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement., 12 months",Novartis,396,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-09
NCT03975088,Sub-macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03975088,COMPLETED,Diabetic Macular Edema,PROCEDURE: Sub-macular injection of Ranibizumab,"The primary endpoint for this study was the change in CMT at the final visit., Central macular thickness, at the 6 month follow up visit",University of Alexandria,19,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-01-01
NCT02665689,Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab,https://clinicaltrials.gov/study/NCT02665689,TERMINATED,"Visual Acuity Reduced Transiently|Macular Edema, Cystoid",DRUG: ranibizumab,"Difference of Best Corrected Visual Acuity Measured in ETDRS Letters Score Between Month 12 Baseline Visit, Measured by the difference in ETDRS letters score between month 12 and baseline according to internal guideline of Charité department of ophthalmology., Baseline to 12 months",Prof. Dr. Antonia M. Joussen,4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-01-18
NCT04543331,Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04543331,RECRUITING,Neovascular Age-related Macular Degeneration (nAMD)|Diabetic Macular Edema (DME),DRUG: brolucizumab,"Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF), This outcome measure is part of the BLUE SKY AMD module. This primary study objective will be addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch)., Month 12|Mean change in visual actuity (VA) under clinic specific routine treatment schemes, This outcome measure is part of the BIRL module. This primary study objective will be addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye., Baseline, month 12|Morphological CNV-Changes under clinic specific routine treatment schemes, This outcome measure is part of the BIRL module. This primary study objective will be addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye., Baseline, month 12|Percent of patients maintained on q12w dosing after loading through Week 52, This outcome measure is part of the BLUE SKY DME module. This primary study objective will be addressed considering treatment naïve patient eyes included in the study., After loading, month 12|Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months), This outcome measure is part of the BLUE SKY DME module. This primary study objective will be addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes., Baseline, month 12",Novartis Pharmaceuticals,900,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-05
NCT01628289,The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong,https://clinicaltrials.gov/study/NCT01628289,COMPLETED,Diabetic Retinopathy,OTHER: charging a co-payment for Diabetic Retinopathy screening|OTHER: free screening without charging a co-payment,"Retinopathy profile in the two groups, The extent of diabetic retinopathy in two groups were measured in the first year screening., the first year",The University of Hong Kong,4644,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2009-02
NCT00606138,Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging,https://clinicaltrials.gov/study/NCT00606138,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: ranibizumab|PROCEDURE: Laser photocoagulation,"The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography), This is a measurement of how much change in neovascularization has occurred, using the Optomap FA readings to calculate the increase or decrease in surface area of the retina that is affected by neovascularization., Baseline to Week 4; Baseline to Month 4-6|The Mean Percentage Change of Macular Edema Measured by Retinal Thickness by OCT (Optical Coherence Tomography), Baseline to Week 4; Baseline to Month 6|Incidence and Severity of Ocular Adverse Events, as Identified by Ophthalmic Examination, Month 6|Number of Participants With Occurrence of Adverse Events, Patients were randomized to receive IVR vs. additional PRP. Number of participants with adverse events., Week 1, 2, 4; Month 2, 3, 4, 5, 6",Rush University Medical Center,9,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-01
NCT01489189,Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01489189,COMPLETED,Proliferative Diabetic Retinopathy,OTHER: Prompt Panretinal Photocoagulation|DRUG: 0.5-mg Ranibizumab|OTHER: Deferred panretinal photocoagulation,"Mean Change in Visual Acuity From Baseline, Visual acuity is measured as a continuous integer letter score from 0 to 100, with higher numbers indicating better visual acuity. A letter score of 85 is approximately 20/20 and a letter score of 70 is approximately 20/40, the legal unrestricted driving limit in most states. A 5-letter change for an individual is approximately equal to a 1-line change on a vision chart., 2-years",Jaeb Center for Health Research,305,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-03
NCT04160988,"A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus",https://clinicaltrials.gov/study/NCT04160988,COMPLETED,Diabetic Retinopathy,,"Sensitivity, To evaluate the clinical performance of VeriSee DR by determining the sensitivity.

Sensitivity = 100% x TP/(TP+FN), 2 months|Specificity, To evaluate the clinical performance of VeriSee DR by determining the specificity.

Specificity = 100% x TN/(TN+FP), 2 months",Acer Being Health Inc.,703,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-12-16
NCT05007262,Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05007262,ACTIVE_NOT_RECRUITING,Type2 Diabetes|Diabetic Retinopathy,DRUG: Tangningtongluo tablets|DRUG: Calcium dobesilate capsules,"Best corrected vision acuity (BCVA), using ETDRS vision chart measure vision change from Baseline, At 24 weeks|diabetic retinopathy(DR)progression rate, Using ETDRS Classification to evaluate DR Progress rate, At 24 weeks",Guizhou Bailing Group Pharmaceutical Co Ltd,240,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-08-31
NCT00600262,Intravitreal Bevacizumab for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00600262,COMPLETED,Severe Nonproliferative|Proliferative Diabetic Retinopathy|Active Photocoagulated Diabetic Retinopathy,DRUG: intravitreal bevacizumab,,Asociación para Evitar la Ceguera en México,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-12
NCT00571142,Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00571142,UNKNOWN,* Diffuse Diabetic Macular Edema,PROCEDURE: Bevacizumab + Pars plana vitrectomy|PROCEDURE: Bevacizumab + pars plana vitrectomy,"Retinal thickness, 3 months",Asociación para Evitar la Ceguera en México,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11
NCT05512962,Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05512962,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Triamcinolone Acetonide|DEVICE: Semi-automated Suprachoroidal Microcatheter,"Frequency of ocular adverse events, systemic adverse events, serious, and treatment-emergent non-serious adverse events, Treatment-emergent adverse events are defined as an event that emerges following administration of Triesence® with the Oxulumis® microcatheter administered at Visit 2 (Baseline, Day 0), 24 Weeks|Frequency of adverse device effects and frequency of serious adverse device effects, Adverse device effects and serious adverse device effects are defined as effects that emerge following the administration of the Oxulumis® microcatheter at Visit 2 (Baseline, Day 0), 24 Weeks",Oxular Limited,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2022-08-31
NCT02121262,A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02121262,COMPLETED,Macular Edema,DRUG: Dexamethasone|PROCEDURE: Laser Photocoagulation,"Average Change From Baseline (CFB) in Best Corrected Visual Acuity (BCVA) in the Study Eye, BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The eligible eye with worse visual acuity was selected as the study eye. The average change was computed by subtracting the baseline BCVA from the area under the BCVA curve (AUC) divided by the total follow-up time for each participant. Analysis of covariance (ANCOVA) model was used for the analysis., Baseline to Month 12",Allergan,284,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-01-08
NCT04087746,Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT04087746,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept|DRUG: Ranibizumab,"measuring the main change in visual acuity, measuring the main change in visual acuity in logarithm of the minimum angle of resolution (log MAR) using projector chart as functional outcome, 2 years",Minia University,400,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-01
NCT05607810,Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT),https://clinicaltrials.gov/study/NCT05607810,ENROLLING_BY_INVITATION,Diabetic Macular Edema|Diabetic Retinopathy,GENETIC: ADVM-022,"Incidence of ocular and non-ocular adverse events (AEs), 168 Weeks|Severity of ocular and non-ocular AEs, 168 Weeks","Adverum Biotechnologies, Inc.",22,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-08-10
NCT02816710,Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02816710,COMPLETED,Proliferative Diabetic Retinopathy|Tractional Retinal Detachment,DRUG: Conbercept,"Best-corrected Visual Acuity, 6 months|Duration of Surgery, To evaluate the influence of these three methods to the final duration of surgery. We carefully estimated the time of the vitrectomy from insertion to extraction of the 23-gauge three-port trocars., during the operation time|Intraoperative Bleeding, The grading criteria for intraoperative bleeding: Grade 1, spontaneous cessation of minor bleeding or bleeding that stopped by transient elevation of perfusion pressure; Grade 2, moderate bleeding requiring endodiathermy or broad blood clots formed far away from the bleeding site; Grade 3, thick blood clots exceeding half of the posterior pole or affecting the operation field., Time between the insertion and extraction of three 23-gauge vitrectomy ports",Ruijin Hospital,112,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-07
NCT02435862,A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02435862,COMPLETED,Non-Proliferative Diabetic Retinopathy,DRUG: 1.0mg Luminate®|DRUG: 2.0mg Luminate®|DRUG: 3.0mg Luminate®|OTHER: Balanced Salt Solution for intravitreal injection in 0.10cc,"Observation of pharmacologic induction of PVD., The primary endpoint of this study is observation of pharmacologic induction of at least a stage 3 PVD, with PVD defined as a complete PVD to the equator except for vitreopapillary adhesion as seen on B-scan Ultrasound and confirmed by OCT where possible by study day 90 as determined by the reading center., 90 days","Allegro Ophthalmics, LLC",105,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-02-01
NCT01824862,Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01824862,COMPLETED,Diabetic Retinopathy|Clinically Significant Macular Edema,,"foveal sensitivity, the ability of the fovea to perceive a light stimulus in 16 central points, which is measured in dB with a 10 degree central macular perimetry, 1 day",Hospital Juarez de Mexico,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01
NCT06154746,Analysis of Risk Factors of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06154746,NOT_YET_RECRUITING,Diabetic Retinopathy,DIAGNOSTIC_TEST: slit lamb & OCT,"aeffect of risk factors in progression of diabetic retinopathy., analysis of risk factors affecting progression of diabetic retinopathy and test if they can be modified or not., baseline",Assiut University,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-06
NCT01692938,Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO,https://clinicaltrials.gov/study/NCT01692938,COMPLETED,Age-Related Macular Degeneration|Geographic Atrophy|Diabetic Retinopathy|Macular Edema|Retinal Vein Occlusion|Central Serous Retinopathy|Pattern Dystrophy of Macula|Epiretinal Membrane|Macular Hole,,"Standard Deviation and Mean Test Results of Normal and With Pathology Participants Taken by 3 Different Operator-device Configurations, A precision study was conducted that used 3 devices (each with a different operator). Each device was used to measure 4 normal subjects and 4 subjects with relevant eye pathology, with a total of 24 subject eyes (12 normal, 12 with pathology) measured across all three devices. For each subject, one eye was evaluated using 3 tests with repositioning at the start of each test. Test results were given in decibels which is the unit used in microperimetry testing. Overall mean and standard deviation in decibels were calculated for the two groups: normal and with pathology., 1 Month|Repeatability of Microperimetry Tests in Normal and With Pathology Participants Based on 3 Microperimetry Tests Taken for Each Participant for a Given Operator-device Combination., A precision study was conducted that used 3 devices (each with a different operator). Each device was used to measure 4 normal subjects and 4 subjects with relevant eye pathology, with a total of 24 subject eyes (12 normal, 12 with pathology) measured across all three devices. Test results were given in decibels as that is the standard measurement in microperimetry testing. For each subject, one eye was evaluated using 3 microperimetry tests with repositioning at the start of each test. Overall Repeatability SD and Repeatability SD Limit were calculated for the two groups: normal and with pathology., 1 Month","Optos, PLC",32,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-10
NCT01573572,Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium,https://clinicaltrials.gov/study/NCT01573572,COMPLETED,Age-Related Macular Degeneration|Retinal Vein Occlusion|Diabetic Macular Edema,DRUG: pegaptanib sodium injection,"Change From Baseline in Mean Endothelial Cell Density, The effect on the corneal endothelium will be assessed by specular microscopy, by assessing mean cell density change from baseline. This is to evaluate that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen., Baseline, Week 54",Bausch & Lomb Incorporated,131,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2010-04-22
NCT01307072,Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01307072,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Vitrectomy,"Preoperative status, Plasma level of glycosylated hemoglobin (HbA1c), Preoperative period|Preoperative status, Best-corrected visual acuity (BCVA),, Preoperative period",Kyorin University,94,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-09
NCT03422965,Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus,https://clinicaltrials.gov/study/NCT03422965,UNKNOWN,"Retinal Vascular|Retinal Disease|Retinal Ischemia|Retinal Ischaemia Due to Type 1 Diabetes Mellitus|Diabetes Mellitus|Diabetic Retinopathy|Diabetes Mellitus, Type 1|Vessels; Retina, Tortuous",DIAGNOSTIC_TEST: Optical Coherence Tomography Angiography|DIAGNOSTIC_TEST: Blood test|DIAGNOSTIC_TEST: Urine test,"Perifoveal vessel density, OCTA images will be processed to obtain vascular density measurements in this area (mm-1), 24 months",Hospital Clinic of Barcelona,600,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2017-05-08
NCT04650165,10-year Progression of Diabetic Retinopathy: Identification of Signs and Surrogate Outcomes,https://clinicaltrials.gov/study/NCT04650165,RECRUITING,Diabetic Retinopathy,,"Phenotypic classification of DR in a 5-year period, Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy), 5 years|DR severity level, Early Treatment Diabetic Retinopathy Study Research Group, grading (7 fields-CFP), 5 years",Association for Innovation and Biomedical Research on Light and Image,221,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-01
NCT01486238,Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study,https://clinicaltrials.gov/study/NCT01486238,COMPLETED,Diabetic Macular Edema,DRUG: Macugen® pegaptanib sodium,"Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline., The primary efficacy outcome measure is the proportion of subjects who gain two or more lines in BCVA score in the Study Eye compared with baseline at 24 weeks. The BCVA is to be measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol., 24 weeks",Valley Retina Institute,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-04
NCT03973138,Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab,https://clinicaltrials.gov/study/NCT03973138,UNKNOWN,Diabetic Macular Edema,DRUG: Ranibizumab,"Best-corrected visual acuity, changes of best-corrected visual acuity, one year",Sun Yat-sen University,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-01-01
NCT02571972,"Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.",https://clinicaltrials.gov/study/NCT02571972,COMPLETED,Wet Macular Degeneration|Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,DRUG: Dorzolamide-timolol,"Mean Central Subfield Thickness (CST), Mean central subfield thickness (CST) on spectral domain optical coherence tomography (SD-OCT) on 1 visit prior to enrollment and all visits subsequent to study enrollment, 3 visits (8-12 weeks)",Wills Eye,14,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02-01
NCT05883072,Exploring the Effectiveness of AI Generative Models for Diabetic Patients,https://clinicaltrials.gov/study/NCT05883072,RECRUITING,"Diabetes Mellitus, Type 2|Diabetic Retinopathy|Diabetes",BEHAVIORAL: Exploring AI-Chatbot,"Usability of the Chatbot for diabetic patient, To assess the usability of the Chatbot, we will employ the mHealth App Usability Questionnaire (MAUQ) to gather feedback from patients following their interaction. Our study will utilize Table 4 of this questionnaire, which consists of three sections: ease of use, interface, and satisfaction and usefulness. Specifically, we will focus our evaluation on 10 out of the 18 questions presented in this table. The selected questions are S1, S2, S6, S7, S9, S11, S12, S13, S14, and S18. Patients will provide their responses on a scale of 1 to 5, where ""1"" indicates very poor and ""5"" denotes very good., One time|Internet Speed, Minimum downloading speed of internet will be measured during the chat. This will be recorded in Mega bits per second., One time",Pakistan Council of Scientific and Industrial Research,300,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-01-05
NCT03917472,Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03917472,COMPLETED,Diabetic Macular Edema,DRUG: Brolucizumab|DRUG: Aflibercept,"Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52, BCVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.

Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 23 (per the inclusion criteria) (approximate Snellen equivalent of 20/40 to 20/320) in the study eye were included.

Min and max possible scores are 0-100 respectively. A higher score represents better functioning.

Last observation carried forward (LOCF) was used for the imputation of missing values., Baseline, Week 52",Novartis Pharmaceuticals,517,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-07-17
NCT01383772,Retinal Laser by Multi-spot Photocoagulator and Driving Eligibility,https://clinicaltrials.gov/study/NCT01383772,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Pan retinal Photocoagulation,"Risk of failing visual field criteria to hold a driving licence., All patients requiring bilateral PRP will be identified. These patients will undergo binocular and uniocular full-field static and kinetic visual field testing; All patients will receive their PRP via the multi-spot Photocoagulator using standardised parameters for treatment.

At 6 months following the completion of PRP the patients will undergo repeat visual field testing as conducted at baseline.

Analysis of visual fields will principally involve qualitative assessment of whether patients have met the UK driving standards on Estermann VF testing., visual fields at baseline and at 6 months.",Moorfields Eye Hospital NHS Foundation Trust,43,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2012-06
NCT02646072,Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients,https://clinicaltrials.gov/study/NCT02646072,COMPLETED,"Cystoid Macular Edema, Postoperative|Diabetes Mellitus",DRUG: Ketorolac tromethamine ophthalmic solution 0.45%,"Level of aqueous inflammatory cytokines post treatment as assessed using Bio-plex Pro Assays, Aqueous samples were analyzed at the same after complete samples collection., 9 months",University of Malaya,80,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2014-08
NCT01698788,Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01698788,COMPLETED,Diabetic Macular Edema|Vision Disorders,DRUG: Dexamethasone Drug delivery system (Ozurdex),"change in central macular thickness, The primary outcome measure is the change in the central macular thickness, either an increase or decrease, as measured by optical coherence tomography as compared to the preoperative thickness, Baseline to 3 months",Postgraduate Institute of Medical Education and Research,5,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-05
NCT00367133,Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00367133,COMPLETED,Diabetic Macular Edema,PROCEDURE: Standard of Care Group|DRUG: 1mg triamcinolone acetonide|DRUG: 4mg triamcinolone acetonide,"Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years., Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., Baseline to 2 Years|Median Change in Visual Acuity Baseline to 2 Years, Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement., Baseline to 2 Years|Distribution of Change in Visual Acuity Baseline to 2 Years, Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method., baseline to 2 years",Jaeb Center for Health Research,840,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2004-07
NCT00664183,A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects,https://clinicaltrials.gov/study/NCT00664183,TERMINATED,Diabetic Retinopathy,DRUG: Vitreosolve,"Ultrasound, 7 Months","Vitreoretinal Technologies, Inc.",400,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2008-03
NCT00346983,Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics,https://clinicaltrials.gov/study/NCT00346983,TERMINATED,Cystoid Macular Edema,DRUG: Pegaptanib sodium|DRUG: Control,"Proportion of subjects avoiding 15 letters (3 lines) of best-corrected distance visual acuity loss at 18 weeks after cataract surgery. Distribution of visual acuity changes at 18 weeks after cataract surgery, 1 to 18 weeks post-cataract surgery|Distribution of absolute levels of distance visual acuity at 18 weeks after cataract surgery, 1 to 18 weeks post-cataract surgery|Analysis of time to 15 letter improvement of best-corrected distance visual acuity through 18 weeks after cataract surgery using a 2-state stochastic model to account for events and recoveries from events, 1 to 18 weeks post-cataract surgery",Johns Hopkins University,4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-06
NCT03769948,Clinical Decision Support Algorithm to Predict Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03769948,UNKNOWN,Diabetic Retinopathy,OTHER: risk factors for diabetic retinopathy,"Diabetic retinopathy indicator (yes/no), Diabetic patients with 362.0x ICD-9 codes are classified as DR patient, March, 2019",Oklahoma State University Center for Health Sciences,500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02
NCT05446948,Observation of the Efficacy of Different Vitrectomy Systems to Treat Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05446948,COMPLETED,Proliferative Diabetic Retinopathy|Vitrectomy,DEVICE: beveled 27G+ vitrectomy system|DEVICE: standard 25G+ vitrectomy system,"the convenience in operating, The convenience will be indicated by times of ancillary instrument using, which evaluated based on the recorded surgical video., during surgery|the efficiency of stripping membrane, It will be measured by the area of membrane removed per minute by probe., during surgery",Tianjin Medical University Eye Hospital,52,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-11
NCT02472366,"A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy",https://clinicaltrials.gov/study/NCT02472366,COMPLETED,Chronic Diabetic Macular Edema,DRUG: ILUVIEN,"Changes in Best Corrected Visual Acuity From Baseline, Best Corrected Visual Acuity is measured using an ETDRS eye chart and is reported as the number of letters read correctly in the study and/or fellow eye., Change from Baseline to 12 months post ILUVIEN administration",Alimera Sciences,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-01
NCT01945866,Phase II Combination Steroid and Anti-VEGF for Persistent DME,https://clinicaltrials.gov/study/NCT01945866,COMPLETED,Diabetic Macular Edema,DRUG: intravitreal ranibizumab 0.3 mg|DRUG: dexamethasone intravitreal implant|PROCEDURE: Sham injection,"Mean Change in Visual Acuity Letter Score, At 24 weeks after randomization, mean change in visual acuity letter score, adjusted for visual acuity at time of randomization, 24 weeks after randomization",Jaeb Center for Health Research,129,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-02
NCT02985619,Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02985619,COMPLETED,Diabetic Macular Edema,DRUG: Bevacizumab Injection [Avastin] (IVB-I)|DRUG: Triamcinolone Acetonide 10mg/mL (IVT-II)|DRUG: Bevacizumab Injection [Avastin] (IVB-III),"OCT measurements, Optical Coherence Tomography measurements in the central subfield thickness between baseline and 6 months 1st endpoint., 6 months.",University of Sao Paulo,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-07-21
NCT05301751,AG-73305 Single Ascending Dose Cohort Study in DME,https://clinicaltrials.gov/study/NCT05301751,RECRUITING,Diabetic Macular Edema,DRUG: AG-73305,"Safety as Assessed by Incidence of Adverse Events (AEs) and Serious AEs (SAE), Screening to 6 months",Allgenesis Biotherapeutics Inc.,25,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-06-09
NCT05683912,Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece,https://clinicaltrials.gov/study/NCT05683912,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept,"Change in best-corrected visual acuity, 12 months",University of Athens,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-09-01
NCT02976012,Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH,https://clinicaltrials.gov/study/NCT02976012,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Aflibercept|PROCEDURE: Endolaserless Vitrectomy,"• Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks:, Examples include worsened acuity \>30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52., Through 52 weeks from Baseline","Southeast Retina Center, Georgia",24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-06
NCT02088151,Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina,https://clinicaltrials.gov/study/NCT02088151,TERMINATED,Macular Edema|Central Serous Chorioretinopathy|Retinal Vein Occlusion|Age-related Macular Degeneration|Retinal Neovascularization,DEVICE: Selective retinal pigment epithelium laser therapy using the R:GEN Laser System,"Visual Acuity according to ETDRS protocol, 6 months","Insel Gruppe AG, University Hospital Bern",18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-06
NCT03765112,Macular Involvement in Diabetic Retinopathy Evaluated With Swept-Source OCT,https://clinicaltrials.gov/study/NCT03765112,UNKNOWN,Diabetes Mellitus|Diabetic Retinopathy,DEVICE: Optical coherence tomography angiography,"Perfusion density, The density of perfused capillaries (metric variable) measured with optical coherence tomography angiography (OCTA) will be compared between the different severity levels of diabetic retinopathy as well as to the control arm., 6 months",University of British Columbia,175,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2018-09-20
NCT00001612,Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS),https://clinicaltrials.gov/study/NCT00001612,COMPLETED,Diabetic Retinopathy,,,National Eye Institute (NEI),170,OBSERVATIONAL,Observational Model: |Time Perspective: p,1997-05
NCT00901186,Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00901186,COMPLETED,Diabetic Macular Edema|Visual Impairment,DRUG: RFB002|PROCEDURE: Laser photocoagulation,"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA), Visual acuity (VA) was assessed on the study eye during every study visit using best correction determined from protocol refraction. VA measurements were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters., Baseline, 12 months",Novartis Pharmaceuticals,83,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-11
NCT05471986,Multicenter Diagnostic Clinical Performance Study For Automated Detection of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05471986,NOT_YET_RECRUITING,Diabetic Retinopathy,DEVICE: Color Fundus Photography/Non-Mydriatic Opthalmic Cameras,"Sensitivity and Specificity of EyeCheckup to detect more than mild diabetic retinopathy, 1 visit (1 day)|Sensitivity and Specificity of EyeCheckup to detect vision-threatening diabetic retinopathy, 1 visit (1 day)",URAL Telekomunikasyon San. Trade Inc.,900,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-08-01
NCT01646047,Diabetes Visual Function Supplement Study,https://clinicaltrials.gov/study/NCT01646047,COMPLETED,Diabetes Mellitus - Type 1|Diabetes Mellitus - Type 2|Non-proliferative Diabetic Retinopathy,DIETARY_SUPPLEMENT: multi-component nutritional supplement capsules|DIETARY_SUPPLEMENT: multi-component dietary supplement,"Changes in visual function, Change in contrast sensitivity, color vision and macular perimetry thresholds, At baseline and again at six months","ZeaVision, LLC",70,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2012-05
NCT00505947,Treatment of Refractory Diabetic Macular Edema With Infliximab,https://clinicaltrials.gov/study/NCT00505947,TERMINATED,Diabetic Macular Edema|Visual Acuity|Diabetic Retinopathy,DRUG: infliximab|DRUG: placebo,"improvement in best corrected visual acuity, 32 weeks",University of Athens,12,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-07
NCT06075147,The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema,https://clinicaltrials.gov/study/NCT06075147,NOT_YET_RECRUITING,Visual Impairment|Neovascular Age-related Macular Degeneration (nAMD)|Diabetic Macula Edema (DME),"DRUG: Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)","The change of best corrected visual acuity (BCVA) from baseline to 12 months as evaluated in routine clinical practice, BCVA measurements at baseline (first injection of aflibercept 8 mg) and at 12 months as ETDRS letters (according to the Early Treatment Diabetic Retinopathy Study (ETDRS) chart or other methods (e.g. Snellen charts) used in the routine clinical practice in participating countries or sites (with conversion to ETDRS)), At baseline and 12 months",Bayer,2500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-02-29
NCT02718547,The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02718547,UNKNOWN,Complications of Diabetes Mellitus,DRUG: Combigan,"Change of at least 50 micron in Macular edema, The participants will be examined every month from the time of recruitment as mentioned before, at each visit the Macular Edema will be assessed, but the Outcome measure will be defined as Change of at least 50 Micron in Macular Edema at the third visit, 3 months from recruitment, Baseline measurement will be conducted at the recruitment of the participant, the second measurement will be preformed after one moth from recruitment and the third and last measurement will be preformed after 3 months from recruitment",Meir Medical Center,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-03-26
NCT00556114,A Pilot Study of Functional Optical Coherence Tomography for Ocular Imaging,https://clinicaltrials.gov/study/NCT00556114,COMPLETED,Glaucoma|Diabetic Retinopathy|Age-Related Macular Degeneration|Central Retinal Vein Occlusion|Branch Retinal Vein Occlusion,DEVICE: Optical Coherence Tomography,"Medical exam tool, Optical Coherence Tomography imaging technique of the retina and ability to diagnose and manage many eye diseases, 24 hours","University of California, Irvine",23,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-01
NCT05105607,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants",https://clinicaltrials.gov/study/NCT05105607,COMPLETED,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,DRUG: D-4517.2,"Number of Participants With Adverse Events, Day 1 up to Day 15","Ashvattha Therapeutics, Inc.",16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-01-11
NCT04795037,First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers,https://clinicaltrials.gov/study/NCT04795037,COMPLETED,Diabetic Macular Edema,"DRUG: CU06-1004, Single dose|DRUG: CU06-1004, Multiple doses|DRUG: Placebo","The number and severity of treatment emergent adverse events (TEAEs), To assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects., From the date of first dose through 7 days after the last dose","Curacle Co., Ltd.",81,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-07-15
NCT03953807,A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated,https://clinicaltrials.gov/study/NCT03953807,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone Intravitreal Implant,"Mean change in best corrected visual acuity (BCVA) 2 months (± 2 weeks) after the last injection, Baseline, at Month 10 through 12",Allergan,82,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-09-05
NCT02424019,Phase 4 IOP Signals Associated With ILUVIEN®,https://clinicaltrials.gov/study/NCT02424019,COMPLETED,Diabetic Macular Edema (DME),DRUG: ILUVIEN 0.19 MG,"Intraocular Pressure, Intraocular pressure of the ILUVIEN treated eye, 36 months",Alimera Sciences,153,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-05-06
NCT03094819,PROTECT2: Diabetes Care - Eye Exam,https://clinicaltrials.gov/study/NCT03094819,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema,BEHAVIORAL: Financial Incentive|BEHAVIORAL: Retinal Care DR,"Qualified eye examination rate, Percent of participants in each study group obtaining a qualified eye examination., 12 months",Retinal Care Inc.,4500,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH",2016-03-17
NCT04477707,"A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)",https://clinicaltrials.gov/study/NCT04477707,COMPLETED,Diabetic Retinopathy,DRUG: Finerenone (BAY94-8862),"Progression of non-proliferative diabetic retinopathy (NPDR), Progression of non-proliferative diabetic retinopathy (NPDR) defined by the occurrence of vision-threatening events i.e. proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), anterior segment neovascularization (ASN) until the end of Year 2 after start of treatment, After start of treatment until end of Year 2",Bayer,206,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-07-23
NCT01805297,Aflibercept Injection for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01805297,COMPLETED,Vitreous Hemorrhage,DRUG: Intravitreal Aflibercept Injection|OTHER: Standard Vitrectomy,"Rate of Resolved Post-operative Vitreous Hemorrhage., Percentage of patients who had no vitreous hemorrhage before or at week 24, 24 weeks",University of Oklahoma,12,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-03
NCT00994955,Selective Retina Therapy (SRT) for Clinically Significant Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00994955,COMPLETED,Diabetic Macular Edema,DEVICE: selective retina therapy (SRT),"best-corrected visual acuity, 2 years",University Hospital Schleswig-Holstein,39,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2006-01
NCT02826655,Adaptive Optics for Ophthalmic Technologies,https://clinicaltrials.gov/study/NCT02826655,TERMINATED,Diabetic Retinopathy|Diabetic Macular Edema,DEVICE: WF-AO-OCT,"Image Quality, Assessment of quality of images obtained by WF-AO-OCT unit., 30 minutes|Peripheral Retina Structure Differences between Healthy Controls and participants with diabetic retinopathy., Differences between the control and case populations will be described using descriptive statistics. This data can then be used to power future, more dedicated studies., 30 minutes",Duke University,4,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DEVICE_FEASIBILITY,2016-06
NCT01875783,OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits,https://clinicaltrials.gov/study/NCT01875783,COMPLETED,Diabetes|Diabetic Macular Edema|Diabetic Retinopathy,DEVICE: OCT imaging,"Rates of Retina Care Referral for Patients With Diabetic Macular Edema, Percentage of participants who are referred to a retina specialist for evaluation and management of DME after OCT imaging and OCT-guided referral algorithm, Baseline visit",Joslin Diabetes Center,385,INTERVENTIONAL,"Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: DIAGNOSTIC",2014-03-17
NCT01100307,A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01100307,COMPLETED,Macular Edema|Diabetic Mellitus|Retinal Disease,DRUG: pegaptanib sodium|OTHER: sham injection,"Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week 24: Double Masked Phase, Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts., Baseline and Week 24",Pfizer,243,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-05
NCT01312207,Macular Tractional Retinoschisis in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01312207,UNKNOWN,Proliferative Diabetic Retinopathy,,"visual acuity change after surgery, visual acuity (in logMAR ) before and after surgery, before surgery and 3 months after surgery",National Taiwan University Hospital,32,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-02
NCT05019807,Comparing the Compliance to Follow-up in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05019807,COMPLETED,Diabetic Macular Edema,OTHER: WhatsApp group|OTHER: Control group,"Follow-up rate in patients with diabetic macular edema receiving education materials about diabetes and its complications., To investigate the compliance of diabetes management in patients diagnosed with diabetic macular edema after providing educational materials in WhatsApp and compare with control group in a tertiary eye care institute in South India., 12 months",Lions Club International Foundation,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2020-12-18
NCT04636307,Characterization of Retinal Disease Progression in Eyes With Non Proliferative Diabetic Retinopathy in Diabetes Type 2 Using Non-invasive Procedures (CHART),https://clinicaltrials.gov/study/NCT04636307,ACTIVE_NOT_RECRUITING,"NPDR - Non Proliferative Diabetic Retinopathy|Diabetes Mellitus, Type 2|Retinal Disease",OTHER: Biomarkers,"DRSS severity progression, DRSS severity progression of one, two or more ETDRS step changes, 36 months|Progression to vision-threatening complications, CIME defined as eyes with a CRT ≥ 290 μm in women and ≥ 305 μm in men (Zeiss Cirrus SD-OCT); CSME identified on clinical evaluation as defined by ETDRS by retinal thickening within 500 μm of the center of the fovea or presence of hard exudates (with thickening of the adjacent retina) within 500 μm of the center of the fovea, or thickening of at least 1 disc area located less than 1 disc diameter from the center of the fovea. (Zeiss Cirrus SD-OCT); PDR identified by the presence of abnormal new vessels in the retina., 36 months|Presence of ischemia, dentified by decrease of 2 or more Standard deviations (in relation to healthy control population) on the values of vessel density, perfusion density or FAZ circularity., 36 months",Association for Innovation and Biomedical Research on Light and Image,202,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-09-22
NCT00345917,Safety Study in Retinal Transplantation for Retinitis Pigmentosa.,https://clinicaltrials.gov/study/NCT00345917,COMPLETED,Retinitis Pigmentosa.,DEVICE: Retinal transplantation instrument|DEVICE: Fetal tissue.,Snellen|Visual acuity|Microperimetry|Goldmann visual field|Optical coherent tomography|Fluorescein angiography,"Radtke, Norman D., M.D.",10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2002-02
NCT04496817,Enriched Eggs for Retina Health in Type 2 Diabetes,https://clinicaltrials.gov/study/NCT04496817,RECRUITING,Diabetic Retinopathy|Type 2 Diabetes,OTHER: Docosahexaenoic Acid and Lutein Enriched Eggs|OTHER: Regular Eggs,"Change in Retina Function, Measured by Full Field Electroretinography, 6 weeks",University of Manitoba,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2022-07-11
NCT05655117,Application of Artificial Intelligence in Early Detection of Eye Complications in Diabetics,https://clinicaltrials.gov/study/NCT05655117,NOT_YET_RECRUITING,Artificial Intelegence|Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus|Macular Edema Due to Type 2 Diabetes Mellitus,OTHER: AI based eye screening,"The detection rate of diabetic retinopathy in the intervention group vs. control group, The proportion of the detected cases of diabetic retinopathy in the intervention group vs. control group, 6 month from the start of the study|The detection rate of macular oedema in the intervention group vs. control group., The proportion of the individuals who screened positive for macular oedema in the intervention group vs. control group., 6 month from the start of the study","The New Model of Care, Hail Health Cluster",440,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2023-01
NCT01983917,Mobile Application to Enhance Diabetic Care,https://clinicaltrials.gov/study/NCT01983917,WITHDRAWN,Diabetes Mellitus,BEHAVIORAL: Diabetes Mobile Application,"Change of diabetic retinopathy risk factors, risk factors normalization by assessment of hemoglobin A1c percent, blood lipids level and blood pressure level as continuous variables., 1 year","University of California, Los Angeles",0,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2012-09
NCT02321904,Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children,https://clinicaltrials.gov/study/NCT02321904,COMPLETED,Type 1 Diabetes|Neuropathy|Retinopathy,PROCEDURE: Corneal Confocal Microscopy|PROCEDURE: Nerve Conduction Studies|PROCEDURE: Quantitative sensory testing|PROCEDURE: Neuropathy Symptom Score|PROCEDURE: Clinical nerve examination,"The utility of corneal confocal microscopy to assess diabetic neuropathy in children., To confirm the utility of corneal confocal microscopy (CCM) as a new technique to rapidly assess diabetic neuropathy (DN) in children. This non-invasive eye imaging method may be a superior alternative to traditional nerve conduction studies.

This study will be divided into two phases: Phase 1 will be a cross-sectional study of children with Type 1 Diabetes (T1D) and normal controls, while phase 2 will be a longitudinal assessment of a subgroup of T1D children recruited during Phase 1., 2 years",University of Calgary,176,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-06
NCT00676559,Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study,https://clinicaltrials.gov/study/NCT00676559,WITHDRAWN,Diabetic Macular Edema,DRUG: Efalizumab|DRUG: Ranibizumab,"To assess the safety and tolerability of efalizumab, compared to and in combination with ranibizumab, measuring the frequency and severity of adverse events., 6 mos",Johns Hopkins University,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2008-04
NCT04395859,Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents,https://clinicaltrials.gov/study/NCT04395859,COMPLETED,Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,PROCEDURE: Questionnaire|OTHER: Data collection up to 1 year,"Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic, Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up, Baseline (Before confinement) and 6 months after resumption of follow-up",Fondation Ophtalmologique Adolphe de Rothschild,233,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-05-27
NCT00576459,Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00576459,COMPLETED,Diabetic Macular Edema,DRUG: 0.59 mg fluocinolone acetonide intravitreal implant|DRUG: 2.1 mg fluocinolone acetonide intravitreal implant|PROCEDURE: standard of care laser photocoagulation,"Between group difference in mean visual acuity change (from baseline), 1 year",Bausch & Lomb Incorporated,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2003-03
NCT03927859,Increasing DR Screening Through TOP: Supporting Implementation and Identifying Opportunities for Scale up in Ontario,https://clinicaltrials.gov/study/NCT03927859,UNKNOWN,"Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","OTHER: a mail letter, a phone call and a phone call plus mailed letter","Number of bookings made through the TOP program, The primary outcome for the study is the number of bookings made through the TOP program, 1 year",Women's College Hospital,420,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2018-07-05
NCT01315275,A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema,https://clinicaltrials.gov/study/NCT01315275,COMPLETED,Visual Impairment|Macular Edema,DRUG: Ranibizumab,"proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA), 6 months",Novartis Pharmaceuticals,394,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-02
NCT05494775,Effect of Corona Virus on Intravitreal Injections,https://clinicaltrials.gov/study/NCT05494775,RECRUITING,Diabetic Macular Edema|Age-Related Macular Degeneration|Choroidal Neovascularization|Myopic Choroidal Neovascularisation|Diabetic Retinopathy,DRUG: Anti-vascular endothelial growth factors (Anti-VEGFs),"Visual acuity, Assessing the changes in best corrected visual acuity in logMAR unit measured by snellen chart., Baseline and monthly after injection till one year of follow-up",Benha University,250,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-02-01
NCT02956759,Early Laser Treatment for Diabetic Eye Disease in China : A Pilot Randomized Trial,https://clinicaltrials.gov/study/NCT02956759,RECRUITING,Diabetic Retinopathy,PROCEDURE: Pan-retinal photocoagulation laser treatment,"Proportion of eyes progressing to any degree of PDR, The diagnosis of PDR will be made by detecting either active new vessels in the optic nerve head or elsewhere in the retina as determined by fundus photography read by a masked investigator or preretinal/vitreous haemorrhage at any time during the 12 month follow-up period., 1 year",Sun Yat-sen University,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-10
NCT02229175,Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02229175,WITHDRAWN,Diabetic Macular Edema,DRUG: bevacizumab|DEVICE: PASCAL Endpoint Management (EpM) laser treatment,"Retinal thickness, Change in retinal thickness on SD-OCT from baseline to 12 months., 12 months","University of California, San Francisco",0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-01-01
NCT00511875,Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00511875,COMPLETED,Diabetic Retinopathy,DRUG: doxycycline monohydrate|DRUG: placebo,"Change in Dark Adaptation, Rod Intercept, Change in dark adaptation is measured as dark adaptation time at baseline measured in minutes minus dark adaptation time measured at 24 months, Baseline and 24 months|Change in Photopic Visual Field, Change in photopic visual fields between baseline and 24 months, Baseline and 24 months|Change in Frequency Doubling Perimetry (FDP), Change in Frequency Doubling Perimetry (FDP) from baseline, shown as mean and foveal (center of retina) scores, 24 months|Change in Early Treatment Diabetic Retinopathy Study (ETDRS), Change in ETDRS visual acuity letter score from baseline. ETDRS is measured on a scale of 0 to 70 where 0 means inability to see anything on the chart and 70 is normal (20/20) acuity., Baseline and 24 months",Thomas Gardner,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-07
NCT05391659,E-CLAIR: Efficiency and Cost-effectiveness of Artificial Intelligence Based Diabetic Retinopathy Screening in Flanders,https://clinicaltrials.gov/study/NCT05391659,RECRUITING,Diabetic Retinopathy,DEVICE: deep learning|DIAGNOSTIC_TEST: remote grading of fundus images|DIAGNOSTIC_TEST: gold standard,"sensitivity, To evaluate the efficiency of the use of AI in screening for DRP: sensitivity, 6 months|specificity, To evaluate the efficiency of the use of AI in screening for DRP: specificity, 6 months|AUC, To evaluate the efficiency of the use of AI in screening for DRP: AUC, 6 months",Universitaire Ziekenhuizen KU Leuven,1200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2021-06-17
NCT04565756,A Study to Evaluate the Safety and Tolerability of EXN407,https://clinicaltrials.gov/study/NCT04565756,COMPLETED,Diabetic Macular Edema,DRUG: EXN407,"The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Escalation phase., Measured by frequency and severity of ocular AEs in the study and contralateral eyes., Assessed starting from Day 1 of treatment to Day 36 in Dose Escalation.|The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Expansion phase., Measured by frequency and severity of ocular AEs in the study and contralateral eyes., Assessed starting from Day 1 of treatment to Day 113 in Dose Expansion phase.",Exonate Limited,48,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-11-05
NCT04014556,Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04014556,COMPLETED,Diabetic Macular Edema,DEVICE: micropulse laser|DRUG: Aflibercept,"The number of Aflibercept injections in both groups, The number of Aflibercept injections in both groups, 12 months",University of Alexandria,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-04-01
NCT05787990,Time-In-Range Based Risk Stratification of Type 2 Diabetes Microvascular Complications,https://clinicaltrials.gov/study/NCT05787990,RECRUITING,"Type 2 Diabetes|Diabetes Related Complications|Diabetes; Retinopathy (Manifestation)|Diabetes; Neuropathy, Polyneuropathy (Manifestation)|Diabetes; Nephropathy (Manifestation)",DIAGNOSTIC_TEST: Diabetes Microvascular Complication Tests,"Presence of Diabetes Retinopathy, Based on Fundal Photography grading, 10 years|Presence of Diabetes Neuropathy, Based on 10g monofilament foot examination, 10 years|Presence of Diabetes Nephropathy, Urine microalbumin-creatinine ratio in mg/g, 10 years",Singapore General Hospital,500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-14
NCT03918590,Post Intravitreal Injection Topical NSAID vs. Patching,https://clinicaltrials.gov/study/NCT03918590,UNKNOWN,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,"DRUG: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|DRUG: Theratears tear drop, (Akron, Ann 111 Arbor, MI)|OTHER: patching","Post Intravitreal Injection Measurement of Pain, Change from Baseline post intravitreal injection pain at 6 and 24 hours as measured by the Numeric Pain Rating Scale. The pain numeric rating scale (NRS), on which patients rate their current pain intensity from 0 (""no pain"") to 10 (""worst possible pain""), at the screening, 6 hours and 24 hours., 6 hours and 24 hours after intravitreal injection",The New York Eye & Ear Infirmary,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-12-03
NCT05223556,Self-testing Diagnosis Imaging Model for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05223556,COMPLETED,Diabetic Retinopathy,DEVICE: Full Self-Diagnostic device in a remote diagnostic imaging site|DEVICE: Human imager operated diagnostic device in the hospital,"Accuracy in the diagnosis of referral retinal lesions, Accuracy in the diagnosis of referral retinal lesions using the self-testing diagnosis imaging, 1 week","Zhongshan Ophthalmic Center, Sun Yat-sen University",167,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-01
NCT04108156,"This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab",https://clinicaltrials.gov/study/NCT04108156,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|DRUG: Intravitreal Ranibizumab 0.5 mg Injection,"Change in BCVA score from baseline averaged over Weeks 60 and 64 as measured using the ETDRS chart in the efficacy population using a treatment policy strategy for all intercurrent events, BCVA = Best-Corrected Visual Acuity

ETDRS = Early Treatment Diabetic Retinopathy Study

A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind., Baseline to Week 64",Hoffmann-La Roche,634,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-09-30
NCT05343156,Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05343156,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone nanoparticles eye drops,"Mean Change in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA), The primary efficacy endpoint was summarized by treatment group using descriptive statistics, including 70%, 90% and 95% confidence intervals (CIs). Change from baseline to Week 12 is also summarised by treatment group.

The primary analysis of the primary endpoint employed a linear model with change from baseline ETDRS BCVA letters as the response, baseline ETDRS BCVA letters as a covariate, and treatment as a main effect factor, using the ITT population and with multiple imputation pattern mixture model techniques used to impute missing data., Baseline & Week 12",Oculis,144,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-09-18
NCT00969956,Time To Complications Occurs in Diabetes,https://clinicaltrials.gov/study/NCT00969956,TERMINATED,Retinopathy|Nephropathy|Diabetic Neuropathy|Vascular Disease|Ischemic Heart Disease,,"Time to nephropathy, 0, 3-5, 8-10 and 13-15 years|Time to autonomous neuropathic ulcers and Amputation, 0, 3-5, 8-10 and 13-15 years|Time to peripheral neuropathy, 0, 3-5, 8-10 and 13-15 years|Time to peripheral Macro-Vascular Disease, chronic Foot ulcers and Amputation, 0, 3-5, 8-10 and 13-15 years|Time to retinopathy, 0, 3-5, 8-10 and 13-15 years",Karolinska Institutet,17,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04
NCT03603990,Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03603990,WITHDRAWN,Edema|Macular Edema|Diabetic Retinopathy|Macular Degeneration|Diabetic Angiopathies|Retinal Disease,PROCEDURE: Vitrectomy|PROCEDURE: Usual care,"Visual acuity, The difference between the change in the score of visual acuity between randomization and 6 months after treatment, between groups, 6 months after randomization",Fondation Ophtalmologique Adolphe de Rothschild,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2018-09-01
NCT05057403,UK Imaging Diabetes Study Seeing Diabetes Clearly,https://clinicaltrials.gov/study/NCT05057403,ENROLLING_BY_INVITATION,Type2 Diabetes|Diabetic Retinopathy,,"3-point MACE incidence rate, Investigate the effect of baseline liver magnetic resonance (MR) metrics on the incidence rate of 3-point major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal stroke, myocardial infarction), 1 year from baseline|3-point MACE incidence rate, Investigate the effect of baseline liver magnetic resonance (MR) metrics on the incidence rate of 3-point major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal stroke, myocardial infarction), 3 years from baseline|3-point MACE incidence rate, Investigate the effect of baseline liver magnetic resonance (MR) metrics on the incidence rate of 3-point major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal stroke, myocardial infarction), 10 years from baseline",Perspectum,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-30
NCT05885503,Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05885503,RECRUITING,Diabetic Macular Edema,BIOLOGICAL: RC-28E|BIOLOGICAL: Aflibercept,"Change from baseline in BCVA at Week 52, BCVA=best-corrected visual acuity; Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts at a starting distance of 4 meters, Baseline, week 52","RemeGen Co., Ltd.",316,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-06-08
NCT05188703,Patient Navigator Intervention for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05188703,RECRUITING,Diabetic Retinopathy|Diabetic Blindness,BEHAVIORAL: Patient Navigation,"Number of participant who had baseline eye exam, The number of participants who had their baseline eye exam will be determined using the electronic health record, 18 months|Number of participants who completed a follow-up eye exam 12+ months after baseline eye exam, The number of participants who completed a follow-up eye exam 12+ months after baseline eye exam will be determined using the electronic health record, up to 18 month",Yale University,35,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2022-07-25
NCT03904056,ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR,https://clinicaltrials.gov/study/NCT03904056,COMPLETED,Diabetic Retinopathy,PROCEDURE: ISQ-RP|PROCEDURE: ETDRS-PRP group,"Fluorescein leakage area of active new vessels (FLA), Compare the Area of fluorescein leakage from active new vessels in both groups in mm2 measured by wide field fluorescein angiography (Optomap 200TX; Optos PLC., Dunfermline, Scotland, United Kingdom), 48 weeks",São Paulo State University,23,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2014-01-01
NCT04594603,Changes of Macular Vasculature After Uncomplicated Phacoemulsification Surgery Using Optical Coherence Tomography Angiography,https://clinicaltrials.gov/study/NCT04594603,RECRUITING,Diabetic Retinopathy,OTHER: Phacoemulsification for cataract,"To record the vascular changes that may be present in the macular after uncomplicated phacoemulsification surgery by using OCTA, 1 week after surgery",Tanta University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-04-13
NCT01908816,An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.,https://clinicaltrials.gov/study/NCT01908816,COMPLETED,"Choroidal Neovascularization|Macular Edema|Glaucoma, Neovascular|Diabetic Retinopathy",DRUG: ranibizumab,"Number of Participants With Adverse Events as a Measure of Safety and Tolerability, Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) for ocular and non-ocular events. Due to early termination, only descriptive analysis was conducted., 24 months",Novartis Pharmaceuticals,270,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-09-26
NCT06116916,A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT06116916,NOT_YET_RECRUITING,Diabetic Macular Edema (DME),DRUG: KHK4951|DRUG: Aflibercept Injection,"Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline, For 36 weeks until the end of the trial","Kyowa Kirin, Inc.",150,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-11
NCT03003416,Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT03003416,COMPLETED,Diabetic Macular Edema,DRUG: dexamethasone intravitreal implant,"Best Gain in Best Corrected Visual Acuity (BCVA) compared to Baseline Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, Baseline to Month 24",Allergan,115,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-19
NCT06038968,Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT06038968,RECRUITING,Diabetic Retinopathy|Vitreomacular Traction,DRUG: Methotrexate 25 MG/ML|PROCEDURE: parsplana vitrectomy,"assess retinal layers by optical coherence tomography, presence of epiretinal membrane, cystic changes in retina, central macular thickens, one month after pars plana vitrectomy and one month after silicone oil evacuation|assess functional outcomes by multifocal electroretinogram, latency and amplitude of main P wave, one month after pars plana vitrectomy and one month after silicone oil evacuation",Minia University,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: OTHER",2022-09-01
NCT00344968,Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00344968,COMPLETED,Diabetic Macular Edema,DRUG: fluocinolone acetonide|DRUG: Fluocinolone Acetonide|PROCEDURE: Standard of care laser photocoagulation,"Visual Acuity, The percentage of subjects with an increase from baseline of 15 or more letters in best corrected visual acuity letter score as assessed by ETDRS eye chart (study eye)., 36 months",Alimera Sciences,956,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-09
NCT03859245,Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention,https://clinicaltrials.gov/study/NCT03859245,UNKNOWN,Diabetic Retinopathy (DR)|Age-related Macular Degeneration (AMD)|Mid-peripheral Drusen Formation|Diabetic Macular Edema (DME),BEHAVIORAL: Photobiomodulation|BEHAVIORAL: Ketogenic diet,"Diabetic Retinopathy (DR) pathology, Improvement in number and severity of hemorrhages and hard and soft exudates as measured by the Daytona Plus (Panoramic Ophthalmoscope P200T), 36 weeks|Diabetic Macular Edema (DME) pathology, Lower incidence of macular edema as measured by Optos Daytona Plus (Panoramic Ophthalmoscope P200T) and Optovue XR Avanti 3 OCT (Ocular Coherence Tomography) Imaging Systems, 36 weeks|Dry Age-related Macular Degeneration (AMD) pathology, Reduction in size and number of drusen in early and intermediate stages of Dry AMD pathology as measured byOptos Daytona Plus (Panoramic Ophthalmoscope P200T) and Optovue XR Avanti 3 OCT (Ocular Coherence Tomography) Imaging Systems, 36 weeks|Hard Drusen in the Mid-periphery pathology, Reduction in size and/or density of drusen as measured by the Optos Daytona Plus (Panoramic Ophthalmoscope P200T), 36 weeks","Bristlecone Health, Inc.",30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-02-23
NCT05080803,Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome,https://clinicaltrials.gov/study/NCT05080803,COMPLETED,Diabetic Macular Edema,DRUG: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone,"Functional and morphological improvement in DME after initial therapeutic loading phase, according to ESASO stage of progression of the disease., Visual acuity and morphological (OCT) stage of the disease (as described in ESASO DME classification) will be evaluated at time 0 and four months after the first injection of intravitreal dexamethasone or one month after the loading phase (3 monthly injections) with anti-VEGF., Four months",European School of Advanced Studies in Ophthalmology,608,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-01
NCT00343603,Tracking Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT00343603,COMPLETED,Macular Degeneration|Glaucoma|Diabetic Retinopathy|Choroidal Disease,,,University of Pittsburgh,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2004-10
NCT02232503,Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia,https://clinicaltrials.gov/study/NCT02232503,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema|Diabetes Mellitus,GENETIC: Studied cohort,"The prevalence of diabetic retinopathy as the proportion of patients with DR (any stage) in a given subgroup according to DM duration, The results will be accompanied by Wald 95% confidence intervals. The combined prevalence results from more subgroups will be evaluated using weighted average using the best available epidemiology data., participants screened each working day within 8 working hours during a 6 months period in selected diabetology centers according to protocol criteria","Novartis Slovakia, s.r.o.",4011,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-02
NCT04619303,Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO,https://clinicaltrials.gov/study/NCT04619303,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy,DRUG: Dexamethasone intravitreal implant|DRUG: Bevacizumab Injectable Product,"Difference in best corrected visual acuity change between treatment arms, The primary outcome measure will be the difference in the BCVA change from baseline to 12 months between treatment arms, with a non-inferiority margin of 0.1 LogMAR (equivalent to one line of Snellen visual acuity). The BCVA will be measured for all study participants at each clinic visit., 12 months","Lions Eye Institute, Perth, Western Australia",59,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-02-07
NCT04910503,Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT04910503,RECRUITING,Diabetic Macular Edema,DRUG: Dexamethasone intravitreal implant|DRUG: Fluocinolone Acetonide Intravitreal Implant,"Cost per healthy year gained, 3 years after starting treatment",Centre Hospitalier Universitaire Dijon,106,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-10-29
NCT04668703,Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04668703,UNKNOWN,Diabetic Macular Edema|Diabetic Retinopathy|Cataract Diabetic,PROCEDURE: Conbercept intravitreal injection,"change in central retinal thickness (CRT) with optical coherence tomography (OCT), to compare the mean change from baseline of CRT between treatment group and control group at month 1 and 3, Baseline, 1 month and 3 month after operation|change in diabetic retinopathy severity score (DRSS), to compare the mean change from baseline of DRSS between treatment group and control group at month 1 and 3, Baseline, 1 month and 3 month after operation",Eye & ENT Hospital of Fudan University,40,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2021-01-01
NCT03866005,Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03866005,UNKNOWN,Center-involved Diabetic Macular Edema (CI-DME),"DIETARY_SUPPLEMENT: Diabetes Visual Function Study (DiVFuSS) softgels|OTHER: canola oil placebo softgels, 2 per day","Best-corrected visual acuity, Best-corrected visual acuity at entry and conclusion of study, two years|SD-OCT macular subfield thicknesses, Change in macular subfield thicknesses from baseline to study conclusion, two years|Required number of anti-VEGF injections, The number of intravitreal anti-VEGDF injections required for treatment of center-involved diabetic macular edema, two years","ZeaVision, LLC",150,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-11-01
NCT01331005,NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT01331005,COMPLETED,Diabetic Macular Edema,DRUG: nepafenac 0.1% drops|OTHER: Nepafenac Vehicle,"Mean Change in Optical Coherence Tomography Measure Retinal Volume, mm3, From Baseline to 12 months",Jaeb Center for Health Research,125,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-05
NCT00596505,Intravitreal Bevacizumab Pretreatment for Reducing Preretinal Hemorrhage in Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT00596505,COMPLETED,Proliferative Diabetic Retinopathy,,"The severity of intraoperative and postoperative preretinal hemorrhage, Six months|Reabsorption time of blood around the disc area, Six months|The changes of visual acuity, Six months",National Taiwan University Hospital,41,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-04
NCT02933905,Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection,https://clinicaltrials.gov/study/NCT02933905,COMPLETED,Diabetic Macular Edema|Vitreomacular Interface|Anti-VEGF Treatment,DRUG: Intravitreal Ranibizumab injection,"Change in best-corrected visual acuity, One year",Fundació Institut Germans Trias i Pujol,38,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT03374020,Retinal Imaging Using NOTAL-OCT,https://clinicaltrials.gov/study/NCT03374020,COMPLETED,Age-Related Macular Degeneration|Diabetic Retinopathy,DEVICE: Notal OCT,"The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula., OCT B-scans from both devices will be graded for fluid by an eye care professional and results per macula will be analyzed. A binary decision ""there is fluid"" or ""there is no fluid"" will be given to each macula (10 central degrees). Then agreement between decisions, commercial and Notal OCT, will be compared, 1 year",Notal Vision Ltd.,33,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-17
NCT03660345,PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME,https://clinicaltrials.gov/study/NCT03660345,COMPLETED,Diabetic Retinopathy|Macular Edema,PROCEDURE: PPV/MP|DRUG: Intravitreal injection,"BCVA, Best-corrected visual acuity, 6 months",Rush Eye Associates,11,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-09-04
NCT03694145,Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images,https://clinicaltrials.gov/study/NCT03694145,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema,OTHER: In-Person Eye Examination,"Proportion of patients accurately diagnosed with retinopathy, Proportion of patients accurately diagnosed with retinopathy using machine learning versus proportion accurately diagnosed by teleretinal screening optometrists with in-person eye examinations by ophthalmologists used as a gold standard., 11/2022",Charles Drew University of Medicine and Science,300,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-25
NCT04215445,Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD,https://clinicaltrials.gov/study/NCT04215445,UNKNOWN,Diabetic Retinopathy|Chronic Kidney Diseases|Diabetes Mellitus,DRUG: Empagliflozin 25 MG|DEVICE: OCT-A,"Comparison of change in fovea avascular zone within retina of proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor, Change in fovea vascular zone (FAZ) size (um2) from Baseline using Optical Coherence Tomography Angiography (OCT-A) post-SGLT-2 treatment, After 28 days of treatment|Comparison of change in retinal and choroidal vessel density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor, Change in vessel density (mm-1) from Baseline using Optical Coherence Tomography Angiography (OCT-A) post-SGLT-2 treatment, After 28 days of treatment|Comparison of change in retinal and choroidal vascular perfusion density in proteinuric and non-proteinuric chronic kidney disease patients treated with SGLT2-inhibitor, Change in perfusion density from Baseline using Optical Coherence Tomography Angiography (OCT-A) post-SGLT-2 treatment, After 28 days of treatment",National University of Malaysia,90,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-12-01
NCT03969303,NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients,https://clinicaltrials.gov/study/NCT03969303,COMPLETED,AMD - Age-Related Macular Degeneration|Diabetic Macular Edema,DEVICE: Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5),"Comparison of presence/absence of fluid on OCT images from NOTAL-OCT v.2.5 device with a commercial OCT device, in AMD (Age-related Macular Degeneration) patients, To evaluate the sensitivity and specificity regarding the presence and absence of fluid on OCT images of AMD patients. OCT images from the central 10 degrees of the macula in AMD patients will be obtained using the NOTAL OCT v.2.5 and a commercial OCT device (Zeiss Cirrus / Heidlberg SPECTRALIS). These images will be evaluated for the presence/absence of fluid in the images by a human grader. The sensitivity and specificity will be determined by comparison of the presence/absence of fluid in the NOTAL OCT v2.5 images with the presence/absence of fluid in the commercial OCT images., less than an hour",Notal Vision Ltd.,287,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-20
NCT03470103,A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America,https://clinicaltrials.gov/study/NCT03470103,COMPLETED,Macular Degeneration,"DRUG: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity as measured by ETDRS or Snellen chart, ETDRS: Early treatment diabetic retinopathy study, At baseline and 12 months",Bayer,643,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-03-28
NCT02002403,Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02002403,COMPLETED,Diabetic Macular Edema,DRUG: Danazol,"OCT, Change in Central Macular Thickness (CMT), measured by time-domain optical coherence tomography (OCT), from baseline to study endpoint at 12 weeks of study treatment compared to placebo, 12 weeks",Unity Health Toronto,34,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-01
NCT01724554,Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion,https://clinicaltrials.gov/study/NCT01724554,COMPLETED,Central Retinal Vein Occlusion|Proliferative Diabetic Retinopathy,DRUG: Intravitreal Aflibercept Injection,"Mean Change in Capillary Non-Perfusion, To determine mean change in the presence and amount of capillary non-perfusion as measured by wide-angle angiography using Optos 200Tx system at Baseline, Month 3, Month 6, and Month 12., 12 months",Ophthalmic Consultants of Boston,24,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-11
NCT00445003,Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00445003,COMPLETED,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Triamcinolone Acetonide|BEHAVIORAL: Sham injection|PROCEDURE: Focal/grid laser,"Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks, Visual Acuity was measured with the Electronic Early Treatment Study (E-ETDRS) visual acuity test. Unit of measure is based on the E-ETDRS letter score scale, 0-97, where 0 = worst and 97 = best., baseline to 14 weeks",Jaeb Center for Health Research,333,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2007-03
NCT01726075,Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01726075,COMPLETED,Diabetic Retinopathy,DRUG: COLIRIOBCN070660|DRUG: Placebo|DRUG: Brimonidine,"Changes in the Implicit Time assessed by mfERG (IT-mfERG) at month 6, 12, 18 and 24, month 24",BCN Peptides,450,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2013-02
NCT02249897,PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs,https://clinicaltrials.gov/study/NCT02249897,COMPLETED,DIABETES|DIABETIC RETINOPATHY|DIABETIC NEUROPATHY,DRUG: CHOLESTYRAMINE,"CML SERUM LEVELS, REDUCTION OF CARBOXYMETHYL (CML) SERUM LEVELS, 12 WEEKS",University of Chile,7,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: PREVENTION,2015-01
NCT00567372,POSTERIOR SUB-TENON'S Avastin,https://clinicaltrials.gov/study/NCT00567372,UNKNOWN,Diffuse Diabetic Macular Edema,DRUG: bevacizumab (Sub-tenon´s injection),"macular volume, baseline, 3,6 and 12 weeks",Asociación para Evitar la Ceguera en México,7,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-06
NCT01853072,Nepafenac Once Daily for Macular Edema - Study 1,https://clinicaltrials.gov/study/NCT01853072,COMPLETED,Non-Proliferative Diabetic Retinopathy|Cataract,"DRUG: Nepafenac Ophthalmic Suspension, 0.3%|OTHER: Nepafenac vehicle|DRUG: Prednisolone acetate","Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90, BCVA (with spectacles or other visual corrective devices) was reported in letters read correctly, using the Early Treatment Diabetic Retinopathy Study (ETDRS) test of 70 letters. Improvement of BCVA was defined as an increase (gain) in the number of letters read, compared to the baseline assessment. One eye (study eye) contributed to the analysis., Baseline to Day 14, and maintained through Day 90|Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0), Macular edema was defined as ≥ 30% Increase from pre-operative baseline in central subfield macular thickness, as measured with Spectral Domain Ocular Coherence Tomography (SD-OCT). One eye (study eye) contributed to the analysis., Day 0 to Day 90",Alcon Research,881,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-06
NCT05441072,Validation of Bulbicam for DR- and AMD-patients,https://clinicaltrials.gov/study/NCT05441072,RECRUITING,Diabetic Retinopathy|Age-Related Macular Degeneration,DEVICE: BulbiCam,"Visual Field, Saccadic Reaction Time, 0 hours|Visual Field, Saccadic Reaction Time, 2 hours|Visual Field, Saccadic Reaction Time, 4 hours|Visual Field, Saccadic Reaction Time, 24 hours|Visual Field, Saccadic Reaction Time, 26 hours|Visual Field, Saccadic Reaction Time, 28 hours|Ptosis, Margin to reflex distanse, 0 hours|Ptosis, Margin to reflex distanse, 2 hours|Ptosis, Margin to reflex distanse, 4 hours|Ptosis, Margin to reflex distanse, 24 hours|Ptosis, Margin to reflex distanse, 26 hours|Ptosis, Margin to reflex distanse, 28 hours",Meddoc,64,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-19
NCT05511038,A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05511038,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Number of ocular and non-ocular treatment-emergent adverse events (TEAEs), At week 52",Bayer,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-08-26
NCT02337972,Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients,https://clinicaltrials.gov/study/NCT02337972,UNKNOWN,Diabetic Retinopathy|Diabetic Macular Edema,DRUG: povidone-iodine 4%,"Change of conjunctival flora and bacterial resistance, 4 month",Sheba Medical Center,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2015-01
NCT04627272,AutoDx-DR Prospective Clinical Validation Study Protocol,https://clinicaltrials.gov/study/NCT04627272,UNKNOWN,Diabetic Retinopathy,DEVICE: AutoDX-DR,"Sensitivity, The ability of AutoDX-DR to correctly identify those with the disease (true positive rate), Each subject will only have one day study visit and will provide the AutoDX-DR and gold standard reading during their one visit.|Specificity, The ability of AutoDX-DR to correctly identify those without the disease (true negative rate), Each subject will only have one day study visit and will provide the AutoDX-DR and gold standard reading during their one visit.",Hill-Rom,1539,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2020-12-01
NCT01880372,The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01880372,TERMINATED,Moderate Non-proliferative Diabetic Retinopathy,DIETARY_SUPPLEMENT: Alpha Lipoic Acid,"Decreased progression of diabetic retinopathy., Decreased progression of diabetic retinopathy as measured and graded by using Standard ETDRS 7 -field color stereoscopic funds photograph, and also by measuring the serum levels of interleukin 6 and 8, VEGF, interferon 2 alpha and M-CSF using ELISA technique, Visual examination and serum analysis will be done at baseline, 6 and 12 month",Ferris State University,1,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-09
NCT03786146,Changes in Retinal Nerve Fiber Layer Thickness Detected by OCT in Diabetic Retinopathy After Panretinal Photocoagulation,https://clinicaltrials.gov/study/NCT03786146,UNKNOWN,Retinal Disease,,"Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers., A 3.4 mm OCT circular scan will be positioned around the optic nerve head., 0 (before laser treatment ).|Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers., A 3.4 mm OCT circular scan will be positioned around the optic nerve head., 1 month post laser treatment.|Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers., A 3.4 mm OCT circular scan will be positioned around the optic nerve head., 3 months post laser treatment.|Retinal nerve fiber layer thickness measured by Optical Coherence Tomography (OCT) and expressed in micrometers., A 3.4 mm OCT circular scan will be positioned around the optic nerve head., 6 months post laser treatment.",Assiut University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01
NCT02448446,The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates,https://clinicaltrials.gov/study/NCT02448446,COMPLETED,Diabetic Macular Edema|Hard Lipid Exudates,DRUG: ranibizumab 0.3mg,"Best Corrected Visual Acuity as Measured by ETDRS at 6 and 12 Months, Compare Group 1 and Group 2 for best correct visual acuity (BCVA), as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters., 6-12 months","South Coast Retina Center; Carson, McBeath, Boswell, Inc.",25,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-08
NCT00001346,Diabetic Retinopathy and Visual Function Study,https://clinicaltrials.gov/study/NCT00001346,COMPLETED,"Diabetic Retinopathy|Macular Degeneration|Vision, Subnormal",,,National Eye Institute (NEI),100,OBSERVATIONAL,Observational Model: |Time Perspective: p,1992-11
NCT03970161,Evaluation of Early Retinal Nerve Injury in Type 2 Diabetes Patients Without Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03970161,UNKNOWN,Diabetes Mellitus|Diabetic Retinopathy|Nerve Injury,DEVICE: routine ophthalmic examination,"Peripapillary RNFL thickness, Peripapillary RNFL thickness, 96 weeks|GCL+ in the macular area obtained using the 3D wide mode, GCL+ in the macular area obtained using the 3D wide mode, 96 weeks|Retinal thickness in all macular regions, Retinal thickness in all macular regions, 96 weeks|RNFL thickness in the macular area obtained using the 3D Macula (v) mode, RNFL thickness in the macular area obtained using the 3D Macula (v) mode, 96 weeks|GCL+ thickness in the macular region obtained using the 3D Macula (v) mode, GCL+ thickness in the macular region obtained using the 3D Macula (v) mode, 96 weeks","Third Affiliated Hospital, Sun Yat-Sen University",720,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2019-05-29
NCT01202461,Triple Therapy of Pars Plana Vitrectomy and Grid/Focal Laser for Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT01202461,COMPLETED,Diabetic Retinopathy|Macular Edema,"PROCEDURE: Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation","Best-corrected visual acuity, Measurement of visual acuity at every visit. VA at every visit was compared from VA at baseline, At baseline, 6,12,24,36 months after surgery",Samsung Medical Center,41,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-08
NCT02927561,Automated Diagnostic Test for Diabetic Retinopathy in Brazilian Mass Screening,https://clinicaltrials.gov/study/NCT02927561,COMPLETED,Diabetic Retinopathy,OTHER: Diabetic Retinopathy screening,"To compare the sensitivity and specificity of automated grading system versus human grading in detecting diabetic retinopathy, The aim of this study is to determine the sensitivity and specificity of automated grading system in detecting diabetic retinopathy compared with human grading on the population of annual massive screening campaign for diabetes conducted in the Northeast of Brazil., 6 months","Retina Clinic, Sao Paulo, Brazil",220,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-06
NCT04265261,A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04265261,COMPLETED,Diabetic Retinopathy,DRUG: Placebo|DRUG: RG7774,"Proportion of Participants with >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) from Baseline at Week 36 Measured in the Study Eye, Week 36|Percentage of Participants with Adverse Events (AEs), From baseline up to 52 weeks",Hoffmann-La Roche,104,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-06-05
NCT00917553,Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00917553,COMPLETED,Diabetic Retinopathy,DRUG: doxycycline monohydrate|DRUG: Placebo,"The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group, Baseline and 24 months",Thomas Gardner,33,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-07
NCT00516464,Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy,https://clinicaltrials.gov/study/NCT00516464,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Lucentis (ranibizumab),"To evaluate the effect of ranibizumab on vitrectomy complications such as recurrent vitreous hemorrhage, postoperative retinal detachment rates, and development of intraoperative retinal breaks., 6 months","Retina Associates, Kansas City",40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-08
NCT04976361,Macular Vessels Density Before and After PRP in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04976361,COMPLETED,PRP,"OTHER: PRP was done using visulas green laser machine (Carl Zeiss Meditec AG Geoschwitzer Str. 51-52,07745 jena, Germany)","Measurement of vessel density, Measurement of vessel density at superficial, deep, and outer retina at base line, after 1 month, and after 6 months., 6 months|Measurement of retinal thickness, central retinal thickness at base line, after 1 month, and after 6 months., 6 months",Minia University,21,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2019-03-01
NCT01694212,Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01694212,COMPLETED,Macular Edema|Cataract|Diabetic Retinopathy,DRUG: Perioperative Diclofenac eye-drops administration|DRUG: placebo,"Change of Central Macular Thickness, The central macular thickness will be measured with OCT machine., -7, 0, 1, 7, 30, 90 days after the cataract surger",Eye Clinic Medic Zuljan Jukic,55,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2012-10
NCT02443012,Topical Nepafenac as Supplement for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02443012,COMPLETED,Diabetic Macular Edema,DRUG: Topical Gutt Nepafenac 0.1%|PROCEDURE: Laser,"Changes in Logarithm Best Minimal Angle of Resolution Corrected Visual Acuity (LogMAR BCVA) (Measurement of Visual Acuity), Measurement of Best Corrected Visual Acuity by means of refraction using the ETDRS Chart, 3 months",Universiti Sains Malaysia,47,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2013-03
NCT00709319,Evaluation of Vitrectomy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00709319,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema,,"Visual Acuity, Change in best correct visual acuity letter score from baseline to six months as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0., Baseline to 6 months|Change in Optical Coherence Tomography Measured Central Subfield Thickness From Baseline, Change in central subfield thickness is followup central subfield retinal thickness minus baseline thickness., Baseline to 6 Months|Percent of Participants With Change in Visual Acuity From Baseline to Six Months, Baseline to 6 months|Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 6 Months, Change in thickness is followup thickness minus baseline thickness., Baseline to 6 months",Jaeb Center for Health Research,87,OBSERVATIONAL,Observational Model: |Time Perspective: p,2005-07
NCT05815212,Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K),https://clinicaltrials.gov/study/NCT05815212,COMPLETED,Diabetic Macular Edema,,"Mean change from baseline in BCVA at Week 24 (±2 weeks), Baseline and Week 24 (±2 weeks)",Novartis Pharmaceuticals,87,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-11
NCT00491166,Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser,https://clinicaltrials.gov/study/NCT00491166,UNKNOWN,Diabetic Macular Edema,DRUG: Bromfenac ophthalmic solution,"The mean change in visual acuity and central retinal thickness from baseline to month 3,and the incidence and severity of ocular adverse events and other adverse events., Baseline to month 3",Ophthalmic Consultants of Boston,10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-06
NCT06066021,Evaluation of a Health Education Program for Type 2 Diabetes Patients,https://clinicaltrials.gov/study/NCT06066021,NOT_YET_RECRUITING,"Retinopathy, Diabetic",OTHER: health educational sessions in diabetic patients type 2.,"Change in Depression, Anxiety, and Stress Scale-21 (DASS-21), total and subscales scores (depression; anxiety; stress) three months after the health education intervention training sessions. The scale score,(lower scores mean a better result), (the minimum and maximum values): 0 - Nothing applied to me

1. - It applied to me a few times
2. - It has applied to me many times
3. - It applied to me most of the time, 3 months|Change in the Summary of Diabetes Self-Care Activities (SDSCA), total and subscales scores (general diet; specific diet; exercise; blood-glucose testing; foot-care; smoking) three months after the health education intervention training sessions.

The scale used is number of days (from 0 to 7), 3 months|Change in the Diabetes Knowledge Questionnaire (DKQ - Portuguese version), Subscales scores (treatment, control and complications; causes; duration) three months after the health education intervention training sessions.

This consists of 20 items distributed by three dimensions (Treatment, control and complications, Causes and Duration).The minimum and maximum values is 0-100, the 0 is minimum and 100 is maximum, 3 months",Association for Innovation and Biomedical Research on Light and Image,27,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2023-10-02
NCT05686421,Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations,https://clinicaltrials.gov/study/NCT05686421,COMPLETED,"Age-Related Macular Degeneration|Diabetic Retinopathy|Central Serous Chorioretinopathy|Glaucoma|Glaucoma, Suspect|Eye Diseases",DEVICE: OCT Imaging Using Device N|DEVICE: OCT Imaging Using Device C,"Percentage of Participants who Indicate Device N Provided a More Comfortable Experience, Compared with Device C, Participants will be asked which device provided a more comfortable experience: Device C or Device N., Post-Imaging Session (Day 1)|Comfort Level Rating of Device N on 0-5 Scale, Participants will be asked to rate how comfortable Device N was, on a scale of 0-5. Higher scores indicate higher levels of comfort., Post-Imaging Session (Day 1)|Comfort Level Rating of Device C on 0-5 Scale, Participants will be asked to rate how comfortable Device C was, on a scale of 0-5. Higher scores indicate higher levels of comfort., Post-Imaging Session (Day 1)",NYU Langone Health,42,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE",2023-03-30
NCT04008121,Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium,https://clinicaltrials.gov/study/NCT04008121,NOT_YET_RECRUITING,Retinopathy|Retinal Vein Occlusion|Diabetic Retinopathy|Macular Degeneration,COMBINATION_PRODUCT: Fluorescein sodium and Zeiss FF450 fundus camera|COMBINATION_PRODUCT: MB-102 and Zeiss FF450 fundus camera|COMBINATION_PRODUCT: Fluorescein sodium and commercially available optical angiography imaging system|COMBINATION_PRODUCT: MB-102 and commercially available optical angiography imaging system,"Binary assessment by the Principal Investigator of the feasibility of MB-102 imaging as compared to fluorescein dye, Ocular angiography will be performed using a commercially available, FDA-approved clinical Zeiss FF450 fundus camera. Images will be taken of both eyes, acquired by a trained ophthalmic photographer. In at least 2 participants, imaging will also be conducted using 2 different additional clinically-approved ocular angiography imaging systems., From the time of fluorescein sodium administration through optical angiography study completion, up to 2 weeks",MediBeacon,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2024-02
NCT06179030,Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT06179030,COMPLETED,Diabetic Macular Edema|Inflammation,DIAGNOSTIC_TEST: serum samples|DRUG: dexamethasone implant versus ranibizumab,"systemic inflammatory biomarkes correlates with OCT biomarkers and higher in poor responders, serum inflammatory biomarkers such as ICAM-1, MCP-1 , Il-6, IL-8, VEGF-A and TNFa will be studied. then, the levels of the aferometioned parameters will be compared with the treatment response and OCT parameters., 6 months",Saglik Bilimleri Universitesi,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-01
NCT01179555,Confronting Unequal Eye Care in Pennsylvania,https://clinicaltrials.gov/study/NCT01179555,COMPLETED,"Diabetic Retinopathy|Diabetes Mellitus, Type 2|Glaucoma",BEHAVIORAL: Behavioral Activation|BEHAVIORAL: Supportive Therapy,"Pt. 1 Dilated Fundus Exam (DFE), At the 6-month follow-up assessment, patients will be asked if they got a dilated fundus exam since the baseline assessment. If a DFE is self-reported, it will be confirmed by ophthalmology chart review, 6-month follow-up assessment",Wills Eye,206,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2010-10
NCT00828425,Management of Diabetes Mellitus Patients With Retinopathy,https://clinicaltrials.gov/study/NCT00828425,COMPLETED,Retinopathy|Diabetes Mellitus,,"Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight, every 3 months|evolution of diabetic retinopathy, every 3 months",AstraZeneca,2500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-12
NCT00886392,Diabetic Macular Edema Severity at Diagnosis,https://clinicaltrials.gov/study/NCT00886392,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Macular Edema,,"Thickening measured by optical coherence tomography in 3 zones: central subfield (when field 1 was thickened), inner ring (when any of fields 2, 3, 4 or 5 was thickened), and inner ring or outer ring (when any of fields 6, 7, 8, or 9 was thickened), at the diagnosis moment",Hospital Juarez de Mexico,118,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-06
NCT02812030,Aflibercept for Retinopathy in the Real World,https://clinicaltrials.gov/study/NCT02812030,WITHDRAWN,Diabetic Retinopathy,OTHER: National Eye Institute Visual Functioning Questionnaire,"Change in Best-Corrected Visual Acuity (BCVA), Best-corrected visual acuity using a standardised measure involving number of Early Treatment Diabetic Retinopathy Study (ETDRS) letters., Baseline - 12 months",Timothy Jones,0,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09
NCT00148330,Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study,https://clinicaltrials.gov/study/NCT00148330,COMPLETED,Diabetic Macular Oedema,DRUG: Triamcinolone acetate,"Increase of ≥5 letters at the 5-year study visit on a LogMAR chart compared with (a) the initial baseline level and (b) the level at the 2-year study visit., Changes from Baseline to 5 years: Improvement of ≥5 letters after 5 years was found in 14/33 (42%) eyes initially treated with triamcinolone compared with 11/34 (32%) eyes initially treated with placebo (zGEE=0.81, P=0.4).

Changes from 2 to 5 years (open-label extension):Improvement of ≥5 letters of best-corrected visual acuity was found in 8/29 (28%) eyes initial-triamcinolone compared with 7/28 (25%) initial-placebo eyes (zGEE=0.20, P=0.8)., 3 year extension, total 5 years study from baseline|Incidence of moderate or severe adverse events over the 3 years of the open-label extension, The incidence of cataract surgery declined in the third year: 5/11 (45%) eyes from the initial-triamcinolone group that were phakic at the beginning of the 3rd year required cataract surgery., 3 year extension study, total 5 year study from baseline",University of Sydney,64,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-05
NCT03974425,One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab,https://clinicaltrials.gov/study/NCT03974425,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept Injection [Eylea],"central macular thickness after one year, Optical Coherence Tomography changes after 12 months., 12 months",University of Alexandria,37,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-04-01
NCT03902925,Pain During Pars Plana Vitrectomy With Sub-tenon Anesthesia,https://clinicaltrials.gov/study/NCT03902925,COMPLETED,Retinal Disease|Diabetic Retinopathy|Maculopathy,PROCEDURE: Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|PROCEDURE: Peribulbar injection,"Pain score, Pain score referred by the patient measured with a Visual Analogue Scale (VAS). The VAS consists of ruler with 100 cm in length and scale from 0 to 100, where the numbers of this one are visible only in the side of the examiner. It is constructed from a metal ruler with a total length of one meter, supported by two transparent acrylic side supports and a sliding and movable metal weight on the metallic part of the ruler.

Before the measurement of pain, the examiner will explain to the patients the functioning of the VAS. Each patient will be encouraged to pass the marker along the scale, with the help of the examiner. It will be made clear to him that point ""0"" is the point of the scale which represented ""no pain"", what is considered the better outcome, and point ""100"" corresponded to the most intense pain he could feel. The patient will be asked about: Intraoperative pain - the intensity of pain throughout the procedure., Once 30 minutes after the end of the vitrectomy surgery",University of Sao Paulo,56,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-01-01
NCT01355692,Evaluation of the Effects of Selective Photocoagulation for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01355692,COMPLETED,Diabetic Macular Edema,DEVICE: Nd: YLF laser treatment,"progression of macular edema, Proportion progressing to center involved macular edema by month 12 as confirmed on SD-OCT, 12months",Lumenis Be Ltd.,32,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-12
NCT00931125,Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone,https://clinicaltrials.gov/study/NCT00931125,UNKNOWN,Diabetic Retinopathy,DRUG: ranibizumab and vitrectomy|PROCEDURE: vitrectomy without preoperative ranibizumab,"Efficacy of preoperative intravitreal ranibizumab, Efficacy, measured by surgical time, number of intraoperative bleedings, intraoperative retinal breaks,required endodiathermy, OP day",Attila Vajas,70,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-03
NCT01319487,Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01319487,COMPLETED,Diabetic Macular Edema,DRUG: 2304 Eye Drops High Dose|DRUG: 2304 Eye Drops Low Dose|DRUG: Placebo Eye Drops,"change from baseline of central retinal thickness as determined by logOCT, Week 12",Fovea Pharmaceuticals SA,267,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05
NCT01748487,The Effect of Intravitreal Ozurdex on DME After Cataract Surgery,https://clinicaltrials.gov/study/NCT01748487,COMPLETED,Diabetic Macular Edema,DRUG: dexamethasone intravitreal implant (OZURDEX),"The primary outcome measure will be the change from baseline for the central retinal thickness (CRT) measured by OCT at 3 months after surgery., 3 months","University Health Network, Toronto",24,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2012-12
NCT00027287,Laser and Medical Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00027287,COMPLETED,Diabetes Mellitus|Macular Edema,DRUG: Vitamin E,,National Eye Institute (NEI),60,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2001-11
NCT00993525,Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study),https://clinicaltrials.gov/study/NCT00993525,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Intravitreal injection of ranibizumab,"total area of fluorescein leakage from active new vessels, baseline, weeks 1,6,12,24,36,48|Best corrected Visual Acuity (BCVA), Baseline, weeks 1,6,12,24,36,48|central macular thickness, baseline, weeks 1,6,12,24,36,48",University of Sao Paulo,22,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-09
NCT02186119,A Study of Abicipar Pegol in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02186119,COMPLETED,Macular Edema,DRUG: abicipar pegol|DRUG: ranibizumab|OTHER: sham procedure,"Change from Baseline in Best Corrected Visual Acuity (BCVA), Baseline, Week 28",Allergan,151,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-07
NCT05127525,"EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)",https://clinicaltrials.gov/study/NCT05127525,TERMINATED,Diabetic Macular Edema|Branch Retinal Vein Occlusion|Glaucoma/Closed Angle Glaucoma,DRUG: IRX-101|DRUG: Control,"Incidence of infectious endophthalmitis after topical use of IRX-101 combined with IVT, To evaluate the rate of infectious endophthalmitis after topical use of IRX-101 following intravitreal injection therapy (IVT) (% occurrence or rate of population randomized to IRX-101 test arm), 2 hours post-injection","iRenix Medical, Inc.",5,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2021-11-15
NCT01496625,National Eye Institute Biorepository for Retinal Diseases,https://clinicaltrials.gov/study/NCT01496625,RECRUITING,Age-Related Macular Degeneration|Diabetic Retinopathy|Von Hippel-Lindau Syndrome|Retinal Disease|Retinal Vein Occlusion,,"Interaction of key parameters of phenotype with genetic variants, and characterization of new experimental models of eye health and disease., Potential outcome measures for subsequent studies using this data set may include the interaction of key parameters of phenotype (such as visual acuity and retinal features on ocular imaging) with genetic variants and other biomarkers identified from biospecimens, and the characterization of new experimental models of eye health and disease., Ongoing",National Eye Institute (NEI),650,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-06-18
NCT05581225,Prediction of Progression of Retinal Ischemia in Diabetes,https://clinicaltrials.gov/study/NCT05581225,RECRUITING,Diabetic Retinopathy,,"One and 2-steps change on ETDRS severity level (using standard 7-fields CFP acquisitions at 30º and in Wide-field 100º acquisitions)., Identify and characterize the progression of retinal microvascular changes (vascular occlusion) occurring in eyes with moderate to severe NPDR (ETDRS severity levels 43, 47 or 53)., 48 months|Changes in Vessel density (VD) metrics (skeletonized VD, binarized VD (PD), considering macular region and midperiphery., Explore new OCTA vascular metrics and identify which can be used as imaging biomarkers to better identify DR progression (skeletonized VD, binarized VD (PD)., 48 months|Changes in geometric perfusion deficits (GPD) on the superficial and deep retinal vascular layers on SS-OCTA, considering macular region and midperiphery., Explore new OCTA vascular metrics and identify which can be used as imaging biomarkers to better identify DR progression geometric perfusion deficits (GPD) using 3mm x 3mm and wide-field 15mm x 15mm OCTA acquisitions., 48 months",Association for Innovation and Biomedical Research on Light and Image,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-12-02
NCT04005430,A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema,https://clinicaltrials.gov/study/NCT04005430,ACTIVE_NOT_RECRUITING,Refractory Diabetic Macular Edema,DRUG: Episcleral Dexamethasone,"The primary outcome measure of the study is safety assessment., The main outcome of the study is safety assessment., 12 Months","Targeted Therapy Technologies, LLC",1,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-04-03
NCT04119921,Short-term Additive Effect of Topical Ketorolac on the Management of Diabetic Macular Edema With Intravitreal Bevacizumab,https://clinicaltrials.gov/study/NCT04119921,COMPLETED,DME,DRUG: prescription topical ketorolac in group 1|DRUG: prescription artificial tear in group 2|DRUG: prescription topical ketorolac in group 2|DRUG: prescription artificial tear in group1,"visual acuity, Snellen E-chart, 6 weeks",Shahid Beheshti University of Medical Sciences,26,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2018-01-01
NCT02811692,Study for Collection of Aflibercept Data in Routine Practice,https://clinicaltrials.gov/study/NCT02811692,COMPLETED,Eye Diseases,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Change in Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) or converted to ETDRS., Baseline and 12 months|Change in Central retinal thickness (CRT) as measured by Optical Coherence Tomography (OCT)., Baseline and 12 months",Bayer,425,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09-30
NCT03056092,Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab,https://clinicaltrials.gov/study/NCT03056092,RECRUITING,Age Related Macular Degeneration|Diabetic Macular Edema|Macular Edema|Retinal Vein Occlusion,DRUG: Intravitreal ranibizumab,"Association between aqueous cytokine levels and optimal treatment interval, Optimal treatment intervals based on aqueous cytokine levels, 18 months",Unity Health Toronto,168,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-02-28
NCT05496530,Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results),https://clinicaltrials.gov/study/NCT05496530,RECRUITING,Diabetic Macular Edema|Vogt Koyanagi Harada Disease|Retinal Vein Occlusion,DRUG: Suprachoroidal triamcinolone acetonide injection,"Visual acuity, Changes noted in vision after injection measured 8n logMar units by snellen chart., Baseline and up to one year after injection.",Benha University,100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-10
NCT00904592,A Study on Traditional Chinese Medicine (TCM) Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00904592,COMPLETED,Diabetic Retinopathy,DRUG: Qi ming granula|DRUG: Placebo Comparator,"incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation, 12 months",Chengdu University of Traditional Chinese Medicine,480,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION",2008-09
NCT02281292,A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02281292,WITHDRAWN,Diabetic Macular Edema,BIOLOGICAL: LKA651 ophthalmic solution|BIOLOGICAL: Ranibizumab ophthalmic solution|BIOLOGICAL: Sham injection,"Number of subjects with a serious adverse event (SAE) that, in the opinion of the investigator, is related to the study drug, Up to Day 85|Number of subjects experiencing a non-serious adverse event, Up to Day 85",Alcon Research,0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-12
NCT05413330,Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes.,https://clinicaltrials.gov/study/NCT05413330,COMPLETED,Diabete Type 2|Cataract|Triamcinolone Acetonide|Intravitreal Injection,DRUG: Triamcinolone Acetonide,"Change in central subfield mean macular thickness as a measurement of efficacy, The primary endpoint is the change in central subfield mean macular thickness in the 1 mm area (central subfield macular thickness, CSMT) as compared to baseline within the first 6 months postoperatively., T0_ 1 month- T1_ 3 months- T2_ 6 months postoperatively]|Change in diabetic retinopathy grade as a measurement of efficacy, The primary endpoint is the change in diabetic retinopathy grade as compared to baseline within the first 6 months postoperatively., T0: 1 month- T2: 3 months- T3: 6 months postoperatively",Damascus University,73,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2020-09-12
NCT02806830,Ocular Discomfort Assessment After Intravitreal Injections,https://clinicaltrials.gov/study/NCT02806830,COMPLETED,"Macular Degeneration|Diabetic Retinopathy|Retinal Artery Occlusion|Myopia, Degenerative",DRUG: Optive,"Comparison of the overall scores of the ocular discomfort questionnaire after the 2 first intravitreal injection in naïve patients, within the 72h after the first and the second intravitreal injections",Centre Hospitalier Intercommunal Creteil,45,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2016-04
NCT05066230,A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR),https://clinicaltrials.gov/study/NCT05066230,TERMINATED,Non-proliferative Diabetic Retinopathy,DRUG: KSI-301|OTHER: Sham injection,"Proportion of eyes improving ≥2 steps on the ETDRS Diabetic Retinopathy Severity Scale (DRSS), Day 1 to Week 48",Kodiak Sciences Inc,253,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-30
NCT03823092,Polarization Perception in Health and Disease. Testing a New Sight Test,https://clinicaltrials.gov/study/NCT03823092,UNKNOWN,Cataract|Age Related Macular Degeneration|Pseudophakia|Macular Disease|Diabetic Retinopathy|Retinal Disease,DIAGNOSTIC_TEST: polarization sensitivity,"polarization sensitivity, determine and compare polarization sensitivity between groups, 18 month",South Warwickshire NHS Foundation Trust,300,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-09
NCT03999125,Anti-VEGF Therapy Versus Dexamethasone Implant for DME,https://clinicaltrials.gov/study/NCT03999125,UNKNOWN,Clinically Significant Macular Edema Due to Diabetes Mellitus,"DRUG: Aflibercept,|DRUG: Ranibizumab Injection|DRUG: Ozurdex Drug Implant Product","Best Corrected Visual Acuity, BCVA measured at baseline and final follow-up, 2 years",Sudhalkar Eye Hospital,150,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-06-25
NCT00846092,Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study,https://clinicaltrials.gov/study/NCT00846092,COMPLETED,Diabetic Macular Edema,DEVICE: Warp 10 LED Device|DEVICE: Near-infrared light (NIR),"Excess retinal thickness on OCT at 1 month, 3 months and 6 months. goal = reduce excess thickness by at least 50%, 1 month, 3 months and 6 months",Medical College of Wisconsin,4,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-11
NCT05324592,Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05324592,COMPLETED,Diabetic Macular Edema,DRUG: 9MW0813|DRUG: Aflibercept,"Incidence of adverse events, baseline to week 6","Mabwell (Shanghai) Bioscience Co., Ltd.",24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-02-26
NCT00959725,Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00959725,UNKNOWN,Diabetic Macular Edema,"DRUG: Infliximab (intravitreal, 2.0mg/0.05ml)","Best-corrected visual acuity, Three months",Icahn School of Medicine at Mount Sinai,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-08
NCT01921192,"Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT01921192,UNKNOWN,Non Proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy,"DRUG: Folic Acid, vit B6 and B12|DRUG: Placebo","homocysteine, 12 months",University of Catania,160,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-09
NCT03143192,Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser,https://clinicaltrials.gov/study/NCT03143192,COMPLETED,Diabetic Macular Edema,COMBINATION_PRODUCT: Micropulse Laser|DEVICE: Sham Laser,"Number of injections for each group, Number of intravitreal injections for each group, 48 weeks",Keyvan Koushan,31,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-03-08
NCT03343730,RetinaVue Diabetic Screening,https://clinicaltrials.gov/study/NCT03343730,UNKNOWN,Diabetic Retinopathy,DIAGNOSTIC_TEST: Non-mydriatic color fundus photography with the RetinaVue camera|DIAGNOSTIC_TEST: Referral for dilated eye exam with an eye care professional,"Rate of Diabetic Retinopathy Detection, This study will examine the rate of detection of diabetic retinopathy using an in-clinic retinal camera and standard referral to eye care professional for dilated eye exam, 3 months",Bassett Healthcare,50,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SCREENING,2018-02-27
NCT00443521,Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00443521,COMPLETED,Diabetic Retinopathy,DRUG: Triamcinolone Acetonide 4 mg intravitreal injection|PROCEDURE: Panretinal photocoagulation,Visual acuity (ETDRS)|Optic coherence tomography|Vitreous haemorrhage,University of Sao Paulo,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-03
NCT00536692,Topical Ocular Mecamylamine in Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT00536692,COMPLETED,Diabetic Macular Edema,DRUG: mecamylamine,,CoMentis,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-09
NCT04527107,A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT04527107,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,DRUG: THR-149 dose level 1|DRUG: THR-149 dose level 2|DRUG: THR-149 dose level 3|DRUG: THR-149 0.13mg|DRUG: THR-149 0.13mg + aflibercept 2mg|DRUG: aflibercept 2mg + THR-149 0.13mg|DRUG: Aflibercept 2mg,"Mean change in best-corrected visual acuity (BCVA) ETDRS letter score from Baseline, in subjects in Part B of the study, At Month 3",Oxurion,135,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-07-31
NCT02639507,International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients,https://clinicaltrials.gov/study/NCT02639507,COMPLETED,Diabetes With Diabetic Retinopathy With Macular Edema,PROCEDURE: Vitrectomy,"average (mean) improvement in Best Corrected Visual Acuity (BCVA) as measured with Snellen visual acuity, 6 months",Mayo Clinic,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-06
NCT02103283,"A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT02103283,COMPLETED,Diabetic Macular Edema,DRUG: Teprotumumab,"Safety of RV001in subjects with Diabetic Macular Edema, Number of subjects with adverse events, serious adverse events and early discontinuations due to adverse events. Number of subjects with clinical significant abnormal laboratory values, electrocardiograms (pre and post infusions), abnormal vital signs, ophthalmic and physical examinations., Change from Baseline to Week 9",River Vision Development Corporation,5,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-10
NCT01492400,Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01492400,COMPLETED,Macular Edema,DRUG: dexamethasone Intravitreal Implant|DRUG: ranibizumab,"Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye, BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening., Baseline, 12 Months",Allergan,363,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-03-09
NCT01871207,Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy,https://clinicaltrials.gov/study/NCT01871207,COMPLETED,Diabetic Retinopathy,,"Ocular concentration of Erythropoietin and VEGF., eight months",Università degli Studi di Brescia,53,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-05
NCT04328207,Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits,https://clinicaltrials.gov/study/NCT04328207,RECRUITING,"Glaucoma|Diabetic Retinopathy|Refractive Errors|Cataract|Behavior, Health",OTHER: No Financial Incentive|BEHAVIORAL: Financial Incentive,"Percentage of participants that adhere to referral appointment, The percentage of patients who adhere to attending their referral appointments who received a financial incentive and eye health education will be compared with the percentage of patients who adhere to attending their referral appointments who received standard of care eye health education alone and no financial incentive for completing a referral visit., The time frame will be from baseline through 3 years of recruitment in the study.",University of Alabama at Birmingham,1000,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING",2020-11-18
NCT01135914,"Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT01135914,COMPLETED,Diabetic Macular Edema,DRUG: ranibizumab|PROCEDURE: Laser,"Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12, Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement., Baseline and 12 months",Novartis Pharmaceuticals,241,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-07
NCT01523314,Topical Dexamethasone - Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01523314,UNKNOWN,Diabetic Macular Edema,DRUG: dexamethasone - Cyclodextrin eye drops|OTHER: intravitreal Avastin injection +/- macular laser,"Best Corrected Visual Acuity on ETDRS chart, 3 months",King Saud University,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-03
NCT01732614,Topcon Endpoint Management,https://clinicaltrials.gov/study/NCT01732614,COMPLETED,Diabetic Macular Edema,PROCEDURE: Topcon Endpoint Management laser,"Changes in Visual acuity, Improvement in visual acuity \> 10 letters or two lines in the ETDRS chart, 12 months|Reduction of the central macular thickness by SD-OCT, Reduction of the central macular thickness by SD-OCT, 12 months",Retinal Consultants of Arizona,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-08
NCT02924987,Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02924987,UNKNOWN,Diabetic Macular Edema,DRUG: Aflibercept Injection,"Macular central subfield thickness in micrometers, Central subfield thickness in micrometers at 6 months measured by optical coherence tomography in micrometers (HRT+OCT Spectralis model, Heidelberg Engineering, Heidelberg, Germany)., 6 Months",Maisonneuve-Rosemont Hospital,40,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-11
NCT03590587,Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates,https://clinicaltrials.gov/study/NCT03590587,UNKNOWN,Diabetic Macular Edema,DRUG: 0.19 mg fluocinolone acetonide (FAc) implant|DEVICE: 0.19 mg fluocinolone acetonide (FAc) implant,"BCVA, best corrected visual acuity, 12 months",Benha University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01-13
NCT03278587,Village-Integrated Eye Worker Trial II - Pilot,https://clinicaltrials.gov/study/NCT03278587,COMPLETED,Cataract|Glaucoma|Age Related Macular Degeneration|Diabetic Retinopathy|Refractive Errors,OTHER: Community-based screening program|OTHER: Cataract camp program|OTHER: Community health worker program,"Visual acuity, Primary outcome for specific aim 1, comparison between screening and case detection arms, 1 year|Cataract surgical rate, Primary outcome for specific aim 2, comparison between community health worker program and no program arms, 1 year","University of California, San Francisco",16075,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2018-05-31
NCT02753400,Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02753400,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: emixustat hydrochloride|OTHER: Placebo,"Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values, All values for IL-1β were below the lower limit of detection and were recorded as zero. Tests for IP-10 and MCP-1 failed accuracy and stability testing during assay development and were dropped from the study. The assay for PDGF-AA could not be developed.and results were not reported., Baseline and 12 weeks",Kubota Vision Inc.,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-05
NCT05996822,"Evaluation of Macular Edema After AcF Implant's Injection, 1 Month After the Last DXM Implant",https://clinicaltrials.gov/study/NCT05996822,NOT_YET_RECRUITING,Macular Edema,DRUG: ACF injection,"Efficiency (ETDRS), change in visual acuity by ETDRS between baseline(before AcF injection) and 1 month after, 1 month after AcF injection",Nantes University Hospital,34,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-09
NCT02554747,Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa,https://clinicaltrials.gov/study/NCT02554747,COMPLETED,Diabetic Macular Oedema,DEVICE: Navigated laser|DEVICE: Conventional laser,"Percentage of eyes that received additional aflibercept injections after laser at month 12 in group A and B, 1 year",Odense University Hospital,48,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-10
NCT03690947,Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME,https://clinicaltrials.gov/study/NCT03690947,COMPLETED,Diabetic Macular Edema,DRUG: Intravitreal Ranibizumab|PROCEDURE: Micropulse Laser|DRUG: Intravitreal Ranibizumab as needed,"Best Corrected Visual Acuity changes, Compare the changes of BCVA between two groups, 12 months",Beijing Hospital,72,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-10-01
NCT01638858,Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis),https://clinicaltrials.gov/study/NCT01638858,COMPLETED,Age-Related Macular Degeneration,DRUG: Lucentis (Ranibizumab),"Main outcome measures are the changes of retinal function of the macula monitored by multifocal-ERG as measured 12 months, Main outcome measures are the changes of retinal function of the macula monitored by multifocal-ERG as measured 12 months, 12 months",University of Luebeck,25,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2011-10
NCT05393284,Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05393284,RECRUITING,Non-proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy,DRUG: OPL-0401 Dose 1|DRUG: Placebo,"Improvement in Diabetic Retinopathy Severity Scale (DRSS) score, Proportion of patients with a ≥2-step improvement from baseline in DRSS, 24 weeks/168 days","Valo Health, Inc.",90,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-08-16
NCT05940428,A Study of ASKG712 in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05940428,NOT_YET_RECRUITING,Diabetic Macular Edema,BIOLOGICAL: ASKG712,"1. Incidence of ocular adverse events (AEs) of the study eyes, Any relevant ocular observations derived from best corrected visual acuity (BCVA), intraocular pressure, slitlamp examination, ophthalmoscopy, optical coherence tomography (OCT), fundus photography, and angiography, 24 weeks|2. Incidence of non-ocular AEs, Any clinical safety observations assessed by physical examination, vital signs, electrocardiograph (ECG) and clinical laboratory tests, 24 weeks","AskGene Pharma, Inc.",26,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2023-07-30
NCT02457884,Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT02457884,COMPLETED,Diabetic Macular Oedema|Parafoveal Scotoma,OTHER: Temporal Group|OTHER: Spatial Group|OTHER: Combined Group|OTHER: Control Group,"Change in visual processing speed, Using trigrams to measure the character-recognition accuracy while characters are presented at different exposure times, Change from baseline at week 6 and change from baseline at week 12 week|Change in visual span size, Using trigrams to measure the character-recognition accuracy while characters are presented at different positions, Change from baseline at week 6 and change from baseline at week 12 week",The Hong Kong Polytechnic University,55,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: OTHER,2015-05
NCT02127684,Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing,https://clinicaltrials.gov/study/NCT02127684,WITHDRAWN,Persistent Diabetic Macular Edema,DRUG: ranibizumab|DRUG: ranibizumab,"mean change in optical coherence topography central subfield thickness at 12 weeks and 24 weeks after randomization, mean change in optical coherence topography central subfield thickness at 12 weeks and 24 weeks after randomization, 24 weeks","Maturi, Raj K., M.D., P.C.",0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,
NCT06150495,Glycemic Control and Retinal Microvascular Changes,https://clinicaltrials.gov/study/NCT06150495,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy|Neurodegeneration|Blood Sugar; High,,"The foveal avascular zone (FAZ) area (mm^2), FAZ was defined as the avascular area in the foveal center., Upon initial registration and through study completion, an average of 1 year|central foveal retinal thickness (um) and macular ganglion cell-inner plexiform layer (GC-IPL) thickness (um), Retinal layer thickness were calculated automatically using the bundled software, Upon initial registration and through study completion, an average of 1 year|Retinal vessel density (VD, %), The VD (%) was calculated using the following formula: VD (%) = vascular area (pixel) / (total area - FAZ area) (pixel) × 100., Upon initial registration and through study completion, an average of 1 year",Seoul National University Hospital,259,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01
NCT04448496,Prospective Trial of Dexamethasone implAnt for Treatment Naïve diabeTic Macular Edema,https://clinicaltrials.gov/study/NCT04448496,UNKNOWN,Diabetic Retinopathy,DRUG: Dexamethasone implant,"Mean change of best corrected visual acuity, The mean change of best corrected visual acuity from baseline to Month 6 in early treatment diabetic retinopathy (ETDRS) letter score by using Logarithm of the Minimum Angle of Resolution (LogMAR) chart, From baseline to month 6",Yeungnam University College of Medicine,49,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-06-22
NCT01506895,A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01506895,COMPLETED,"Retinopathy, Diabetic",DRUG: darapladib|DRUG: placebo,"Change from baseline in Visual Acuity as measured by ETDRS BCVA, Mean change from baseline in ETDRS Best Corrected Visual Acuity (BCVA) after 3 months of treatment, 3 months|Change from baseline in Spectral Domain Optical Coherance Tomography, Mean change from baseline in SD-OCT after 3 months of treatment, 3 months",GlaxoSmithKline,54,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-02
NCT05527535,Expansion of Integrated AI Solution for Diabetic Retinopathy Screening in Thailand,https://clinicaltrials.gov/study/NCT05527535,NOT_YET_RECRUITING,Diabetic Retinopathy,DIAGNOSTIC_TEST: Diabetic retinopathy screening by artificial intelligence|DIAGNOSTIC_TEST: Diabetic retinopathy screening by healthcare personnel,"Effectiveness of AI in diabetic retinopathy screening, Referral adherance of patients in AI group in percentage, Throughout the whole period of screening, approximately 6 months|Efficiency of AI in diabetic retinopathy screening, Down time and failure rate of AI system, Throughout the whole period of screening, approximately 6 months|Efficiency of AI in diabetic retinopathy screening, Cost in development and implement of AI system in Thai baht unit, Throughout the whole period of screening, approximately 6 months",Rajavithi Hospital,34500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-10-03
NCT05773495,Implementation of Teleophthalmology in Urban Health Systems Study,https://clinicaltrials.gov/study/NCT05773495,NOT_YET_RECRUITING,Diabetic Retinopathy,OTHER: I-SITE Intervention|OTHER: Usual Care Teleophthalmology,"Change in Diabetic Screening Rate, Proportion of patients with diabetes with medical record documentation of diabetic eye screening within the last 12 months among patients with type 1 or type 2 diabetes who had at least 2 clinic visits with primary care provider within the past 24 months., baseline (data is retrospective to evaluate pre-intervention beginning November 2022), 6 months post-intervention (up to 18 months), 12 months post-intervention (up to 24 months)","University of Wisconsin, Madison",2000,INTERVENTIONAL,Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2024-03
NCT00403195,Clinical and Pathophysiological Description of Ocular Ischemic Syndrome,https://clinicaltrials.gov/study/NCT00403195,COMPLETED,Retinal Degeneration|Diabetic Retinopathy,,,"Glostrup University Hospital, Copenhagen",13,OBSERVATIONAL,Observational Model: |Time Perspective: p,2006-11
NCT05791695,"A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022",https://clinicaltrials.gov/study/NCT05791695,COMPLETED,Intraocular Inflammation|Suspected Endophthalmitis,OTHER: Non Applicable,"Frequency of patients receiving aflibercept injections, End of Study, Approximately 8 Years|Frequency of aflibercept injections by ophthalmic delivery mechanism, Ophthalmic delivery mechanism defined as prefilled syringe (PFS) and vial, End of Study, Approximately 8 Years|Incidence of Intraocular inflammation (IOI), Incidence will be defined as the number of events during the at-risk period divided by the total number of injections, identified using international classification of diseases (ICD-9 and ICD-10) diagnosis codes., End of Study, Approximately 8 Years|Incidence of Intraocular inflammation (IOI) by ophthalmic delivery mechanism, Incidence will be defined as the number of events during the at-risk period divided by the total number of injections, identified using international classification of diseases (ICD-9 and ICD-10) diagnosis codes.

Ophthalmic delivery mechanism defined as prefilled syringe (PFS) and vial, End of Study, Approximately 8 Years|Incidence of suspected endophthalmitis, Incidence will be defined as the number of events during the at-risk period divided by the total number of injections, identified using international classification of diseases (ICD-9 and ICD-10) diagnosis codes., End of Study, Approximately 8 Years|Incidence of suspected endophthalmitis by ophthalmic delivery mechanism, Incidence will be defined as the number of events during the at-risk period divided by the total number of injections, identified using international classification of diseases (ICD-9 and ICD-10) diagnosis codes.

Ophthalmic delivery mechanism defined as prefilled syringe (PFS) and vial, End of Study, Approximately 8 Years",Regeneron Pharmaceuticals,155413,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-16
NCT00552435,"Micropulse 810 Nanomolar (nm), Diode Laser for Diffuse Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT00552435,UNKNOWN,Diabetic Macular Edema,DEVICE: Laser photocoagulation,"Macular thickness measured by optical coherence tomography (OCT), 12 months",Federal University of São Paulo,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2007-03
NCT03609996,Retrospective Review of Proliferative Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT03609996,UNKNOWN,Proliferative Diabetic Retinopathy,DEVICE: Panretinal Photocoagulation|DRUG: Lucentis,"Clinical regression of neovascularization not requiring further treatment beyond RBZ, Clinical regression of neovascularization not requiring further treatment beyond RBZ, 2009-2018",Elman Retina Group,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-01
NCT02581995,Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.,https://clinicaltrials.gov/study/NCT02581995,COMPLETED,Macular Edema,"DRUG: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Change From Baseline to Week 52 in NEI VFQ-25 Total Score, National eye institute 25-item visual function questionnaire (NEI VFQ-25) is a condition-specific measure which was designed to capture the specific impact of vision loss on health-related quality of life (HRQoL). The calculation for NEI VFQ-25 sub-scale scores and total score was performed according to the ""NEI VFQ-25 Scoring Algorithm - August 2000"". The NEI VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. In this format scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score., Baseline, Week 52",Bayer,560,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-11-19
NCT01535495,Propranolol for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01535495,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Propranolol,"Area of retinal neovascularization on fundus photography, 12 weeks","University of Wisconsin, Madison",9,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-02
NCT02235935,The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02235935,UNKNOWN,Does Hyperbaric Chaber Treatment Improve Diabetic Retinopathy,,"OCT results, the reduction in retina width as recorded on OCT following 20 treatments in Hyperbaric Chamber, 1 month",Assaf-Harofeh Medical Center,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-09
NCT00370669,Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema,https://clinicaltrials.gov/study/NCT00370669,UNKNOWN,Diabetic Macular Edema,DRUG: bevacizumab|DRUG: triamcinolone acetonide,visual acuity|central macular thickness,Shahid Beheshti University of Medical Sciences,150,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2005-11
NCT01982435,Safety and Efficacy of Ranibizumab for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01982435,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Ranibizumab,"Number of Participants With Non-severe Ocular Adverse Events, As identified by eye examination (including visual acuity testing), identified by physical examination, subject reporting, and changes in vital signs. These outcome measures are also included in more detail in the adverse event section of the results., 12 months|Number of Participants With Severe Ocular Adverse Events, As identified by eye examination (including visual acuity testing), identified by physical examination, subject reporting, and changes in vital signs., 12 months|Number of Participants With Non-severe Non-ocular Adverse Event, As identified by physical examination, subject reporting, and changes in vital signs. These outcome measures are also included in more detail in the adverse event section of the results., 12 months|Number of Participants With Severe Non-ocular Adverse Event, As identified by physical examination, subject reporting, and changes in vital signs. These outcome measures are also included in more detail in the adverse event section of the results., 12 months",Justis Ehlers,27,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-06-24
NCT05832996,Cool vs Room-temperature Artificial Tears,https://clinicaltrials.gov/study/NCT05832996,COMPLETED,"Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis)|Central Retinal Vein Occlusion With Macular Edema|Exudative Age-Related Macular Degeneration, Unspecified Eye|Cystoid Macular Edema|Ocular Surface Disease|Dry Eye Sensation|Eye Pain",DRUG: Refresh Plus Preservative-free Lubricant Eye Drops,"The efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection ocular discomfort as measured by pain scale survey., The level of subjectively reported pain scale from 1 to 10, where 1 is minimal pain and 10 is extreme pain, with 72 hours of the intervention",University of Iowa,124,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2022-03-01
NCT00673296,Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation,https://clinicaltrials.gov/study/NCT00673296,UNKNOWN,Diabetic Retinopathy With Premacular Hemorrhage,DRUG: Intravitreal Bevacizumab,"Interval between the treatment and clearing of premacular hemorrhage, Before treatment, weekly after the treatment, and monthly after hemorrhage reabsorption",National Taiwan University Hospital,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-01
NCT01787669,Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT01787669,COMPLETED,Diabetes|Diabetic Macular Oedema|Diabetic Macular Edema|Diabetic Retinopathy,DRUG: Avastin (Bevacizumab)|DRUG: Ozurdex (dexamethasone),"Proportion of eyes that have central macular thickness <300 microns 6 months after switching, 6 months",University of Sydney,19,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2013-06
NCT05640895,Intravitreal Injection Site and Perceived Pain,https://clinicaltrials.gov/study/NCT05640895,RECRUITING,Pain,PROCEDURE: Intravitreal injection site,"Visual scale analogues for pain, Self-reported perception of pain according to analogue pain scale. The analog pain scale is a scale of numbers from 0 to 10 representing the degree of patient's perceived pain. A score of 0 indicates no perception of pain; a score of 10 indicates a perception of the worst pain possible. The scale is also illustrated with face emojis corresponding to a written description of pain perception from no perception of pain, represented by a green, fully smiling face to perception of the worst pain possible, represented by a red, crying, fully frowning face., Immediately post-injection","The University of Texas Medical Branch, Galveston",60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-14
NCT00656435,Bevacizumab and Long Acting Gas in Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT00656435,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Bevacizumab,"The severity of intraoperative bleeding and vitreous clear-up time., Six months",National Taiwan University Hospital,16,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-12
NCT01318941,Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting,https://clinicaltrials.gov/study/NCT01318941,COMPLETED,"Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion|Wet Age Related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion",DRUG: Ranibizumab|OTHER: Ranibizumab,"Mean Visual Acuity (VA) and mean change in VA, 3,6, and 12 months from the baseline visit, and annually thereafter|Incidence rate, relationship and severity of treatment emergent ocular and non-ocular adverse events, Defined time periods during study duration from FPFV until 30 days after LPLV|Mean visual acuity at quarterly intervals for the primary treated eye set, Quarterly intervals from baseline visit during study duration (5 years)",Novartis Pharmaceuticals,30490,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-03
NCT03622580,A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE),https://clinicaltrials.gov/study/NCT03622580,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept|DRUG: Faricimab|PROCEDURE: Sham Procedure,"Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 48, 52, and 56, ITT and Treatment-Naive Populations, Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. For the Mixed Model for Repeated Measures (MMRM) analysis, the model adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (\<64 vs. ≥64 letters), prior intravitreal anti-VEGF therapy (yes vs. no), and region of enrollment. An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded. 97.5% CI is a rounding of 97.52% CI., From Baseline through Week 56",Hoffmann-La Roche,940,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-05
NCT00600301,Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study,https://clinicaltrials.gov/study/NCT00600301,UNKNOWN,Diffuse Diabetic Macular Edema,DRUG: Triamcinolone Acetonide and Bevacizumab,,Asociación para Evitar la Ceguera en México,,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,
NCT02585401,Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada,https://clinicaltrials.gov/study/NCT02585401,COMPLETED,Age-related Macular Degeneration (AMD)|Central Retinal Vein Occlusion (CRVO)|Diabetic Macular Edema (DME),"DRUG: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Knowledge and understanding of key information contained in the aflibercept educational materials: the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph, The source of information for the study will be self-reported data collected from physicians using standard questionnaires with closed-ended response choices., Up to 8 weeks after the start of data collection",Bayer,99,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-02-18
NCT04140201,Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients,https://clinicaltrials.gov/study/NCT04140201,UNKNOWN,Diabetic Retinopathy,DRUG: Simvastatin 40mg|DRUG: Fenofibrate 200mg|DRUG: Omega 3 fatty acid,"The 80 participants will be evaluated through reduction of macular edema, assessed by ocular coherence tomography, 18 weeks",Alaa Hassan ElBaz,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-02
NCT01879501,Living Successfully With Chronic Eye Diseases,https://clinicaltrials.gov/study/NCT01879501,UNKNOWN,Chronic Diseases|Low Vision|Diabetic Retinopathy|Glaucoma|Age-related Macular Degeneration,BEHAVIORAL: Low Vision Self-Management Program,"Vision-related quality of life, up to 12 months post intervention",Singapore Eye Research Institute,160,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2013-01
NCT01030601,Analysis of the Effect of Intravitreal Dexamethasone Injection on Diabetic Macular Edema After Cataract Surgery (IDDMECS),https://clinicaltrials.gov/study/NCT01030601,COMPLETED,Diabetes|Macular Edema|Pseudophakia,DRUG: Dexamethasone sodium phosphate,"Central Retinal Thickness, within 3 months after cataract surgery","University Health Network, Toronto",48,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2010-01
NCT02062034,Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02062034,COMPLETED,Non-proliferative Diabetic Retinopathy|Diabetes Mellitus Type 2,DRUG: Ubiquinone|DRUG: Combined antioxidant therapy|DRUG: Placebo,"Oxidative Stress markers, In this study the oxidative stress markers are composed of lipid peroxidation, nitric oxide, erythrocyte glutathion peroxidase activity, erythrocyte catalase activity, total antioxidant capacity and erythrocyte membrane fluidity.

* Lipid peroxidation (baseline and final values) given as malondialdehyde (MDA) and 4-hydroxyalkenals (4HDA) expressed in μmol/L
* Nitric oxide (NO) Levels of the NO catabolites nitrites/nitrates expressed in pmol/mL (baseline and final values)
* Erythrocyte glutathion peroxidase activity measured in U/min/mg protein (baseline and final values)
* Erythrocyte catalase activity expressed in U/mg protein (baseline and final values)
* Total antioxidant capacity measured in milliequivalent/mL (baseline and final values)
* Erythrocyte membrane fluidity, calculated using the fluorescence ratio of the excimer (Ie) to monomer (Im). The Ie/Im ratio., 24 weeks",University of Guadalajara,61,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2011-02
NCT03384901,The Results of Pars Plana Vitrectomy in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03384901,UNKNOWN,Diabetic Macular Edema,PROCEDURE: vitrectomy,"Visual acuity, Visual acuity will be measured using the Snellen Chart before and after vitrectomy, 6 months",Hillel Yaffe Medical Center,70,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01
NCT01077401,Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study,https://clinicaltrials.gov/study/NCT01077401,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: ranibizumab,"Deaths Due to Myocardial Infarction, 6 Months",Johns Hopkins University,152,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2010-02
NCT05147701,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases,https://clinicaltrials.gov/study/NCT05147701,RECRUITING,Eye Diseases|Retinitis Pigmentosa|Glaucoma|Diabetic Retinopathy|Macular Degeneration|Traumatic Optic Neuropathy|Optic Atrophy,BIOLOGICAL: AlloRx,"Safety (adverse events), Clinical monitoring of possible adverse events or complications, Four year follow-up",The Foundation for Orthopaedics and Regenerative Medicine,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01
NCT02425501,Special Drug Use Investigation of EYLEA for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02425501,COMPLETED,Macular Edema,"DRUG: Aflibercept (Eylea, BAY86-5321)","Number of participants of Adverse Events, Up to 12 months|Number of participants of Serious Adverse Events, Up to 12 months",Bayer,646,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-01-20
NCT02194634,Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing),https://clinicaltrials.gov/study/NCT02194634,UNKNOWN,Diabetic Macular Edema,DRUG: Conbercept|OTHER: Sham injection|PROCEDURE: Laser|OTHER: Sham laser,"Mean change from baseline in best corrected visual acuity (BCVA) at month 12, To compare mean change from baseline BCVA between treatment group and controlled group at month 12., Baseline and month 12","Chengdu Kanghong Biotech Co., Ltd.",248,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-07
NCT02842541,Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02842541,WITHDRAWN,Diabetic Macular Edema,DRUG: EBI-031,"Safety, tolerability, and immunogenicity as measured by adverse events and anti-drug antibody development of single and repeat doses of EBI-031, Number of Participants With Abnormal Laboratory Values, Adverse Events, and/or antibodies to EBI-031, Measure over the 84 days",Eleven Biotherapeutics,0,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-09
NCT01792141,"Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment",https://clinicaltrials.gov/study/NCT01792141,COMPLETED,Macular Edema,,"Primary objective is to assess the effectiveness of FA-ICG guided focal laser therapy for the treatment CSME by means of serial FA-1CGs before and every 3 months after treatment., Visual Acuity will be measured by using the Early Treatment Diabetic Retinopathy Study. (ETDRS) Macular volume will be measured by Optical coherence tomography., 3 months",Retina Institute of Hawaii,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-01
NCT04085341,A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion,https://clinicaltrials.gov/study/NCT04085341,COMPLETED,Diabetic Macular Edema|Retina Vein Occlusion,DRUG: GB-102,"Occurrence of Adverse Events (AEs) Across All Study Visits, Number of subjects with an adverse event across all study visits, Baseline through Month 6",Graybug Vision,21,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-09-11
NCT01292798,Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab,https://clinicaltrials.gov/study/NCT01292798,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab,"Overall Mean Change in Visual Acuity Scores at Month 6 Compared to Baseline, To determine the mean change in the best-corrected visual acuity on an ETDRS visual acuity chart at a starting distance of 4 meters from baseline to 6 months., baseline and 6 months",California Retina Consultants,43,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-03
NCT02308644,Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study,https://clinicaltrials.gov/study/NCT02308644,COMPLETED,Diabetic Macular Edema,DRUG: intravitreal bevacizumab injection(1.25mg),"Contrast sensitivity, Evaluate the Contrast Sensitivity measured by Pelli-Robson charts (Clement Clarke Inc., Columbus, OH) at baseline, weeks 2,6,12,14,18 and 24 to be compared with visual acuity gold standard - Early Treatment of Diabetic Retinopathy Study - ETDRS charts, 6 months (24 weeks )",University of Sao Paulo,41,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-02
NCT00737074,Macular Hole in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00737074,COMPLETED,Macular Hole|Proliferative Diabetic Retinopathy,,"Final opening or closure of macular hole, Six months",National Taiwan University Hospital,23,OBSERVATIONAL,Observational Model: |Time Perspective: p,2002-01
NCT05231174,Efficacy of Using Large Language Model to Assist in Diabetic Retinopathy Detection,https://clinicaltrials.gov/study/NCT05231174,COMPLETED,Diagnosis|Diabetic Retinopathy,OTHER: A self-evlaution tool based on Large Language Model,"AUROC of the self-evaluation tool, The performance of the self-evaluation tool is evaluated with accuracy with reference to the diagnostic labels by senior ophthalmologists based on fundus photos., Immediately after using the chatbot",Sun Yat-sen University,535,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2023-05-01
NCT01610557,Ranibizumab and Bevacizumab for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01610557,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Bevacizumab,"Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study), The primary outcome for 3-months change in BCVA utilized data from Weeks 12, 24 and 36 aggregated in a linear mixed-effects model. This model included adjustments accounting for period (i.e., Weeks 12, 24 and 36), treatment in current period, treatment in prior period, and baseline BCVA to provide the estimated 3-month BCVA change.

Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20., Baseline and 36 Weeks",National Eye Institute (NEI),56,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-05
NCT00347698,Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00347698,UNKNOWN,Diabetic Retinopathy,DRUG: intravitreal injection of bevacizumab|PROCEDURE: panretinal photocoagulation,Best corrected visual acuity at six months and one year|Macular thickness measured by OCT at six months and one year|Median deviation in visual fields at one year|Score on a patient satisfaction scale at six months and one year,Asociación para Evitar la Ceguera en México,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-03
NCT03889444,Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT03889444,COMPLETED,Diabetic Macular Edema,DRUG: Dexamethasone intravitreal implant,"Mean Number of OZURDEX® Implant Reinjections in the Study Eye, Study eye was defined as the eye that received the most OZURDEX® injections., Up to 44 months|Time to OZURDEX® Reinjection, The time to reinjection is defined as the time in months from the date of one OZURDEX® injection to the subsequent OZURDEX® injection., Up to 44 months",Allergan,141,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-15
NCT05151744,A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05151744,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Vamikibart|DRUG: Ranibizumab|OTHER: Sham Procedure,"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants, Baseline, Week 44 and Week 48",Hoffmann-La Roche,187,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-12-17
NCT06172257,Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2),https://clinicaltrials.gov/study/NCT06172257,NOT_YET_RECRUITING,Diabetic Macular Edema,DRUG: Dexamethasone ophthalmic suspension (OCS-01)|DRUG: Vehicle,"Mean change from baseline in BCVA (Best Corrected Visual Acuity), Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the EDTRS chart representing better visual acuity, Week 52",Oculis,350,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2023-12
NCT03452657,Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR),https://clinicaltrials.gov/study/NCT03452657,UNKNOWN,Diabetic Retinopathy|Ranibizumab,DRUG: Ranibizumab|PROCEDURE: No drug,"Proportion of eyes with a ≥ 2-step improvement in the ETDRS Diabetic Retinopathy Severity Scale (DRSS) score, Baseline ETDRS DRSS: None (level 10); Mild to moderate nonproliferative DR (levels 14, 15, 20, 35, and 43); Moderately severe/severe nonproliferative DR (levels 47 and 53); Mild/moderate/high-risk/advanced proliferative DR (levels 61, 65, 71,75, 81, and 85), 1 year","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",118,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-04
NCT01845844,Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab,https://clinicaltrials.gov/study/NCT01845844,UNKNOWN,Diabetic Macular Edema,DRUG: Ranibizumab 0.3mg/0.05cc,"Incidence of ocular and systemic adverse events will be compared between experimental and active comparator groups, Examples include worsened acuity of greater than 30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous hemorrhage, new PDR or neovascularization of the iris or angle, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic serious adverse events, 1 year|Severity of ocular and systemic adverse events will be compared between experimental and active comparator groups, Examples include worsened acuity of greater than 30 letters, retinal detachment, endophthalmitis, cataract progression, vitreous hemorrhage, new PDR or neovascularization of the iris or angle, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs and will include thromboembolic events, deaths and systemic serious adverse events, 1 year","Southeast Retina Center, Georgia",30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2013-04
NCT00041444,Multi-Ethnic Study of Atherosclerosis (MESA) - Ancillary Eye Study,https://clinicaltrials.gov/study/NCT00041444,COMPLETED,"Atherosclerosis|Cardiovascular Diseases|Coronary Arteriosclerosis|Coronary Disease|Cerebrovascular Disorders|Heart Failure, Congestive|Myocardial Infarction|Heart Diseases|Diabetes Mellitus, Non-insulin Dependent|Hypertension|Diabetic Retinopathy|Macular Degeneration|Diabetes Mellitus",,,"University of Wisconsin, Madison",6176,OBSERVATIONAL,Observational Model: |Time Perspective: p,2002-06
NCT02085681,Study of Effectiveness of Telemedicine in Identifying Diabetic Retinopathy Cases,https://clinicaltrials.gov/study/NCT02085681,COMPLETED,Diabetic Retinopathy,OTHER: Tele-medicine|OTHER: Conventional referral,"Proportion of patients with confirmed Diabetic Retinopathy (DR) diagnosed at the eye hospital, Out of the patients referred from the diabetes clinics to the eye hospital, the number of patients with confirmed DR will be measured. This proportion will be compared between the two arms., 6 months",Aravind Eye Care System,801,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2014-05
NCT02096874,Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02096874,COMPLETED,Non-proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Bevacizumab,"Peripheral retinal ischemia, Change in peripheral retinal ischemia after intravitreal bevacizumab injection in non proliferative diabetic retinopathy and proliferative diabetic retinopathy., 24 weeks",King Khaled Eye Specialist Hospital,50,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-06
NCT02559180,Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab,https://clinicaltrials.gov/study/NCT02559180,COMPLETED,Diabetic Retinopathy|Macular Edema,DRUG: aflibercept,"Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline, Subjects were evaluated for efficacy by the change in best corrected visual acuity from baseline.

Best Corrected Visual Acuity (BCVA) was measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. More letters read correctly results in a higher letter score, which represents better visual acuity., Baseline and 12 months|Mean Absolute Change on Central Foveal Thickness, Mean absolute Central Foveal Thickness change from baseline at month 12 as measured by Spectral Domain Optical Coherence Tomography (SD-OCT), defined as the average thickness within the central 1 mm subfield of the central retina.

Thicker measures can represent more macular edema, Baseline and 12 months",Rishi Singh,20,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-10
NCT02818998,Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02818998,COMPLETED,Macular Edema,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52, Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity., From baseline to Week 52",Bayer,463,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-11-16
NCT00759044,Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function,https://clinicaltrials.gov/study/NCT00759044,COMPLETED,Age-Related Maculopathy|Diabetic Macular Edema,,Blood-Retinal Barrier (BRB) function measured by Retinal Leakage Analysis (RLA).,Association for Innovation and Biomedical Research on Light and Image,90,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-03
NCT00131144,Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00131144,COMPLETED,Diabetic Retinopathy,DRUG: Octreotide Acetate in Microspheres 20 mg|DRUG: Octreotide Acetate in Microspheres|DRUG: Placebo,"time to progression of diabetic retinopathy, throughout study",Novartis,583,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",1999-11
NCT01487044,A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema,https://clinicaltrials.gov/study/NCT01487044,AVAILABLE,Diabetic Macular Edema,DRUG: Macugen (Pegaptanib Sodium),,Retina Institute of Hawaii,,EXPANDED_ACCESS,,
NCT02902744,Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study,https://clinicaltrials.gov/study/NCT02902744,WITHDRAWN,Diabetic Macular Edema,DRUG: ILUVIEN®,"Percentage of patients that require a surgical procedure for increased IOP that could not be controlled by IOP-lowering drops., Percentage of patients that require a surgical procedure for increased intraocular pressure that could not be controlled by IOP-lowering drops., 5 years|Percentage of patients requiring 1, 2, or 3 medications to control IOP., Percentage of patients requiring 1, 2, or 3 medications to control intraocular pressure., 5 years|Percentage of patients with IOP > 25mmHg on two occasions and percentage of patients with IOP > 30mmHg on two occasions, Percentage of patients with intraocular pressure \> 25mmHg on two occasions and percentage of patients with intraocular pressure \> 30mmHg on two occasions, 5 years|Percentage of patients losing > 15 letters at month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, Percentage of patients losing \> 15 letters at month 6, 12, 18, 24, 30, 36, 42, 48, 54 and 60, 5 years",Johns Hopkins University,0,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-03-01
NCT02620644,Retinal Ganglion Cell Complex Changes by Optical Coherence Tomography in Diabetic Patients Without Retinopathy,https://clinicaltrials.gov/study/NCT02620644,COMPLETED,Diabetes,DEVICE: OCT Retinal GCC,"Retinal Ganglion Cell Complex in microns by Optical Coherence Tomography measurements, Baseline",Cairo University,35,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2013-01
NCT00407381,The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study,https://clinicaltrials.gov/study/NCT00407381,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|PROCEDURE: Laser photocoagulation,"Mean Change in Best Corrected Visual Acuity (BCVA) at Month 6, Mean change of best corrected visual acuity letters (BCVA) at month 6, 6 months",Johns Hopkins University,126,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2006-12
NCT02876744,Correlation Between Macular Ischemia and Peripheral Ischemia in Patients With Diabetes,https://clinicaltrials.gov/study/NCT02876744,COMPLETED,Diabetic Retinopathy,OTHER: ophthalmologic examination,"Detection and measure of ischemic territories in central and peripheral retina, immediate",Fondation Ophtalmologique Adolphe de Rothschild,101,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-04-04
NCT00556244,Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling,https://clinicaltrials.gov/study/NCT00556244,UNKNOWN,Patients With Proliferative Diabetic Retinopathy Who Have Active Fibrovascular Proliferation,PROCEDURE: ILM peeling,"Snellen BCVA and epiretinal membrane formation measured with OCT, within 6 months after the surgery",National Taiwan University Hospital,40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2007-04
NCT01771081,Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy,https://clinicaltrials.gov/study/NCT01771081,COMPLETED,Ophthalmology|Macular Edema|Macular Degeneration,DRUG: Ranibizumab (or other DME treatment),"Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN, Baseline, after 12 months",Bayer,911,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-04
NCT03641144,Navigation Laser Versus Traditional Laser Photocoagulation for Mild Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03641144,UNKNOWN,Diabetic Macular Edema,DEVICE: Navigation laser|DEVICE: Traditional laser,"Best corrected visual acuity, Best Corrected Visual Acuity will be measured by standard Early Treatment Diabetic Retinopathy Study (ETDRS) protocol, 12 months",Sun Yat-sen University,80,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-06-01
NCT00874744,Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00874744,COMPLETED,Diabetic Macular Edema,DRUG: Bevacizumab|DRUG: Triamcinolone acetonide,"Comparison between the efficacy of a single intravitreal injection of 4.0mg of triamcinolone acetonide or 1.25mg of bevacizumab in the treatment of diabetic macular edema, 6 months",Universidade Federal de Goias,13,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-03
NCT05736081,Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05736081,COMPLETED,Diabetic Macular Edema,PROCEDURE: Intravitreal dexamethasone implant,"Change in central retinal thickness, Difference among the baseline and the posterior measurements of the CRT with OCT, Prospective: from baseline to 2 hours, 3 hours, 24 hours, 1 week and 1 month post IDI",Asociación para Evitar la Ceguera en México,15,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-02-15
NCT01947881,Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES),https://clinicaltrials.gov/study/NCT01947881,COMPLETED,Diabetic Macular Edema,,"Central Retinal Thickness (Change from screening), Measured by Spectral Domain Optical Coherence Tomography (OCT), Change from Screening at 3 Months|Presence of OCT diffuse macular edema (without cyst formation) (change from screening), Change from Screening at 3 Months|Presence of neurosensorial retinal detachment. (change from screening), Change from Screening at 3 Months|Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening), Change from Screening at 3 Months|Presence and extension of capillary occlusion (change from screening), Change from Screening at 3 Months|Area of macular leakage (intraretinal fluid volume and retinal thickness) (change frmo screening), Change from Screening at 3 Months",Association for Innovation and Biomedical Research on Light and Image,71,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-01
NCT05324774,Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05324774,RECRUITING,Diabetic Macular Edema,DRUG: 9MW0813|DRUG: Aflibercept,"Change from Baseline in Best Corrected Visual Acuity (BCVA), Change from Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study(ETDRS) letter score, 8 weeks|Change from Baseline in Central Retinal Thickness（CRT）, Change from Baseline in CRT as measured by optical coherence tomography, 8 weeks","Mabwell (Shanghai) Bioscience Co., Ltd.",346,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2022-02-28
NCT01306981,"Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study",https://clinicaltrials.gov/study/NCT01306981,COMPLETED,Diabetic Retinopathy|Retinal Neovascularisation,DRUG: Ranibizumab|DRUG: Saline,"Best corrected visual acuity, 12 weeks post-op",Moorfields Eye Hospital NHS Foundation Trust,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-03-30
NCT06011798,Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE),https://clinicaltrials.gov/study/NCT06011798,RECRUITING,Diabetic Macular Edema|Retinal Disease|Macular Edema|Diabetes Mellitus|Diabetic Retinopathy|Retinal Degeneration|Retinal Diseases|Eye Diseases|Edema,DRUG: Aflibercept|DRUG: foselutoclax,"Mean change from baseline in BCVA by ETDRS letter, Mean change from baseline in Best-Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) letter, 24 weeks","Unity Biotechnology, Inc.",40,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-08-23
NCT01594281,Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE),https://clinicaltrials.gov/study/NCT01594281,COMPLETED,Proliferative Diabetic Retinopathy (PDR),DRUG: Ranibizumab 0.5 mg|PROCEDURE: Panretinal laser photocoagulation,"Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS), The area of neovascularizations (NV) was assessed by a central reading center via fluorescein angiography (FA) images. The area of NV was calculated as the sum of area of neovascularization of the disc (NVD) and neovascularization elsewhere (NVE) and was recorded in square millimeters. A higher positive change value may indicate a greater formation of new, abnormal blood vessels and thus disease progression. One eye (study eye) contributed to the analysis., Baseline, EOCS",Novartis Pharmaceuticals,107,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-12-11
NCT05728476,Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05728476,NOT_YET_RECRUITING,Diabetic Macular Edema|Pars Plana Vitrectomy|Conbercept,PROCEDURE: Vitrectomy combined with ILM peeling|DRUG: Conbercept intravitreal injection,"Best corrected visual acuity change (BCVA), Early Treatment Diabetic Retinopathy Study (ETDRS) Alphabet Chart, 1, 3, 6, 12 month postoperatively|Central subfield thickness (CST) change, Three-dimensional spectral domain optical coherence tomography (SD-OCT), 1, 3, 6, 12 month postoperatively",Tianjin Medical University Eye Hospital,102,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-11-01
NCT00119535,Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes,https://clinicaltrials.gov/study/NCT00119535,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy,BEHAVIORAL: Implementation of Proactive Diabetes Eye Care Program,� Optimal timing of photocoagulation (prior to intervention and 12 months after interventions,US Department of Veterans Affairs,2000,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: PREVENTION,2004-08
NCT01091896,Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage,https://clinicaltrials.gov/study/NCT01091896,UNKNOWN,Vitreous Hemorrhage Secondary to PDR,DRUG: Bevacizumab|DRUG: bevacizumab,"Recurrent vitreous hemorrhage incidence after vitrectomy, 3 months",University of Sao Paulo,1,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION,2010-01
NCT04847895,Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications,https://clinicaltrials.gov/study/NCT04847895,COMPLETED,Neovascular (Wet) Age-related Macular Degeneration,DRUG: Lucentis,"mean change in visual acuity, Visual acuity will be measured according to the method used by each participating physician in his/her routine practice. To be able to integrate different visual acuity assessment methods for analysis, visual acuity assessments performed using Snellen or decimal notation will be converted into an Early Treatment Diabetic Retinopathy Study (ETDRS) letter score equivalent., Baseline, Up to month 24|mean change in central retinal thickness, As central retinal thickness data is optional, this analysis will be performed only if data allow., Baseline, Up to month 24",Novartis Pharmaceuticals,5500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-06-01
NCT04857996,"Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)",https://clinicaltrials.gov/study/NCT04857996,COMPLETED,Diabetic Macular Edema (DME),DRUG: UBX1325|OTHER: Sham,"Ocular and systemic safety and tolerability of a single IVT injection of UBX1325 evaluated by incidence of treatment emergent adverse events (TEAEs), Week 24","Unity Biotechnology, Inc.",65,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-06-25
NCT05409235,Nesvategrast (OTT166) in Diabetic Retinopathy (DR),https://clinicaltrials.gov/study/NCT05409235,COMPLETED,Diabetic Retinopathy,DRUG: OTT166|DRUG: Vehicle control,"Proportion of participants with treatment-emergent adverse events (TEAEs), To characterize the safety of topical OTT166 in participants with DR., Upto end of the study (Week 24)|Proportion of participants who have improved by ≥ 2 steps from baseline in Diabetic Retinopathy Severity Scale (DRSS) scores, To characterize the efficacy of topical OTT166 in participants with DR. Difference between treatments in proportion of participants achieving ≥ 2 steps improvement from baseline as determined by central reading center assessment using the DRSS will be assessed. Greater DR scores confer a greater chance of converting to PDR. Higher scores are also associated with decreased vision-related quality of life measures., At week 24","OcuTerra Therapeutics, Inc.",225,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-07-29
NCT04290195,Use of Ziv Aflibercept in Different Retinal Diseases,https://clinicaltrials.gov/study/NCT04290195,COMPLETED,Central Retinal Vein Occlusion With Macular Edema,DRUG: Ziv-Aflibercept 25 MG/ML [Zaltrap],"Improvement of BCVA by log MAR(minimum angle of resolution) and reduction of CMT after intravitreal injection, To assess sustained improvement of BCVA(Best corrected visual acuity) and reduction of the CMT (central macular thickness) after intravitreal injection of zivaflibercept, 6 months",Amin El Sayed Nawar,55,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-06-01
NCT00266695,Treatment for Completers of the Study B7A-MC-MBCM,https://clinicaltrials.gov/study/NCT00266695,COMPLETED,Diabetic Retinopathy,DRUG: Ruboxistaurin,"Sustained Moderate Visual Loss (SMVL), The number of participants who experienced SMVL in at least 1 diabetic retinopathy (DR) study eye. SMVL was a ≥15-letter decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) that was sustained for the last 6 months of the study. Best-corrected ETDRS VA was measured at 4 meters (m) using an eye chart with 5 letters per row of decreasing letter size in each successive row. Participants read the chart from the top down until reaching a row where ≥3 letters in the row could not be read correctly. If \<20 letters were read correctly at 4 m, the chart was re-read at 1 m. The best-corrected ETDRS VA score was the total number of letters read correctly per eye at 4 m, plus a correction factor of 30 if ≥20 letters were read correctly at 4 m, plus the total number of letters read correctly at 1 m, if assessed. Best-corrected ETDRS VA scores ranged from 0 (no letters read correctly) to 100 (all letters read correctly)., Baseline, 18 months up to 24 months","Chromaderm, Inc.",203,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-01
NCT00799695,Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population,https://clinicaltrials.gov/study/NCT00799695,COMPLETED,Diabetic Retinopathy,BEHAVIORAL: phone call contact,"a change in the proportion of diabetic patients who acted as a result of the phone contact, and obtained a retina eye exam., 3 months",Henry Ford Health System,561,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2008-01
NCT03590444,Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser,https://clinicaltrials.gov/study/NCT03590444,COMPLETED,Diabetic Retinal Edema,DRUG: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution,"Visual acuity, Functional alterations will be followed during treatment phase, essential for verification of treatment success. Units: Snellen equivalents, 1 year",Hospital Hietzing,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-04-02
NCT00745498,Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT00745498,COMPLETED,Proliferative Diabetic Retinopathy|Vitreous Hemorrhage,DRUG: Bevacizumab,"Recurrent VH Incidence (Early and Late), Recurrent VH was defined as a new episode of grade 1 or more VH occurring more than 1 week after surgery. ""Early recurrent VH"" was VH occurring \<= 4 weeks and ""late recurrent VH"" was VH occurring \>4 weeks after surgery., 6 months",Seoul National University Bundang Hospital,126,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-06
NCT03453281,"Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection",https://clinicaltrials.gov/study/NCT03453281,COMPLETED,Diabetic Macular Edema|Diabetic Retinopathy|Clinically Significant Macular Edema,DRUG: Aflibercept Injection [Eylea],"Central macular thickness, Central macular thickness (CMT) measured by Cirrus® HD OCT, Carl Zeiss, Germany \[in µm\], One month after intravitreal Aflibercept injection",Indonesia University,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2017-10-10
NCT01823081,Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01823081,COMPLETED,Diabetic Macular Edema,DRUG: Intravitreal injection of bevacizumab (Avastin)|DRUG: Intravitreal injection of fasudil and bevacizumab (Avastin),"Best corrected visual acuity, Snellen E-chart, 6 months|central macular thickness, spectral domain optical coherence tomography (SD OCT), 6 months",Shahid Beheshti University of Medical Sciences,74,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-01
NCT01228981,Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01228981,COMPLETED,Type-2 Diabetic Retinopathy,,"Phenotypes of Diabetic Retinopathy progression., June 2011",Association for Innovation and Biomedical Research on Light and Image,400,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-03
NCT00939276,Macular Edema Incidence/Severity Reduction With Nevanac,https://clinicaltrials.gov/study/NCT00939276,TERMINATED,Diabetic Retinopathy,"DRUG: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|DRUG: Nepafenac ophthalmic suspension vehicle","Percentage of patients who develop macular edema within 90 days following cataract surgery, Time to event",Alcon Research,175,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-08
NCT01609881,The Role of Prostaglandins in the Progression of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01609881,WITHDRAWN,Inflammation,DRUG: Acuvail|OTHER: Placebo,"Vitreous and anterior chamber levels of prostaglandins, other cytokines, and Acuvail, Vitreous and anterior chamber levels of prostaglandins, other cytokines, and Acuvail, 3 days",Vanderbilt University,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2012-03
NCT02705274,PRP vs Bevacizumab for PDR Treatment,https://clinicaltrials.gov/study/NCT02705274,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Bevacizumab|PROCEDURE: Panretinal photocoagulation,"Proportion of visual acuity improvement using Snellen chart or equivalent from baseline and 1 year, 1 year",Marashi Eye Clinic,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-02
NCT01171976,"Efficacy and Safety of Ranibizumab in Two ""Treat and Extend"" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus",https://clinicaltrials.gov/study/NCT01171976,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab,"Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12, Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters., Baseline to Month 12",Novartis Pharmaceuticals,373,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2010-09
NCT00701181,Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00701181,TERMINATED,Diabetic Retinopathy|Diabetes Complications,PROCEDURE: Laser Treatment|DRUG: PF-04523655 high|DRUG: PF-04523655 middle|DRUG: PF-04523655 low,"Mean Change from Baseline in the Best Corrected Visual Acuity Score, Month 24",Quark Pharmaceuticals,184,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2008-06
NCT01298076,Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT01298076,COMPLETED,Diabetic Retinopathy|Macular Edema,DRUG: bevacizumab|DRUG: dexamethasone,"Visual acuity gain, The comparison of the proportion of eyes gaining 10 letters of visual acuity between the bevacizumab (Avastin®) and dexamethasone (Ozurdex™) implant arms after 104 weeks., 2 years",University of Sydney,61,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2010-10
NCT02878681,24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.,https://clinicaltrials.gov/study/NCT02878681,WITHDRAWN,Visual Impairment Due to Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Aflibercept,"Area under the curve (AUC) of VEGF-A levels from baseline to week 24, Systemic VEGF-A levels following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept (Area under the curve) expressed in pg/ml\*days. The AUC will be standardized (=divided) by the individual follow-up time and will be calculated by the trapezoidal rule.., baseline to week 24",Novartis Pharmaceuticals,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-09
NCT01331681,Intravitreal Aflibercept Injection in Vision Impairment Due to DME,https://clinicaltrials.gov/study/NCT01331681,COMPLETED,Diabetes Mellitus|Macular Edema,BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|BIOLOGICAL: VEGF Trap-Eye (BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation (Control),"Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF), Visual function of the study eye was assessed using the ETDRS protocol. A higher score represents better functioning., Baseline up to Week 52",Bayer,406,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05-09
NCT02309476,Sub-threshold Photocoagulation of Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT02309476,WITHDRAWN,Diabetic Macular Oedema,"DEVICE: PASCAL Laser, Green Laser 0.75|DEVICE: PASCAL Laser, Green Laser 1|DEVICE: PASCAL Laser, 70% Yellow Laser 0.75|DEVICE: PASCAL Laser, 70% Yellow Laser 1|DEVICE: PASCAL Laser, 40% Yellow Laser 0.75|DEVICE: PASCAL Laser, 40% Yellow Laser 1","reduction of diabetic macular edema (central retinal thickness) within the 6 arms of the study, To compare Green Pascal® laser and Yellow Pascal® laser using EM among 6 groups of participants using Pascal® laser with an application of full grid 112 burns in a single session, 12 months",Manchester University NHS Foundation Trust,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-10
NCT03863535,PRP vs PRP+IVC for Severe nPDR,https://clinicaltrials.gov/study/NCT03863535,UNKNOWN,Severe Nonproliferative Diabetic Retinopathy|Diabetic Retinopathy|Diabete Mellitus,DRUG: Conbercept|PROCEDURE: Panretinal coagulation,"Change in best-corrected visual acuity (BCVA), To assess the effects of two therapies on visual acuity, from baseline to month 12",Ruijin Hospital,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-01-18
NCT05254535,I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study,https://clinicaltrials.gov/study/NCT05254535,ENROLLING_BY_INVITATION,Diabetic Retinopathy,OTHER: I-SITE,"Proportion of Patients Who Complete Annual Diabetic Eye Screening, Comparison of proportion of patients with diabetes adherent with yearly diabetic eye screening guidelines (i.e., ""screening rates"") between baseline and 24 months following initiation of I-SITE implementation at each site., 24 months","University of Wisconsin, Madison",10,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2023-03-28
NCT03962296,"A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon®",https://clinicaltrials.gov/study/NCT03962296,COMPLETED,Diabetic Retinopathy,DRUG: Vitis vinifera extract|DRUG: Calcium Dobesilate|DRUG: Placebo,"The change(Improvement)in the hard exduates, The improvement of HE was defined as a decrease in the HE severity by at least two categories of severity at T12 compared with the baseline visit., T0(baseline), T12(12months)",Hanyang University,153,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-11-21
NCT00806169,Combined Triple Therapy in Diabetic Retinopathy (DRP),https://clinicaltrials.gov/study/NCT00806169,COMPLETED,Macular Edema|Diabetic Retinopathy,DRUG: triamcinolone and bevacizumab,"Best Corrected Visual Acuity, Day of exam",Johann Wolfgang Goethe University Hospital,40,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2006-04
NCT00703235,Intravitreal Bevacizumab for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00703235,UNKNOWN,Macular Edema|Diabetic Retinopathy,DRUG: Bevacizumab,,Isfahan Ophthalmology Research Center,,INTERVENTIONAL,"Allocation: |Intervention Model: |Masking: |Primary Purpose: ",
NCT01297569,"Ranibizumab ""Treat and Extend"" in Diabetic Macular Edma",https://clinicaltrials.gov/study/NCT01297569,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab,"Change in Best Corrected Visual Acuity(BCVA), from month 0 (baseline) to month 12",Novartis Pharmaceuticals,7,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01
NCT02867735,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema",https://clinicaltrials.gov/study/NCT02867735,COMPLETED,Macular Edema|Diabetic Macular Edema|Neovascular Age-related Macular Degeneration|Retinal Vein Occlusions,DRUG: LKA651|OTHER: Sham Comparator,"Number Of participants with Adverse Events as a measure of Safety and Tolerability, To evaluate the safety and tolerability of LKA651 by reviewing any adverse events after medical or ophthalmic examinations that are possibly or probably related to study drug., Day 1 through study completion",Novartis Pharmaceuticals,28,INTERVENTIONAL,"Allocation: NA|Intervention Model: SEQUENTIAL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-09-21
NCT02914613,Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02914613,COMPLETED,Diabetic Macular Edema,DRUG: SF0166 Topical Ophthalmic Solution,"Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8, Percentage of subjects with red blood cell counts in the anterior chamber in the ranges from 0 to \> 30 with the higher number being worse, Baseline, 2, 4, 6, and 8 weeks|Number of Subjects With Flare Observed Following Slit Lamp Examination From Baseline to Week 8, Number and percentage of subjects with flare in the anterior chamber graded on a scale from 0 (none) to 4 (severe)., Baseline, 2, 4, 6, and 8 weeks|Number of Subjects With Hyphema Observed Following Slit Lamp Examination From Baseline to Week 8, Number and percentage of subjects with hyphema, Baseline, 2, 4, 6 and 8 weeks|Number of Subjects With Bulbar Conjunctival Injection Observed Following Slit Lamp Examination From Baseline to Week 8, Number and percentage of subjects with bulbar conjunctival injection, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Erythema Observed Following Slit Lamp Examination From Baseline to Week 8, Number and percentage of subjects with erythema, Baseline, 2, 4, 6 and 8 weeks|Number of Subjects With Edema Observed Following Slit Lamp Examination From Baseline to Week 8, Number and percentage of subjects with edema, Baseline, 2,4, 6 and 8 weeks|Number of Subjects With Any Lens Opacity Observed Following Slit Lamp Examination From Baseline to Week 8, Number and percentage of subjects with any lens opacity, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Abnormal Findings in Optic Nerve Following Fundus Examination From Baseline to Week 8, Number and percentage of subjects with abnormal findings in the optic nerve, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Abnormal Findings in Vitreous Following Fundus Examination From Baseline to Week 8, Number and percentage of subjects (both eyes) with abnormal findings in the vitreous, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Abnormal Findings in Fundus Following Fundus Examination From Baseline to Week 8, Number and percentage of subjects with abnormal findings in the fundus, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Abnormal Findings in Macula/Choroid Following Fundus Examination From Baseline to Week 8, Number and percentage of subjects with abnormal findings in the macula/choroid, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Abnormal Findings in Vessels Following Fundus Examination From Baseline to Week 8, Number and percentage of subjects with abnormal findings in the retinal vessels, Baseline, 2,4,6 and 8 weeks|Cup:Disc Ratio of Subjects Following Fundus Examination From Baseline to Week 8, Number and percentage of subjects with specified Cup:Disc ratio in the range from 0.1 to 0.6 with the higher number being worse, Baseline, 2,4,6 and 8 weeks|Number of Subjects With Abnormal Findings Following A Fluorescein Angiogram at Week 4 Compared to Baseline (Day 0), Number and percentage of subjects with abnormal fluorescein angiogram findings, Baseline and 4 weeks|Change in Intraocular Pressure From Baseline to Week 8, Mean and standard deviation of change from Baseline in intra-ocular pressure, 2,4,6 and 8 weeks|Change in Central Retinal Thickness (CRT) for Study Eye From Baseline (Day 0) to Week 8, 2,4,6 and 8 weeks","OcuTerra Therapeutics, Inc.",44,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2016-08-24
NCT02193113,A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME,https://clinicaltrials.gov/study/NCT02193113,COMPLETED,Diabetic Macular Edema,DRUG: KVD001 Injection,"Number of participants with Adverse Events as a measure of safety and tolerability, 56 days","KalVista Pharmaceuticals, Ltd.",14,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-07-18
NCT01324869,Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT01324869,COMPLETED,Diabetic Macular Edema,BIOLOGICAL: KH902,"Incidence rate of adverse event, To evaluate the safety of multiple intravitreal injection of KH902 to treat DME., up to 12 months","Chengdu Kanghong Biotech Co., Ltd.",20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-04
NCT02540369,To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.,https://clinicaltrials.gov/study/NCT02540369,COMPLETED,Wet Macular Degeneration,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity., Treatment in naïve and previously treated patients for wAMD and DME., Baseline and 12 months",Bayer,2150,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12-14
NCT01281098,"Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.",https://clinicaltrials.gov/study/NCT01281098,COMPLETED,High Risk Proliferative Diabetic Retinopathy|Diabetes Mellitus Type I|Diabetes Mellitus Type II,PROCEDURE: Panretinal Photocoagulation (PRP)|DRUG: Intravitreous injection of pegaptanib,"Regression of retinal neovascularization, Retinal neovascularization will be measured in disc area units, and progression of neovascularization will be defined as an increasing of 0.5 disc area associated or not with vitreous haemorrhage, and/or pre-retinal haemorrhage, and/or rubeosis, and/or traccional retinal detachment., 12-month treatment",Association for Innovation and Biomedical Research on Light and Image,22,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-03
NCT00248157,Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00248157,TERMINATED,Diabetic Retinopathy,DRUG: Octreotide acetate in microspheres,long-term safety and tolerability,Novartis Pharmaceuticals,105,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2005-11
NCT03901898,Feasibility of an Intervention to Increase Diabetic Retinopathy Screening Attendance,https://clinicaltrials.gov/study/NCT03901898,COMPLETED,Diabetes|Retinopathy,"BEHAVIORAL: Training, audit, and reminders|BEHAVIORAL: Intervention after 6 months (wait list)","Number of patients who intend to contact RetinaScreen, Patient self-report during phone call from the practice, 6 months|Number of patients who have contacted the national screening programme, Patient self-report during phone call from the practice, 6 months|Number of patients who have attended screening, Number obtained from practice electronic health records. Letter received from the national screening programme on patient record., 6 months",University College Cork,8,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-07-16
NCT00542178,Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study),https://clinicaltrials.gov/study/NCT00542178,COMPLETED,Diabetic Retinopathy,DRUG: Hypoglycemic Agents|DRUG: Standard glycemia control|DRUG: Intensive BP treatment|DRUG: Standard BP control|DRUG: Fenofibrate|DRUG: Simvastatin|DRUG: Placebo,"Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or Vitrectomy, Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher., Measured at Year 4","National Heart, Lung, and Blood Institute (NHLBI)",3472,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2003-10
NCT00908778,A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects,https://clinicaltrials.gov/study/NCT00908778,UNKNOWN,Diabetic Retinopathy,DRUG: Vitreosolve|DRUG: Vitreosolve,"Ultrasound, OCT, and clinical exam, 6 months","Vitreoretinal Technologies, Inc.",160,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2008-10
NCT01284478,Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery,https://clinicaltrials.gov/study/NCT01284478,COMPLETED,"Pseudophakic Cystoid Macular Edema,|Diabetic Macular Edema",DRUG: Dexamethasone Implant,"BEST CORRECTED VISUAL ACUITY (ETDRS), AT DAY 180",Northern California Retina Vitreous Associates,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01
NCT02000102,Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab,https://clinicaltrials.gov/study/NCT02000102,COMPLETED,Diabetic Macular Edema,DRUG: Intravitreal Injection of Aflibercept,"Visual Acuity, 1 year",Stanford University,14,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-09
NCT02662010,The Relationship Between Advanced Glycation Endproducts and Diabetes,https://clinicaltrials.gov/study/NCT02662010,COMPLETED,Diabetic Retinopathy|Type 2 Diabetes Mellitus,,"Change in Advanced Glycation Endproducts (AGE) Levels, 1 year","University of Colorado, Denver",157,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-03
NCT01472510,Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy,https://clinicaltrials.gov/study/NCT01472510,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab|DRUG: Ranibizumab,"Change in Visual Acuity Scores at Month 12 Compared to Baseline, 12 months","Vitreo-Retinal Associates, PC",20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-12
NCT01102946,Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01102946,COMPLETED,Diabetic Retinopathy|Retinal Neovascularization,DRUG: Ranibizumab|PROCEDURE: Panretinal Photocoagulation,"Fluorescein leakage area (mm2), Neovascularization area measured during fluorescein agiography middle phase, Week 48 after inclusion in the study",University of Sao Paulo,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-02
NCT01988246,Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery,https://clinicaltrials.gov/study/NCT01988246,COMPLETED,Diabetic Retinopathy,DRUG: Aflibercept|DRUG: Sham,"Number of Participants With Ocular and Non-Ocular Adverse Events, Number of participants with ocular and non-ocular adverse events (AEs) in both treatment arms., Day 90",Rishi Singh,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION,2013-12
NCT03866746,Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03866746,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept Injection|OTHER: micropulsed yellow laser,"the number of intravitreal injections, the total number of intravitreal aflibercept injections were recorded, 18th month follow-up.|Central macular thickness, in um, 18 month",Al Hadi Hospital,51,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2017-05-08
NCT03340610,IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab,https://clinicaltrials.gov/study/NCT03340610,COMPLETED,Diabetic Macular Edema,DRUG: Alflibercept,"Reduction in Macular Edema, Reduction in macular edema measured as

* Proportion of eyes with baseline SD OCT CST \>350 um demonstrating \>15% reduction at week 52 from baseline
* Proportion of eyes that demonstrate SD OCT CST \<305um (males) and \<290 um (females) at week 52 from baseline, 52 weeks from baseline","Southeast Retina Center, Georgia",30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-06
NCT02663141,Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02663141,COMPLETED,Diabetic Macular Edema,DRUG: Losartan|DRUG: Intravitreal bevacizumab|DRUG: Placebo,"difference in ETDRS best-corrected visual acuity (BCVA) between arms, Within 6 months from therapy|Difference in frequency of intravitreal Bevacizumab injection between arms, Within 6 months from therapy",Tehran University of Medical Sciences,57,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2015-06
NCT01702441,Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01702441,COMPLETED,Diabetic Macular Edema (DME),DRUG: Subcutaneous AKB-9778,"Incidence and severity of adverse events (AEs)., 28 days|Change from baseline in physical exams., 28 days|Change from baseline in vital signs., 28 days|Change from baseline in electrocardiograms (ECGs)., 28 days|Change from baseline in opthalmic exams., 28 days|Change from baseline in clinical laboratory assay results., Blood chemistry, hematology and urinalysis., 28 days",Aerpio Therapeutics,24,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-09
NCT03006081,The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03006081,UNKNOWN,Diabetic Retinopathy,DRUG: Intravitreal Aflibercept injection,"Improvement of retinal nonperfusion, Mean changes (%) of retinal nonperfusion (Ischemic index) from baseline, 1 year",Asan Medical Center,40,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-05
NCT00446381,Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema),https://clinicaltrials.gov/study/NCT00446381,COMPLETED,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Macugen (pegaptanib)|DRUG: Macugen (Pegaptanib),"Levels of intravitreal Macugen post injection of intravitreal Macugen., 2 to 8 weeks|Levels of intravitreal VEGF 165 pre and post injection of intravitreal Macugen., 0 to 8 weeks|Levels of intravitreal VEGF, TGFbeta, ET-1, PDGF, IGF-1,angiopoietin, HIF 1 alpha, HIF 1 beta pre and post injection of intravitreal Macugen., 0 to 8 weeks",Lawson Health Research Institute,28,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2006-10
NCT03519581,Micropulse for Suppression of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03519581,COMPLETED,Diabetic Macular Edema,DEVICE: Micropulse Laser Treatment|DEVICE: Sham Treatment,"Percentage of subjects with vision loss to 20/40 or worse, Visual acuity (VA) measured using ETDRS testing. If visual acuity is 20/40 or worse, subject will be asked to return for retesting within 28 days to confirm findings., 12 month|Percentage of subjects with vision loss to 20/40 or worse, Visual acuity (VA) measured using ETDRS testing. If visual acuity is 20/40 or worse, subject will be asked to return for retesting within 28 days to confirm findings., 24 month","University of California, Davis",27,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-04-20
NCT01743781,Uptake of Comprehensive Eye Examination Trial,https://clinicaltrials.gov/study/NCT01743781,COMPLETED,Glaucoma|Diabetic Retinopathy,BEHAVIORAL: video,"The acceptance rate of comprehensive eye examination in both groups, acceptance rate of comprehensive eye examination, 1 day",Sun Yat-sen University,459,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2013-07
NCT01141881,Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01141881,TERMINATED,Diabetic Macular Edema,"DRUG: Tissue Plasminogen Activator,bevacizumab ,follow up",,Mashhad University of Medical Sciences,,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2009-05
NCT00476918,Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00476918,UNKNOWN,Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Intravitreal injection (triamcinolone acetonide),"Visual acuity, no of treatments, duration of efficacy, 12 months",Heidelberg University,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT,2006-07
NCT04665102,Pilot Study on Deep Learning in the Eye,https://clinicaltrials.gov/study/NCT04665102,UNKNOWN,Central Serous Chorioretinopathy|Diabetic Retinopathy|Cataract,OTHER: Image classification using deep learning algorithm,"Validation of Image classification by transfer learning algorithm, 1 year",CRG UZ Brussel,120,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-02-01
NCT02788877,Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study),https://clinicaltrials.gov/study/NCT02788877,UNKNOWN,"Macular Edema, Diabetic",DRUG: aflibercept,"Changes in visual acuity from baseline to 104 weeks, Visual acuity is assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The ETDRS chart includes 100 letters as the maximum possible score, and 0 letters read as the minimum possible score. Visual acuity of 85 letters is equivalent to 20/20. Higher scores represents better functioning., baseline and 104 weeks",Pusan National University Hospital,48,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2016-04-10
NCT02088229,Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02088229,COMPLETED,Diabetic Macular Edema,,"Dark adaptation (AdaptRx), Rod intercept (minutes), 12 Months",University of Michigan,35,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-09
NCT01364129,The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01364129,COMPLETED,Diabetic Retinopathy,PROCEDURE: Ophthalmic Telemedicine,"Proportion of Participants that Receive Annual Eye Exam, This outcome measure will be used to determine (1) whether the telemedicine system increases the proportion of participants that receive an annual eye exam, and (2) what health belief factors are associated with adherence., Baseline; Change from Baseline at 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years (number of follow-up exams depends on number of years enrolled in the study)",Legacy Health System,567,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SCREENING,2006-08
NCT03069729,Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN),https://clinicaltrials.gov/study/NCT03069729,COMPLETED,Diabetic Neuropathies|Diabetic Foot|Diabetic Retinopathy,OTHER: no intervention,"Pattern of thermal recovery, The thermal recovery pattern after cold provocation will be different for each group studied., 24 months",VisionQuest Biomedical LLC,331,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-08
NCT03466177,Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease,https://clinicaltrials.gov/study/NCT03466177,RECRUITING,Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Dementia|Glaucoma|Age-Related Macular Degeneration|Diabetic Retinopathy,"DIAGNOSTIC_TEST: Non-invasive, multimodal retinal imaging","Retinal biomarkers for AD: specificity, To evaluate the diagnostic performance of selected ocular biomarkers for Alzheimer's disease, 5 years|Retinal biomarkers for AD: sensitivity, To evaluate the diagnostic performance of selected ocular biomarkers for Alzheimer's disease, 5 years|Retinal biomarkers for AD: number needed to image, To evaluate the diagnostic performance of selected ocular biomarkers for Alzheimer's disease, 5 years|Retinal biomarkers for AD: area under the curve (AUC), To evaluate the diagnostic performance of selected ocular biomarkers for Alzheimer's disease, 5 years|Retinal biomarkers for AD: receiver operating characteristic (ROC), To evaluate the diagnostic performance of selected ocular biomarkers for Alzheimer's disease, 5 years",Universitaire Ziekenhuizen KU Leuven,320,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-03-01
NCT04976777,A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina,https://clinicaltrials.gov/study/NCT04976777,COMPLETED,Macular Edema,DEVICE: Updated DEX PS DDS Applicator|DEVICE: Approved DEX PS DDS Applicator|DRUG: Dexamethasone,"Number of Participants Experiencing at Least One Adverse Events (AEs), An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study., Up to 7 Days After Study Drug Administration",AbbVie,54,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-10-12
NCT03059277,Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab,https://clinicaltrials.gov/study/NCT03059277,WITHDRAWN,Diabetic Macular Edema,DRUG: Intravitreal Aflibercept,"Change in Central Subfield Thickness (CST), Percentage of patients who experience a \> 10% decrease in mean Central Subfield Thickness (CST) from baseline or whose CST \< 300 microns at 52 weeks., 52 weeks","Southeast Clinical Research Associates, LLC",0,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2018-06-01
NCT06183476,Circadian Amplification in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06183476,NOT_YET_RECRUITING,Diabetic Retinopathy,BEHAVIORAL: Amplify-RHYTHM,"Sleep, Objective and Subjective Sleep Parameters, baseline and 6-week",University of Illinois at Chicago,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2024-02
NCT01769599,Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections,https://clinicaltrials.gov/study/NCT01769599,UNKNOWN,Diabetic Macular Edema|Diabetus Mellitus,,"Macular thickness, by measuring the retinal thickness and comparing in both aproaches. and see if there is any difference., 36 months",Ziv Hospital,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01
NCT02858076,Anti-VEGF vs. Prompt Vitrectomy for VH From PDR,https://clinicaltrials.gov/study/NCT02858076,COMPLETED,Proliferative Diabetic Retinopathy|Vitreous Hemorrhage,DRUG: 2-mg Intravitreous Aflibercept Injection|PROCEDURE: Prompt Vitrectomy Plus Panretinal Photocoagulation,"E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline), The area under the curve (units = letters·weeks) was divided by 24 weeks (units = weeks) to obtain an average change in letter score (units = letters) over the 24-weekr follow-up.

Best-corrected visual acuity following protocol-defined refraction. Visual Acuity was measured with the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity test on a scale from 100 letters (Snellen equivalent of 20/10) to 0 letters (Snellen equivalent of \<20/800). Higher scores indicate better visual acuity and lower scores indicate worse visual acuity., 24 weeks",Jaeb Center for Health Research,205,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2016-11
NCT01023698,Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters,https://clinicaltrials.gov/study/NCT01023698,UNKNOWN,Neovascular,PROCEDURE: laser photocoagulation,"Stabilization of proliferative diabetic retinopathy, 2010",Asociación para Evitar la Ceguera en México,30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2009-04
NCT05282680,The Hong Kong Diabetes Biobank,https://clinicaltrials.gov/study/NCT05282680,RECRUITING,Diabetes Mellitus|Type 2 Diabetes|Type 1 Diabetes|Diabetic Nephropathies|Diabetic Kidney Disease|Diabetic Angiopathies|Cardiovascular Diseases|Coronary Heart Disease|Diabetic Retinopathy|Stroke|Diabetes,,"Diabetic kidney disease, Diabetic kidney disease will be defined as: eGFR \<60 ml/min per 1.73 m2. +/- presence of elevated urine microalbumin

Other hospital discharge diagnoses based on eGFR or ICD-9 codes or other equivalent will be used.

Kidney failure/end stage renal disease (ESRD) will be defined by the presence of a dialysis code (procedure codes 39.95 or 54.98), a code of kidney transplant (procedure code 55.6 or diagnosis codes 996.81 or V42.0), or eGFR \<15 ml/min per1.73 m2. The onset time will be defined as the period from baseline visit to the date of kidney failure onset or the censored date, whichever came first.

The rate of decline in eGFR and % drop in eGFR, as well as changes in urine albuminuria will also be explored as additional clinical endpoints in diabetic kidney disease.

Identification of genetic variants or other biomarkers associated with diabetic kidney disease by association analyses may utilize one or more of the clinical definitions of diabetic kidney disease., 1-99 years|Cardiovascular complications in diabetes, Cardiovascular complications in diabetes will be defined as coronary heart disease (CHD), stroke, and/or peripheral vascular disease (PVD), and/or congestive heart failure.

Coronary Heart Disease is defined as myocardial infarction, ischemic heart disease, or cardiac revascularisation.

Stroke is defined as ischemic stroke except transient ischemic attack, hemorrhagic stroke, or acute but ill-defined cerebrovascular disease

Peripheral vascular disease is defined as amputation, gangrene, or peripheral revascularization.

Hospitalization for heart failure is defined as hospitalization for congestive heart failure.

Identification of genetic variants or other biomarkers associated with cardiovascular disease in diabetes may utilize one or more of the clinical definitions of cardiovascular complications in diabetes., 1-99 years",Chinese University of Hong Kong,48000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-02-01
NCT05838898,Specular Microscopy in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05838898,NOT_YET_RECRUITING,Corneal Endothelial Cell Changes in Diabetic Patients,DEVICE: Specular microscopy,"To predict the effect of Diabetes on the cornea of diabetic patients, To evaluate corneal endothelial changes in patients with Proliferative diabetic retinopathy compared to normal group of the same age and gender using Specular microscopy, Baseline",Assiut University,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-01
NCT01625598,Computer Detection of Diabetic Retinopathy Compared to Clinical Examination,https://clinicaltrials.gov/study/NCT01625598,COMPLETED,Diabetic Retinopathy,PROCEDURE: Photography of the retina|PROCEDURE: Retinal photography,"Sensitivity of detecting moderate non proliferative diabetic retinopathy or more severe DR and/or significant macular edema on a person-specific basis., If the interval excludes differences of 10% or more (IDx worse than clinical examination), then the IDx system will be considered non-inferior to clinical examination by ophthalmologists. If IDx is non-inferior to clinical examination, a two-sided test of the null hypothesis that the difference in sensitivities is 0 will be conducted to determine if the IDX is superior to clinical examination. 24 McNemar's test for paired proportions will be used to test the difference in proportions., Recruitment over 4 months","Digital Diagnostics, Inc.",600,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04
NCT03511898,A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT03511898,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,DRUG: THR-149 dose level 1|DRUG: THR-149 dose level 2|DRUG: THR-149 dose level 3,"Incidence of dose-limiting toxicities up to the Day 14 visit, up to Day 14",ThromboGenics,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-18
NCT00605280,"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.",https://clinicaltrials.gov/study/NCT00605280,COMPLETED,Macular Edema Associated With Diabetes Mellitus,DRUG: Standard of Care|DRUG: Macugen,"Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year, Refraction and best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts, Baseline, Year 1",Pfizer,317,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2005-09
NCT00337298,The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes,https://clinicaltrials.gov/study/NCT00337298,COMPLETED,Type 1 Diabetes|Diabetic Retinopathy|Eye Diseases|Diabetes Complications,DRUG: Amlodipine|DRUG: Lisinopril,"Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer, 120,240,360,480,600,720 and at 840secs",University of Aarhus,25,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: ",2006-07
NCT03618498,Internal Limiting Membrane Flaps for Coexistent Macular Hole and Retinal Detachment,https://clinicaltrials.gov/study/NCT03618498,COMPLETED,Retinal Detachment,PROCEDURE: ILM flaps insertion techniques or free ILM flaps.,"Wilcoxon Sign-Rank test, A statistical comparison of average of two dependent samples, Baseline, 12 months.",Changhua Christian Hospital,10,INTERVENTIONAL,Allocation: |Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-03-07
NCT04888598,Microvascular Changes in OCT-angiography in Type 1 Diabetes Mellitus at the Onset of the Disease and After Optimization of Glycemic Control.,https://clinicaltrials.gov/study/NCT04888598,RECRUITING,Type 1 Diabetes|Diabetic Retinopathy,DIAGNOSTIC_TEST: Optical Coherence Tomography (OCT) Angiography,"Vessel density, Density of retinal vessels and perfusion in the macula, 3 months",Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-06-01
NCT01358396,Glycemic Control and Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01358396,COMPLETED,Diabetic Macular Edema,OTHER: Respond to therapy for diabetic macular edema,"Visual Acuity, Correlate baseline HBA1c to the visual outcomes., 3 months",Cairo University,52,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-01
NCT06213896,Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images,https://clinicaltrials.gov/study/NCT06213896,RECRUITING,Glaucoma|Age-Related Macular Degeneration|Retinal Vein Occlusion|Diabetic Retinopathy|Diabetic Macular Edema|Eye Diseases,DRUG: Mydriatic Agent|PROCEDURE: Color Fundus Photography|DEVICE: EyeCheckup v2.0,"To determine the accuracy of diagnosis with artificial intelligence algorithm, Comparison of the compatibility of the diagnosis of the artificial intelligence algorithm with the diagnoses of retina and glaucoma specialists, through study completion, an average of 1 year",URAL Telekomunikasyon San. Trade Inc.,1528,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-01
NCT03920878,Cataract DME - Peri vs. Intraop,https://clinicaltrials.gov/study/NCT03920878,WITHDRAWN,Diabetic Macular Edema|Cataract,DRUG: Aflibercept injected Pre- and Post-operatively|DRUG: Aflibercept injected intraoperatively,"Change in best-corrected visual acuity (BCVA), BCVA is a measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if uncorrected eyesight is 20/200, but patient can see 20/20 with glasses, the BCVA is 20/20., 1 month, 3 months and 6 months after cataract surgery",Emory University,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-05
NCT01920984,Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01920984,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: intravitreal injection of 1.25 mg of bevacizumab,"Vitreous levels of Fractalkine, Cyr61, and VEGF of patients with proliferative diabetic retinopathy, 7 days",National Taiwan University Hospital,100,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE,2005-01
NCT02556723,Intravitreal Injections of Ziv-aflibercept for Macular Diseases,https://clinicaltrials.gov/study/NCT02556723,COMPLETED,Diabetic Macular Edema|Age Related Macular Degeneration|Branch Retinal Vein Occlusion With Macular Edema|Central Retinal Vein Occlusion With Macular Edema,DRUG: Intravitreal injections of ziv-aflibercept,"Multifocal electroretinogram responses at Week 24 and 48, 24 and 48 weeks","Retina Clinic, Sao Paulo, Brazil",60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-09
NCT04729023,Pars Plana Vitrectomy Combined With Phacoemulsification Cataract Surgery in Phakic Diabetes Retinopathy Patients,https://clinicaltrials.gov/study/NCT04729023,COMPLETED,Diabetic Retinopathy|Diabetic Cataract,PROCEDURE: Pars plana vitrectomy combined with cataract surgery.|PROCEDURE: Pars plana vitrectomy with subsequent cataract surgery.,"Best correct visual acuity (BCVA), BCVA with early treatment diabetic retinopathy study (ETDRS) letters, Change from Baseline at 1 week after the surgery(s)|Best correct visual acuity, BCVA with ETDRS letters, Change from Baseline at 1 month after the surgery(s)|Best correct visual acuity, BCVA with ETDRS letters, Change from Baseline at 3 months after the surgery(s)|Best correct visual acuity, BCVA with ETDRS letters, Change from Baseline at 6 months after the surgery(s)","Zhongshan Ophthalmic Center, Sun Yat-sen University",129,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-02-01
NCT06099184,Study of EYP-1901 in Patients With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT06099184,NOT_YET_RECRUITING,Diabetic Macular Edema,"DRUG: EYP-1901|DRUG: Aflibercept 2Mg/0.05Ml Inj,Oph","Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs Aflibercept, Week 24","EyePoint Pharmaceuticals, Inc.",25,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2024-01-15
NCT05759884,Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05759884,RECRUITING,Macular Edema Due to Type 2 Diabetes Mellitus,DRUG: Anti-VEGF|RADIATION: subthreshold micropulse laser,"central macular thickness (CMT), CMT, up to 6 months","Second Affiliated Hospital, School of Medicine, Zhejiang University",40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-02-01
NCT01168258,Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01168258,TERMINATED,Diabetic Retinopathy|Diabetic Macular Edema,,Genotype frequency of SNP in the study genes of DME participants and control participants.,National Eye Institute (NEI),68,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-07-07
NCT02391558,Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography,https://clinicaltrials.gov/study/NCT02391558,COMPLETED,Diabetic Retinopathy,,"Comparison between examination techniques on the detection of morphological changes in the retina (such as vessels morphology, vascular ischemia, retinal neovascularization, choroidal neovascularization, and other vascular abnormalities)., Single Visit",Association for Innovation and Biomedical Research on Light and Image,62,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-09
NCT03499223,A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME),https://clinicaltrials.gov/study/NCT03499223,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Macular Edema,DRUG: Ranibizumab 0.5mg|DRUG: THR-317 8mg|DRUG: Sham injection,"Change from baseline in BCVA, At Day 84 (Month 3)",Oxurion,70,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-04-20
NCT03911323,Real-world Diagnostic Effectiveness of Artificial Intelligence Algorithm in Diabetic Retinopathy Screening,https://clinicaltrials.gov/study/NCT03911323,UNKNOWN,Diabetic Retinopathy,OTHER: diabetic retinopathy,"Sensitivity and specificity, To evaluate the sensitivity and specificity of the model in detecting referable DR (more than mild NPDR), No more than 1 day for each subject",Shenzhen Second People's Hospital,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-10-01
NCT02126423,Resistance to Antibiotics in Patients Receiving Eye Injections,https://clinicaltrials.gov/study/NCT02126423,COMPLETED,Age-Related Macular Degeneration|Retinal Vein Occlusion|Diabetic Retinopathy,OTHER: Conjunctival and nasopharyngeal swabs,"Kirby Bauer disc diffusion antimicrobial susceptibility, One set of conjunctival and nasopharyngeal swabs obtained from patient shortly after recruitment. Antibiotic susceptibility is determined using the Kirby Bauer disc diffusion method for the following antibiotics: amoxicillin/clavulanate, cefazolin, cefoxitin, erythromycin, moxifloxacin, trimethoprim/sulfamethoxazole, linezolid, clindamycin, and doxycycline., 15 minutes",Prism Vision Group,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-05
NCT02353923,OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy,https://clinicaltrials.gov/study/NCT02353923,UNKNOWN,Diabetic Retinopathy,DIETARY_SUPPLEMENT: OcuStem Supplementation,"Change in Electronic-ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing, Electronic-ETDRS visual acuity testing at 3 meters using the Electronic Visual Acuity Tester (including protocol refraction) in each eye, 0 months, 3 months, 6 months",Aidan Products LLC,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-09
NCT00000160,Diabetic Retinopathy Study (DRS),https://clinicaltrials.gov/study/NCT00000160,COMPLETED,Diabetic Retinopathy|Blindness,PROCEDURE: Xenon Photocoagulation|PROCEDURE: Argon Photocoagulation|PROCEDURE: Photocoagulation,,National Eye Institute (NEI),,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,1972-01
NCT05138029,Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation,https://clinicaltrials.gov/study/NCT05138029,RECRUITING,Diabetic Retinopathy,DRUG: Ranibizumab Injection [Lucentis]|PROCEDURE: Inner limiting membrane stripping|DRUG: Dexamethasone intravitreal implant,"Review the patient's vision before surgery, Optical Coherence Tomography (OCT) is currently the main examination method for measuring retinal thickness and evaluating DME morphology and fine structure. DME OCT examination has a variety of morphological manifestations and accompanying images, and various manifestations reflect different pathological basis., The day before the patient's surgery",Affiliated Hospital of Nantong University,60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-11-15
NCT04742829,Effects of a Therapy With INTRAVIT® Tablets in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04742829,UNKNOWN,Diabetic Retinopathy,DIETARY_SUPPLEMENT: INTRAVIT ®,"number of participants with signs of improvement/worsening of diabetic retinopathy, report presence/absence of signs with Yes/NO relative to: microaneurysms, haemorrhages, soft exudates, hard exudates, venous beading, IRMA, new vessels on optical discs, new vessels outside the optical discs, cystoid edema, capillary occlusions, degenerative alterations and vein size., 6 months|number of participants in a certain stage of diabetic retinopathy according to the ETDRS modified AAO 2003, careful evaluation of funduscopic signs (e.g exudates, neovases, micronaneurysms) to be able to stadiate patients, 6 months|number of patients with improved/worsened visual acuity, visual acuity measurement with ETDRS boards. The number of letters seen by the patient at each check-up visit will be noted., 6 months|number of patients with improved/worsened macular edema, Foveal thickness (measured with Optical Coherence Tomography) at each check-up visit will be noted., 6 months",University of Molise,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2020-10-01
NCT01225653,Topical Application of Latanoprost in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01225653,COMPLETED,Diabetic Retinopathy,DRUG: Latanoprost,"The diameter of retinal arterioles, The diameter of retinal arterioles will be assessed using the Dynamic Vessel Analyzer, 24 months",University of Aarhus,27,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2010-11
NCT04631653,Verisee Software for Diabetic Retinopathy Screening,https://clinicaltrials.gov/study/NCT04631653,UNKNOWN,Diabetic Retinopathy,DEVICE: VeriSee®,"diagnostic accuracy, diagnostic accuracy compared to the baseline, 12 months",Taichung Veterans General Hospital,1000,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2020-12-01
NCT01440660,"Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)",https://clinicaltrials.gov/study/NCT01440660,COMPLETED,Type-2 Diabetes|Diabetic Retinopathy,,"Multimodal testing/imaging procedures - Ophthalmological Imaging, Retinal thickness measured with OCT;, 24 months|Multimodal testing/imaging procedures - Ophthalmological Imaging, MA turnover computed based on CFP., 24 months|Multimodal testing/imaging procedures - Ophthalmological Imaging, Macular area with increased retinal fluorescein leakage based on RLA., 12 months|Multimodal testing/imaging procedures - Ophthalmological Imaging, Implicit time local and ring amplitudes measured with mfERG., 12 months|Multimodal testing/imaging procedures - Psychophysical Testing, Psychophysical tests for speed discrimination, achromatic contrast, and chromatic contrast., 12 months|Multimodal testing/imaging procedures - Barin Imaging, Perfusion change measured with ASL., 12 months|Multimodal testing/imaging procedures - Ophthalmological Imaging, Blood-Brain Barrier alterations assessed contrast agent with Dynamic MR., 12 months|Multimodal testing/imaging procedures - Brain Imaging, Metabolite concentrations assessed with MR Spectroscopy., 12 months",Association for Innovation and Biomedical Research on Light and Image,20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-01
NCT02995629,Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation,https://clinicaltrials.gov/study/NCT02995629,COMPLETED,Proliferative Diabetic Retinopathy - High Risk,PROCEDURE: laser indirect ophthalmoscopy pan retinal photocoagulation,"Perceived patient pain assessment, Assessed using a standardized Wong-Baker faces pain scale, a single time point within 2 minutes of completing laser treatment",Wills Eye,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-03
NCT02691429,Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans,https://clinicaltrials.gov/study/NCT02691429,COMPLETED,Epiretinal Membrane|Macular Hole|Diabetic Retinopathy,OTHER: Acai dye 10%,"ocular inflammation, signs of ocular inflammation, up to 30 days",Federal University of São Paulo,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: OTHER",2016-02
NCT05802329,Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT05802329,NOT_YET_RECRUITING,Center Involved Diabetic Macular Edema|Diabetic Macular Edema,DRUG: OCU200 Low Dose|DRUG: OCU200 Medium Dose|DRUG: OCU200 High Dose,"Study Drug-related adverse events (SDAE), Counts, frequencies and percentages of SDAEs., 20 weeks|treatment-emergent adverse events (TEAEs), Counts, frequencies and percentages TEAEs. TEAEs are defined as an event that was not present prior to administration of the dose of study drug and present after the dose, or if it represents the exacerbation of an event that was present prior to the dose., 20 weeks|serious adverse events (SAEs), Counts, frequencies and percentages of SAEs including Resulted in Death, Life-threatening, Hospitalization, Disabling/incapacitating, Congenital anomaly or birth defect and Medically significant AEs ( AE that did not meet any of the above criteria but could have jeopardized the subject and might have required medical or surgical intervention to prevent one of the outcomes listed above)., 20 weeks",Ocugen,28,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-04
NCT05464953,Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.,https://clinicaltrials.gov/study/NCT05464953,COMPLETED,Diabetic Macular Edema of Left Eye,DRUG: Triamcinolone Acetonide|DRUG: Formulated Triamcinolone,"BCVA, Best-corrected visual acuity, Base line|BCVA, Best-corrected visual acuity, at 1st month|BCVA, Best-corrected visual acuity, at 3rd month|BCVA, Best-corrected visual acuity, at 6th month|CMT, CENTRAL MACULAR THICKNESS, at baseline|CMT, CENTRAL MACULAR THICKNESS, at 1st month|CMT, CENTRAL MACULAR THICKNESS, at 3rd month|CMT, CENTRAL MACULAR THICKNESS, at 6th month",Al-Azhar University,75,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-01-20
NCT03481660,A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03481660,COMPLETED,Diabetic Macular Edema,DRUG: Brolucizumab|DRUG: Aflibercept,"Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye, Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The overall BCVA score (number of letters read correctly by the patient) was calculated using the BCVA worksheet 0-100 letter score, with higher score indicating improvement in acuity. A positive change from baseline is a favorable outcome. BCVA assessments after start of alternative diabetic macular edema (DME) treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment., Baseline, Week 52",Novartis Pharmaceuticals,360,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-07-27
NCT00727038,Lucentis for New Onset Neovascular Glaucoma,https://clinicaltrials.gov/study/NCT00727038,WITHDRAWN,Glaucoma|New Onset Glaucoma|Neovascular Glaucoma|New Onset Neovascular Glaucoma,DRUG: Ranibizumab (Lucentis),"Mean change in best corrected visual acuity (BCVA) as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters from baseline to Month 6., Baseline to Month 6.",University of Illinois at Chicago,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2008-01-04
NCT05429229,Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05429229,RECRUITING,Dry Eye Syndromes|Diabetic Retinopathy|Oxidative Stress|Tear Film Deficiency,DRUG: VisuXL®|DRUG: Lagricel PF®|DRUG: Humylub PF®,"Change from baseline in levels of tumor necrosis factor alpha (TNF-a) in tear film at 30 days., Tears will be collected with Drummond glass® micro capillary tubes without stimulation of tear secretion and placed in an eppendorf tube at -80 celsius degrees. The cytokine concentration will be determined with multiplex bead immunoassays technique and reported in picogram per milliliter units (pg/mL), 30 days|Change from baseline in levels of interleukin 8 (IL-8), Tears will be collected with Drummond glass® micro capillary tubes without stimulation of tear secretion and placed in an eppendorf tube at -80 celsius degrees. The cytokine concentration will be determined with multiplex bead immunoassays technique and reported in picogram per milliliter units (pg/mL), 30 days|Change from baseline in levels of interleukin 6 (IL-6), Tears will be collected with Drummond glass® micro capillary tubes without stimulation of tear secretion and placed in an eppendorf tube at -80 celsius degrees. The cytokine concentration will be determined with multiplex bead immunoassays technique and reported in pg/mL., 30 days|Change from baseline in levels of interleukin 10 (IL-10), Tears will be collected with Drummond glass® micro capillary tubes without stimulation of tear secretion and placed in an eppendorf tube at -80 celsius degrees. The cytokine concentration will be determined with multiplex bead immunoassays technique and reported in picogram per milliliter units (pg/mL), 30 days|Changes from baseline in total antioxidant capacity in the tear film at 30 days., Tears will be collected with Drummond glass® micro capillary tubes without stimulation of tear secretion and placed in an eppendorf tube at -80 celsius degrees. Total antioxidant capacity concentration will be determined with colorimetric assay technique and reported in units called Trolox equivalents (TE), nmol/sample., 30 days|Change from baseline in lipoperoxides levels in tear film at 30 days., Tears will be collected with Drummond glass® micro capillary tubes without stimulation of tear secretion and placed in an eppendorf tube at -80 celsius degrees. Lipoperoxides concentration will be determined with colorimetric assay technique and reported in nmol/mL., 30 days",Adolfo Daniel Rodriguez-Carrizalez,78,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-11-01
NCT00000153,Krypton-Argon Regression of Neovascularization Study (KARNS),https://clinicaltrials.gov/study/NCT00000153,COMPLETED,Diabetic Retinopathy|Retinal Neovascularization|Diabetes Mellitus,PROCEDURE: Blue-Green Argon Laser Treatment|PROCEDURE: Red Krypton Laser Treatment,,National Eye Institute (NEI),,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: |Primary Purpose: TREATMENT,1984-12
NCT03030729,Macular Thickness Measurements Using Retinal-thickness OCT,https://clinicaltrials.gov/study/NCT03030729,COMPLETED,Age-Related Macular Degeneration|Diabetic Retinopathy,,"Comparison between retinal measurements, done by the RTOCT device and a commercial OCT, 1 year",Notal Vision Ltd.,14,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-03-14
NCT01280929,"Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT01280929,COMPLETED,High Risk Proliferative Diabetic Retinopathy,PROCEDURE: Panretinal Photocoagulation (PRP)|DRUG: Intravitreous injection of ranibizumab,"Regression of neovascularization, To demonstrate superiority of one of the treatment arms: ranibizumab 0.5 mg monotherapy, panretinal photocoagulation monotherapy or combination therapy (ranibizumab 0.5 mg plus panretinal photocoagulation) over a 12-month treatment period in the regression of neovascularization., 12-month treatment",José Cunha-Vaz,54,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-09
NCT05698329,Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME,https://clinicaltrials.gov/study/NCT05698329,RECRUITING,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,DRUG: AIV007,"Adverse Events, Incidence of adverse events and serious adverse events, Approximately 168 days","AiViva BioPharma, Inc.",30,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2023-03-02
NCT04885153,Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume,https://clinicaltrials.gov/study/NCT04885153,COMPLETED,Diabetic Retinopathy|Dyslipidemias|Diabetes Mellitus,DRUG: Fenofibrate|DRUG: Placebo,"Changes from Baseline Central Macular Thickness (CMT) at 3 Months, Thickness of fovea centralis based on OCT, Evaluated at baseline and monthly for three months|Changes from Baseline Macular Volume at 3 Months, Volume of the retina in the central 6 mm of the macula based on OCT, Evaluated at baseline and monthly for three months|Changes from Baseline Endothelial Nitric Oxide Synthase (eNOS) at 3 Months, Enzyme that produces protective molecule of the blood vessels, Evaluated at baseline and after three months (by the end of the study)|Changes from Baseline Vascular Endothelial Growth Factor (VEGF) at 3 Months, Signaling protein that promotes angiogenesis, Evaluated at baseline and after three months (by the end of the study)|Changes from Baseline Vascular Cell Adhesion Molecule-1 (VCAM -1) at 3 Months, Protein that functions for cell adhesion, Evaluated at baseline and after three months (by the end of the study)",Indonesia University,36,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (CARE_PROVIDER)|Primary Purpose: TREATMENT,2016-11-01
NCT04544553,Barriers to Eye Screening for People With Diabetes in India,https://clinicaltrials.gov/study/NCT04544553,COMPLETED,Diabetic Macular Edema,OTHER: SMS reminder|OTHER: No SMS reminder,"Attendance rates in patients with diabetic macular edema receiving short messaging services, To investigate the effect of SMS informational reminders on adherence with scheduled eye examinations among patients with center involving DME receiving intravitreal injections in a tertiary eye care institute in South India., 7 months",Lions Club International Foundation,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SCREENING,2019-01-24
NCT01589029,A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP),https://clinicaltrials.gov/study/NCT01589029,TERMINATED,Proliferative Diabetic Retinopathy,DRUG: CANAKINUMAB (ILARIS®),"Regression of retinal neovascularizations (NVE and NVD) in FA., 24 weeks",PD Dr. med. Stephan Michels,6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-04
NCT01487629,Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01487629,UNKNOWN,Diabetic Retinopathy|Macular Edema,DRUG: Bevacizumab|DRUG: Ranibizumab,"Central subfield macular thickness (CSFT) change, Central subfield macular thickness (CSFT) measured with spectral-domain optical coherence tomography (OCT), Monthly from baseline to Week 48",University of Sao Paulo,53,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2010-04
NCT04071977,Combined Antioxidant Therapy on Oxidative Stress in Aqueous and Vitreous Humor of Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT04071977,COMPLETED,Diabetic Retinopathy|Oxidative Stress|Diabetes,DRUG: Combined antioxidant therapy|OTHER: Placebo,"Compare levels of markers of oxidative stress in aqueous humor and vitreous humor, The investigators will measure oxidative stress markers in aqueous and vitreous humor taken during vitrectomy procedure and compare such results between both intervention groups., 1 measure will be made after 2 months of intervention|Changes in concentration of plasma 8-isoprostanes after intervention., The investigators will consider changes presented in plasma concentrations of 8-isoprostanes from baseline to the end of the intervention. The investigators expect to find a decrease in 8-isoprostanes concentrations in the supplemented group., 2 measures will be made, 1 at baseline, and one after completion of 2 months of intervention|Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline., The investigators will consider changes presented in plasma concentrations of total antioxidant capacity (TAC) from baseline to the end of the intervention. The investigators expect to find TAC augmentation in the supplemented group., 2 measures will be made, 1 at baseline, and one after completion of 2 months of intervention",University of Guadalajara,40,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2020-03-25
NCT05582577,Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05582577,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,COMBINATION_PRODUCT: Intravitreal bevacizumab injection with subthreshold micropulse laser|DRUG: Intravitreal bevacizumab injection alone,"Change from baseline central macular thickness at 2 months, Change from baseline central macular thickness at 2 months using Optical Coherence Tomography, Change from baseline to 2 months|Change from 2 months central macular thickness at 3 months, Change from 2 months central macular thickness at 3 months using Optical Coherence Tomography, Change from 2 months to 3 months|Change from 3 months central macular thickness at 4 months, Change from 3 months central macular thickness at 4 months using Optical Coherence Tomography, Change from 3 months to 4 months|Change from 4 months central macular thickness at 6 months, Change from 4 months central macular thickness at 6 months using Optical Coherence Tomography, Change from 4 months to 6 months|Change from 6 months central macular thickness at 8 months, Change from 6 months central macular thickness at 8 months using Optical Coherence Tomography, Change from 6 months to 8 months|Change from 8 months central macular thickness at 10 months, Change from 8 months central macular thickness at 10 months using Optical Coherence Tomography, Change from 8 months to 10 months|Change from 10 months central macular thickness at 12 months, Change from 10 months central macular thickness at 12 months using Optical Coherence Tomography, Change from 10 months to 12 months",Shahid Beheshti University of Medical Sciences,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-10-15
NCT02630277,Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN,https://clinicaltrials.gov/study/NCT02630277,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Aflibercept,"Assess ocular and non-ocular adverse events, 12 Months",Valley Retina Institute,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2016-01
NCT02262260,Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME,https://clinicaltrials.gov/study/NCT02262260,COMPLETED,Diabetic Macular Edema,DRUG: Labeled regime arm|DRUG: Wait and Extend regime arm,"Mean Change in ""Best-corrected Visual Acuity"" at Month 12, Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of ETDRS is 0 to 100 letters. A positive average change from baseline of BCVA indicates improvement, 12 months",Novartis Pharmaceuticals,87,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-12-12
NCT03927118,Effect of Dexamethasone Implant on Optic Disc,https://clinicaltrials.gov/study/NCT03927118,COMPLETED,Glaucoma and Ocular Hypertension|Diabetic Macular Edema|Intravenous Drug Usage|Optic Disk Disorders,PROCEDURE: intravitreal dexamethasone implant application,"Peripapillary RNFL thickness measurements, micrometer, six month",Bulent Ecevit University,43,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-02-01
NCT04186702,New Concepts in Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT04186702,COMPLETED,"Diabetes Mellitus, With Complications",PROCEDURE: INTRAVITREAL RANIBIZUMAB INJECTION,"visual acuity letter score, The visual acuity letter score at one-year, one-year follow up|central subfield thickness (CST), the mean CST observed at one-year, one-year follow up",Ain Shams University,150,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-09-10
NCT02005432,PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02005432,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Intravitreal Ranibizumabe|DRUG: panfotocoagulation (PASCAL)|DRUG: panfotocoagulation (PRP) single shoot (ETDRS),"fluorescein angiography leakage area, The primary endpoint for this study is the mean change in the total area of active retinal neovessels, as measured by fluorescein angiography leakage area, in mm2., from baseline to week 48.",University of Sao Paulo,31,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-02
NCT00167518,Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO),https://clinicaltrials.gov/study/NCT00167518,COMPLETED,Diabetic Macular Oedema,DRUG: Triamcinolone acetate,"• Proportion of treated versus untreated eyes with improvement of visual acuity by 5 letters or more on the ETDRS chart at 24 months, no less than 3 months after the most recent treatment episode. An interim analysis of the primary and secondary outcome|• Incidence of moderate or severe adverse effects related to treatment",University of Sydney,70,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-03
NCT03490318,Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03490318,COMPLETED,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,,"Sensitivity of the new pathway (ophthalmic grader pathway) in detecting active DMO/PDR, using the standard care pathway as the reference standard., Sensitivity analysis, 30 months",Belfast Health and Social Care Trust,401,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-10-26
NCT04597918,A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab,https://clinicaltrials.gov/study/NCT04597918,COMPLETED,Diabetic Macular Edema,DRUG: Faricimab,"Percentage of Participants With a ≥2-Step Improvement From Baseline on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in the Study Eye at Week 24, The ETDRS DRSS score of each participant's study eye was assessed using ultra-wide field color fundus photography (UWF-CFP) taken by trained personnel at the study sites. Analysis of the fundus photographs was performed by the central reading center, and the percentage of participants with a ≥2-step improvement from baseline was summarized along with a two-sided 95% Clopper-Pearson exact confidence interval. Baseline was defined as the participant's last observation prior to initiation of study drug., Baseline and Week 24",Hoffmann-La Roche,99,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-25
NCT01422018,Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01422018,UNKNOWN,Diabetes Complications,DRUG: Avastin (bevacizumab),"Changes in best-corrected visual acuity (BCVA), ETDRS BCVA will be measured after 6 6 serial IVB., from month 0 to month 6 in monthly schedule (upto 6 months)",Seoul St. Mary's Hospital,10,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-08
NCT02530918,Study of DS-7080a for the Treatment of Macular Degeneration,https://clinicaltrials.gov/study/NCT02530918,COMPLETED,Neovascular Age-Related Macular Degeneration|Diabetic Macular Edema,DRUG: DS-7080a|DRUG: Ranibizumab,"Number of participants experiencing any treatment-emergent adverse event (TEAE), Treatment-emergent AEs (TEAEs) are defined as those adverse events (AEs) that were new or got worse between the start of study treatment and the end of the follow-up period., 16 weeks|Best Corrected Visual Acuity (BCVA) score, Visual acuity of both eyes will be assessed at all study visits using the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. The patient starts are the top of the chart and begins to read down the chart. The patient reads down the chart until he or she reaches a row where a minimum of three letters on a line cannot be read. The patient is scored by how many letters could be correctly identified. Added to the score for the last row where the participant could read all five letters correctly are scores for each additional letter that could be read correctly in the next row. This is the BCVA score. A higher score means better visual acuity (sharpness of vision)., 12 weeks","Daiichi Sankyo, Inc.",56,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-07
NCT03437018,MONITORING OF MODERATE DIABETIC RETINOPATHY BY TELE-EXPERTISE,https://clinicaltrials.gov/study/NCT03437018,COMPLETED,Diabetic Retinopathy,OTHER: moderate diabetic retinopathy follow-up by tele-expertise,"classification of diabetic retinopathy (DR), DR is classified in 3 stages : moderate non proliferative DR, severe non proliferative DR, and proliferative DR, 1 month",Centre Hospitalier Sud Francilien,97,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-10-10
NCT04505618,Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease,https://clinicaltrials.gov/study/NCT04505618,RECRUITING,"Diabetic Retinopathy|Retinal Vein Occlusion|Hypertension,Essential|Retinal Vascular Disorder",DEVICE: Swept-Source OCT Angiography|DEVICE: Spectral-Domain OCT Angiography|DEVICE: Fundus Imaging|DEVICE: Axial Length Measurement Device,"Correlation of Imaging, Correlation of diagnostic imaging findings (vessel skeleton density) from OCT based images with disease stage, 5 years",Johns Hopkins University,1050,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2019-10-01
NCT02328118,25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China,https://clinicaltrials.gov/study/NCT02328118,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: Ranibizumab|DRUG: Triamcinolone Acetonide,"composite outcome including amotio retinae,vitreous hemorrhage within 12 months after vitrectomy, 12 months after the last subject accepts vitrectomy",JUNYAN ZHANG,120,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-02
NCT00229918,PST/Laser v. Laser Alone for CSME,https://clinicaltrials.gov/study/NCT00229918,UNKNOWN,Diabetic Retinopathy,DRUG: triamcinolone acetonide,Vision loss|Vision gain|Central macular thickness,Edward Hines Jr. VA Hospital,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2005-09
NCT01589718,"A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT01589718,WITHDRAWN,Proliferative Diabetic Retinopathy,DRUG: Macugen|DRUG: Sham,"Tractional Retinal Detachment Repair, Overall score of perceived improvement during surgery as determined by a surgeon's subjective questionnaire., 6 months",Greater Houston Retina Research,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2012-04
NCT01253694,Ranibizumab as a Rescue Therapy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01253694,WITHDRAWN,Diabetic Macular Edema,DRUG: injection of 0.5 mg of Intravitreal Ranibizumab,"Proportion of subjects with resolution of diabetic macular edema compared to baseline as determined by mean foveal thickness on Spectralis < 300 microns., 6 months",New England Retina Associates,0,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-03
NCT03783832,Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography,https://clinicaltrials.gov/study/NCT03783832,UNKNOWN,Diabetic Macular Edema,OTHER: OCT ANGIOGRAPHY DATA,"Quantitative data from OCT angiography, The macular perfusion measurement with Foveal Avascular Zone assessment (area in mm2, boundary in mm, circularity in %) measured by OCT angiography, 1 Year|Quantitative data from OCT angiography, The perfusion density assessment (%) measured by OCT angiography, 1 Year|Quantitative data from OCT angiography, The vascular density assessment (%) measured by OCT angiography, 1 Year",Aquitania Opthalmologica,48,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-06-19
NCT05852132,Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy,https://clinicaltrials.gov/study/NCT05852132,NOT_YET_RECRUITING,Non Proliferative Diabetic Retinopathy(NPDR),PROCEDURE: pars plana vitrectomy(PPV)|PROCEDURE: Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)|PROCEDURE: Panretinal photocoagulation(PRP),"Incidence of proliferative diabetic retinopathy (PDR), fluorescence fundus angiography and fundus photos are used to evaluate the fundus vessels., 24months postoperatively",Fei Gao,249,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-05-01
NCT01571232,Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01571232,COMPLETED,Diabetic Macular Edema|Non-proliferative Diabetic Retinopathy|Proliferative Diabetic Retinopathy,DRUG: dexamethasone intravitreal implant|DRUG: intravitreal bevacizumab,"The Change in Visual Acuity (Number of ETDRS Letters)., The measure the change in ETDRS letters for each treatment group from baseline to 6 months., 6 months|The Change in Central Foveal Thickness (Microns on High Resolution OCT)., The measure the change in central foveal thickness for each treatment group from baseline to 6 months., 6 months",Retina Macula Institute,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-04
NCT03680794,Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies,https://clinicaltrials.gov/study/NCT03680794,RECRUITING,Diabetic Retinopathy|Retinal Vein Occlusion,OTHER: sampling of ophthalmic liquid,"sCD160 concentration in the vitreous humor, ELISA test, Day 0|sCD160 concentration in the aqueous humor, ELISA test, Day 0",CHU de Reims,120,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER,2018-06-27
NCT02587741,Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens,https://clinicaltrials.gov/study/NCT02587741,RECRUITING,Diabetic Retinopathy,DRUG: Metformin|DRUG: Lantus|DRUG: Novomix30,"The incidence of diabetic retinopathy, 5-year incidence rate of diabetic retinopathy（%）, 5years","Third Affiliated Hospital, Sun Yat-Sen University",600,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2015-07
NCT01069341,Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery,https://clinicaltrials.gov/study/NCT01069341,COMPLETED,Rubeosis Iridis|Proliferative Diabetic Retinopathy,DRUG: Ranibizumab,"Adverse Event (AE), Incidence and severity of AEs that were cataract surgery related (for instance, hyphema and vitreous hemorrhage) and AEs that occurred during the treatment of proliferative diabetic retinopathy (PDR)., first 12 months","Bhagat, Neelakshi, M.D., M.P.H.",4,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-07
NCT00840541,Phenotyping Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00840541,COMPLETED,Diabetic Retinopathy,,"CSME, 1 year",Association for Innovation and Biomedical Research on Light and Image,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-01
NCT05063734,A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.,https://clinicaltrials.gov/study/NCT05063734,TERMINATED,Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,DRUG: THR-687 dose level 1|DRUG: THR-687 dose level 2|DRUG: THR-687 selected dose level|DRUG: Aflibercept,"Change From Baseline in BCVA ETDRS Letter Score, at Month 3, in Treatment-naïve Subjects in Part B of the Study, At Month 3",Oxurion,16,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-08-27
NCT02866734,Diabetic Retinopathy Screening in Private Practice,https://clinicaltrials.gov/study/NCT02866734,COMPLETED,Diabetic Retinopathy,OTHER: Free screening group|OTHER: Pay screening group ($150)|OTHER: Pay screening group ($300),"The overall, & at different fee level, uptake (as a percentage of participants) of screening from those at-risk patients who attend private GP's, one year",The University of Hong Kong,238,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: HEALTH_SERVICES_RESEARCH,2016-09-01
NCT02645734,The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02645734,UNKNOWN,Diabetic Macular Edema,DRUG: bevacizumab|DRUG: ziv-aflibercept 1.25 mg|DRUG: ziv-aflibercept 2.5mg,"visual acuity, until 6 month",Shahid Beheshti University of Medical Sciences,133,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",
NCT04805541,Assessment of EyeCheckup as an Automated Diabetic Retinopathy Screening Tool,https://clinicaltrials.gov/study/NCT04805541,RECRUITING,Diabetic Retinopathy|Diabetic Eye Problems|Diabetic Macular Edema,PROCEDURE: Color fundus photography|DRUG: Mydriatic Agent|DEVICE: Diabetic retinopathy screening,"Number of subject eyes whose EyeCheckup results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME)., The performance of EyeCheckup will be evaluated using sensitivity and specificity measures., 1 visit (1 day)|Number of subject eyes whose EyeCheckup results match the reading center grading for identifying vision threatening diabetic eye disease (severe NPDR or PDR or surrogate markers for CSME)., The performance of EyeCheckup will be evaluated using sensitivity and specificity measures., 1 visit (1 day)",URAL Telekomunikasyon San. Trade Inc.,900,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-01
NCT00502541,Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00502541,COMPLETED,Diabetic Macular Edema,DRUG: fluocinolone acetonide|PROCEDURE: Standard of Care,"A change from baseline in visual acuity using ETDRS charts • Humphrey Visual Field Mean Defect (24-2) • Masked reading of the size of the area of retinal thickening on color photographs and OCT, where available, and of severity of fluorescein leakage, at 26 weeks and yearly through completion of the study",Bausch & Lomb Incorporated,196,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2001-09
NCT04254536,Changes in Optical Coherence Tomography Leakage Mapping in Diabetic Macular Edema After Conbercept Treatment,https://clinicaltrials.gov/study/NCT04254536,UNKNOWN,Diabetic Macular Edema,,"central retinal thickness（CRT）, CRT will be measured by OCT software and the changes before treatment, 1 week after treatment and 1 month after treatment will be compared, 2020-12|best corrected visual acurity(BCVA), Compare the changes of BCVA before treatment, 1 week after treatment and 1 month after treatment, 2020-12|low optical ratio(LOR), The image will be processed by OCT leakage mapping software, and the changes of LOR will compared before treatment, 1 week after treatment and 1 month after treatment, 2020-12",Renmin Hospital of Wuhan University,35,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-01
NCT02299336,Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial,https://clinicaltrials.gov/study/NCT02299336,COMPLETED,Diabetic Macular Edema,DRUG: Aflibercept|PROCEDURE: Focal Laser,"Mean Number of Intravitreal Aflibercept Injections for Subjects Who Were Enrolled and Completed the 3-year VISTA DME (VGFT-OD-1009) Trial, Measured by evaluating mean number of injections required for subjects who were enrolled and completed the 3-year VISTA DME (VGFT-OD-1009) trial, Week 104",Greater Houston Retina Research,60,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-11-24
NCT05276778,Diabetic Retinopathy Screening in General Practice,https://clinicaltrials.gov/study/NCT05276778,ENROLLING_BY_INVITATION,Diabetic Retinopathy|Type2 Diabetes,DIAGNOSTIC_TEST: Diabetic Retinopathy Screening,"Patients' acceptance of diabetic retinopathy screenings in general practice, Questionnaire, 1 day (the questionnarie is fufilled one time after the retinopaty screening in general practice)",Aalborg University,300,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-02-28
NCT00336323,A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin),https://clinicaltrials.gov/study/NCT00336323,COMPLETED,Diabetic Retinopathy,PROCEDURE: Laser Photocoagulation|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab|DRUG: Bevacizumab,"Change in Central Subfield Retinal Thickness From Baseline Over All Study Visits, Change in central subfield retinal thickness from baseline measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. The OCT scans were sent to the DRCR.net Reading Center for grading. Negative changes represent a decrease in retinal thickening., Baseline to 3,6,9, and 12 weeks|Percentage of Participants With <250 Microns or ≥ 50% Reduction in Retinal Thickening From Baseline Over All Study Visits, Central subfield retinal thickness measured on Optical Coherence Tomography (OCT). OCT images were obtained at each visit following pupil dilation by a certified operator using the OCT3 machine (Carl Zeiss Meditec Inc., Dublin, CA). Scans were 6 mm length and included the 6 radial line pattern for quantitative measures and the cross hair pattern (6-12 to 9-3 o'clock) for qualitative assessment of retinal morphology. The OCT scans were sent to the DRCR.net Reading Center for grading., Baseline to 3,6,9, and 12 Weeks",Jaeb Center for Health Research,121,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2006-06
NCT00231023,Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00231023,COMPLETED,Diabetic Retinopathy,DRUG: Peribulbar Triamcinolone Acetonide,,National Eye Institute (NEI),10,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2005-09
NCT04516278,A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders,https://clinicaltrials.gov/study/NCT04516278,COMPLETED,Age-related Macular Degeneration|Neovascular Age-related Macular Degeneration|Wet Macular Degeneration|BRVO - Branch Retinal Vein Occlusion|Diabetic Macular Edema,BIOLOGICAL: bevacizumab,"Frequency and incidence of treatment-emergent adverse events, 3 months","Outlook Therapeutics, Inc.",195,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-01
NCT03533478,Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema,https://clinicaltrials.gov/study/NCT03533478,COMPLETED,Diabetic Macular Edema,DIETARY_SUPPLEMENT: Oral treatment Alzer y Diamel|DIETARY_SUPPLEMENT: Placebo,"Macular retinal thickness, macular retinal measure, 1 year",Catalysis SL,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION",2015-03-01
NCT00970723,High Blood Pressure and Sleep Apnea in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00970723,COMPLETED,Diabetic Retinopathy,BEHAVIORAL: high blood pressure treatment|BEHAVIORAL: sleep apnea treatment|BEHAVIORAL: diabetic macular edema treatment,"The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye., M13",Assistance Publique - Hôpitaux de Paris,86,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2009-09
NCT01042678,Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01042678,TERMINATED,Diabetic Macular Edema,BIOLOGICAL: MP0112,"Number of Participants With Adverse Events as a Measure of Safety and Tolerability, Safety and tolerability was assessed by vital signs, clinical laboratory evaluations, ophthalmological examinations, intraocular pressure, the presence of anti-drug antibodies and the collection of adverse events. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events., 16 weeks",Allergan,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-02
NCT03666923,A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT03666923,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Diabetic Macular Edema,DRUG: THR-687 dose level 1|DRUG: THR-687 dose level 2|DRUG: THR-687 dose level 3,"Incidence of dose-limiting toxicities up to the Day 14 visit, From Day 0 up to Day 14",ThromboGenics,12,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2018-09-17
NCT03458923,Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.,https://clinicaltrials.gov/study/NCT03458923,UNKNOWN,Diabetic Macular Edema,DRUG: Diclofenac Sodium 0.1 ml containing 500µg|DRUG: Ranibizumab 0.5 mg Solution for Injection,"Change in best corrected visual acuity, Measuring the best corrected visual acuity, 3 months of follow up|Change in central macular thickness, Measuring the change in central macular thickness using Optical Coherence Tomography, 3 months of follow up",Cairo University,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-01
NCT02388984,Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02388984,UNKNOWN,Non-proliferative Diabetic Retinopathy,DRUG: Compound danshen dripping pills|DRUG: Placebo,"The total effective rate of Fundus changes, the severity of diabetic retinopathy change from baseline at the end of week 24 compared to placebo, 24weeks","Tasly Pharmaceuticals, Inc.",480,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-05
NCT00403884,Selective RPE Laser Treatment (SRT) for Various Macular Diseases,https://clinicaltrials.gov/study/NCT00403884,UNKNOWN,Age-Related Macular Degeneration|Diabetic Maculopathy|Central Serous Chorioretinopathy,PROCEDURE: Selective RPE laser treatment,"Visual acuity, up to 2 years",University of Regensburg,60,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2004-10
NCT00767884,Effect of Panretinal Photocoagulation on Optic Nerve Head Topography,https://clinicaltrials.gov/study/NCT00767884,TERMINATED,Diabetic Retinopathy,,"Changes in optic nerve head topography before and after panretinal photocoagulation, Compare changes in optic nerve head topography before and after panretinal photocoagulation (PRP), 3 years",University of Nebraska,13,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-10-29
NCT04829084,Augmenting Referral Pathway to Improve Uptake of Retinal Services by Diabetic Patients,https://clinicaltrials.gov/study/NCT04829084,COMPLETED,Diabetic Retinopathy,BEHAVIORAL: Pre-post educational intervention,"Increased number of DR patients at REMEH for eye screening, The proposed result of the study is the proportional change in number of patients availing retinal services will be calculated and to find out proportional increase in number of diabetes screening from the baseline., 4 months",Seva Foundation,19,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2021-02-26
NCT03240458,Screening For Diabetic Macular Edema Among Diabetic Patients Using Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT03240458,UNKNOWN,Diabetic Macular Edema,DEVICE: Optical Coherence Tomography,"The prevalence of diabetic macular edema in diabetic patients, The prevalence of diabetic macular edema in diabetic patients using optical coherence tomography ., 5 minutes",Assiut University,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-10
NCT04697758,Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04697758,COMPLETED,Diabetic Macular Edema (DME),DRUG: AXT107 0.1 mg|DRUG: AXT107 0.25 mg|DRUG: AXT107 0.5 mg,"Safety as Assessed by Incidence of Adverse Events (AEs), Incidence of ocular (study eye) and systemic AEs, Screening to Week 48","AsclepiX Therapeutics, Inc.",6,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2020-12-10
NCT02050828,"The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT02050828,COMPLETED,Diabetic Macular Edema (DME),DRUG: AKB-9778|DRUG: ranibizumab|DRUG: Placebo|DRUG: Sham,"Mean change from baseline in spectral domain optical coherence tomography (sdOCT)-measured central subfield thickness (CST), Month 3",Aerpio Therapeutics,144,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-01
NCT03835884,A Study Assessing AR-13503 Implant in Subjects With nAMD or DME,https://clinicaltrials.gov/study/NCT03835884,COMPLETED,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,DRUG: AR-13503 Implant 10.6 Dose|DRUG: AR-13503 Implant 21.2 Dose|DRUG: AR-13503 42.4 Dose|DRUG: AR-13503 63.6 Dose,"Number of ocular and non-ocular TEAEs, Number of ocular and non-ocular treatment-emergent adverse events (TEAEs), summarized at the subject level by system organ class and preferred term, and also by severity and relatedness to treatment., 24 weeks",Aerie Pharmaceuticals,18,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2019-06-24
NCT05681884,Safety and Efficacy of Faricimab in Patients With NPDR,https://clinicaltrials.gov/study/NCT05681884,RECRUITING,Non-Proliferative Diabetic Retinopathy,DRUG: Faricimab,"Primary Objective, Analyze the change in the area of retinal non-perfusion (RNP) within the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) and optical coherence tomography-angiography (OCT -A) within eyes that have NPDR., 48 weeks|Primary Objective, Analyze the change in the area of retinal non-perfusion (RNP) outside the macula over 48 weeks using ultrawide-field fluorescein angiography (UWFA) and optical coherence tomography-angiography (OCT -A) within eyes that have NPDR., 48 weeks",Greater Houston Retina Research,150,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-05-16
NCT01976923,Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01976923,COMPLETED,Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy,DRUG: Intravitreal bevacizumab|PROCEDURE: Small-gauge pars plana vitrectomy,"Intraoperative bleeding, 12 months|Total surgical time, 12 months|Post-operative vitreous hemorrhage, Early (\<1 month) and late (≥ 1 month) post-operative vitreous hemorrhage (VH) (Yes or No), 12 months|Visual acuity change, Mean change in best-corrected visual acuity (BCVA) at 12 months, 12 months","J. Fernando Arevalo, MD FACS",224,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2013-11
NCT02486484,Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection,https://clinicaltrials.gov/study/NCT02486484,UNKNOWN,Neovascularization|Macular Degeneration|Diabetic Retinopathy|Retinal Vein Occlusion|Choroidal Neovascularization|Retinal Neovascularization|Recurrent Pterygium|Cystoid Macular Edema,DRUG: ziv-aflibercept,"vision before and after ziv-aflibercept, EDTRS, 24 months",Rafic Hariri University Hospital,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-03
NCT00758628,"Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.",https://clinicaltrials.gov/study/NCT00758628,COMPLETED,Diabetic Macular Edema,DRUG: Bromefenac|DRUG: Blink,"Macular/Foveal Thickness (on OCT) v/s Control Arm, compared to baseline evaluation., 3 months","Bp Consulting, Inc",50,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-08
NCT03899623,Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application,https://clinicaltrials.gov/study/NCT03899623,UNKNOWN,Diabete Mellitus|Diabetic Retinopathy,,"The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence（AI） system compared with reference standard (ophthalmologist)., Sensitivity: the percentage of diabetic retinopathy（DR） patients who are correctly identified as having the condition by AI. Sensitivity=True positive/(True positive+False negative). Specificity: the percentage of healthy people who are correctly identified as not having the condition by AI. Specificity=True negative /(True negative +False positive). The ROC curve was plotted with true positive rate (sensitivity) as the ordinate and false positive rate (1-specificity) as the abscissa., It will take 15~20min for each subject to take the exams.","Zhongshan Ophthalmic Center, Sun Yat-sen University",3000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-04-23
NCT00563628,Changes in Macular Thickness After Patterns Scan Laser,https://clinicaltrials.gov/study/NCT00563628,UNKNOWN,Non Proliferative Diabetic Retinopathy.|Proliferative Diabetic Retinopathy.,DEVICE: Panretinal photocoagulation with PASCAL system,"Retinal thickness after treatment, 12 weeks",Asociación para Evitar la Ceguera en México,8,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-10
NCT05368623,"Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device",https://clinicaltrials.gov/study/NCT05368623,COMPLETED,Diabetes|Diabetic Retinopathy|Diabetic Macular Edema|Diabetic Eye Problems,DIAGNOSTIC_TEST: Color fundus photograph|DIAGNOSTIC_TEST: Optical Coherence Tomography (OCT) of the retina|DRUG: Mydriatic Agent,"To determine the sensitivity and specificity of RETINA-AI Galaxy v2.0 for diabetic retinopathy screening in the primary care setting., 1 visit (1 day)","RETINA-AI Health, Inc.",1100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-11-03
NCT00005784,Evaluation and Treatment of Patients With Retinal Disease,https://clinicaltrials.gov/study/NCT00005784,COMPLETED,Retinal Disease,,,National Eye Institute (NEI),1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2000-05-31
NCT04537884,Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration,https://clinicaltrials.gov/study/NCT04537884,COMPLETED,Diabetic Macular Edema|Neovascular Age-related Macular Degeneration,DRUG: UBX1325,"Ocular and systemic safety and tolerability of a single intravitreal injection of UBX1325 evaluated by the incidence of dose limiting toxicities (DLTs) and treatment emergent adverse events (TEAEs), 24 weeks","Unity Biotechnology, Inc.",19,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-10-08
NCT04782128,Evaluation of RC28-E Injection in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04782128,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,BIOLOGICAL: RC28-E injection,"The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52, The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24, 52 from baseline, At Week 24, 52","RemeGen Co., Ltd.",120,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2021-05-25
NCT03297684,Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection,https://clinicaltrials.gov/study/NCT03297684,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,DRUG: Aflibercept Injection [Eylea],"Measure biomarkers in aqueous humor from individuals with DME, Identify temporal effects of treatment with intravitreal afflibercept, 2 years",Advanced Eye Research Associates,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-04-11
NCT03660384,Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy,https://clinicaltrials.gov/study/NCT03660384,COMPLETED,Diabetic Retinopathy|Retinal Detachment,PROCEDURE: PPV/SO|PROCEDURE: PPV/C3F8,"BCVA, best-corrected visual acuity, 6 months",Rush Eye Associates,302,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2018-09-04
NCT04362241,DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery,https://clinicaltrials.gov/study/NCT04362241,UNKNOWN,"Retinopathy, Diabetic",DRUG: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE],"To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure., Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 7 on Optical Coherence Tomography at Day 7 by a masked grader., 7 days|To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure., Percentage of eyes that developed post-surgical PME in each group measured on optical coherence tomography at Day 30 by a masked grader., 30 days|To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure., Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 60 and on optical coherence tomography at Day 60 by a masked grader., 60 days",Ophthalmic Consultants of the Capital Region,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-08-07
NCT03686436,Vitreomacular Interface Abnormalities in Diabetic Retinopathy Using OCT,https://clinicaltrials.gov/study/NCT03686436,UNKNOWN,on Vitreomacular Interface Abnormalities in Diabetic Retinopathy,DEVICE: ocular coherence tomography,"measuring visual acuity by snellen chart, measuring visual acuity by snellen chart full ophthalmic examination dilating the pupil by mydriatic 1-tropicamide1%drop phenylephrine 2.5%eye drop fundus photography is achived by using TRC 8PLUS TOPCON MEDICAL System,Inc OCT imaging is achived by using Spectral domain OCT (hiedelbrge), two hours",Assiut University,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-01
NCT05248334,A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05248334,RECRUITING,Diabetic Retinopathy|Postoperative Recurrent Vitreous Hemorrhage|Pars Plana Vitrectomy|Ranibizumab,DRUG: Ranibizumab Injection|PROCEDURE: PPV,"The cleaning time of postoperative recurrent vitreous hemorrhage, Record VH by B scan and funds examination, two months|Visual acuity, ETDRS Alphabet Chart, six moths",Tianjin Medical University Eye Hospital,120,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-04-10
NCT03481634,Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03481634,COMPLETED,Diabetic Macular Edema,DRUG: Brolucizumab|DRUG: Aflibercept,"Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52, BCVA was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts.

Visual Function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 78 to 23 (approximate Snellen equivalent of 20/32 to 20/320) in the study eye were included.

Min and max possible scores are 0-100 respectively. A higher score represents better visual functioning.

This endpoint was analyzed via the pairwise ANOVA method where the 2 dose groups of Brolucizumab are compared to Aflibercept., Baseline, Week 52",Novartis Pharmaceuticals,566,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-07-23
NCT00600236,HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population,https://clinicaltrials.gov/study/NCT00600236,COMPLETED,Diabetes Mellitus Type 2|Proliferative Diabetic Retinopathy,PROCEDURE: blood sample,,Asociación para Evitar la Ceguera en México,300,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: PREVENTION,2004-09
NCT02963441,A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02963441,COMPLETED,Diabetic Retinopathy,DEVICE: LumineticsCore (formerly IDX-DR),"Sensitivity Corrected for Enrichment, Sensitivity corrected for enrichment using logistic regression, Day 1|Specificity Corrected for Enrichment, Specificity corrected for enrichment using logistic regression, Day 1|Observed Sensitivity, The sensitivity observed without adjustment by logistic regression, Day 1|Observed Specificity, The specificity observed without adjustment by logistic regression, Day 1|Sufficient vs. Insufficient Image Quality Output From IDx-DR, Image-ability, defined as the percentage of participants with a completed reading center grading and a disease level output from the investigational device (IDx-DR), Day 1","Digital Diagnostics, Inc.",900,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-01
NCT04490941,A Trial on Ophthalmologist-delivered Health Education on Top of Routine Community Care,https://clinicaltrials.gov/study/NCT04490941,RECRUITING,"Diabetes Mellitus, Type 2",OTHER: Ophthalmologist-delivered health education|OTHER: Usual care,"Glycated haemoglobin (HbA1c), Proportion of participants who had optimal control of HbA1c level at 12 months, 12-months follow-up","Zhongshan Ophthalmic Center, Sun Yat-sen University",652,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2020-07-22
NCT05132660,Treating Early Stage Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05132660,ENROLLING_BY_INVITATION,Diabetic Retinopathy,DRUG: Sinemet CR|DRUG: placebo,"Electroretinogram, Electrical activity of the retina measured by non-invasive electrodes on the face to a flash to light. A waveform will be recorded and timing of the waves measured in milliseconds, 24 months",VA Office of Research and Development,244,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-07-01
NCT05990829,Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial,https://clinicaltrials.gov/study/NCT05990829,NOT_YET_RECRUITING,Diabetic Macular Edema|Pars Plana Vitrectomy|Dexamethasone Intravitreal Implant|Intraoperative Optical Coherence Tomography,DRUG: Ozurdex|DRUG: Aflibercept,"Average change in central foveal thickness (CFT), Three-dimensional swept source optical coherence tomography (SS-OCT), 1, 3, 6 month postoperatively",Tianjin Medical University Eye Hospital,64,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2023-10-01
NCT04380077,Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Diabetics,https://clinicaltrials.gov/study/NCT04380077,ACTIVE_NOT_RECRUITING,Proliferative Diabetic Retinopathy,PROCEDURE: vitrectomy with sulfur hexafluoride gas|PROCEDURE: vitrectomy with balanced salt solution,"postoperative vitreous hemorrhage rate, incidence of postoperative vitreous hemorrhage between cohorts, 6 months",Rush Eye Associates,150,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2020-05-15
NCT01821677,A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug) in the Treatment of Diabetic Macular Edema.,https://clinicaltrials.gov/study/NCT01821677,COMPLETED,Diabetic Macular Edema,DRUG: Danazol Capsules|DRUG: Placebo,"Change in Best Corrected Visual Acuity (BCVA), Change from baseline score to the week 12 score in the number of letters read on an eye chart in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) of the Intent to Treat (ITT) population of all treated subjects. A positive number indicates more letters could be read., Determined at Baseline and Week 12",Ampio Pharmaceuticals. Inc.,354,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-02-26
NCT00789477,DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact,https://clinicaltrials.gov/study/NCT00789477,COMPLETED,Diabetic Macular Edema,PROCEDURE: Laser Photocoagulation|DRUG: Intravitreal Aflibercept Injection,"Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF), Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Measurements were taken at every study visit.

Missing values were imputed with post-baseline values during on-treatment period by using last observation carried forward (LOCF)., At week 24",Regeneron Pharmaceuticals,221,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-12
NCT00252694,DIabetic Retinopathy Candesartan Trials,https://clinicaltrials.gov/study/NCT00252694,COMPLETED,Type 2 Diabetes,DRUG: candesartan,"Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale, 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments., From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.",AstraZeneca,4717,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2001-08
NCT06173232,Assessment of Retinal Fundus Imaging Camera,https://clinicaltrials.gov/study/NCT06173232,RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema,DEVICE: Camera Imaging,"Primary Objective, Agreement of AI device results (mtmDR(+), mtmDR(-)) obtained from fundus cameras, 1 Day","Digital Diagnostics, Inc.",100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-11-20
NCT02348918,Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02348918,COMPLETED,Diabetic Macular Edema,DRUG: Luminate 1.0mg|DRUG: Luminate 2.0mg|DRUG: Luminate 3.0mg|DRUG: Avastin|DRUG: Luminate 0.5mg,"Change in BCVA at Week 24, Primary efficacy outcome is BCVA changes at Week 24 as compared to baseline, Value of 24 Weeks minus baseline value","Allegro Ophthalmics, LLC",218,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2014-10-13
NCT00529594,Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation,https://clinicaltrials.gov/study/NCT00529594,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: placebo (Control Group)|DRUG: Etoricoxib (Treatment Group),"The group taking the etoricoxib feel less pain then the group taking placebo, After each laser session",University of Sao Paulo,44,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-08
NCT02420132,Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®),https://clinicaltrials.gov/study/NCT02420132,COMPLETED,Macular Edema|Macular Degeneration,OTHER: Ranibizumab,"Number of ""Clicks"" on Study Information Advertisements on Participant Advocacy, Digital Media, and Professional Society Websites (Main Study Only), Baseline up to 6 months|Percentage of Participants Participating at Specified Milestones in the Recruitment/Enrollment Process (Main Study Only), Baseline up to 6 months|Percentage of Participants Performing Self-Testing Two Times per Week Using the Mobile Medical Application, Baseline up to 6 months|Percentage of Participants Visiting their Ophthalmologist at Least Every 8 Weeks (Main Study Only), Baseline up to 6 months|Percentage of Office Visits for which Visual Acuity Data Were Provided to Scripps Translational Science Institute (STSI) (Main Study Only), Baseline up to 6 months|Percentage of Office Visits for which OCT Data Were Provided to STSI (Main Study Only), Baseline up to 6 months|Degree of Correlation Between mVT Test Results and Certified ETDRS Protocol Visual Acuity (Traditional Substudy Only), Baseline up to 6 months|Degree of Correlation between mVT Test Results and OCT Characteristics (Traditional Substudy Only), Baseline up to 6 months",Hoffmann-La Roche,47,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-04-20
NCT04288232,Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan,https://clinicaltrials.gov/study/NCT04288232,COMPLETED,Center-involved Diabetic Macular Edema,DRUG: Aflibercept Injection [Eylea],"Mean change of best corrected visual acuity (BCVA) from baseline to week 52, BCVA is measured by ETDRS chart, baseline to week 52","Taipei Veterans General Hospital, Taiwan",45,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08-31
NCT01549132,Retinal Oximtery Following Treatment for Diabetic Maculopathy,https://clinicaltrials.gov/study/NCT01549132,COMPLETED,Diabetic Maculopathy,,"Retinal oximetry differences in patients with sight threatening diabetic macular oedema after treatment, Does retinal oxygen levels in small blood vessels as measured by spectral imaging photography using the oxymap device at the centre of the retina (macula) differ in diabetic retinopathy in sight threatening disease?, 1 year",East Kent Hospitals University NHS Foundation Trust,45,OBSERVATIONAL,Observational Model: |Time Perspective: p,2012-04
NCT00101764,Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders,https://clinicaltrials.gov/study/NCT00101764,COMPLETED,Macular Degeneration|Retinal Vein Occlusion|Diabetic Retinopathy,DRUG: Triamcinolone Acetonide,,National Eye Institute (NEI),120,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,2005-01-05
NCT01189461,Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01189461,COMPLETED,Anti- VGF Inhibitor|Diabetic Macular Edema|Diabetic Retinopathy,DRUG: pegaptanib sodium,"Incidence of Ocular and Non-Ocular Adverse Events (AEs), An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Total number of participants who had ocular and non-ocular AEs was reported., Baseline up to 30 days after last dose|Mean Total Number of Injections, Mean number of injections per participant was calculated as (number of injection administered per participant - 1)/duration of treatment. Mean number of injections administered for total participants was summarized., Baseline up to Week 48 (End of treatment)",Pfizer,46,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01
NCT01201161,Ranibizumab for Diabetic Traction Retinal Detachment,https://clinicaltrials.gov/study/NCT01201161,COMPLETED,Diabetic Retinopathy|Retinal Detachment,DRUG: Ranibizumab|OTHER: Sham injection,"amount of intraoperative intra-ocular bleeding, amount of intra-ocular bleeding that occurred during pars plana vitrectomy, one week",University of Sao Paulo,19,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-12
NCT03866473,A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03866473,COMPLETED,Diabetic Macular Edema,DEVICE: Retilux|DEVICE: Sham Light Device,"Change in Optical Coherence Tomography Central Subfield Thickness From Baseline to 4 Months, Only eyes that completed the 4-month visit were included in calculation of descriptive statistics of optical coherence tomography (OCT) data. For eyes that received alternate DME treatment prior to 4 months (N=3 \[PBM\]; N = 1 \[placebo\]), the last OCT measurements prior to alternative diabetic macular edema (DME) treatment were used in place of the 4-month measurements. All analyses followed the intent-to-treat principle. Multiple imputation (m = 100) was used for missing values of central subfield thickness and retinal volume change, with imputation models that included variables for treatment group, baseline values, and change from baseline at all monthly interim visits up to the primary outcome visit and the randomization stratification factor of recent or planned intravitreous treatment in the non-study eye. Multiple imputation was not performed for center-involved DME given the thresholds are gender and machine specific.

OCT CST change was truncated to the mean ± 3 SD (13 ± 3 × 5, Baseline to 4 months",Jaeb Center for Health Research,135,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-04-10
NCT03397264,A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03397264,COMPLETED,Diabetic Macular Edema,BIOLOGICAL: Aflibercept|BIOLOGICAL: OPT-302|OTHER: Sham intravitreal injection,"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Safety and Tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events and CTC v4.0 (if available, otherwise protocol defined grading were used), Baseline to Week 12|Phase 2a: Response Rate as Defined by Proportion of Participants Receiving Combination of OPT-302 and Aflibercept Achieving at Least a 5-letter Gain in BCVA Compared to Baseline at Week 12 According to ETDRS Criteria, BCVA will be measured according to Early Treatment Diabetic Retinopathy Score (ETDRS) criteria, Baseline to Week 12",Opthea Limited,153,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-01-16
NCT05930561,4D-150 in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05930561,RECRUITING,Diabetic Macular Edema|Diabetic Retinopathy,BIOLOGICAL: 4D-150 IVT|BIOLOGICAL: Aflibercept IVT,"Annualized number of aflibercept injections in the study eye, 52 weeks",4D Molecular Therapeutics,72,INTERVENTIONAL,"Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2023-08-09
NCT02032173,Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase,https://clinicaltrials.gov/study/NCT02032173,TERMINATED,Macular Edema|Macular Degeneration|Diabetes,DRUG: Ranibizumab 0.5mg,"Number of Participants With a Stable BCVA in the Study Eye at 24 Months Compared With BCVA at 6 Months, Best-Corrected Visual Acuity (BCVA) letters were measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement. Best value on the scale 100, worst 0. The number of participants with a stable BCVA (BCVA score at 6 months minus BCVA score at 24 months ≤4 letters) were reported., Month 6 and 24",Novartis Pharmaceuticals,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-05-19
NCT02671864,Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy,https://clinicaltrials.gov/study/NCT02671864,ACTIVE_NOT_RECRUITING,Type 2 Diabetes,OTHER: 1: incretin-based therapy|OTHER: 2: other antidiabetic,"Prevalence of Severe DR at V1 (inclusion), Retinography, at inclusion",Assistance Publique - Hôpitaux de Paris,7200,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2016-04-11
NCT00005761,Blood Factors and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00005761,COMPLETED,Diabetic Retinopathy,,,National Eye Institute (NEI),173,OBSERVATIONAL,Observational Model: |Time Perspective: p,2000-05-23
NCT03811561,A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes,https://clinicaltrials.gov/study/NCT03811561,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2",DRUG: Semaglutide|DRUG: Placebo (semaglutide),"Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression., Percentage of subjects (yes/no)., Year 5",Novo Nordisk A/S,1500,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2019-05-08
NCT00071773,A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00071773,COMPLETED,Diabetic Macular Edema,PROCEDURE: modified-ETDRS photocoagulation|PROCEDURE: Mild Macular Grid photocoagulation,"Change in the central subfield of the ETDRS grid measured by OCT., 1 Year",Jaeb Center for Health Research,263,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2003-07
NCT05543564,Prophylactic PRP in Moderate NPDR,https://clinicaltrials.gov/study/NCT05543564,COMPLETED,Eye Diseases|Diabetes|Diabetic Retinopathy,PROCEDURE: PRP,"BCVA, 3 months",Assiut University,68,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-01
NCT04380064,Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT04380064,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy Visually Threatening,PROCEDURE: ILM Peeling|PROCEDURE: No ILM Peeling,"Postoperative ERM Development, Postoperative Epiretinal Membrane Development, 6 months",Rush Eye Associates,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-05-01
NCT02669953,Aflibercept in Recurrent or Persistent CNV,https://clinicaltrials.gov/study/NCT02669953,RECRUITING,Age Related Macular Degeneration|Intravitreal Injections|Diabetic Macular Edema,DRUG: Aflibercept,"Percent change in Best-Corrected Visual Acuity (BCVA), After one year compared to baseline|Anatomic changes in the macula as assessed with OCT (central retinal thickness, morphologic changes, fundus photos), after one year compared to baseline",Medical University of Vienna,80,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-12
NCT03821753,The Effect of the Glycemic Variability on Macular Retinal Microcirculation and Cognitive Functions in Patient With Type 1 Diabetes,https://clinicaltrials.gov/study/NCT03821753,UNKNOWN,Microvascular Complications|Diabetic Retinopathy|Diabetes|Microangiopathy|Angiography,OTHER: Case|OTHER: Control,"Macular capillary density in the external deep capillary network, Macular capillary density in the external deep capillary network measured by OCT-Angiography (no later than 3 months after inclusion), 3 months",Assistance Publique - Hôpitaux de Paris,120,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-07
NCT03759860,Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03759860,UNKNOWN,Diabetic Macular Edema,COMBINATION_PRODUCT: R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy,"Best Corrected Visual Acuity (BCVA) change in the study group, Compare BCVA change evaluated between the group where Ranibizumab was combined with R:GEN (Selective Retina Therapy) and the group where Ranibizumab monotherapy was applied, 12 months",LUTRONIC Corporation,12,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-01-08
NCT05966753,"Describing Patient With DME, Their Patient Journey and Disease Progression",https://clinicaltrials.gov/study/NCT05966753,COMPLETED,Diabetic Macular Edema,,"Change in visual acuity, From January 2015 to April 2023|Progression to DME in the fellow eye, From January 2015 to April 2023|Initial treatment of DME, From January 2015 to April 2023|Central retinal thickness (CRT), From January 2015 to April 2023",Boehringer Ingelheim,182000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-08-03
NCT00346060,Safety Study in Retinal Transplantation for Dry Age Related Macular Degeneration.,https://clinicaltrials.gov/study/NCT00346060,COMPLETED,Dry Age Related Macular Degeneration.,DEVICE: Retinal transplantation instrument|DEVICE: Fetal tissue.,Snellen|Visual acuity|Microperimetry|Goldmann visual field|Optical coherent tomography|Fluorescein angiography,"Radtke, Norman D., M.D.",10,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,2002-02
NCT04723160,Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph,https://clinicaltrials.gov/study/NCT04723160,COMPLETED,Diabetic Retinopathy|Retinal Vein Occlusion|Retinal Artery Occlusion|Central Serous Chorioretinopathy|Pathologic Myopia|Retinitis Pigmentosa|Epiretinal Membrane|Macular Holes|Nonexudative Age-related Macular Degeneration|Exudative Age Related Macular Degeneration|Suspect Glaucoma|Optic Atrophy|Retinal Detachment,DIAGNOSTIC_TEST: Software assisted imaging diagnosis,"consistent rate of diagnoses, Formula for calculation: consistent rate of diagnoses=number of images with consistent diagnosis/ total number of images × 100%.

Method: the diagnoses from the test group and the control group were compared with diagnoses from the gold standard. For each image, if one or more diagnoses were consistent with those of the gold standard, which means at least one label existed in the intersection of diagnoses from the test group(or the control group)and those from the gold standard, it would be classified as ""image with consistent diagnosis"". Otherwise, it would be classified as ""image without consistent diagnosis"". After above-mentioned steps, the investigators had obtained the number of images with consistent diagnosis in each group. As images with 1-2 labels account for the majority in actual work, the investigators stipulated that each image in both groups could be marked with 3 labels at most in case of invalid improvement in consistent rate owing to multiple selections., through study completion, an average of 1 year",Visionary Intelligence Ltd.,748,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-08-10
NCT05526729,Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection,https://clinicaltrials.gov/study/NCT05526729,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,OTHER: Beovu,"Proportion of patients with adverse events corresponding to each of the safety specifications during the observation period, Proportion of patients with adverse events corresponding to each of the safety specifications during the observation period is going to be collected.

Safety specifications: intraocular inflammation, endophthalmitis, intraocular pressure elevation, retinal detachment and retinal tear, retinal arterial embolic events, non-ocular arterial thromboembolic events, retinal vasculitis and retinal vascular occlusion, Up to 52 weeks|Proportions of patients with adverse events in the eyes on therapy during the observation period, Proportions of patients with adverse events in the eyes on therapy during the observation period is going to be collected, Up to 52 weeks|Proportion of patients with systemic adverse events during the observation period, Proportion of patients with systemic (non-ocular) adverse events during the observation period is going to be collected, Up to 52 weeks",Novartis Pharmaceuticals,205,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-09-02
NCT02221453,Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide,https://clinicaltrials.gov/study/NCT02221453,COMPLETED,Diabetic Macular Edema,DRUG: Triamcinolone Acetonide,"Change in cytokine levels (picograms per mL) between baseline triamcinolone acetonide injection and 3 months, The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1., 3 months after baseline triamcinolone acetonide injection|Change in cytokine levels (picograms per mL) 3 months after 2nd triamcinolone acetonide injection, Note that the 2nd triamcinolone acetonide injection occurs 3 months after baseline injection. The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1., 3 months after 2nd triamcinolone acetonide injection",Unity Health Toronto,3,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-09
NCT00815360,Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion,https://clinicaltrials.gov/study/NCT00815360,COMPLETED,Diabetic Macular Edema,DRUG: intravitreal injection of ranibizumab|PROCEDURE: peripheral laser|DRUG: intravitreal injection of triamcinolone acetonide|PROCEDURE: macular laser,"Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6., 6 months","Retina Associates of Florida, P.A.",22,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-02
NCT01941329,"Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.",https://clinicaltrials.gov/study/NCT01941329,COMPLETED,High Risk Proliferative Diabetic Retinopathy,PROCEDURE: Panretinal Photocoagulation (PRP)|DRUG: Intravitreous injection of ranibizumab,"Regression of neovascularization, Defined as any decrease in the area of neovascularization, 12-month treatment",Association for Innovation and Biomedical Research on Light and Image,94,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2014-04
NCT05386160,Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05386160,UNKNOWN,Mild Non-proliferative Diabetic Retinopathy|Cataract Diabetic|Diabetic Retinopathy,DRUG: Ranibizumab Injection [Lucentis]|DEVICE: Phacoemulsification,"capillary non-perfusion zone of non-proliferative diabetic retinopathy, Patient were divided into two groups, the control group is phacoemulsification surgery group and the intervention group is phacoemulsification surgery combine intravitreal injection of Ranibizumab group. Eye examination including visual acuity, intraocular pressure (IOP), fundus fluoroscopy, macular OCT examination, were taken before cataract surgery. The anterior aqueous humor was extracted before cataract phacoemulsification in the combined operation group, and 0.05 ml of ranibizumab was injected into the vitreous immediately after the operation. The BCVA, IOP and fundus lesions changes were observed in the two groups after operation. Diabetic retinopathy capillary non-perfusion zone were evaluated one year after phacoemulsification surgery., 1 year",Ruijin Hospital,96,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2022-07-01
NCT05099094,VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases,https://clinicaltrials.gov/study/NCT05099094,RECRUITING,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,GENETIC: BD311,"Treatment-related adverse events, Observe and record incidences of AE and SAE related to VEGFA-targeting gene therapy drug BD311 (IDLV expressing VEGFA antibody) administration., At multiple timepoints after infusion up to 12 months.","Shanghai BDgene Co., Ltd.",18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-25
NCT05224102,"A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT05224102,RECRUITING,Diabetic Macular Edema,DRUG: Faricimab,"Main Phase: Change in Best Corrected Visual Acuity (BCVA) from Baseline at Week 56, as Measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at a Starting Distance of 4 Meters, From Baseline to Week 56|Long-Term Extension Phase: Incidence and Severity of Ocular Adverse Events, From Day 1 until end of long-term extension (up to 100 weeks)|Long-Term Extension Phase: Incidence and Severity of Non-Ocular Adverse Events, From Day 1 until end of long-term extension (up to 100 weeks)","Genentech, Inc.",218,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-02-28
NCT01744132,Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes,https://clinicaltrials.gov/study/NCT01744132,COMPLETED,Diabetic Retinopathy|Diabetes Mellitus,BEHAVIORAL: Aim 3: Contract,"All Aims: DFE follow-up adherence rate, In Aim 1 and Aim 2 specifically the influence patients' ethnicity and severity of diabetic retinopathy will be examined with the rate of dilated fundus examine (DFE) follow-up adherence.

In Aim 3, the rate of DFE follow-up adherence will be examined for both patients in the contract and the no contract group., 2 years",Wills Eye,3000,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION,2012-10
NCT05836194,Evaluation of Diabetic Retinopathy Using Ultra-Widefield Fundus Images Compared With Two-Field Fundus Images,https://clinicaltrials.gov/study/NCT05836194,RECRUITING,Retinal Diseases|Diabetic Retinopathy|Diabetes Complications|Diabetes Mellitus|Screening,,"The International Clinical Diabetic Retinopathy Disease Severity Scale within the 2-fields fundus photography and Ultra-Wide field scanning laser ophthalmoscopy (Optomap) imaging and statistical comparison, To compare nonmydriatic 2-fields fundus photographs with nonmydriatic ultra-wide field images for determining diabetic retinopathy(DR) severity. DR severity level agreement will be cross-tabulated, and Kappa value will be calculated., 60 days",Ningbo Eye Hospital,752,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-02-01
NCT01546402,Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01546402,COMPLETED,"Macular Edema, Cystoid|Vision Disorders|Diabetic Macular Edema|Cystoid Macular Edema Following Cataract Surgery|Cataract",DRUG: Dexamethasone Drug delivery system (Ozurdex)|PROCEDURE: Cataract surgery,"Change in the Central Macular Thickness, The primary outcome is the change in the central macular thickness, either an increase or decrease, as measured by optical coherence tomography as compared to the preoperative thickness., Baseline and 6 MONTHS",Postgraduate Institute of Medical Education and Research,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-05
NCT01591902,Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®,https://clinicaltrials.gov/study/NCT01591902,TERMINATED,Diabetic Retinopathy|HIV,DRUG: Tesamorelin|DRUG: Placebo-Control,"Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale., Subjects will undergo an opthamologic examination including fundus photographs at 3 month intervals for duration of 36 months, 3 years",Theratechnologies,129,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2012-06
NCT01441102,Dextromethorphan for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01441102,COMPLETED,Diabetic Macular Edema,DRUG: Dextromethorphan hydrobromide,"Percentage Change in Retinal Thickness in the Study Eye at 6 Months Compared to Baseline, Retinal thickness was assessed by spectral-domain optical coherence tomography (Cirrus HD-OCT; Carl Zeiss Meditec, Dublin, CA), a non-invasive imaging technique that uses long-wavelength light to capture micrometer-resolution cross-sectional images from biological tissue. The participant's eye that met the study eye eligibility criteria was selected as the study eye. For cases in which both eyes met the study eye eligibility criteria, the study eye was selected according to the ""choice of study eye in cases of bilateral disease"" selection criteria outlined in the eligibility criteria. The eye not chosen as the study eye is referred to as the ""fellow eye."", Baseline and 6 months",National Eye Institute (NEI),7,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-08
NCT02309502,Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02309502,WITHDRAWN,Severe Non-proliferative Diabetic Retinopathy,DEVICE: Green Pascal|DEVICE: Yellow Pascal,"prevention on the developing of proliferative diabetic retinopathy (assessed with slitlamp, color fundus, and fluorangiography), assessed with slitlamp, color fundus, and fluorangiography, 12 months",Manchester University NHS Foundation Trust,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2012-10
NCT03912961,The Santa Cruz Diabetic Retinopathy Utilizing Artificial Intelligence Study,https://clinicaltrials.gov/study/NCT03912961,COMPLETED,Diabetic Retinopathy,OTHER: Picture of the retina with a handheld retinal camera,"Number of subjects where the image readout by retina specialists match the readouts by EyeStar AI system for identifying diabetic eye disease, To quantify image analysis performance of the EyeStar AI system paired with Pictor Plus cameras for the detection of referable Diabetic Retinopathy (DR), defined as severe non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), or diabetic macular edema (DME) against adjudicated reads of retinal images by retina specialists, 3 months",Retina Global,1034,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-21
NCT01393873,Progression of Diabetic Retinopathy Post Bariatric Surgery (BS),https://clinicaltrials.gov/study/NCT01393873,TERMINATED,Obesity|Diabetes Mellitus,,"rapid changes in the level of retinopathy, whether rapid changes in the level of retinopathy do or do not occur in the transition period following surgery, where weight loss may be rapid causing improvement in insulin resistance and glycemic control., 12 months",NYU Langone Health,2,OBSERVATIONAL,Observational Model: |Time Perspective: p,2011-07
NCT05491746,Diabetic Retinopathy Tethered Augmented Reality With Eye4 Study,https://clinicaltrials.gov/study/NCT05491746,COMPLETED,Diabetic Retinopathy|Low Vision,DEVICE: Eye4|OTHER: Placebo,"Visual acuity at distance, Visual acuity at distance using Snellen Visual Acuity Chart, Day 1",Eyedaptic,20,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2022-07-01
NCT02392364,Variable Interval Versus Set Interval Aflibercept for DME,https://clinicaltrials.gov/study/NCT02392364,COMPLETED,Cystoid Macular Edema|Diabetic Macular Edema,DRUG: Intravitreal Aflibercept Injection,"BCVA Change, Change in mean BCVA from baseline to week 52, Week 0 to Week 52",California Retina Consultants,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04-15
NCT05112861,A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders,https://clinicaltrials.gov/study/NCT05112861,ACTIVE_NOT_RECRUITING,Age-Related Macular Degeneration|Neovascular Age-related Macular Degeneration|Wet Macular Degeneration|BRVO - Branch Retinal Vein Occlusion|Diabetic Macular Edema,BIOLOGICAL: bevacizumab,"Frequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFS, 3 months","Outlook Therapeutics, Inc.",120,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2021-11-15
NCT00677664,Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation,https://clinicaltrials.gov/study/NCT00677664,UNKNOWN,Diabetic Retinopathy,DRUG: Glatiramer acetate (Copaxone)|DRUG: Mannitol,"Retinal function, one year",Federal University of São Paulo,30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2006-07
NCT03780361,Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT),https://clinicaltrials.gov/study/NCT03780361,UNKNOWN,Diabetic Macular Edema,DRUG: Aflibercept Injection,"Change in the level of sCD14 in the aqueous humor, Change in the level of sCD14 in the aqueous humor measured by ELISA, From baseline to week 20",Hyewon Chung,47,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2019-05-17
NCT04063358,Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery,https://clinicaltrials.gov/study/NCT04063358,UNKNOWN,Diabetic Macular Edema|Cataract,DRUG: Lucentis,"Change in best-corrected visual acuity (BCVA), BCVA is a measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if uncorrected eyesight is 20/200, but patient can see 20/20 with glasses, the BCVA is 20/20., 1 month, 3 months , 6 months and 12 months after cataract surgery|Change in optical coherence tomography (OCT) central subfield (CSF) thickness, Optical coherence tomography (OCT) is an important imaging modality in the evaluation and management of retinal diseases. Change in central subfield (CSF) thickness will be measured and recorded., 24 hours post-operatively, 1 month, 3 months , 6 months and 12 months after cataract surgery",Second Military Medical University,90,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-08-22
NCT04661358,Fenofibrate for Prevention of DR Worsening,https://clinicaltrials.gov/study/NCT04661358,RECRUITING,Diabetic Retinopathy,DRUG: Fenofibrate|OTHER: Placebo,"Worsening of diabetic retinopathy, Defined as

* 2 or more step worsening on Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy severity on fundus photographs.
* Development of neovascularization within the 7-modified ETDRS fields on fluorescein angiography.
* Intraocular procedure undertaken to treat diabetic retinopathy including panretinal photocoagulation, intraocular anti-vascular endothelial growth factor, corticosteroid, or vitrectomy., 6- years",Jaeb Center for Health Research,560,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-03-05
NCT01627977,"Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy",https://clinicaltrials.gov/study/NCT01627977,COMPLETED,Epiretinal Membrane|Macular Hole|Proliferative Diabetic Retinopathy,"OTHER: Dye of Lutein, Zeaxanthin and Brilliant Blue","Visibility of the membrane after injection of the dye, The visibility of the membrane after injection of the dye should be graduated by the physician as Bad, OR Fair, OR Good, OR Very Good, during the surgery",Federal University of São Paulo,18,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SUPPORTIVE_CARE,2012-10
NCT06191094,Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06191094,NOT_YET_RECRUITING,Diabetic Retinopathy|Vitreous Hemorrhage Due to Diabetes Mellitus,DRUG: Faricimab Injection|DRUG: sham treatment,"Rates of post-operative vitreous hemorrhage, Following treatment and surgery, the development of vitreous hemorrhage will be quantified and evaluated., 6 months","University of Colorado, Denver",100,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: SUPPORTIVE_CARE,2024-01
NCT01107132,Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT01107132,UNKNOWN,Type 2 Diabetes Mellitus|Non-Proliferative Diabetic Retinopathy|Diabetic Macular Edema,,,Soroka University Medical Center,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-05
NCT03531294,Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement,https://clinicaltrials.gov/study/NCT03531294,COMPLETED,Diabetic Retinopathy,DRUG: Aflibercept Injection,"Incidence of Adverse Events for diabetic retinopathy subjects who receive intravitreal Aflibercept, Assess the safety of 2 mg intravitreal aflibercept injections (IAI) to achieve and maintain DRSS improvements (2 or more steps) in patients with a baseline DRSS level of 47A to 71A inclusive as determined by reading center determined DRSS gradings on OPTOS fundus photos and leakage index on OPTOS WF-FA, 104 weeks",Greater Houston Retina Research,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2018-05-23
NCT02261194,Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration or Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02261194,COMPLETED,Depression|Age-related Macular Degeneration,BEHAVIORAL: Self-Care Tools,"Change in depressive symptoms, Depressive symptoms will be measured by the PHQ-9, a validated 9 item instrument., Baseline and 8 weeks",Maisonneuve-Rosemont Hospital,80,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-10
NCT00885794,Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT00885794,UNKNOWN,Diabetic Macular Edema,DRUG: Ranibizumab,"Retinal thickness, at 3 months",The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2008-05
NCT02329132,Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02329132,COMPLETED,Diabetic Macular Edema,DRUG: Ranibizumab,"The change of retinal oxygen saturation and consumption from baseline at 6 months, Retinal oximetry will be performed with Oxymap (Oxymap ehf, Reykjavik, Iceland). Briefly, the device simultaneously acquires digital images at two wavelengths and automatically tracks retinal vessels on both images. Retinal vessel oxygen saturation is estimated by spectrophotometric analysis of light reflected from retinal vessels and from the immediately surrounding retina. Oxygen saturation measurements are made on major temporal arteries and veins. Briefly, the first and second degree vessels are used, with the addition of third degree vessels in images where peripapillary haemorrhage prevented analysis close to the optic disc. Vessel segments chosen for analysis are used consistently for consecutive measurements in the same retina. Oxygen saturation measurements will be measured at each visit for 6 months., At 6 months after ranibizumab (Lucentis) treatment.",Kagawa University,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2015-11
NCT04464694,Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04464694,UNKNOWN,Proliferative Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Ranibizumab|OTHER: Sham injection|PROCEDURE: Pars plana vitrectomy,"Early postoperative vitreous haemorrhage, To compare the incidence of the early postoperative vitreous haemorrhage between two arms, From day 1 to week 4 after the vitrectomy","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",142,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2020-09-01
NCT02590094,Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV,https://clinicaltrials.gov/study/NCT02590094,COMPLETED,Diabetic Retinopathy,DRUG: Intravitreal bevacizumab or intravitreal ziv-aflibercept,"Visual Acuity, Change in BCSVA from baseline, 6 months","Panhandle Eye Group, LLP",568,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT",2015-10
NCT03922932,WF and PR OCTA in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03922932,RECRUITING,Diabetic Retinopathy,,"PR-OCTA Measure of Non-Perfusion Areas, Non-perfusion areas of the 3 retinal plexuses and choriocapillaris will be measured in mm2., 3 years|Non-PR-OCTA Measure of Retinal Non-Perfusion Areas, Non-perfusion areas of the 3 retinal plexuses will be measured in mm2., 1 year|Non-PR-OCTA Retinal Neovascularization Areas, Retinal neovascularization areas will be measured in mm2., 1 year|Structural OCT Cyst Volume, Cyst volume will be measured in mm3., 1 year|Structural OCT Retinal Thickening Area, The area of retinal thickening will be measured in mm2., 1 year",Oregon Health and Science University,290,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-08-30
NCT03394573,Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study),https://clinicaltrials.gov/study/NCT03394573,TERMINATED,Diabetic Macular Edema,OTHER: OCT guided treatment arm|OTHER: VA guided treatment arm,"Functional outcomes, Mean change in BCVA from baseline to week 104 (EOS), 24 months","Insel Gruppe AG, University Hospital Bern",110,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-09-16
NCT02816073,Pattern Scanning Laser Pan-retinal Photocoagulation in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02816073,COMPLETED,Diabetic Retinopathy|Lasers|Treatment Outcome,DEVICE: Pan-retinal photocoagulation using pattern scanning laser,"Regression of neovascularization, Fluorescein angiogram assessment by independent observer, 3 months",United Christian Hospital,17,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2012-12
NCT01813773,"Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study",https://clinicaltrials.gov/study/NCT01813773,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Intravitreal Aflibercept Injection (IAI),"Incidence and severity of adverse events of intravitreal aflibercept injection in the treatment of PDR., The primary endpoint of the study will be at week 52.",Ophthalmic Consultants of Long Island,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2013-03
NCT01997164,"Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (""Wet"") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT01997164,COMPLETED,Neovascular Age-Related Macular Degeneration|Diabetic Macular Edema,DRUG: REGN910-3|DRUG: REGN910|DRUG: Intravitreal Aflibercept Injection (IAI),"Incidence of treatment-emergent adverse events (TEAEs), Incidence of TEAEs through week 24 in patients treated with IVT REGN910-3 and IVT REGN910 TEAEs through week 24 in patients treated with IVT REGN910-3 and IVT REGN910, Change from baseline to week 24",Regeneron Pharmaceuticals,20,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2014-11
NCT04142164,Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections,https://clinicaltrials.gov/study/NCT04142164,UNKNOWN,Age-related Macular Degeneration|Retinal Vein Occlusion|Diabetic Macular Edema,OTHER: MacInfo presentation|OTHER: Placebo presentation,"Number of correctly answered questions between study group and control group, Patients are asked to complete a multiple choice questionnaire concerning intravitreal drug injections. Correctly answered questions will be summated. The more points the better the patients' knowledge about intravitreal drug injections., 12 months","Prim. Prof. Dr. Oliver Findl, MBA",40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER,2019-10-24
NCT02188173,An Observational Study of OZURDEX® in Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT02188173,COMPLETED,Macular Edema,DRUG: dexamethasone 700 ㎍ intravitreal implant,"Maximum Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye, Baseline, 12 Months|Percentage of Patients with a BCVA Improvement of ≥15 Letters in the Study Eye, Baseline, 12 Months|Average Change from Baseline in BCVA in the Study Eye, Baseline, 12 Months",Allergan,200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2014-07
NCT04699864,Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM,https://clinicaltrials.gov/study/NCT04699864,NOT_YET_RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema|Diabetic Maculopathy,DIAGNOSTIC_TEST: Screening of DR and DME with artificial intelligence using NeoRetina|DIAGNOSTIC_TEST: Routine ophthalmological evaluation of DR and DME|DIAGNOSTIC_TEST: Manual grading of DR and DME by CHUM ophthalmologists based on retinal photographies acquired by Diagnos,"Artificial Intelligence - Absence or Presence of Diabetic Retinopathy (DR), Analysis of retinal images by artificial intelligence (NeoRetina) to determine the absence or the presence of diabetic retinopathy (DR)

* R0 : No DR
* R+ : Presence of DR, Baseline|Eye Examination - Absence or Presence of Diabetic Retinopathy (DR), Eye examination done by an ophthalmologist to determine the absence or the presence of diabetic retinopathy (DR) (blind assessment)

* R0 : No DR
* R+ : Presence of DR, Baseline|Manual Analysis of Retinal Images - Absence or Presence of Diabetic Retinopathy (DR), Manual analysis of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to determine the absence or the presence of diabetic retinopathy (DR) (blind assessment)

* R0 : No DR
* R+ : Presence of DR, Baseline|Artificial Intelligence - Severity of Diabetic Retinopathy (DR), Analysis of retinal images by artificial intelligence (NeoRetina) to grade the severity of diabetic retinopathy (DR)

* R1 - Mild NPDR: Mild Nonproliferative Diabetic Retinopathy
* R2 - Moderate NPDR: Moderate Nonproliferative Diabetic Retinopathy
* R3 - Severe NPDR : Severe Nonproliferative Diabetic Retinopathy
* R4 - PDR : Proliferative Diabetic Retinopathy, Baseline|Eye Examination - Severity of Diabetic Retinopathy (DR), Eye examination done by an ophthalmologist to grade the severity of diabetic retinopathy (DR) (blind assessment)

* R1 - Mild NPDR: Mild Nonproliferative Diabetic Retinopathy
* R2 - Moderate NPDR: Moderate Nonproliferative Diabetic Retinopathy
* R3 - Severe NPDR : Severe Nonproliferative Diabetic Retinopathy
* R4 - PDR : Proliferative Diabetic Retinopathy, Baseline|Manual Analysis of Retinal Images - Severity of Diabetic Retinopathy (DR), Manual revision of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to grade the severity of diabetic retinopathy (DR) (blind assessment)

* R1 - Mild NPDR: Mild Nonproliferative Diabetic Retinopathy
* R2 - Moderate NPDR: Moderate Nonproliferative Diabetic Retinopathy
* R3 - Severe NPDR : Severe Nonproliferative Diabetic Retinopathy
* R4 - PDR : Proliferative Diabetic Retinopathy, Baseline|Artificial Intelligence - Absence or Presence of Diabetic Macular Edema (DME), Analysis of retinal images by artificial intelligence (NeoRetina) to determine the absence or the presence of diabetic macular edema (DME)

* M0 : No DME
* M+ : Presence of DME, Baseline|Eye Examination - Absence or Presence of Diabetic Macular Edema (DME), Eye examination done by an ophthalmologist to determine the absence or the presence of diabetic macular edema (DME) (blind assessment)

* M0 : No DME
* M+ : Presence of DME, Baseline|Manual Analysis of Retinal Images - Absence or Presence of Diabetic Macular Edema (DME), Manual analysis of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to determine the absence or the presence of diabetic macular edema (DME) (blind assessment)

* M0 : No DME
* M+ : Presence of DME, Baseline|Artificial Intelligence - Severity of Diabetic Macular Edema (DME), Analysis of retinal images by artificial intelligence (NeoRetina) to grade the severity of diabetic macular edema (DME)

* M1 : Non Central DME
* M2 : Central DME, Baseline|Eye Examination - Severity of Diabetic Macular Edema (DME), Eye examination done by an ophthalmologist to grade the severity of diabetic macular edema (DME) (blind assessment)

* M1 : Non Central DME
* M2 : Central DME, Baseline|Manual Analysis of Retinal Images - Severity of Diabetic Macular Edema (DME), Manual analysis of retinal images acquired by Diagnos by an ophthalmologist of the CHUM to grade the severity of diabetic macular edema (DME) (blind assessment)

* M1 : Non Central DME
* M2 : Central DME, Baseline",Centre hospitalier de l'Université de Montréal (CHUM),630,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC,2023-09
NCT03610646,Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT03610646,COMPLETED,Diabetic Macular Edema,DRUG: MYL-1701P|DRUG: Eylea,"Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 8, Mean change from baseline in BCVA as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 8.

Best Corrected Visual Acuity (BCVA) is measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the ETDRS chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening., Baseline and 8 weeks",Mylan Pharmaceuticals Inc,355,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-08-23
NCT00763802,Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2,https://clinicaltrials.gov/study/NCT00763802,COMPLETED,Diabetic Retinopathy,,"CSME needing Photocoagulation, 24 months",Association for Innovation and Biomedical Research on Light and Image,400,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-09
NCT04627402,Effects of Adding Triamcinolone Acetonide to Conbercept Treatment for Refractory Diabetic Macular Edema (CONTE),https://clinicaltrials.gov/study/NCT04627402,UNKNOWN,"Diabetes Mellitus, Type 2|Macular Edema",DRUG: Conbercept and TA|DRUG: Conbercept,"Macular thickness, Change in mean central subfield thickness from randomization visit measured with optical coherence tomography., 24 weeks","Zhongshan Ophthalmic Center, Sun Yat-sen University",50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2020-11-12
NCT05489718,A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05489718,COMPLETED,Diabetic Macular Edema,BIOLOGICAL: IBI324|BIOLOGICAL: IBI324|BIOLOGICAL: IBI324|BIOLOGICAL: IBI324|BIOLOGICAL: IBI324,"Safety evaluation indicators, Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse events b) Changes in central subfield thickness by OCT compared with baseline, Through study completion, a maximum of 24 weeks",Innovent Biologics (Suzhou) Co. Ltd.,24,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT,2022-08-01
NCT05169502,Discovering Early Biomarkers in Circulating Endothelial Cells for Diabetes Complications by Single Cell RNA Sequencing,https://clinicaltrials.gov/study/NCT05169502,RECRUITING,Diabetes|Diabetes Mellitus|Proliferative Diabetic Retinopathy|Diabetic Maculopathy|Circulating Endothelial Cells,,"Genome wide expression profile of circulating cells in blood samples from each cohort group, Flow cytometry and single-cell RNA sequencing will be used to identify and consolidate potential biomarkers for diabetes complications, by making a genome wide expression profile used to characterise the different phenotypes of circulating cells in each cohort group., The PBMCs (including circulating endothelial cells) will be freshly isolated from the whole blood sampel, and frozen until all samples are collected (8 months). Afterwards flow cytometry and scRNA-seq analysis will be performed on all samples (2 months).",Aarhus University Hospital,40,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-12-08
NCT04648618,Obstructive Sleep Apnea and Diabetic Macular Edema Inflammatory Mediators,https://clinicaltrials.gov/study/NCT04648618,UNKNOWN,Diabetic Macular Edema|Obstructive Sleep Apnea|Diabetic Retinopathy,,"Cytokines, Level of cytokines between patients with and without OSA, Jan 2018- Mar 2020",Uptown Eye Specialists,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-01
NCT04693702,Observational Study of Vision Improvement in Patients With Retinal Disorders,https://clinicaltrials.gov/study/NCT04693702,COMPLETED,Age-related Macular Degeneration|Diabetic Macular Edema,DEVICE: Corneal treatment by a low vision aid device,"CDVA, Best spectacle-corrected distance visual acuity, 12 months",Optimal Acuity Corporation,54,OBSERVATIONAL,Observational Model: |Time Perspective: p,2021-10-01
NCT05358080,Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05358080,RECRUITING,Non Proliferative Diabetic Retinopathy,DRUG: Entelon Tab. 50mg|DRUG: Placebo,"Proportion of subjects maintained or improved in DRSS level, Change at 24 months of treatment with the drug from baseline(day 0) in DRSS(Diabetic Retinopathy Severity Scale) level, 24 months(Visit 10)","Hanlim Pharm. Co., Ltd.",396,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2022-05-27
NCT00853424,A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease,https://clinicaltrials.gov/study/NCT00853424,WITHDRAWN,Diabetic Retinopathy|Diabetic Macular Edema,PROCEDURE: islet cell transplant|OTHER: Medical therapy,"Composite outcome consisting of progression of DR, development of significant ME, or moderate visual loss in patients who have significant ME at randomization.",University of British Columbia,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-12
NCT00893724,Supplemental Adjuvants for Intracellular Nutrition and Treatment,https://clinicaltrials.gov/study/NCT00893724,UNKNOWN,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,"DRUG: Neutral pills with no medicinal effect|DIETARY_SUPPLEMENT: Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|DRUG: Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline","Degree of regression (Optical Coherence Tomography), Monthly|Duration of regression (Optical Coherence Tomography), Monthly|Visual change (ETDRS), Monthly","Mid-Atlantic Retina Consultations, Inc.",60,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2009-06
NCT03843840,Dual Wavelength OCT,https://clinicaltrials.gov/study/NCT03843840,COMPLETED,AMD|Diabetic Retinopathy|Retinal Degeneration|Retinal Dystrophies,DEVICE: Combined Coaxial Optical Coherence Tomography,"Test retest reliability, Comparison of device test retest variability with those of standard OCT for measurement of tissue reflectivity., 14 months",Moorfields Eye Hospital NHS Foundation Trust,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-02-15
NCT04930224,Serum GPER-1 and Oxidant/Antioxidant Levels on Retinopathy in Diabetic Patients,https://clinicaltrials.gov/study/NCT04930224,COMPLETED,Diabetes Mellitus|Diabetic Retinopathy|Hormones,DIAGNOSTIC_TEST: The effect of GPER-1 on the formation of diabetic retinopathy,"G receptor-mediated protein-1 (GPER-1), Variation of GPER-1 during the development of diabetic retinopathy, Baseline|Oxidative/antioxidative stress markers (malondialdehyde [MDA]), Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy, Baseline|Oxidative/antioxidative stress markers (catalase [CAT]), Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy, Baseline|Oxidative/antioxidative stress markers (superoxide dismutase [SOD], Variation of oxidative/antioxidative stress markers during the development of diabetic retinopathy, Baseline|Thyroid stimulating hormone (TSH), Variation of TSH during the development of diabetic retinopathy, Baseline|Progesterone, Variation of progeterone during the development of diabetic retinopathy, Baseline|oestradiol, Variation of oestradiol during the development of diabetic retinopathy, Baseline",Kahramanmaras Sutcu Imam University,120,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-07-01
NCT01229540,Clinical Research on Retinal Neovascularization of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01229540,TERMINATED,The Mechanism of Retinal Neovascularization of Diabetic|Retinopathy.,GENETIC: genetic analyzer,,Tianjin Medical University,,INTERVENTIONAL,"Allocation: |Intervention Model: |Masking: |Primary Purpose: ",
NCT04009980,Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.,https://clinicaltrials.gov/study/NCT04009980,COMPLETED,Diabetic Retinopathy,OTHER: OMK2 group|OTHER: Placebo group,"Changes of Retinal sensitivity and contrast sensitivity function after topical citicoline use in patients with diabetic retinopathy, To evaluate functional retinal parameters : retinal sensitivity by Humphrey Matrix and contrast sensitivity function by Pelli Robson in patients with diabetic retinopathy, Functional retinal changes at 36 months","Fondazione G.B. Bietti, IRCCS",20,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-09-23
NCT05217680,Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05217680,RECRUITING,Diabetic Macular Edema,BIOLOGICAL: Bevacizumab|BIOLOGICAL: Lucentis®,"Best Corrected Visual Acuity, Best Corrected Visual Acuity will be evaluated according the standardized ETDRS. The mean change between two treatments will be used evaluated as difference between baseline and final (12 months) values., Days: 0 (selection), 1 (randomization), 30±3 (Visit 2), 60±3 (Visit 3), 90±3 (Visit 4), 120±3 (Visit 5), 150±3 (Visit 6), 180±3 (Visit 7), 210±3 (Visit 8), 240±3 (Visit 9), 270±3 (Visit 10), 300±3 (Visit 11), 330±3 (Visit 12), 360±3 (Final Visit)",Laboratorios Sophia S.A de C.V.,442,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2021-05-17
NCT02040441,Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria,https://clinicaltrials.gov/study/NCT02040441,COMPLETED,Diabetic Nephropathy|Diabetic Retinopathy,DRUG: Spironolactone|DRUG: Placebo|DRUG: Standard care,"Albuminuria, Development of confirmed microalbuminuria (UACR \>30 mg/g) in at least two out of three first morning voids with ≥ 30% increase (geometric mean) in UACR from ""run-in"" period samples OR \> 40 mg/g (geometric mean)., Screening, (Low-risk: year 1, 2 and 3), (high-risk: week 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156)",Peter Rossing,1777,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: DIAGNOSTIC",2014-03
NCT04069780,Suprachoroidal Injection of Triamcinolone Acetonide for Management of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT04069780,UNKNOWN,Safety|Efficacy,PROCEDURE: Intravitreal injection (4mg/0.1ml)|PROCEDURE: Superachoroidal injection (4 mg/0.1ml)|PROCEDURE: Suprachoroidal injection (2mg/0.1ml),"Best Corrected Visual Acuity (BCVA), Change in BCVA (Log.MAR) equal or more than 1 line, Six months after injection",Azza Mohamed Ahmed Said,45,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2019-03-13
NCT00768040,Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00768040,TERMINATED,Diabetic Macular Edema,DRUG: Aliskiren|DRUG: Placebo,"Change From Baseline in Central Retinal Thickness in Patients With Type 1 or Type 2 Diabetes, After 12 Weeks of Treatment, The central retinal thickness was measured by Optical coherence tomography (OCT). The changes in central retinal thickness (CRT) from baseline to the end of study at week 12 were analyzed using a univariate analysis of covariance model (ANCOVA) with baseline value as a covariate and treatment as a fixed factor, Baseline to week 12",Novartis Pharmaceuticals,39,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-09
NCT05615740,Prevention of Onset and Transition to an Advanced Form of Diabetic Retinopathy in Children,https://clinicaltrials.gov/study/NCT05615740,RECRUITING,Diabetic Retinopathy,DIAGNOSTIC_TEST: Optical coherence tomography (OCTA),"Vascular density in central and peripheral retina - healthy subjects, The primary goal of the project is measurement of vascular density in central and peripheral retina in healthy subjects using OCT Spectralis (Heidelberg Engineering, Germany). Vascular density is ratio between areas with and without vascular tissue. Data will be analysed by ImageJ software (National Institutes of Health, USA). Normative data will be collected from healthy individuals 6-15 years old., 3 years",University Hospital Ostrava,150,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC,2022-05-02
NCT05944640,Dynamic Parameters of Glucose Control in Relation to Biomarkers in Serum and Intraocular Fluid in Patients With Diabetes,https://clinicaltrials.gov/study/NCT05944640,RECRUITING,Diabetes Complications,PROCEDURE: Intraocular surgery,"miRNA, miRNA expression measuer by real-time PCR method in plasma and vitreous samples (units: threshold cycle), Year 2025|TIR, Percentage of time in target ranges, Year 2025","Charles University, Czech Republic",213,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-04-01
NCT02036424,Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02036424,COMPLETED,Diabetic Macular Edema,DRUG: Ozurdex|DRUG: Bevacizumab,"Mean Visual Acuity Change, Visual acuity was obtained using ETDRS method and the total number of letters correct using that method was used to calculate mean visual acuity change., baseline to month 7|Change in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) From Baseline to Month Seven, Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images. The image is presented in grid form which divides that retina into sections. The center most section (CST) is used for this outcome measurement., baseline to month seven","Raj K. Maturi, MD",45,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2014-01
NCT02748824,Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal,https://clinicaltrials.gov/study/NCT02748824,COMPLETED,Age-Related Macular Degeneration,,"Phenotypic classification of AMD in the five-year clinical visit. Comparison of this classification with the grading of 5 years ago., 5 years",Association for Innovation and Biomedical Research on Light and Image,5996,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-07
NCT02503540,Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO,https://clinicaltrials.gov/study/NCT02503540,COMPLETED,Retinal Vein Occlusion|Diabetic Macular Edema|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion,DRUG: Aflibercept,"Change in Panretinal Leakage Index at Month 12 From Baseline, Change in panretinal leakage index (defined as the proportion of retinal area involved in angiographic leakage) at month 12 from baseline as measured by ultra-widefield angiography (UWFA)., 12 months",Justis Ehlers,31,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-08-18
NCT03197480,Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME,https://clinicaltrials.gov/study/NCT03197480,UNKNOWN,Diabetic Macular Edema,DRUG: Aflibercept Injection [Eylea],"CRT, Mean change in Central Retinal Thickness, 12 Months",Singapore National Eye Centre,36,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2019-04-17
NCT02949024,Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02949024,COMPLETED,Diabetic Macular Edema,DRUG: IVT Aflibercept|DRUG: SC CLS-TA,"Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events, Number of participants with treatment emergent adverse events and serious adverse events reported over 6 months of follow-up, Over 6 months of follow-up","Clearside Biomedical, Inc.",20,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-11-10
NCT05675540,Artificial Intelligence Diagnostic Aid,https://clinicaltrials.gov/study/NCT05675540,NOT_YET_RECRUITING,Wet Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,DEVICE: Macusense Assessment Software,"Percentage agreement, The primary outcome measure is the percentage of agreement between the clinical decision of follow up interval and that made by Macusense at every treatment visit for each patient., 9 months",Guy's and St Thomas' NHS Foundation Trust,422,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-01
NCT05151757,Developing and Testing a Low Cost Opportunistic Glaucoma Screening Model by Non-physician Graders in Vietnam,https://clinicaltrials.gov/study/NCT05151757,COMPLETED,"Training Group, Sensitivity",OTHER: A standard image training set,"Comparing the sensitivity, specificity, area under the curve (AUC) of non-physician graders before and after training on a glaucoma test course in Vietnam., The primary outcome is to assess change before and after training in the diagnostic accuracy (sensitivity and specificity) of non-physician graders to detect glaucoma in a standard set consisting of images encountered during diabetic retinopathy screening in Vietnam, images obtained from the standard GONE collection and population-based eye studies in Northern Ireland (Northern Ireland Cohort Longitudinal Study of Ageing, NICOLA) and China (the Handan Eye Study., 3 months","Queen's University, Belfast",42,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: SCREENING,2021-11-22
NCT00956124,Autofluorescence in Uveitic and Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00956124,WITHDRAWN,Uveitis|Macular Edema,,,St. Franziskus Hospital,0,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-10
NCT01758757,Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01758757,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Vitrectomy,"Incidence of retinal breaks, One year",Kyorin University,347,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2007-09
NCT00780780,Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00780780,COMPLETED,Diabetic Macular Edema,DRUG: Triamcinolone + Nepafenac|DRUG: triamcinolone intravitreal injection,"Visual acuity, Weeks 1, 4, 8, 12, 20 and 25|Optical coherence tomography (OCT), Weeks 4, 8, 12, 20 and 25",Federal University of São Paulo,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2007-07
NCT00355680,Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00355680,COMPLETED,Diabetic Retinopathy,"DEVICE: Green Laser (Aurolas, Aurolab)|DEVICE: Green Laser (Iridex)","Pigmentation of burn, 2 months, 4 months, 6 months post laser|Lateral spread of burn, 2 months, 4 months, 6 months post laser|Regression of new vessels, 2 months, 4 months, 6 months post laser",Aurolab,24,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2005-12
NCT01737957,Safety and Efficacy of Low-Fluence PRP for PDR,https://clinicaltrials.gov/study/NCT01737957,UNKNOWN,Proliferative Diabetic Retinopathy,DEVICE: Low-fluence PRP with 532nm green LASER|DEVICE: Full-Fluence PRP with 532nm LASER,"Macular thickness change, Measurement of macular thickness changes by spectral domain optical coherence tomography (OCT), Base-line, 1 week, 6 weeks, 12 weeks, 16 weeks",Asociación para Evitar la Ceguera en México,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2012-11
NCT01504724,Effect of the Adjunctive IVB Before PRP,https://clinicaltrials.gov/study/NCT01504724,COMPLETED,Diabetic Retinopathy,DRUG: bevacizumab,"Central macular thickness, central macular thickness measured by Cirrus HD optical coherence tomography, 6 months after first PRP session",Kyungpook National University Hospital,30,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2011-08
NCT00174824,Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients,https://clinicaltrials.gov/study/NCT00174824,COMPLETED,"Diabetes Mellitus, Type 2",DRUG: Insulin glargine,The percentage of patients with a 3-step or greater progression in the patient|level recoded integer ETDRS retinopathy scale,Sanofi,1024,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2001-06
NCT01115257,Severe Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01115257,COMPLETED,Diabetic Retinopathy,PROCEDURE: vitrectomy|PROCEDURE: panretinalphotocoagulation,,Universita degli Studi di Catania,180,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2001-10
NCT03658980,Integrating DR Into Mainstream Health System in Bangladesh,https://clinicaltrials.gov/study/NCT03658980,UNKNOWN,Diabetic Retinopathy,BEHAVIORAL: Health Education Intervention,"Increase in Successful Referrals, Increase in Successful Referrals resulting from a health education intervention (among non-compliant persons, i.e. those who do not avail appointment with an Eye Consultant at a tertiary hospital after being detected with probable Diabetic Retinopathy at a diabetes hospital) - to be measured using Pre and Post intervention questionnaire based on previously used questionnaires of similar published studies, 5 months",Hiroshima University,180,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION,2018-10-01
NCT02121340,Collaborative Care for Depression and Diabetic Retinopathy in African Americans,https://clinicaltrials.gov/study/NCT02121340,COMPLETED,Diabetic Retinopathy,BEHAVIORAL: Behavioral Activation,"Hemoglobin A1c, Change in hemoglobin A1c from baseline to 12 months, 12 months",Thomas Jefferson University,40,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2014-05
NCT04116398,Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX),https://clinicaltrials.gov/study/NCT04116398,RECRUITING,Diabetic Macular Edema,DRUG: Dexamethasone with 2 loading doses followed by PRN regimen.,"Maximum BCVA (Best Corrected Visual Acuity) change (best improvement) from baseline (during one year of treatment), Best Corrected Visual Acuity (BCVA) is measured on the ETDRS scale at an initial distance of 4 meters., 52 weeks",Hospices Civils de Lyon,100,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2020-11-30
NCT02406157,577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02406157,COMPLETED,Diabetic Macular Edema,DEVICE: 577-MPL|DEVICE: 532-SLP,"Change of Best Corrected Visual Acuity(BCVA), Best Corrected Visual Acuity will be measured by standard Early Treatment Diabetic Retinopathy Study (ETDRS) protocol, 1 year",Sun Yat-sen University,124,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2015-01
NCT00563940,Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00563940,COMPLETED,Diabetic Macular Edema,,"Central retinal thickness, 4, 8, 12, 24, 72, and 168 hours","Insel Gruppe AG, University Hospital Bern",30,OBSERVATIONAL,Observational Model: |Time Perspective: p,2007-03
NCT02399657,Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02399657,UNKNOWN,Diabetes Mellitus|Macular Edema|Retinal Exudates and Deposits,DRUG: Intravitreal dexamethasone 0.7mg implant,"The ratio of eyes showing reduced hard exudates in macula (1500 micrometer from foveal center), after 12 months",Inje University,48,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-02
NCT01382498,Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01382498,UNKNOWN,Diabetic Retinopathy,DRUG: Calcium dobesilate (Doxium)|DRUG: Placebo drug,"high sensitivity CRP and Endothelin-1 serum levels, 3 month",Tabriz University,90,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2009-11
NCT00698698,Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics,https://clinicaltrials.gov/study/NCT00698698,UNKNOWN,Diabetes Mellitus,,,Dow University of Health Sciences,350,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-01
NCT00295828,A Pilot Study for the Treatment of Iris Neovascularization With Macugen,https://clinicaltrials.gov/study/NCT00295828,COMPLETED,Iris Neovascularization|Diabetic Retinopathy,OTHER: Pegaptanib Sodium Injection/Panretinal Photocoagulation|PROCEDURE: Panretinal Photocoagulation (PRP),"Regression of iris neovascularization and prevention of development of neovascular glaucoma, prospective",Hermann Eye Center,10,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: TREATMENT,2006-01
NCT05806957,Pivotal Trial to Assess the Clinical Performance of Ophthal-360 for the Detection of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05806957,NOT_YET_RECRUITING,Diabetic Retinopathy,DEVICE: Fundus Photography,"Sensitivity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images, Performance of the Ophthal-360 Software when compared to results of evaluation of fundus photographs by qualified experts., 1 day|Specificity of the Ophthal-360 Software to detect diabetic retinopathy in fundus images, Performance of the Ophthal-360 Software when compared to ground truth evaluation of fundus photographs by qualified experts., 1 day","Ophthalytics, Inc.",500,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-06-01
NCT00728598,"Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis",https://clinicaltrials.gov/study/NCT00728598,COMPLETED,Proliferative Diabetic Retinopathy|Angiogenesis,,"Vitreous levels and serum levels of Fractalkine, VEGF, other growth factor., vitreous sample collected on vitrectomy",National Taiwan University Hospital,30,OBSERVATIONAL,Observational Model: |Time Perspective: p,1998-01
NCT03384524,"Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME",https://clinicaltrials.gov/study/NCT03384524,WITHDRAWN,Diabetic Macular Edema,DRUG: Bromocriptine 2.5 MG|DRUG: Metoprolol 25 MG|DRUG: Tamsulosin 0.4 MG|OTHER: Placebo,"Change in retinal volume, Effects of bromocriptine/metoprolol/tamsulosin combination therapy on macular retinal volume compared with placebo in eyes with non-central diabetic macular edema (DME), 14 months","Andrew Moshfeghi, MD, MBA",0,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2018-03
NCT03752840,Village-Integrated Eye Worker Trial II,https://clinicaltrials.gov/study/NCT03752840,RECRUITING,Age-related Macular Degeneration|Diabetic Retinopathy|Glaucoma,OTHER: Visual acuity (presenting and pinhole)|OTHER: Optical coherence tomography (OCT)|OTHER: Intraocular pressure|OTHER: Active linkage to care,"Pinhole visual acuity (logMAR) in people aged 60 years and older, Visual acuity will be assessed using the Peek Acuity mobile application during the final census., 4 years","University of California, San Francisco",60000,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: SCREENING,2019-04-21
NCT05364723,Place of Glycation in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05364723,NOT_YET_RECRUITING,Descriptor,OTHER,"distribution of diabetic retinopathy in eastern morocco, 1year",Mohammed VI University Hospital,1000,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-05-15
NCT02684084,Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02684084,TERMINATED,Diabetic Macular Edema,DRUG: Ozurdex|DRUG: Lucentis,"Comparison of mean change from baseline ETDRS BCVA letters, Carried out using Area Under the Curve (AUC) analysis, From randomization (0) to 24+/- 1 weeks",North Toronto Eye Care Laser and Eye Specialists,5,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-11
NCT03362580,Prevalence and Risk Factors of Epiretinal Membrane in Diabetic and Non-diabetic Patients,https://clinicaltrials.gov/study/NCT03362580,COMPLETED,Epiretinal Membrane,DEVICE: Slit lamp examination|DEVICE: Undilated 7-field color fundus photography|DEVICE: Color scan|DEVICE: Spectral domain optical coherence tomography,"Age, Age, First standard of care consultation, up to 3 months|Gender, Gender, First standard of care consultation, up to 3 months|Population sub-type, Population sub-type: Caucasian, African, Asian, Indian, American or Other, First standard of care consultation, up to 3 months|Diabetes type (for group A), Diabetes type (for group A), First standard of care consultation, up to 3 months|Diabetic Retinopathy classification, Diabetic Retinopathy classification, if diagnosed (according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) classification), First standard of care consultation, up to 3 months|Duration of medical treatment of diabetes, Duration of medical treatment of diabetes (measured in months), First standard of care consultation, up to 3 months|HbA1C (Glycated Haemoglobin) rate, HbA1C rate (according to recent blood test), First standard of care consultation, up to 3 months|Smoking status, Smoking status, First standard of care consultation, up to 3 months|Previous cataract surgery, Previous cataract surgery, First standard of care consultation, up to 3 months|Diagnose of ERM, Diagnose of ERM, First standard of care consultation, up to 3 months|Educational level, Educational level, First standard of care consultation, up to 3 months",Laurence Postelmans,200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-12-12
NCT05182580,Bangladesh PRODUCTIVity in Eyecare Trial,https://clinicaltrials.gov/study/NCT05182580,RECRUITING,Diabetic Retinopathy|Diabetic Macular Edema,DIAGNOSTIC_TEST: Results utilized from autonomous AI diagnostic system for diabetic retinopathy and/or diabetic macular edema,"Number of examined participants with diabetes per retina specialist working hour, Number of examined participants with diabetes per retina specialist working hour. Numerator is the number of examined participants (including persons evaluated by autonomous AI on Intervention Days who are determined not to need to see the retina specialist). The denominator is retina specialist working time in hours., summed weekly from baseline through study completion, 1 year|Number of examined retina participants per retina specialist working hour, Number of examined retina participants per retina specialist working hour. Numerator is the number of examined participants (including persons evaluated by autonomous AI on Intervention Days who are determined not to need to see the retina specialist). The denominator is retina specialist working time in hours., summed weekly from baseline through study completion, 1 year",Orbis,924,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: DIAGNOSTIC",2022-03-20
NCT02621580,Investigating the Structural and Functional Changes to the Retina Following PRP in Diabetic Retinopathy Patients,https://clinicaltrials.gov/study/NCT02621580,COMPLETED,Diabetic Retinopathy,DEVICE: Pan-Retinal Photocoagulation,"The rate of structural and functional changes to the retinal thickness following PASCAL PRP in severe PDR patients, assessed by optical coherence tomography., 2 years",Lawson Health Research Institute,24,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2012-09
NCT00682240,Morphological and Functional Retinal Changes Following Retinal Photocoagulation,https://clinicaltrials.gov/study/NCT00682240,COMPLETED,Proliferative Diabetic Retinopathy|Macular Edema,PROCEDURE: laser treatment with PASCAL®|PROCEDURE: laser treatment with PASCAL®|PROCEDURE: laser treatment with PASCAL®|PROCEDURE: laser treatment with conventional laser system,"Retinal morphological changes with time secondary to laser treatment as assessed with optical coherence tomography (OCT)., 2007-2014",Medical University of Vienna,64,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: ",2007-10
NCT03426540,Intravitreal Conbercept After Vitrectomy,https://clinicaltrials.gov/study/NCT03426540,COMPLETED,Early Proliferative Diabetic Retinopathy,DRUG: Conbercept,"best corrected visual acuity, BCVA using a Landolt C acuity chart method, baseline to 24 weeks post-surgery",Tianjin Medical University Eye Hospital,50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,2017-01-01
NCT00619034,Pharmacological Intervention in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00619034,COMPLETED,Diabetic Retinopathy,"DRUG: Latanoprost, diclofenac and dorzolamide (eyedrops)|DRUG: Diclofenac|DRUG: Dorzolamide","Diameter of retinal blood vessels, one year",University of Aarhus,87,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION,2007-09
NCT01363440,Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01363440,COMPLETED,Diabetic Macular Edema,DRUG: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|PROCEDURE: Macular Laser Photocoagulation,"Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF), Visual function of the study eye was assessed using the ETDRS protocol. Participants with a BCVA ETDRS letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye were included; a higher score represents better functioning., Baseline and Week 52",Regeneron Pharmaceuticals,466,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-05
NCT00797524,Function and Structure Imaging in Different Retinal Diseases: Retinal Leakage Analyzer Versus Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT00797524,COMPLETED,Diabetic Retinopathy|Age-Related Macular Degeneration|Macular Edema,,"Retinal leakage and retinal thickness., After the visit",Association for Innovation and Biomedical Research on Light and Image,35,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-11
NCT05172401,"Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema",https://clinicaltrials.gov/study/NCT05172401,WITHDRAWN,Diabetic Macular Edema,DEVICE: Oxulumis® suprachoroidal microcatheterization administration of Triesence®,"Frequency of ocular adverse events, systemic adverse events, serious, and treatment-emergent non-serious adverse events, Treatment-emergent adverse events are defined as an event that emerges following administration of Triesence with the Oxulumis microcatheter administered at Visit 2 (Baseline, Day 0), 24 Weeks|Frequency of adverse device effects and frequency of serious adverse device effects, Adverse device effects and serious adverse device effects are defined as effects that emerge following the administration of the Oxulumis microcatheter at Visit 2 (Baseline, Day 0), 24 Weeks",Oxular Limited,0,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2022-09-15
NCT04132401,AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care,https://clinicaltrials.gov/study/NCT04132401,COMPLETED,Diabetic Retinopathy,DIAGNOSTIC_TEST: algorithm,"Sensitivity of the algorithm, True positive rate of the algorithm, 1 year|Specificity of the algorithm, True negative rate of the algorithm, 1 year|Accuracy of the algorithm, Ratio of number of correct predictions to the total number of input samples, 1 year|Area under the receiver operating characteristic curve of the algorithm, Diagnostic ability of the algorithm, 1 year",Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina,100,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: OTHER,2021-05-01
NCT03751501,Targeted Laser in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT03751501,UNKNOWN,Macular Edema|Diabetic Retinopathy,PROCEDURE: Indocyanine green-Guided Targeted Laser photocoagulation|PROCEDURE: Sham laser,"Number of anti VEGF injections, as measured between baseline and M12, 12months|Change in Visual Acuity (Letters), As measured by the Early Treatment Diabetic Retinopathy Study (ETDRS), 12 months",Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts,270,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-11-22
NCT01025934,Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01025934,COMPLETED,Proliferative Diabetic Retinopathy,DRUG: Bevacizumab|OTHER: sham,,"University of Campania ""Luigi Vanvitelli""",,INTERVENTIONAL,Allocation: |Intervention Model: |Masking: |Primary Purpose: TREATMENT,
NCT03345901,PROMINENT-Eye Ancillary Study (Protocol AD),https://clinicaltrials.gov/study/NCT03345901,TERMINATED,Diabetic Retinopathy|Diabetic Macular Edema,DRUG: Pemafibrate|DRUG: Placebo,"Diabetic Retinopathy Worsening or Diabetic Macular Edema (DME) Development (Composite Outcome), 4 years",Jaeb Center for Health Research,18,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2018-01-15
NCT00797134,Retinal Thickness Analysis Using Optical Coherence Tomography,https://clinicaltrials.gov/study/NCT00797134,COMPLETED,Diabetic Retinopathy,,"Retinal thickness., After visit(s)",Association for Innovation and Biomedical Research on Light and Image,45,OBSERVATIONAL,Observational Model: |Time Perspective: p,2008-11
NCT02735369,A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR,https://clinicaltrials.gov/study/NCT02735369,TERMINATED,Proliferative Diabetic Retinopathy (PDR),DRUG: 2% OC-10X|DRUG: Placebo Comparator,"The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the mean change of area of neovascularization of the disc (NVD) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the mean change of area of neovascularization of the disc (NVD) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., Baseline - 24 weeks|The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of neovascularization elsewhere in the retina (NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of neovascularization elsewhere in the retina (NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., Baseline - 24 weeks|The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of ""Posterior NVE"" from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area change of area of ""Posterior NVE"" from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., Baseline - 24 weeks|The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo., Baseline - 24 weeks","OcuCure Therapeutics, Inc.",40,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2014-12
NCT04025996,REWARD: Using the REtina as a Window To Detect Cardiac microvasculAR Dysfunction In Diabetes Mellitus,https://clinicaltrials.gov/study/NCT04025996,UNKNOWN,"Retinopathy, Diabetic|Diastolic Dysfunction|Microalbuminuria",DIAGNOSTIC_TEST: Cardiac Assessments and Eye Assessments,"Eye Examination, Retinal photography on diabetic patients will be performed to identify those with retinopathy., 1 day|Cross-sectional analyses will be performed to look at the association between diabetic retinopathy with left ventricular diastolic function, coronary flow reserve and urinary albumin excretion., These data will provide initial evidence of the mechanistic link between microvascular dysfunction in the eye, heart and kidneys among patients with diabetes., 2 days",National Heart Centre Singapore,60,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-02-20
NCT01145599,Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures,https://clinicaltrials.gov/study/NCT01145599,COMPLETED,Type 2 Diabetes|Non Proliferative Diabetic Retinopathy,,"Identify ""progressors"", To identify ""progressors"" in retinal vascular disease and central retinal edema, the following 2 biomarkers will be considered: the MA formation rate (biomarker for the progression of retinal vascular disease) and the presence of retinal thickening in the central subfield and/or the inner ring (biomarker for the presence of retinal edema)., 12 months",European Vision Institute Clinical Research Network,374,OBSERVATIONAL,Observational Model: |Time Perspective: p,2010-09
NCT04563299,Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections,https://clinicaltrials.gov/study/NCT04563299,TERMINATED,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion,DRUG: Dextenza 0.4Mg Ophthalmic Insert|DRUG: Prednisolone Acetate,"Mean Change in Pain Scores, As measured by a 10-point standardized pain scale (1 = no pain, 10 = worst pain), As assessed at Baseline Visit, 6 hours (+/- 2 hours), 24 hours (+/- 3 hours), and at 3-6 days after Injection Visit 1, Injection Visit 2, and Injection Visit 3",Retina Vitreous Associates of Florida,10,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020-12-09
NCT05416099,Comparing Conventional Grid Laser Photocoagulation and Subthreshold Micropulse Laser in Diabetic Macular Edema Using OCT Angiography,https://clinicaltrials.gov/study/NCT05416099,RECRUITING,Diabetic Macular Edema,PROCEDURE: laser,"Change in Best Corrected Visual Acuity, 1 month, 3 month and 6 months",Chinese University of Hong Kong,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-06-01
NCT03403699,Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT03403699,RECRUITING,Diabetes Complications|Diabetic Retinopathy,BIOLOGICAL: Generation of inducible pluripotent stem cells,"Generating iPSCs from peripheral blood, Blood will be collected from the patient and cells will be isolated and shipped to ALSTEM for generation of iPSCs, From blood draw to 4 months|Differentiate iPSCs into CD34+ cells and mesoderm, Specific cell culture conditions will be used to differentiate the cells into these two distinct populations, 4 months to 4 years",University of Alabama at Birmingham,20,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-01-11
NCT04919499,A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment,https://clinicaltrials.gov/study/NCT04919499,COMPLETED,Diabetic Retinopathy,DRUG: BI 765128|OTHER: Sham comparator,"Part A: Number of subjects with ocular dose limiting events (DLEs) from drug administration until day 8 (7 days after treatment), up to 7 days|Part B: Number of subjects with drug related Adverse Events (AEs) from drug administration until end of study (EOS), up to 20 weeks",Boehringer Ingelheim,46,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2021-07-30
NCT05808699,Camera Qualification Study,https://clinicaltrials.gov/study/NCT05808699,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,DEVICE: handheld fundus camera,"Sensitivity and Specificity Corrected for Enrichment, Estimation sensitivity and specificity corrected for enrichment using logistic regression, Level 1, Day 1","Digital Diagnostics, Inc.",565,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-03-03
NCT00994799,Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00994799,UNKNOWN,Macular Edema,DRUG: ranibizumab|RADIATION: macular grid-pattern laser,"Mean change in best corrected visual acuity, 12 months",Szeged University,50,OBSERVATIONAL,Observational Model: |Time Perspective: p,2009-07
NCT06146699,Prevalence of Diabetic Retinopathy in Type 2 Diabetic Patients,https://clinicaltrials.gov/study/NCT06146699,NOT_YET_RECRUITING,Diabetic Retinopathy,DEVICE: Optical Coherence Tomography (OCT)|DEVICE: Fundus fluorescein angiography (FFA),"prevalence of diabetic retinopathy, To determine the stage of Diabetic Retinopathy (DR) and the presenting symptoms at the time of ophthalmological examination of diabetic individuals ., Baseline",Assiut University,262,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-12
NCT01373476,"Multicentre, Randomized, Controlled Trial of Qideng Mingmu Capsule in The Treatment of Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT01373476,COMPLETED,Diabetic Retinopathy|Diabetic Eye Problems|Retinal Disorders,DRUG: Qideng Mingmu capsule|DRUG: Placebo Comparator,"Ocular fundus, Change from Baseline in Ocular fundus which is to be examined by color fundus image at 6 months",Chengdu University of Traditional Chinese Medicine,240,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2011-03
NCT05472376,Real-Life Study in Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT05472376,COMPLETED,Diabetic Macular Edema,OTHER: Retrospective study,"Visit and Intravitreal Injection Numbers, The primary outcomes were changes in best-corrected visual acuity and central macular thickness in the first year and frequency of visits and intravitreal anti-VEGF injections., First year",Kocaeli University,854,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-11-29
NCT00764244,Laser Versus Vitrectomy Versus Intravitreal Triamcinolone Injection for Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT00764244,COMPLETED,Diabetic Macular Edema|Diabetes,PROCEDURE: Vitrectomy|DRUG: Intravitreal triamcinolone injections|PROCEDURE: Laser photocoagulation,"Percentage of patients with visual gain ≥ 3 ETDRS lines at 2 years, at 2 years",Assistance Publique - Hôpitaux de Paris,72,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2005-01
NCT03264976,Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR),https://clinicaltrials.gov/study/NCT03264976,UNKNOWN,Diabetic Retinopathy,"DIAGNOSTIC_TEST: hematological examination, ophthalmic examination","exosomal miRNAs in serum samples, In discovery set, miRNA sequencing of serum exosomes will be performed for each sample. Data will be analyzed using statistical methods. Potential miRNAs that show group-differentiation will be selected in combination with information and test results.Based on these selected miRNAs, the same assays will be repeated on all validation set samples to screen out significant miRNA., samples will be collected every 12 months later until 5 years","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",200,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-01
NCT00414999,A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers,https://clinicaltrials.gov/study/NCT00414999,COMPLETED,Macular Degeneration|Diabetic Retinopathy,DRUG: TG100801,"Part A: Safety & tolerability of vehicle & 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 1 day, assessed up to 5 (+/- 1) days following dosing.|Part B: Safety & tolerability of 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 14 days, assessed up to 7-14 days following dosing.",TargeGen,44,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2006-11
NCT02409511,Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy),https://clinicaltrials.gov/study/NCT02409511,UNKNOWN,Microalbuminuria|Endothelial Dysfunction|Diabetic Nephropathy|Diabetic Retinopathy,OTHER: non intervention,"To find markers for a better definition of the meaning of microalbuminuria, Improve diagnosis of diabetic nephropathy, 3 years|Complementary markers for improving the performance of MA, Improve diagnosis of diabetic nephropathy, 3 years",Hospital Universitari Vall d'Hebron Research Institute,75,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-01
NCT04334499,Mitochondrial DNA in Vitreous Fluid and Blood in Patients With Eye Disease or Ocular Trauma.,https://clinicaltrials.gov/study/NCT04334499,WITHDRAWN,Eye Diseases|Ophthalmic Trauma|Mitochondrial DNA|Age Related Macular Degeneration|Glaucoma|Diabetic Retinopathy,OTHER: Sample collection from tissue discard,"Quantitation of mitochondrial DNA in vitreous humor and serum samples, mtDNA quantitation by RTq-PCR, 1 day","The University of Texas Medical Branch, Galveston",0,OBSERVATIONAL,Observational Model: |Time Perspective: p,2020-02-21
NCT03572699,"Simple, Mobile-based Artificial Intelligence AlgoRithms in the Detection of Diabetic ReTinopathy (SMART) Study",https://clinicaltrials.gov/study/NCT03572699,UNKNOWN,Diabetic Retinopathy,OTHER: diabetic retinopathy,"Sensitivity and specificity of the AI in detecting any grade of diabetic retinopathy, 3 months",Medios Technologies Pte. Ltd,900,OBSERVATIONAL,Observational Model: |Time Perspective: p,2018-07-11
NCT01120899,A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT01120899,COMPLETED,Diabetic Macular Edema,DRUG: Minocycline,"Number of Study Eyes Demonstrating an Increase or Decrease in Best-corrected Visual Acuity (BCVA) of 15 or More Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 6 Months Compared to Baseline, Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20.

The participant's eye that met the study eye eligibility criteria was selected as the study eye. For cases in which both eyes met the study eye eligibility criteria, the study eye was selected according to the ""choice of study eye in cases of bilateral disease"" selection criteria outlined in the eligibility criteria. The eye not chosen as the study eye is referred to as the ""fellow eye."", 6 months",National Eye Institute (NEI),6,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2010-04
NCT02646670,Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02646670,COMPLETED,Retinal Diseases,DRUG: Ranibizumab|DRUG: Aflibercept|DRUG: Ranibizumab and Aflibercept|DRUG: Aflibercept and ranibizumab,"Efficacy of Ranibizumab Therapy with Aflibercept in Patients with Diabetic Macular Edema, Were evaluated the therapy with two different drugs used in diabetic retinopathy, and for this were separated twenty patients in four groups:

* First group will be held three applications of intravitreal ranibizumab 0.1 ml, and follow up with OCT.
* Second group will be held three applications of Intravitreal Aflibercept 0.1 ml, and followed by monitoring with OCT.
* Third group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with OCT.
* Fourth group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with OCT.

In all this groups will be observe the time of reduction of macular edema in the days 1, 3, 5, 10 and 30., 3 months",Instituto de Olhos de Goiania,20,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2015-07
NCT00683176,Effect of Choline Fenofibrate (SLV348) on Macular Edema,https://clinicaltrials.gov/study/NCT00683176,COMPLETED,Diabetic Macular Edema,DRUG: Choline Fenofibrate|DRUG: Placebo,"Total macular volume measurement on OCT, after central reading (assessed at baseline and after 3, 6, 9 and 12 months of treatment), 12 months",Abbott Products,110,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2008-09
NCT01175070,Intravitreal Macugen for Ischaemic Diabetic Macular Oedema,https://clinicaltrials.gov/study/NCT01175070,COMPLETED,Diabetic Macular Oedema,DRUG: Intravitreal injection of pegaptanib sodium,"Change in size of FAZ at 30 weeks, 30 weeks",University of Oxford,30,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-01
NCT05778370,Correlation Between HBA1c Level and Thickness of Both Macula and Choroid in Patients With Type 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT05778370,NOT_YET_RECRUITING,Diabetic Retinopathy,DEVICE: Swept Source Optical Coherence Tomography(Topcon DRI Triton),"Correlation between HBA1c level and thickness of both macula and choroid in patients with type II diabetes mellitus, Taking oct record for diabetic patients already know their HBA1c level ( done within 3 months max ) . Without follow up Findings will be compared controlled and non controlled group and with control group (normal people) To correlate if there's relavence between the Hba1c and macular thickness, baseline",Assiut University,45,OBSERVATIONAL,Observational Model: |Time Perspective: p,2023-04-15
NCT00457470,A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME),https://clinicaltrials.gov/study/NCT00457470,WITHDRAWN,Diabetes Mellitus|Diabetic Retinopathy,DRUG: AG-014699,Change of retinal thickness at Day 15 or Day 25 depending on dosing regimen,Pfizer,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2007-06
NCT00802269,Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.,https://clinicaltrials.gov/study/NCT00802269,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Retinal laser photocoagulation,"Pain (NRS-11 scale), Immediately post-treatment",Asociación para Evitar la Ceguera en México,25,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2008-03
NCT00001395,Long Term Follow-Up of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00001395,COMPLETED,Blindness|Cataract|Diabetes Mellitus|Diabetic Retinopathy|Macular Degeneration,,,National Eye Institute (NEI),75,OBSERVATIONAL,Observational Model: |Time Perspective: p,1994-03
NCT03702374,"Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy",https://clinicaltrials.gov/study/NCT03702374,COMPLETED,Diabetic Retinopathy,DRUG: Combined antioxidant therapy|OTHER: Placebo,"Changes in concentration of serum malondialdehyde after intervention., The investigators will consider changes presented in plasma concentrations of malondialdehyde from baseline to the end of the intervention. The investigators expect to find a decrease in malondialdehyde concentrations in the supplemented group., 3 measures will be made, 1 at baseline, another one after 6 months and a last one after completion of 12 months of intervention.|Changes in ATPase activity after intervention from baseline, The investigators will consider changes showed in ATPase activity after the intervention compared to baseline. The investigators expect to find a decrease in ATPase activity in the supplemented group., 3 measures will be made, 1 at baseline, another one after 6 months and a last one after 12 months of intervention|Changes in concentration of total antioxidant capacity (TAC) after intervention from baseline., The investigators will consider changes presented in plasma concentrations of total antioxidant capacity (TAC) from baseline to the end of the intervention. The investigators expect to find TAC augmentation in the supplemented group., 3 measures will be made, 1 at baseline, another one after 6 months and a last one after 12 months of intervention",University of Guadalajara,132,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-09-26
NCT05260281,Performance Evaluation of Artificial Intelligence Assisted Diabetic Retinopathy Grading in the Leuven University Hospital: Can Technology Improve the Resident?,https://clinicaltrials.gov/study/NCT05260281,NOT_YET_RECRUITING,To Evaluate the Added Value of the Use of Artificial Intelligence in the Diagnosis of Referable Diabetic Retinopathy in a Teaching Hospital Setting,DEVICE: MONA algorithm,"does AI augment diagnostic performance of resident, sensitivity and specificity, 4 months",Universitaire Ziekenhuizen KU Leuven,139,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-03-01
NCT02099981,Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients,https://clinicaltrials.gov/study/NCT02099981,COMPLETED,Diabetic Retinopathy,DRUG: Aminoguanidine,"The vascular response to flicker, The vascular response will be defined as the ratio of the maximal vessel diameter observed during the stimulation period, compared to the mean diameter during the control period, 90 minutes",University of Minnesota,34,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2016-07
NCT02731911,Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study,https://clinicaltrials.gov/study/NCT02731911,COMPLETED,Diabetic Macular Oedema,DRUG: dexamethasone intravitreal implant,"Mean change in Best Corrected Visual Acuity (BCVA) from baseline, Baseline, Month 12|Mean change in Central Retinal Thickness (CRT) from baseline, Baseline, Month 12",Allergan,202,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-04-29
NCT03025399,Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy,https://clinicaltrials.gov/study/NCT03025399,UNKNOWN,Diabetic Non-proliferative Retinopathy|Type2 Diabetes,DRUG: Tangwang prescription|DRUG: Placebo,"the changes of degree of retinal microvascular lesions before and after treatment (no, mild non proliferative phase, moderate non proliferative phase, severe non proliferative phase, proliferative phase), 0 week, 24 weeks, 48 weeks",Fengmei Lian,384,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2017-02
NCT03804970,"Information, Networks and Rewards to Optimise Adherence to Diabetic Services",https://clinicaltrials.gov/study/NCT03804970,COMPLETED,Diabetes,BEHAVIORAL: cash rewards for the fellow up|BEHAVIORAL: Showing retinal photos to participants|BEHAVIORAL: SMS reminders for participants and their family|BEHAVIORAL: Watching brief video and basic explanation for disease|BEHAVIORAL: Having the Diabetic Club,"Proportion of scheduled eye care visits attended over 1 year, The visits will be recorded during the 1 year, One year",Sun Yat-sen University,225,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: HEALTH_SERVICES_RESEARCH,2019-08-15
NCT02315170,Assessment of Novel Intraocular Injection Guide,https://clinicaltrials.gov/study/NCT02315170,COMPLETED,Retinal Disease,DEVICE: intraocular injection guide|DEVICE: standard lid speculum,"Visual Analogue Scale (VAS), The VAS is a horizontal line, 100 mm in length, and anchored by word descriptors at each end. The scale scores range from 0mm (no pain) to 100mm (very severe pain). The patient marks on the line the point that they feel represents their perception of their current state (no pain to very severe pain)., one time for about 30 sec or less","Maturi, Raj K., M.D., P.C.",50,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: SUPPORTIVE_CARE,2014-09
NCT00411970,20- Versus 23- Gauge System for Pars Plana Vitrectomy,https://clinicaltrials.gov/study/NCT00411970,COMPLETED,Diabetic Retinopathy|Macular Edema|Postoperative Complications|Vitreous Hemorrhage,DEVICE: 20- and 23 gauge vitreoretinal surgery systems,Conjunctival Injection|Subjective postoperative recovery,The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: TREATMENT,2004-09
NCT01023113,To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation,https://clinicaltrials.gov/study/NCT01023113,UNKNOWN,Macular Edema|Diabetic Retinopathy|Visual Field Loss,PROCEDURE: PASCAL laser|PROCEDURE: Conventional laser,"Comparison of the two methods in relation to visual field loss in terms of MD,CPSD and each quadrants loss of fields, 3 months",L.V. Prasad Eye Institute,60,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2009-09
NCT03466099,"Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)",https://clinicaltrials.gov/study/NCT03466099,COMPLETED,Diabetic Macular Edema,DRUG: KVD001 Injection|OTHER: Sham Procedure,"BCVA, Change from Baseline in Best Corrected Visual Acuity (BCVA), 16 weeks","KalVista Pharmaceuticals, Ltd.",129,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2018-02-16
NCT01872611,Nepafenac Once Daily for Macular Edema - Study 2,https://clinicaltrials.gov/study/NCT01872611,COMPLETED,Non-Proliferative Diabetic Retinopathy|Cataract,"DRUG: Nepafenac Ophthalmic Suspension, 0.3%|OTHER: Vehicle|DRUG: Prednisolone acetate","Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90, BCVA (with spectacles or other visual corrective devices) was reported in letters read correctly, using the Early Treatment Diabetic Retinopathy Study (ETDRS) test of 70 letters. Improvement of BCVA was defined as an increase (gain) in the number of letters read, compared to the baseline assessment. One eye (study eye) contributed to the analysis., Baseline to Day 14, and maintained through Day 90|Percentage of Participants Who Develop Macular Edema Within 90 Days Following Cataract Surgery (Day 0), Macular edema was defined as ≥ 30% Increase from pre-operative baseline in central subfield macular thickness, as measured with Spectral Domain Ocular Coherence Tomography (SD-OCT). One eye (study eye) contributed to the analysis., Day 0 to Day 90",Alcon Research,819,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2013-06
NCT03525899,Macular Hole After Diabetic Vitrectomy,https://clinicaltrials.gov/study/NCT03525899,COMPLETED,Proliferative Diabetic Retinopathy|Macular Holes,PROCEDURE: Pars plana vitrectomy,"Time to macular hole closure, Evaluation by optical coherence tomography, OCT was performed monthly after operation, until MH closure was achieved, up yo 1 year",National Taiwan University Hospital,7,OBSERVATIONAL,Observational Model: |Time Perspective: p,2017-11-01
NCT04030611,The Sensitivity of Traditional Chinese Medical Diagnostic Tools for Diabetic Retinopathy Diabetic retinopathy-a Pilot Study,https://clinicaltrials.gov/study/NCT04030611,UNKNOWN,Diabetic Retinopathy,DIAGNOSTIC_TEST: tongue diagnosis system,"Automatic tongue diagnosis, We observe the tongue features of blood stasis, such as bluish tongue, petechiae, and engorged sublingual vessels, and compare the relationship between diabetic retinopathy and blood stasis., 12 months|body constitution questionnaire, We observe the body constitution questionnaires, such as yi deficiency, yang deficiency and phlegm-stasis, and compare the relationship between diabetic retinopathy and blood stasis., 12 months|Nailfold videocapillaroscopy (NVC), We evaluate the capillary density, length, morphology, distribution, presence of enlarged loops or hemorrhages, and blood flow. NVC score was used to quantitate the aforementioned characteristics., 12 months|pulse examinatin, 12 months",China Medical University Hospital,100,OBSERVATIONAL,Observational Model: |Time Perspective: p,2019-01-01
NCT03522311,Surgical Outcomes for Proliferative Diabetic Retinopathy by Preoperative Glycemic Control and Renal Function,https://clinicaltrials.gov/study/NCT03522311,COMPLETED,Proliferative Diabetic Retinopathy,PROCEDURE: Vitrectomy,"Visual acuity measurement, Visual acuity improvement from baseline, 6 months",Kyorin University,251,OBSERVATIONAL,Observational Model: |Time Perspective: p,2013-01
NCT02924311,Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02924311,COMPLETED,Diabetic Retinopathy,"DRUG: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients, At baseline and 12 months",Bayer,402,OBSERVATIONAL,Observational Model: |Time Perspective: p,2016-09-21
NCT02314299,A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration,https://clinicaltrials.gov/study/NCT02314299,COMPLETED,Diabetic Macular Edema|Age-related Macular Degeneration,DRUG: MTP-131,"Incidence and severity of systemic and ocular adverse events, From Baseline to Day 28|Change from Baseline in vital sign measurements, From Baseline to Day 28|Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy study (ETDRS) scale, From Baseline to Day 28|Change from Baseline in slit lamp examinations, From Baseline to Day 28|Change from Baseline in intraocular pressure, From Baseline to Day 28|Change from Baseline in dilated fundoscopic examinations, From Baseline to Day 28|Change from Baseline in central subfield thickness, From Baseline to Day 28",Stealth BioTherapeutics Inc.,20,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT,2014-11
NCT01445899,"PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)",https://clinicaltrials.gov/study/NCT01445899,COMPLETED,Choroidal Neovascularization|Diabetic Retinopathy|Diabetic Macular Edema,DRUG: PF-04523655 (Stratum I)|DRUG: ranibizumab|DRUG: PF-04523655 (Stratum II),"Safety and dose-limiting toxicities (Stratum I), - To determine the safety and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655 in subjects with low vision, 6 months post-injection|Pharmacokinetics (Stratum I), - To determine the pharmacokinetics (PK) of a single IVT injection of PF-04523655 in subjects with low vision, 6 months post-injection|Safety and tolerability (Stratum II), - To evaluate the safety and tolerability of PF-04523655 alone and in combination with ranibizumab in subjects with diabetic macular edema (DME), 30 days after the last injection|Efficacy (Stratum II), - To evaluate the ability of PF-04523655 alone and in combination with ranibizumab to improve visual acuity compared to ranibizumab alone in subjects with DME, 30 days after the last injection",Quark Pharmaceuticals,258,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2012-02
NCT04455399,Time Efficiency Comparison of Two IntraVitreal Injection Techniques,https://clinicaltrials.gov/study/NCT04455399,COMPLETED,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema|Retinal Vein Occlusion With Macular Edema|Uveitic Macular Edema|Choroidal Neovascularization,DEVICE: Intravitreal injection guide (Malosa)|DEVICE: Dual Blade Eyelid Speculum,"Duration of intravitreal injection procedure, Duration in seconds from application to removal of single-blade or dual blade speculum, At time of injection procedure",Peregrine Eye and Laser Institute,200,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2020-11-09
NCT05079399,Biomarker of Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT05079399,RECRUITING,Diabetic Retinopathy,OTHER: Blood draw,"mRNA and miRNA sequencing of circulating angiogenic cells isolated from study participants, Baseline and change in RNA signature in follow up visit (between 3-5 years)|Surface marker expression of inflammatory markers using flow cytometry, Baseline|miRNA expression, Baseline|Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathy, Baseline",Indiana University,192,OBSERVATIONAL,Observational Model: |Time Perspective: p,2022-01-01
NCT02140411,Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.,https://clinicaltrials.gov/study/NCT02140411,COMPLETED,Retinal Vein Occlusion|Age Related Macular Degeneration,DRUG: Ranibizumab Intravitreal injections,"Mean Change From Baseline in Best Correct Visual Acuity (BCVA), Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of EDTRS is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement., baseline, week 48",Novartis Pharmaceuticals,21,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2015-04-25
NCT02067013,Analysis of Aqueous and Vitreous Humor,https://clinicaltrials.gov/study/NCT02067013,UNKNOWN,Proliferative Diabetic Retinopathy|Macular Degeneration|Macular Hole|Neovascular Glaucoma,DRUG: Ranibizumab|OTHER: No Ranibizumab,"Cytokine Levels, Growth factor, cytokine, chemokine , and ranibizumab (if applicable) concentration in aqueous and vitreous samples collected during pars plana vitrectomy, Collected at Baseline",California Retina Consultants,45,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE,2015-07
NCT00545870,Bevacizumab Versus Ranibizumab for Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT00545870,COMPLETED,Diabetic Retinopathy|Diabetic Macular Edema|Proliferative Diabetic Retinopathy,DRUG: bevacizumab|DRUG: Ranibizumab,"To investigate the change in macular edema and the absolute change in visual acuity. To investigate the change of neovascularisation., 12 Months","Ursula Schmidt-Erfurth, M.D.",30,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",2008-06
NCT01487070,A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT01487070,COMPLETED,PDR,DRUG: Macugen (Pegaptanib Sodium),"Evidence of advancement of tractional detachment post injection of Macugen before surgical intervention., 7-14 days prior to surgical intervention",Retina Institute of Hawaii,5,INTERVENTIONAL,Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2011-04
NCT02055911,Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema,https://clinicaltrials.gov/study/NCT02055911,WITHDRAWN,Diabetic Macular Edema,DRUG: Ranibizumab,"focal macular changes in full-field and photopic negative response (PhRN) amplitude (in µV), The photopic negative response (PhNR) of the full-field cone electroretinograms (ERGs) is a functional indicator of retinal ganglion. The PhNR consists of a negative-going wave that follows the photopic cone b wave. The PhNR is selectively attenuated in patients with optic nerve disease and glaucoma, indicating that the PhNR can be an objective functional measure reflecting the sum of the total response of the retinal ganglion cells in the entire retina., at Baseline and Months 3, 6, 9, 12",Federal University of São Paulo,0,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,2014-03
NCT02984813,Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02984813,TERMINATED,Open-angle Glaucoma|Diabetic Retinopathy,DRUG: GlaucoHealth|DRUG: GlaucoSelect|DRUG: Placebo,"Flavoprotein fluorescence index, Average Intensity and Average Curve Width, 3 months",The New York Eye & Ear Infirmary,21,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION",2016-04-15
NCT00040313,Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula,https://clinicaltrials.gov/study/NCT00040313,COMPLETED,Diabetic Macular Edema,DRUG: pegaptanib sodium (Macugen),,Eyetech Pharmaceuticals,0,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,2002-10
NCT03197870,"The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)",https://clinicaltrials.gov/study/NCT03197870,COMPLETED,Nonproliferative Diabetic Retinopathy,DRUG: AKB-9778|DRUG: Placebo,"Percentage of Subjects With an Improvement in Study Eye Severity of Diabetic Retinopathy (DR) (ETDRS DR Severity Score or DRSS) of ≥ 2 Steps, Change from baseline to Week 48 in Diabetic Retinopathy Severity Scale Score in Study Eye by visit in the modified intent-to-treat population.

ETDRS DR severity levels 10-85; ETDRS Steps 1-12, Baseline to Week 48","EyePoint Pharmaceuticals, Inc.",167,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-06-09
NCT02911311,Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT02911311,UNKNOWN,Proliferative Diabetic Retinopathy,DRUG: intravitreal injection of conbercept|DEVICE: PRP,"The primary outcome is mean visual acuity change(BCVA), Primary outcome is the change in BCVA from screening to 12 moths in the study eye measured in the ETDRS letter score at 4 m, 12 months",Sun Yat-sen University,226,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT,2019-10-12
NCT03321513,DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME,https://clinicaltrials.gov/study/NCT03321513,COMPLETED,Diabetic Macular Edema,DRUG: intravitreous aflibercept|DRUG: Bevacizumab + Deferred Aflibercept Group,"Mean Change in Visual Acuity, Area under the curve mean change in the electronic early treatment diabetic retinopathy study visual acuity, 2 years",Jaeb Center for Health Research,270,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2017-12-07
NCT06188013,Proteomic Study of Plasma Exosomes in Patients With Diabetic Retinopathy,https://clinicaltrials.gov/study/NCT06188013,NOT_YET_RECRUITING,Diabetic Retinopathy,,"differential proteins of exosomes, Exosomes were extracted and isolated from plasma, proteomics analysis of proteins in exosomes was performed to compare the number of types of changes in exosomal proteins of the four groups and to identify proteins that were up-regulated and/or down-regulated, and the relationship between the proteins and diabetic retinopathy was then analysed to look for possible mechanisms and therapeutic targets for diabetic retinopathy., December,2023-June,2024","Xuanwu Hospital, Beijing",24,OBSERVATIONAL,Observational Model: |Time Perspective: p,2024-01-02
NCT02874313,CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea,https://clinicaltrials.gov/study/NCT02874313,COMPLETED,Diabetic Retinopathy|Sleep Apnea,DEVICE: Continuous positive airway pressure|DRUG: Pharmacological treatment|OTHER: Conventional anti-diabetic diet recommendations,"Change from baseline in of retinal microaneurysm or hard exudates, To compare the change in percentage of retinal microaneurysm or hard exudates between the patients allocated to CPAP group and the control group, 12 months",Hospital Universitario La Paz,82,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,2016-08
